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Abstract 
cross sectional and observational data suggest that HIV-positive individuals and those 
receiv ing antiretroviral (ARV) therapy are prone to higher rates of osteoporosis and 
osteopaenia than HIV-negative individuals. Likewise, HIV-positive individuals often have 
low vitamin D status. Evidence is emerging more generally of a strong association 
between HIV infection and poor bone health. There is also evidence that treatment with 
ARV therapy (ART) and suboptimal vitamin D status may exacerbate this problem 
(Brown et al, 2006a, 2010). But, to date, causal relationships have not been fully 
established. This thesis explores the interactions between these separate factors and 
provides novel data about the effects of HIV infection and its treatment, on bone health 
in a particular group of black, South African women. 
Bone loss and poor vitamin D status in the context of HIV infection are important global 
health issues because these conditions may affect millions of individuals. If HIV-
associated bone loss is causally associated with an increased risk of bone fracture then it 
is possible that there will be an epidemic of HIV-associated fractures in coming decades, 
particularly in the developing world, including Africa. Study data have so far often been 
limited by several factors, including cross-sectional design, absence of control groups, a 
preponderance of attention to bone outcomes in males and in Caucasians, and a lack of 
good quality data in Africans living in Africa. 
Th is study aimed to -assess the magnitude of HIV- and ART-associated changes in areal 
bone mineral density (aBMD), size-adjusted bone mineral content (SA-BMC) and vitamin 
D status in adult, premenopausal women living in Johannesburg, South Africa. Ninety-
eight HIV-negative (Negative reference: Nref) and 149 HIV-positive women were 
enrolled to allow for comparison between groups. The HIV-positive women were 
recruited into those eligible to start ART (Positive low CD4 : Plow, n=75) and those 
unli kely to require ART (Posit ive preserved CD4 : Ppres, n=74) during a 12-month follow-
up period. The design was longitudinal with visits at 0, 6 and 12 months for 
measurement of body composition, bone measures and dietary assessment. Blood and 
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urine samples were collected for the evaluation of relevant musculoskeletal analytes, 
including 25(0H)D at each time point. Most women (>80%) who received ART during 
the course of the study received South African standard first-line therapy consisting of 
lamivudine, tenofovir and efavirenz. 
A post hoe analysis of possible effects of ART was performed by retrospectively dividing 
HIV-positive women into ART-unexposed (n=66) and ART-exposed (n=74). 
At baseline there was a high prevalence of overweight with 65%, 65% and 44% with 
BMI >25 kg/m2 in Nref, Ppres and Plow respectively. Plow had lower weight, BMI, fat 
mass, lean mass, waist and hip circumferences than the other groups. Nref and Ppres 
were not different from each other. There were no differences in aBMD or SA-BMC 
1· between groups at baseline and no significant differences in vitamin D status between 
the groups. The mean ±SD serum 25(0H)D concentrations were 59.7 ±16.5, 59.2 ±16.5 
and 61.6 ±22.3 nmol/1 in Nref, Ppres and Plow respectively. Plow had significantly lower 
serum albumin concentration (p<0.0001) and higher serum phosphate concentration 
(p<0.0001). The magnitude of differences in serum phosphate was: Ppres-Nref = 12. 7 
±2.9%; Plow-Nref = 20.3 ±2.9% and Plow-Ppres = 7.6 ±3.1% (p<0.001). 
Tubular maximum Reabsorption of Phosphate/Glomerular Filtration Rate (TmP/GFR) was 
11.2 ±3.2% and 27.4 ±3.2% respectively greater in Ppres and Plow than Nref 
(p<0.0001), and higher in the Plow compared to Ppres 16.2 ±3.4%, (p=0.0002). Serum 
alkaline phosphatase and urine phosphate to creatinine ratio were not significantly 
different (p>0.05). 
At the 12-month follow-up, Plow subjects remained lighter than their Nref and Ppres 
counterparts. However, there was a 3.9 ±0.9% increase in mean weight in the Plow 
group over 12 months (p<0.001), which represented 10.2 ±0.8% (p<0.001) increase in 
fat, rather than lean, mass accumulation. There were significant mean decreases in 
aBMD and SA-BMC in Plow subjects, and those exposed to ART of the order of 2-3% at 
total hip, femoral neck and lumbar spine. 
5 
There were no significant differences in mean vitamin D status between the groups and 
no significant changes, the mean 25(0H)D concentrations were 63.3 ±17.7, 66.0 ±18.4 
and 61.1 ±20.1 nmol/1 in Nref, Ppres and Plow respectively. Serum albumin 
concentrations had risen by a mean of 9.1 ±1.1% in the Plow group to reach comparable 
concentrations with the other groups. Alkaline phosphatase activity had significantly 
risen in the Plow group compared with the other groups (p<0.001). Serum phosphate 
concentration remained higher in Plow than the other groups, though the mean value 
had not increased. Serum phosphate had significantly increased in Nref from baseline to 
12 months 7.0 ±2.3% (p=0.05) and non-significantly in Ppres 5.2 ±2.4%. TmP/GFR had 
declined from baseline by 11.2 ±3.6% in Plow and non-significantly increased in Nref 
and Ppres (6.4 ±3.3% and 3.8 ±3.5% respectively). 
These data suggest that HIV infection in South African women is associated with 
differences in body composition but not with differences in bone measures or vitamin D 
status. However, being in the Plow group, and ART exposure, was associated with a 
significant decrease in mean aBMD and SA-BMC, of the order of 2-3%, over 12 months 
of observation at the hip, femoral neck and lumbar spine. These decreases, in young 
women, exceed those seen in early menopause, which is of the order of 1-2% annual 
decrease. The decreases were evident despite the fact that HIV-positive women exposed 
to ART had increases in fat mass, weight and serum albumin and alkaline phosphatase 
over time. In this group serum phosphate concentration and TmP/GFR decreased after 
the introduction of ART, suggesting an effect of ART on renal phosphate handling. ART 
exposure was not associated with change in vitamin D status. 
In the post hoe analysis the biochemical results in ART-unexposed compared to ART-
exposed was very similar to that in Ppres compared with Plow. 
Further studies to assess skeletal effects over a longer time in HIV-positive, ART-
exposed and na"ive women are warranted. Studies are also required in post-menopausal 
women, children and men. Given the high prevalence of overweight and obesity recorded 
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in the study population, there may also be a need fo r interventions to reduce cardio-
metabolic disease risk in this population. 
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1 Background to the PhD 
1.1 Background information on HIV infection, osteoporosis, and vitamin D status 
HIV infection, osteoporosis, and poor vitamin D status are all enormous global health 
problems, affecting millions of people and requiring careful study because of the ill 
health that results when left untreated. All these conditions are associated with increases 
in individual morbidity and mortality and decreases in quality of life, and huge financial 
healthcare and societal costs. 
Historically, the mortality and morbidity associated with HIV infection have been due to 
opportunistic infections, such as tuberculosis (TB). However, the availability of drugs 
used for antiretroviral therapy (ART), in the management of HIV infection, has seen the 
life expectancy of those infected increase dramatically (Palella et al, 1998). 
Consequently, the focus of healthcare for these patients has shifted from infectious 
disease to non-communicable disease as a cause of morbidity and premature mortality. 
This has been accompanied by an increased recognition of HIV-associated osteoporosis 
as distinct from the more 'typical' HIV-associated bone pathologies such as avascular 
necrosis of the hip (Mehta et al, 2013). There is a growing clinical perception that bone 
_ lqss is occurring at an earlier age in HIV-positive than in HIV-negative adults, and that 
HIV is associated with premature ageing. 
HIV is a global pandemic; however, the burden of HIV/AIDS lies squarely among women 
in Sub-Saharan Africa, notably in South Africa, which has a very large total burden of 
disease. As elsewhere in the world, the demography of HIV infection in South Africa is 
rapidly changing with the emergence of an ageing cohort of infected individuals. 
Consequently, the country faces a 'double burden' of communicable and non-
communicable diseases in the adult population. 
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1 .2 Extent of the problem 
l.2.1 Osteoporosis 
Osteoporosis is a systemic skeletal disorder characterised by "low bone mass, 
microarchitectural deterioration of bone tissue leading to enhanced bone fragility, and a 
consequent increase in fracture risk" (Consensus Development Conference, 1991). It is 
usually diagnosed using imaging techniques, predominantly Dual Energy X-ray 
absorptiometry (DXA). The World Health Organization (WHO) has suggested a working 
definition of osteoporosis and osteopaenia based on a comparison of an individual's areal 
bone mineral density (aBMD) and the mean (SD) aBMD at the time of peak bone mass in 
30-year-olds. Osteoporosis diagnosis uses a T-score (defined as (x-mean)/SD) of less 
than -2.5 SD and osteopaenia as a T-score of between -1.0 and -2.5 SD relative to that 
expected at the time of peak bone mass. In postmenopausal women, the odds ratio for 
lifetime risk of hip fracture is 2.6 for every SD decrease in aBMD (Marshall et al, 1996). 
Osteoporosis is the most common metabolic bone disease in the world. An estimated 10 
million of the US population were affected in 2005 and more than 14 million are 
predicted to be affected by 2020 (Burge et al, 2007). In 2010, it was estimated that 1.8 
million were living with osteoporosis in the UK and this number is predicted to rise to 2.1 
million by 2020 (Gauthier et al, 2011). The prevalence of osteoporosis is greatest in 
women, and increases with age. In addition, as the numbers of older people in a 
population increase, so too does the prevalence of osteoporosis. The burden of 
osteoporotic fragility fractures is compounded by the fact that osteoporosis is frequently 
under-diagnosed and is left under- or un-treated (Walker-Bone, 2012). 
The global burden of osteoporosis presents a pressing pub.lie health problem, particularly 
in the elderly. Aside from significant associated morbidity and mortality, the estimated 
annual costs to health services are, for example, £1.8 billion in the UK and €30 billion in 
Europe (Pollock et al, 2009). National (Lippuner et al, 2005) and global costs of fracture 
are enormous, estimated in 1990 at US$34.8 billion, and expected to increase 
substantially by the middle of this century (Harvey et al, 2010) . The predicted increases 
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by 2050 are greatest in Africa, Asia, and Latin America (Harvey et al, 2010). More up-to-
date estimates of global disease burden are lacking. It is estimated that in Europe each 
year 179,000 men and 611,000 women will suffer a hip fracture. Data for Africa are very 
sparse, so to use a different developing region, Latin America, as an example, there will 
be an estimated 655,648 hip fractures in 2050, with an estimated direct cost of $13 
billion (IOF, 2009). The International Osteoporosis Foundation estimates that between 
1990 and 2000, there was an almost 25% increase in hip fractures and that by 2050, 
the worldwide incidence of hip fracture in men will increase by 310% and 240% in 
women (Gullberg et al, 1997; IOF, 2009). 
In South Africa, the focus of the research described in this thesis, the prevalence of 
osteoporosis in white, Asian, and mixed-race populations "appears to be similar to that 
of developed countries, although no accurate fracture data exist. As in the USA, hip 
osteoporosis is less prevalent in ... black populations, although vertebral bone mass, and 
possibly also fracture prevalence, in black and white South Africans appear to be similar" (Hough, 2010). The National Osteoporosis Foundation of South Africa recognises that 
there is a need for further research into racial differences in osteoporosis and fragility 
fracture risk. More recently, Chantler et al have described differences in aBMD between 
. b~ack and white South African women, with whites having lower hip but higher lumbar 
spine aBMD than blacks. These differences were attributed to differences in body 
composition, lifestyle, and socio-economic factors (Chantler et al, 2012). 
Osteoporosis in postmenopausal women is considered to be a consequence of increased 
bone remodelling due to oestrogen deficiency, whereby bone resorption is uncoupled 
from, and outstrips, bone formation. In older women and men, vitamin D deficiency and 
hyperparathyroidism are important risk factors for low bone mass; other 'traditional' risk 
factors include smoking, excess ethanol, and low physical activity. Low lean mass, is also 
a risk factor for osteoporosis development (Rikkonen et al, 2012). 
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The pathophysiology of low bone mass, and increased fracture risk, in younger adults is 
less well defined but may include slower bone mass acquisition and lower peak bone 
h 
·n healthy individuals or be the result of a specific medical condition such as mass t an , ' 
coeliac disease (Ferrari et al, 2012). The resultant low bone mass can result in an 
d 
·sk of fracture at an earlier age than usually associated with fragility fractures increase n 
and/or increased risk later in life (in the 7th decade and beyond). 
f t . regard1·ng osteoporosis and its underlying bone biology is 
More detailed in orma ion 
given in Chapter 2. 
1.2.2 HIV infection 
1.2.2.1 HIV epidemiology HIV infection is a multisystem disease that can affect every organ in the body, including 
those involved in bone metabolism, e.g. the gut, kidneys, and parathyroid glands (Hellman et al, 1994). In addition, HIV can have a deleterious effect on nutritional status 
and/or intake, body composition (Segatto et al, 2012), and the ability to be physically 
active, all of which have important, potentially negative consequences for bone health. 
worldwide, there were an estimated 33 million people living with HIV infection in 2007, 
with an estimated annual incidence of 2. 7 million, and with Sub-Saharan Africa the most 
affected region, accounting for 67% of all infections and 72% of all HIV-related deaths (UNAIDS, 2008a). In 2011, UNAIDS estimated that there were 34.2 million people living 
with HIV (UNAIDS, 2011). Whilst the global epidemic has been stabilising since 2000, 
the prevalence is continuing to rise because of access to ARV therapy prolonging 
survival, combined with on-going new infections (UNAIDS, 2008a). Within Sub-Saharan 
Africa , the greatest burden of HIV infection is concentrated in the Southern Africa region 
where prevalence in adults ranges between 15 - 28% (UNAIDS, 2008a) and where, as a 
result there has been a decline in life expectancy (Logie, 1999), although there is ' . 
evidence that these declines may be slowing or reversing (Hontelez et al, 2012; Bor et 
al, 2013). 
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The estimated global annual expenditure for treatment and prevention of HIV is $13. 7 
billion (2008 data) (UNAIDS, 2008b; Global Health Council, 2010) (Figure 1-1) with 
predictions that by 2031 the costs will reach $35 billion (Hecht et al, 2009): 
Figure 1-1 Estimated US and global expenditure on HIV/ AIDS 
• US Spending • Global Spending • Global eecl 
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Estimated US and global expenditure on HIV/AIDS compared with the global need for universal access to ART up to 2010 (Global, 2010)* (* Global Health Council, no longer operational so unable to apply for copyright permission) 
1.2.2.2 HIV and chronic diseases of old age 
Recent estimates in the USA suggest that 50% of HIV-positive individuals will be aged 
over 50 years by 2015 (Yin et al, 2009). In the UK it is estimated that 8% of women and 
' 
19% of men with HIV infection were over 50 years of age in 2006 (Pollock et al, 2009). 
The expectation is that older individuals will develop conditions such as cardiovascular 
disease and osteoporosis (Goulet et al, 2007) in a similar manner to the HIV-negative 
ageing population, although these conditions may occur at a younger age. For example, 
proxy markers for increased cardiovascular disease (CVD) risk, such as D-dimer 
concentrations in blood, appear to be increased in HIV-infected patients (Aberg, 2012). 
This suggests that end organ disease (e.g. myocardial infarction) may have an increased 
prevalence in HIV-infected patients as this cohort continues to age (Aberg, 2012). Effros 
et al describe this as HIV infection "compressing the ageing process" (Effros et al, 2008). 
The full spectrum of age-related disease burden in HIV-positive patients has not yet 
been fully elucidated because the population of affected individuals is relatively young at 
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the present time when compared with ageing populations in general, although the 
· of these patients will inevitably make this relationship clearer in coming decades. ageing 
2012 data suggest that in Sub-Saharan Africa, if current coverage (i.e. provision of ART 
to those who are eligible) of ART continue to increase at the current rate, the ratio of 
HIV-positive patients aged over 50 years will increase from 1: 7 of HIV-positive adults 
(2011) to greater than 1 :4 (2040) (Hontelez et al, 2012). 
A more detailed description of HIV infection and its underlying biology is given in Chapter 
2. 
1.2.2.3 ARV therapy 
Effective, combined ARV drugs have been in use widely in the West since the mid-1990s. 
ART usually consists of a combination of three drugs: two nucleoside reverse 
transcriptase inhibitors (NRTI) and one non-nucleoside reverse transcriptase inhibitor 
(NNRTI) or protease inhibitor (PI). Numerically, the vast majority of the population with 
access to ART are in the developing world, and most patients will access an NNRTI-based 
regime since this is significantly cheaper than a PI-based regime. In most European 
countries the first-line ART regime is also NNRTI-based. It was estimated that in 2010, 
15 million individuals were accessing ART globally. There is, however, a huge variation in 
estimates of ART-coverage, with some countries managing only 1 % (Madagascar) and 
others >95% (Comoros) in 2010 (UNAIDS, 2011). This compares with 66% coverage in 
South Africa as of 2011. 
ART is largely able to reverse the deleterious effect of HIV infection by suppressing viral 
replication; this allows for restoration and near normalisation of immune function. HIV 
infection damages the immune system and is mediated by viral infection of CD4-positive 
immune cells (see Section 2.1.1). However, there are multiple effects on body systems, 
particularly kidney, liver, and bone, and long-term ART has been shown to result in a set 
of previously unrecognised toxicities, including kidney disease and osteoporosis. Both 
HIV infection and ART can independently affect the musculoskeletal system (Rosenfeldt 
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et al, 2005; Maagaard et al, 2006) and are associated with increased fracture risk (Triant 
et al, 2008). 
A more in-depth discussion of ART is given in Chapter 2. 
1.2.2.4 HIV infection, ARV therapy, and bone health In the past decade, osteoporosis and osteopaenia have been reported in HIV-positive 
populations in Europe, North and South America, Asia and Australia (Brown et al, 
2006b) . There have been a plethora of case reports and cross-sectional studies 
associating HIV infection with premature bone loss and symptomatic bone disease (Carr 
et al, 2001; Moore et al; 2001, Allison et al; 2003, Amiel et al; 2004, Paccou et al 
' 
2009). In 2005, the estimate of osteoporosis prevalence in HIV-infected adults, based on 
a meta-analysis of aBMD, was as high as 15% (Brown et al 2006b) H , . owever, some 
earlier reports, such as those of Paton et al, suggested that HIV infection was not 
associated with low aBMD (Paton et al, 1997; Bolland et al, 2006). In addition, there is 
some evidence to suggest that ART exposure may accelerate HIV-associated bone loss 
(Brown et al, 2009). There have been few reports of fracture incidence, but there is 
evidence from two studies that HIV-positive patients are at increased risk of fracture in 
' 
~airt because of low aBMD, compared to controls (Triant et al, 2008; Yong et al, 2011). 
Numerous cross-sectional, and some longitudinal, studies have illustrated the negative 
effects of ART exposure on bone health. The effects of ART have also been demonstrated 
in HIV-negative individuals exposed to ART as part of pre-exposure prophylaxis (PrEP) 
trials to prevent HIV infection. This provides powerful evidence that tenofovir (a 
commonly prescribed NRTI), at least, has an effect on bone mineral separate from other 
ART, and indeed HIV infection per se. Not all studies demonstrate a negative effect of 
ART on bone health and for those that do the effect of different classes of ART, and 
w1 in ese c asses, on bone health rema ins to be fully 
indeed individual drugs ·th· th I 
elucidated. 
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The available data on bone health in the context of HIV infection and ART exposure are 
limited because studies have focused largely on younger adults, who have, historically, 
been most affected by HIV but least affected by osteoporosis. In addition, data on aBMD 
in HIV-infected patients are mainly from young males. This makes extrapolation to 
women and older people difficult since lower aBMD in young male patients may not be as 
predictive of subsequent fracture. In the meta-analysis by Brown and Qaqish of all 
studies of aBMD in HIV patients up to 2005, only 11 included HIV-negative controls, the 
majority of whom were male and, apart from one Argentinian study, all were conducted 
in high income countries (Brown et al, 2006b). Most of the studies evaluated were not 
longitudinal and therefore are not able to make the difficult distinction between effects of 
HIV infection and of ART exposure. Finally, HIV infection is associated with risk factors 
for osteoporosis, including abnormal gonadal function (Rietschel et al, 2000) and low 
levels of physical activity (Maharaj et al, 2011). These also need to be taken into account 
when assessing the effect of HIV infection and ART exposure on bone health as such risk 
factors may contribute more to decreases in bone mineral than HIV infection or ART 
exposure. 
A more detailed critique of these studies and the potential mechanisms by which HIV and 
ART affect bone is given in Section 2.4. 
1.2.3 Poor vitamin D status 
1.2.3.1 _Epidemiology 
Vitamin D deficiency causes rickets and osteomalacia in children, and osteomalacia in 
adults. Historically, these were regarded as diseases of temperate latitudes as a result of 
insufficient exposure to sunlight containing ultraviolet radiation B (UVB) for the skin to 
synthesise vitamin D (Holick, 2006; Schoenmakers et al, 2008). Improvements in air 
quality, which allowed mor:e UVB radiation to reach the earth's surface, and fortification 
of foodstu ffs with vitamin D, meant that classical rickets and osteomalacia became rare 
in the general populations of developed countries. However, there are certain groups of 
people, particularly those with darker skin and/or those who dress in a way that almost 
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completely covers their skin, who develop skeletal manifestations of vitamin D deficiency. In addition, it is now recognised that, despite abundant UVB-containing sunlight, rickets and osteomalacia can also occur in tropical count ries (Schoenmakers et al, 2008). 
A biochemical measure of v itamin D status can be used to ascertain if an individual or a population has sufficient vitamin D to meet requirements in order to prevent vitamin D-associated skeletal diseases. The most accepted measure of vitamin D status is via the measurement, in blood, of 25-hydroxyvitamin D (25(0H)D) concentration; this correlates with the skeleta l diseases rickets and osteomalacia (outcomes) caused by poor vitamin D status. 25(0H)D has a relatively long half-life in the circulation and gives an integrated measure of vitamin D supply from endogenous synthesis and the diet. To date there is no single biomarker for vitamin D supply, function and risk of disease (Prentice et al, 2008). 25(0H)D, perhaps, provides the most consistent, reproducible, and affordable measure of vitamin D status, although research is required to better integrate these different aspects of vitamin D metabolism (Prentice et al, 2008). 
Vitamin D status is determined by several factors including dermal manufacture of vitamin D when exposed to UVB. This is under the influence of several factors including atmospheric conditions, use of sunscreen or sun block, latitude, and skin covering and pigmentation . Other important contributors to vitamin D status are intake of vitamin D through diet and supplement use, hepatic and renal capacity to metabolise vitamin D, and tissue requirements fo r vitamin D. 
The optimum UVB sunlight exposure for vitamin D production, vitamin D intake, and the use of markers of vitamin D status at a population level are controversial areas and the subject of much debate. The thresholds of 25(0H)D used to assess status, and define sufficiency, insufficiency, and deficiency, vary depending on the condition being described. For example, it is we ll established that 25(0H)D concentrations of less than 25nmol/l are associated with increased risk of developing ri ckets and osteomalacia . Poor 
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. f t e and increased risk of 
I been linked with osteoporosis, rac ur , 
. in D status has a so 
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. 
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without ART exposure, with poor vitamin D s 
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plasma parathyroid hormone (PTH) concentrations or bone turnover markers (Aukrust et 
al, 1999; Bolland et al, 2008; Fabbriciani et al, 2011; Conesa-Botella et al, 2012; De 
Socio et al, 2012; Kwan et al, 2012). 
HIV infection could have a detrimental effect on vitamin D status through many 
mechanisms, including resu lting from general debility, with less time spent outdoors, 
poor appetite, and therefore less dietary intake, as well as the use of medications that 
induce the metabolism of vitamin D. 
Some studies have found associations between specific ART and low plasma 25(0H)D 
concentrations (Conesa-Botella et al, 2010; Rosenvigne et al, 2010; Welz et al, 2010; 
Dao et al, 2011) while others did not (Stein et al, 2011). Other studies have reported 
different effects of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI) and 
Protease Inhibitor (PI) medication-exposure on vitamin D status with NNRTI-use more 
consistently associated with poor status than PI~use (Kwan et al, 2012) (see section 
2.1.2). 
The association of HIV and ART-use with poor vitamin D status suggests that this may 
be a factor in promoting HIV-associated osteoporosis, and vitamin D deficiency is 
, regarded as a secondary risk factor for low aBMD generally (see Figure 2-23) . However, 
most data describing low aBMD and poor vi tamin D status in t he context of HIV infection 
are from cross-sectional studies that have lacked a HIV-negative control group, and/or 
studies in Caucasian males. In addition, other risk factors for osteoporosis need to be 
considered. These include ' tradi tional' (age, female gender, low body weight , smoking, 
high alcohol intake), 'HIV-related ' (duration of HIV infection and ART exposure, viral 
factors, a pro-inflammatory milieu) and 'secondary' facto rs (renal dysfunction, acid-base 
disturbance, hypogonadism) (Walker-Bone, 2012). An added complexity is t hat t here are 
overlaps between these categories: for example, renal dysfunct ion as a risk factor for 
bone loss may be the consequence of a combination of trad itional (e.g. diabetes) and 
HIV-related (via HIV-associated nephropathy (HIVAN)) factors. In addition, poor vi tamin 
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D status may be linked to sub-optimal immune system functioning, which might 
accelerate HIV-disease progression. 
Greater detail about vitamin D metabolism and function in general and in relation to HIV 
infection and ART exposure will be given in Section 2.3. 
1.3 The situation in South Africa 
Accurate prevalence rates for low aBMD and low 25(0H)D status in urban South African 
women with or without HIV infection are unknown. 
1.3,1 Osteoporosis prevalence 
As previously described, there are limited reference data on the incidence and 
prevalence of osteoporosis in South Africa. The lifetime risk of whites, Asians and mixed-
race populations in South Africa is thought to be similar to those of populations in the 
developed world, where there is a lifetime risk of 30-40% in women and 20% in men; 
"no accurate (South African) fracture data exist" (Hough, 2010). Hip osteoporosis is less 
prevalent in South African blacks than in whites, although vertebral aBMD, and possibly 
fracture risk, seem to be similar. The National Osteoporosis Foundation of South Africa 
set as one of their key recommendations, "local research on the incidence of risk factors 
for, and normal reference data on, osteoporosis" (Hough, 2010). 
1.3.2 HIV prevalence 
The most recent UNAIDS estimates (2011) reveal that South Africa had 5.6 million 
people living with HIV. Of the 5.3 million adult cases, 3.3 million were women. South 
Africa also had 314,000 HIV-related deaths in 2008. I n 2009, overall HIV prevalence was 
17.8%, the fourth highest in the world after Swaziland, Botswana and Lesthoto, and, in 
2010, its ART coverage was estimated to be 55% (Motsoaledi, 2010; UNAIDS, 2011). 
1.3.3 ART practice 
In the UK, it is currently recommended t hat ART commences in · uncomplicated HIV 
infection when blood CD4 cou nt falls to ~350x106 cells/I (see Section 2.1.1) . I n South 
Africa, the corresponding CD4 count threshold for ART initiation was <200xl06 cells/I 
until August 2011 when it was raised to match European/UK standards. First-line ART in 
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South Africa is based on a NNRTI regime and access to second 11·ne th · ( - erap1es see 
Section 2.1.2) is restricted in many public clinics. 
1.3.4 Vitamin D status 
South Africa lies in the latitude band 20-40° S (Prentice et al, 2009a). There are latitude I 
climatic, and cultural differences between the north and south of the country that affect 
the potential for dermal vitamin D synthesis. As a result, there are marked variations in 
vitamin D production in different areas and during different seasons. For example, 
Johannesburg (North East) (26° S) has greater peaks of in vitro vitamin D production in 
the winter when compared with Cape Town (South West) (35° S), but little difference in 
the summer (Pettifor et al, 1996). 
There is a dearth of data regarding vitamin D status in Sub-Saharan Africa generally and 
" South Africa. A review of African and South African studies describing vitamin D status 
was conducted by Prentice at al 2009 (Prentice et al, 2009a). In this review, nine South 
African studies in children, adults, and pregnant women were described. The mean 
25(0H)D concentration was above 50 nmol/1 in all except children with rickets and 
patients with hip fracture (Prentice et al, 2009a) . Other review articles have reported 
similarly good vitamin D status in African populations (Lips, 2010; van Schoor et al, 
?O•ll). More recently, Kruger et al have described vitamin D status in urban and rural 
postmenopausal South African women with mean 25(0H)D concentrations well in excess 
of 50nmol/l, and there was no difference when these figures were corrected for HIV-
status (Kruger et al, 2011). The value of 50nmol/l is referred to as it is the cut off 
identified by the Institute of Medicine (IOM) above which skeletal effects of vitamin D are 
unlikely to occur (see Section 2.3.6). High rates of obesity in South Africans may 
adversely affect vitamin D status by facilitating sequestration of 25(0H)D into adipose 
tissue thereby limiting its bioavailability (Wortsman et al, 2000). This potential for 
vitamin D to be sequestrated in adipose tissue will be reviewed in more detail in Section 
2.3. 
33 
1.3 .s studies of HIV-associated bone loss in South Africa To date, there are no published studies specifically examining HIV-associated bone loss 
in south Africa, although data exist on related matters, such as the relationship between 
vitamin D status and PTH in South Africans, which do not specifically address HIV-status. 
There are unpublished observations of 11 % incidence of osteoporosis in HIV-positive, 
postmenopausal black South African women (Conradie 2008, cited in Kruger et al, 
2011). Data do exist for bone fractures in the general population: 31/100,000 in South 
African black women compared with 402/100,000 in African Americans (Anderson et al, 
1994). The women in Kruger et al's study reported a less than 3% 'incidence' of fracture, 
although this is difficult to interpret because the study design was cross-sectional and is 
likely to represent ever fractured rates rather than annual incidence (Kruger et al, 2011). 
Among published studies of HIV-associated bone loss in the low and middle income 
countries, an Argentinian study, Bruera et al, with a small number of controls (n=31) 
compared to HIV-positive (n=lll) subjects, demonstrated a lumbar spine T-score of 
greater than -1 in 58% of controls compared to between 35-54% of HIV-positive 
subjects, depending on ART regime (p<0.01). At the femoral neck site the figures were 
85% and between 19-31%, depending on ART regime, respectively (p<0.01) (Bruera et 
al, 2003). More recently, a Senegalese study reported lower aBMD in HIV-infected adults 
(n= 204: 134 women and 73 men) compared with controls (n=207 matched), using 
quantitative ultrasound (QUS) of the calcaneus. Adjusted analysis demonstrated a QUS 
BMD difference: -0.27 SD, 95% confidence interval (Cl): -0.53;-0.002, P=0.05. 
Differences in BMI explained a third of the difference in QUS BMD (Cournil et al, 2012). 
1.4 Plan of research 
HIV infection, ART exposure, osteoporosis, and poor vitamin D status are interconnecting 
conditions each likely to negatively influence bone health. This is especially true for 
those with predisposing risk factors for low aBMD and bone loss in adulthood, such as 
advanced age, gonadal dysfunction and concomitant limited physical activity, all of which 
are seen in HIV-positive adult patients. Whilst there has been a concentration of 
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research in HIV-associated communicable diseases (e.g. TB) in South Africa and the 
effects of ART on these, insufficient attention has been given to the future health 
problems such as osteoporosis that may result from long-term ART exposure. 
My own clinical observations of poor bone health and poor vitamin D status as a 
consequence of symptomatic disease in HIV-infected patients in inner city London 
informed my decision to undertake research into the relationship between HIV infection 
and bone health. I have combined this interest with a career-long engagement with 
global health issues. Because the burden of HIV infection is disproportionately heavy in 
the developing world, particularly in Sub-Saharan Africa, this is the region that will also 
shoulder the burden of HIV- and ART-related bone disease, should it exist or develop in 
the future. Nevertheless, virtually all studies on bone health and vitamin D status in 
adult HIV-positive populations have been carried out in Caucasian male subjects, and 
female and non-white subjects are therefore vastly underrepresented. For this reason, I 
designed a study that addresses the potential contribution of HIV infection and ART 
exposure to bone health and vitamin D status in black South African women. The aims 
and objectives of this study are specified below. 
1.~.1 Summary of the study design 
Premenopausal, urban, black South African women were recruited to take part in the 
study. Premenopausal women were chosen in order to avoid the confounding by rapid, 
menopausal bone loss. HIV-positive women with preserved CD4 counts, anticipated not 
to require ART-initiation for the first 12 months of the study, were compared with those 
with low CD4 counts who were due to commence ART soon after the baseline study visit 
(see Section 2.1.1). It was anticipated that this latter group would be exposed to ART-
treatment for the vast majority of the study duration. These groups were defined to try 
to separate the effects of chronic HIV infection (Positive preserved CD4 : Ppres) from 
those of ART exposure (Positive low CD4 : Plow). HIV-negative (Negative reference: Nref) 
women were recruited to act as a reference group. The study used a longitudinal design 
to detect changes in aBMD and vitamin D status over 12 months. Subjects attended for 
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study visits at baseline, 6 and 12 months. At each visit anthropometry, body 
composition, and bone imaging was conducted, and blood and urine samples collected 
for laboratory analysis. A 12-month follow-up period was chosen as it was unlikely that 
significant changes in aBMD would be detectable at less than 12 months, and to account 
for seasonal variation in vitamin D status. A post hoe retrospective division of subjects 
into those who were ART-unexposed and -exposed was undertaken to better explore the 
relationships between ART exposure and body composition, bone and vitamin D status 
variables (Chapter 8). 
There are approximately one million people receiving ART in South Africa, and this 
number is likely to rise significantly over coming years. Once commenced, the majority 
of individuals will continue ART lifelong. The attributable risk for bone health and vitamin 
D status is likely to be significant, even if only a modest effect was found. 
1.5 Aims 
The aims of the study were: 
1. To compare baseline aBMD and size-adjusted BMC (SA-BMC) in HIV-positive 
women (Ppres and Plow), and non-HIV-infected controls (Nref); 
2. To compare baseline body composition in Ppres and Plow, and Nref; 
3. To compare baseline serum concentrations of 25(0H)D in Ppres and Plow, and 
Nref; 
4. To evaluate t~e effects of HIV and ART on body composition (DXA), aBMD (DXA), 
bone strength (pQCT) in ART-na"ive and -exposed, compared with controls at 12 
months after baseline; 
5. To evaluate the effect of ART on serum 25(0H)D in those on and off ART, 
compared with controls at 12 months after baseline. 
1.6 Objectives 
The objectives were to discover and describe whether, in black South African women: 
1. HIV infection is associated with low aBMD and SA-BMC; 
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2. HIV infection is associated with alterations in body composition and fat: lean mass 
proportions; 
3. HIV infection is associated with low 25(0H)D concentrations; 
4. ART exposure is associated with decreases in bone mineral; 
5. ART exposure is associated with decreases in 25(0H)D. 
These hypotheses were tested to determine if HIV-associated bone loss and low 
25(0H)D are prevalent in black, urban South African women and to allow 
quantification of the magnitude of any effects and potential clinical relevance. Of 
particular interest was the comparison of bone change and/or loss at predominantly 
trabecular and cortical sites (Bonnick et al, 2006) to demonstrate if HIV infection or 
ART exposure resulted in preferential change at different sites, as this could 
predispose to particular patterns of osteoporosis and fracture. 
Women were chosen for this study on the following grounds: 
1. They are at greatest lifetime risk of osteoporosis and fragility fractures; 
2. Approximately 2/3 of those diagnosed with HIV infection in South Africa are 
women; 
3. Women in South Africa generally acquire their HIV infection at an earlier age than 
men and therefore are likely to experience a longer duration of infection and ART-
exposure with attendant effects on skeletal health; 
4 . Women are underrepresented in studies of HIV-related bone loss; 
5. To include both sexes would mean that the study would have to be expanded and 
go beyond the confines of a PhD project. 
1.6.1 Approach taken to address objectives/ test hypotheses 
The questions that arose from the aims and objectives were evaluated by using DXA to 
measure aBMD; DXA and anthropometry to measure body composition, and serum 
25(0H)D concentrations to determine vitamin D status. The investigation of change in 
these parameters, was addressed by arranging longitudinal follow up of HIV-positive and 
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HIV-negative women. Subjects were assessed at baseline (time 0) and followed up six 
and 12 months afterwards. Full details are provided in the study design, Chapter 3.3.1. 
In order to control for differences in season, . and in particular seasonal differences in 
vitamin D status, the study was designed so that the participants were seen at baseline 
and 12 months during the summer and autumn months and at the six month visit during 
the winter and spring months. 
At each time point, anthropometry, DXA scans, and fasting blood and urine samples 
were collected in order to assess body composition and bone mineral measures and 
conduct vitamin D-, calcium- and phosphate-related laboratory analysis. Full details of 
the methods employed are described in Chapter 4. 
1.7 Structure of thesis 
Chapter 2: "HIV infection, bone health and vitamin D". This chapter provides a detailed 
overview of HIV infection, ART, bone biology and bone health, especially osteoporosis, 
and vitamin D metabolism and status. 
Chapter 3: "Study design:" describes the design and the process of setting up the study 
in South Africa. 
Chapter 4: "Methods." This chapter describes the methods used. 
Chapter 5: "Baseline results": anthropometry, bone and body composition, socio-
economic status, vitamin D status and biochemical analyses. 
Chapter 6: "Cross sectional analysis." This chapter describes body composition, bone, 
vitamin D and biochemistry data cross sectionally at six and 12 months. 
Chapter 7: "Longitudinal analysis". This chapter describes the change in body 
composition, bone, vitamin D, and biochemical variables over the duration of the study 
in the three groups. 
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Chapter 8: "Post hoe analysis of ART-unexposed and -exposed". This chapter describes 
the change in body composition, bone, vitamin D, and biochemical variables over t he 
duration of the study in the subjects when divided into those unexposed and exposed to 
ART over the duration of the study. 
Chapter 9: Discussion. 
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2 HIV infection, bone health, and vitamin D status 
2.1 HIV/ AIDS, a brief historical perspective 
By March 1981, 8 cases of Kaposi's sarcoma, a rare cancer in young people, had been 
recorded in young gay men in New York City (Figure 2-1). At a similar time there were 
reports of sporadic cases of pneumocystis pneumonia (PCP), a rare form of the disease 
associated with profound immune suppression, reported in young gay men in Californ ia 
and New York. I n June 1981, the Centers for Disease Control (CDC) reported 5 cases of 
PCP in men in Los Angeles; this report is sometimes termed the beginning of 'AIDS' 
awareness, although at that stage the term had not yet been coined. By July 1982, over 
400 cases of PCP were reported to the CDC in gay men but, in the same year, doctors in 
Uganda had begun to recogn ise a condition associated with wasting in young adults that 
was termed 'slim' disease (AVERT, 2011), and when the syndrome was recognised in 
heterosexual Haitian patients later that month, it was no longer possible to continue 
classifying the condition as 'gay compromise syndrome', GRID (gay-related immune 
deficiency), or 'gay cancer'. 
Doctors t hought AIDS was an appropriate name because the condition was acquired 
rather than congenital; because it resulted in a deficiency within the immune system; 
and because it was a syndrome, with a number of manifestations, rather than a single 
disease (an anagram of AIDS (Acquired Immune Deficiency Syndrome), SIDA, was 
created for use in French and Spanish) . But as Mann put it, 
"The dominant feature of this fi rst period was silence, for the human 
immunodeficiency virus (HIV) was unknown and transmission was not 
accompanied by signs or sy mptoms sa lient enough to be noticed. While rare, 
sporadic case reports of AIDS and sero-archaeological studies have documented 
human infections wi th HIV prior to 1970, available data suggest t hat the current 
pandemic started in the mid- to late 1970s. By 1980, HIV had spread to all five 
continents (North America, South America, Europe, Africa and Australasia). 
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During this period of silence, spread was unchecked by awareness or any 
preventive action and approximately 100,000-300,000 persons may have been 
infected" (Mann, 1989). 
In May 1983, researchers at the Pasteur Institute, Paris isolated a new virus thought to 
be the cause of AIDS, but by 1986 there was controversy over the name of the virus. 
There were two competing groups; the Pasteur group termed it LAV (Lymphadenopathy-
Associated Virus) while Gallo's group in the USA called it HTLV-3 (Human T-cell 
Lymphotropic Virus, type three). In May of 1986, the International Committee on the 
Taxonomy of Viruses ruled that both names should be dropped and resolved the dispute 
by providing a new name, HIV (Human Immunodeficiency Virus). By the end of 1986, 85 
countries had reported 38,401 cases of AIDS to the World Health Organization. By WHO 
region these were: Africa 2,323, Americas 31,741, Asia 84, Europe 3,858, and Oceania 
395 (Bureau of Hygiene & Tropical Diseases, 1986). 
A full account of the history of the HIV epidemic can be found at on the AVERT website 
(AVERT, 2011) and in Pepin (Pepin, 2011) . 
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2.1.1 HIV virology 
HIV is a member of the genus lentivirus; a member of the Retroviridae family, and there 
are two different types, HIV-1 and HIV-2. HIV is thought to have evolved in humans 
from two distinct forms of Simian Immunodeficiency Virus (SIV): HIV-1 from 
chimpanzee-SIV, and HIV-2 from Sooty mangabey-SIV (Lemey et al, 2003). SIV 
probably crossed into humans through blood contact via hunting of monkeys and apes 
for food. HIV-1 and HIV-2 share approximately 40% of their genetic structure. However, 
the transmissibility is lower for HIV-2 and it is generally considered to be less pathogenic 
than HIV-1. HIV-2 can, however, cause AIDS that is indistinguishable from AIDS caused 
by HIV-1 and has a different pattern of susceptibility to ART. HIV-2 is largely restricted 
to West Africa with smaller numbers of patients in some southern European countries as 
a result of West African association. For a more detailed description see de Silva et al 
(2008, 2012). In this thesis any further reference to HIV refers to HIV-1 infection. 
Three groups of HIV-1 have been identified based on structural differences in the viral 
envelope (env): M, N, and 0. Group M is the most common and consists of 8 subtypes 
with distinct geographical variability. The most prevalent are subtype B (found mainly in 
North America and Europe), subtypes A and D (found mainly in Africa), and subtype c 
Cfound mainly in Africa and Asia). 
Lentiviruses are transmitted to host cells as single-stranded, positive-sense, enveloped 
RNA viruses. In the case of HIV the target cells are helper T cells (specifically CD4_ 
positive T cells), macrophages, and dendritic cells. When the virus enters the target cell , 
the viral RNA genome is converted into double-stranded DNA by the virally encoded 
reverse transcriptase enzyme. Reverse transcriptase is transported with the viral 
genome in the virus particle. The resulting viral DNA is then imported into the cell 
nucleus and integrated into the cellular DNA by a virally encoded integrase and host co-
factors. Once integrated, the virus may become latent, allowing the virus and its host 
cell to avoid detection by the immune system. Alternatively, the virus may be 
transcribed, producing new RNA genomes and viral proteins that are packaged and 
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released from the cell into the blood stream as new virus particles that begin the 
repl ication cycle again (see Figure 2-2). 
Figure 2-2 HIV and life cycle 
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(Gross, 2012) [Content under open content licenses may be reused without any need to contact the licensor. 
See : http://commons.wikimedia.org/wiki/Commons :Reusing content outside Wikimed ia ] 
HIV infection leads to a destruction of target cells by means of three principal 
mechanisms. First, HIV is responsible for direct viral killing of infected cells; second 
infected cells undergo increased rates of apoptosis (cell death); and, third, infected CD4-
positive T cells are destroyed by CD8-positive T cells, which recognise virally infected 
cells. The virus infects and destroys CD4-positive T-lymphocytes causing CD4 cell decline, 
usually over many years, eventually leading to CD4 cell collapse (NIAID, 2010) with loss 
of cell mediated immunity. A ' normal ' blood CD4 count of a non-HIV infected person is in 
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the region of 500-1200 x106/I. When the CD4 cell count falls below 200 x106/1 , 
opportunistic infections begin to appear and tend to increase in number and severity as 
CD4 levels continue to decline. The development of opportunistic infection (or HIV-
associated malignancy or severe constitutional symptoms) indicates severe immune 
dysfunction and this is the stage of infection defined as AIDS. If untreated the prognosis 
for survival following an AIDS diagnosis is in the region of 18 months (see Figure 2-3). 
Figure 2-3 Natural history of untreated HIV infection 
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(Sigve, 2013) [The person who associated a work with this deed has dedicated the work to the public 
domain by waiving all of his or her rights to the work worldwide under copyright law, including all related and 
neighbouring rights, to the extent allowed by law. See: http ://en.wikipedia.org/w/index.php?title=File :Hiv-
timecourse copy.svq&page=l ] · 
For information on the treatment of HIV infection, see section 2.1.2. 
2.1.2 ART general 
I n pa rts of the world where t here is ready access to ART, the li fe expectancy of those 
infected has improved. As a result, health can be resto red and life expectancy improved 
by several decades. Estimates of prognosis of survival may be as great as 50 years, for a 
patient in their 20s diagnosed now with HIV infection, depend ing on nadi r (lowest 
recorded) CD4 count (The Antiretroviral Therapy Cohort Collaboration, 2008). Currently, 
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there are 31 individual different drugs to treat HIV infection, and more being added each 
yea r, but none eliminate the virus. Different classes of individual ARV drugs are 
therefore taken in combination in order to disrupt HIV replication at different stages of 
its life cycle (Pieribone, 2003) .In order fo r HIV to remain suppressed, ART has to be 
taken daily. Poor compliance with ART frequently results in the virus becoming resistant 
to one or more of the constituent ARV drugs. There are currently five different classes of 
ART (see Appendix 1). 
Reverse transcriptase (RT) inhibitors interfere with the critical viral process of 
reverse t ranscription during which the viral enzyme RT converts its RNA into DNA. The 
two types of RT inhibitor are: 
A. Nucleoside RT inhibitor (NRTI) - these are 'faulty DNA building blocks' that are 
incorporated into HIV DNA resulting in incomplete DNA chain formation; 
B. Non-nucleoside RT inhibitor (NNRTI) - these bind to RT, interfering with the 
process of converting viral RNA into the required DNA. 
Protease inhibitors (PI) inhibit the viral protease enzyme that is central to forming 
infectiou s v iral pa rticles. 
Fusion and entry inhibitors prevent viral fusion with the host cell membrane. 
I ntegrase inhibitors block the viral enzyme integrase that allows v ira l genetic material 
to integrate with the host DNA (see Figure 2-4) . 
When a patient first requires ART, three drugs are generally combined to form highly 
active ART (HAART) . Second- line ART is used when first-line ART is no longer effective in 
controlling viral replication. Second-line therapy is available in developing countries, e.g. 
South Africa but not always easi ly available (South African Department of Health : 
Motsoaledi, 2010). Fusion, entry, and integrase inhibitors are usually reserved for 
patients who have developed extensive vira l res istance; t hey are extremely expensive 
and therefore not readily available in the developing world . Figure 2-4 illustrates the 
si tes of actions of current ART. 
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Figure 2-4 HIV life cycle and sites of ARV-drug actions 
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(Apostolova et al, 2011) [Reproduced with permission] 
The first reports of anti-HIV drug trials were in September 1986 using zidovudine (AZT) 
and reported the following year (Fischl et al, 1987). The effects on those using the drug 
were so markedly better than on the placebo group, in terms of improved survival, that 
the trial was halted early, even though AZT was associated with significant toxicity 
(Richman et al, 1987). But it was not until 1995 that a new class of ART was licensed; 
the protease inhibitors (PI) followed in 1996 by Nevirapine (a NNRTI). By 1996, a potent 
combination of ARV drugs was available, capable of reversing the devastating effects of 
AIDS, and the health of many improved enormously when they started taking this 
combination therapy. Some of those who had been ill in hospital were then able to go 
home, the improvement was so dramatic that it was referred to as the 'Lazarus 
Syndrome' (Andriote, 1999). From 1996 onwards, combination ART also meant that the 
mortality associated with HIV infection dramatically fell in the developed world. By 1998 
there were, however, reports of abnormal fat-distribution (lipodystrophy) in HIV-positive 
individuals, particularly in association with PI-exposure. Toxic effects of tenofovir on the 
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kidney are also well established in clinical studies. They include phosphate wasting, 
acute renal injury and Fanconi syndrome (Fernandez-Fernandez et al, 2011). 
2.1.3 HIV in South Africa 
HIV infection is a major epidemic in Southern Africa, and the effect on morbidity, 
morta lity, society, and culture cannot be overstated in countries where a large minority 
of the adult population are affected. Even in countries with relatively advanced medical 
infrastructure and free access to HIV-testing and treatment, such as South Africa, many 
individuals do not present to clinical services until they have advanced disease or AIDS. 
However, even at this stage, ART use can reverse symptoms and restore immune 
function and life expectancy. Nevertheless, where ART is available and where medical 
structures are in place to facilitate roll-out to the community, the shape of the epidemic 
is changing: young adults are no longer dying in vast numbers. Countries like South 
Africa have, recently at least, made great progress in increasing ART coverage to its 
population in a relatively short period of time. Indeed many HIV-infected patients are 
living long enough to develop non-communicable conditions such as obesity, diabetes, 
and hypertension. 
It is therefore, in countries like South Africa, that overlapping epidemics of 
com municable and non-communicable disease are likely to be most evident because of 
the very large numbers of individuals affected by both. This is termed a 'double burden' 
of disease given the ageing population (and associated non-communicable disease) and 
high communicable -disease prevalence (Mayosi et al, 2009; Chisholm et al, 2012; 
Marquez et al, 2012). In fact, in recent years, South Africa has described its population 
suffering from a 'quadruple burden' of disease, which includes maternal and perinatal, 
and injury-related conditions (Mayosi et al, 2009). 
In 2000, there was increasing global criticism of the stance of the South African 
President, Thabo Mbeki, on HIV/AIDS. He was commonly described as being an AIDS 
denialist; that is, denying the link between HIV infection and AIDS. As a result, there 
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was a lack of a coordinated response to South Africa's burgeoning HIV-epidemic, which 
may have resulted in the loss of thousands of lives (Chigwedere et al, 2008; Chigwedere 
et al, 2010). In August 2001, AIDS activists took legal action against the South African 
Health Ministry over its continuing refusal to supply ART to prevent mother-to-child 
transmission (PMTCT) of HIV. In December of that year, it was ruled that the South 
African government should give pregnant women free access to the drug nevirapine. The 
judge ordered the government to set up a nationwide PMTCT programme with a deadline 
for an implementation report to be handed back to the court by March 2002. The initial 
commitment was to establish PMTCT services and, later, to increase ART coverage more 
generally in the population. However, the South African Government did not develop a 
comprehensive plan for widespread ART distribution until 2007 (AVERT, 2011). 
2.2 Osteoporosis 
2.2.1 Osteoporosis epidemiology 
The term osteoporosis was introduced in France and Germany in the nineteenth century, 
based on histological observations of porous bone (Hillier et al, 1997). The main 
consequences of osteoporosis are fractures of the hip, vertebrae, and wrist. These 
fractures place a huge burden of morbidity and cost on societies with a high prevalence 
of osteoporosis. In the general population the incidence of bone fracture is bimodal with 
peaks in adolescence and the elderly. In young people the incidence of fracture is higher 
in males and the cause is more likely to be traumatic, but after the age of 35 years the 
overall fracture incidence in women increases dramatically so that female rates are 
double those of men (ibid.), and is more likely to occur with minimal trauma. 
The major determinants of risk for osteoporotic fracture in older people, therefore, are 
increasing age and female sex. Age is also important because of its positive association 
with increased risk and rate of falling, so that by age 80 - 84 years a third of women in 
the USA will sustain at least one fall per year. Similar data available from the UK show 
that at an age greater than 85 years, 50% of women, and a third of men, will sustain at 
least one fall per annum. Despite this very high rate of falls it is estimated that only 
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approximately 1 % of falls result in a hip fracture (ibid.), which however in absolute 
terms results in a very large incidence of fragility fractures. Men are relatively protected 
from osteoporotic fractures for several reasons; these include higher peak bone mass, 
less loss of bone mass with ageing, preserved gonadal function (compared to women), 
fewer falls, and the fact that they have a shorter life span in general (ibid.). 
osteoporotic fractures, particularly of the hip, may be devastating; such fractures lead 
directly to complications such as pressure sores as well as long term complications, 
including permanent impairment of ambulation in as many as 50% of those sustaining a 
hip fracture. Within 12 months of sustaining such fractures 5-20% will die, and the 
majority of those will die within 6 months of the fracture event. Mortality is, in part, 
dependant on age, with increasing age a risk for mortality (Beaupre et al, 2012). These 
figures are consistent in Western and non-Western settings (Yoon et al, 2011; Valizadeh 
et al, 2012). Osteoporotic fractures of the lumbar spine, and to a lesser degree the 
forearm, are also associated with significant morbidities (Hillier et al, 1997). These 
include pain, kyphosis and loss of height and associated respiratory symptoms, and are 
independently associated with increased risk of mortality (Hasserius et al, 2005) . An 
important explanatory mechanism behind this increase in fracture risk is the decrease in 
bone strength, via decreases in bone mass, with advancing age. It is estimated, for 
example, that from its peak, femoral neck density declines by 58% in women and 39% 
in men after age 50 years (see Figure 2-11). The figures are similar for the 
intertrochanteric hip region, 53% and 35% respectively. 
The epidemiology of vertebral fracture is more difficult to delineate because many of 
these fractures are occult and they have no universally accepted definition. Since many 
of these fractures are asymptomatic or associated with minor symptoms, patients are 
less likely to present to their medical practitioner and undergo a diagnostic x-ray 
examination. In general, the risk factors are thought to be similar for vertebral and non-
vertebral fracture. However the incidence of vertebral fracture may be twice that of hip 
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fracture and this is important because the excess mortality is similar to that seen 
following hip fracture (Hillier et al, 1997). 
Ethnicity, geography, and seasonality are also important factors in determining fractu re 
risk. As outlined in Sections 1.2.1 and 1.3.1, white populations are more likely to sustain 
fractures than non-white populations. These ethnic differences have been explained by 
greater bone mass and density in non-whites compared to whites. However, th is 
difference in bone mass and density is insufficient to explain all ethn ic differences; for 
example, women of Japanese heritage have lower aBMD than their white counterparts, 
but their incidence of hip fracture is approximately 50% lower (Ross et al, 1991) and 
may, in part, be explained by differences in hip axis length. As studies in developing 
world populations continue to be publ ished, the balance of evidence may show that 
these historical, ethn ic differences may be more complex and nuanced than previously 
thought (Aspray et al, 1996; Yan et al, 2003; Aspray et al, 2005; Leslie, 2012). There 
are, moreover, very wide geographical differences in rates of fracture between, and even 
within, countries, and there are many epidemiological associations that have been 
suggested as explanations. I n a US study, poverty and access to fluoridated water were 
positive correlates and southern latitude and water hardness were negative correlates of 
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fracture rates (Jacobsen et al, 1990). Fractures are also seasonal, with increases in 
winter months. Since most fractures occur after falls indoors it is not likely that slips on 
ice and snow are the only primary causa l factors . Other factors such as abnormal muscle 
funct ion ing in cold weather and poor vitamin D status have been suggested. I n contrast , 
the peak in distal forearm fractures seen in winter months is much more closely re lated 
to falls out of doors (Hillie r et al, 1997). Future pred ictions of globa l fracture prevalence 
are difficu lt to est imate but appear to be set to increase dramat ically, particu larly in the 
developing world (Harvey et al, 2010). 
2.2.2 Osteoporotic hip fracture 
The most important f ragility fractu re site is t he hip; it has the greatest ind ividual , health 
care-related, and societal costs. Osteoporotic hip fractures tend to occur following a fall 
51 
but can occur with other low impact trauma or even spontaneously. They cause pain and 
deformity of t he affected limb and, in the developed world, almost always result in 
hospitalisation. In this acute setting, hip fracture is confirmed using X-ray examination 
and is classified depending on t.he anatomical location. Most are defined as intracapsular 
or extracapsular. The most common ly used classification system for intracapsular, or 
femoral neck fractures, is some variation of the Garden classification (see Figure 2-5 and 
Table 2-1). As its basis, the classification separates non-displaced fractures from 
displaced fractures because of the better rate of healing in the former. 
Figure 2-5 Garden's classification 
Garden's classification 
rD C-'1'.J \J III Jrv 
(Glasgow, 2012) 
Table 2-1 Garden's classification of intracapsular hip fracture 
Stage 
Stage I 
Stage II 
Stage III 
Stage IV 
Description 
Incomplete fracture of the neck 
Complete without displacement 
Complete with partial 
displacement 
Complete femoral neck fracture 
with full displacement 
Remarks 
May be impacted and in valgus 
Fragments are still connected by 
posterior retinacular attachment 
Allows the femoral head to rotate 
back into anatomical position 
Extracapsu lar fractures are divided into trochanteric or sub-trochanteric depending on 
their anatomy; stability (stable or unstable) and displacement (present or absent) (see 
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Figure 2-6). These classifications are important as they often determine the choice of 
therapeutic intervention employed (Hillier et al, 1997). 
Figure 2-6 Schematic of intracapsular and extracapsular fracture 
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2.2.3 Osteoporosis pathogenesis 
The pathophysiological mechanisms underpinning osteoporosis are complex (Raisz et al, 
2008). What can be briefly stated, however, is that an understanding of the 
pathophysiology of osteoporosis has changed perceptions of the disorder from "an 
inevitable consequence of aging ... [to] ... a disease of multifactorial aetiology for which 
an increasing number of therapeutic interventions are now available" (Compston, 2000). 
An understanding of the pathophysiological mechanisms allows for directed research into 
new therapies and treatments. 
Genetic and environmental factors play important roles in the pathogenesis of 
osteoporosis since both affect peak bone mass and determine rates of subsequent age-
related bone loss. The secondary causes of osteoporosis can be divided into five general 
areas: endocrine dysfunction, e.g. hyperparathyroidism; malignancy, e.g. lymphoma; 
drug use, e.g. corticosteroids; connective tissue disease, e.g. Marfan's syndrome; 
miscellaneous, e.g. chronic liver disease (Premaor et al, 2010). Despite this variety of 
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secondary causes, however, the majority of cases of osteoporosis are primary or 
idiopathic with no other cause identified (Compston, 2000). 
In popuiations with adequate nutrition, bone mass accretion occurs during childhood and 
adolescence with rapid linear and appositional bone growth. By age 17 or 18 years the 
vast majority of peak bone mass has been achieved, although small increments may 
occu r during the third decade of life (Compston, 1997). In other populations, such as 
those with delayed puberty (Naicker et al, 2010) this may occur over a longer duration. 
The onset of age-related bone loss is not precisely defined; a number of studies have 
discovered bone loss in premenopausal women and in men in the fifth decade 
(Compston, 2000). Women have an accelerated rate of bone loss following the 
menopause but the duration of this accelerated phase is not fully understood (Compston, 
2000). In postmenopausal women, and men of 50 years and older, age-related bone loss 
conti nues for the remainder of their lives. 
Raisz et al (2008) describe three "critical factors" that can lead to the development of 
osteoporosis: 
1. A failure to achieve a satisfactory peak bone mass and strength. This is largely 
genetically determined but substantially affected by lifestyle; 
2. Accelerated bone loss due to resorption. This is less dependent on genetic factors, 
with deficiencies in oestrogen, and calcium and/or vitamin D playing important 
roles; 
3. An impairment of bone formation during remodelling. Soon after peak bone mass 
has been achieved there seems to be an inadequate capacity to form new bone to 
maintain skeletal mass during remodelling. The mechanism(s) underpinning this 
are not clear but are likely to include changes in local and systemic growth factor 
production and an accelerated absorption and impaired formation, driven by 
cytokine release. 
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2.2.3.1 Menopausal bone loss 
The adult female skeleton reaches peak bone mass by age 30 years and data on 
premenopausal bone loss are inconsistent. Age-related bone loss probably starts during 
the fourth decade of life and continues thereafter; it accelerates in women during the 
years around the menopause (Compston, 1997). Age of menopause and menopausal 
bone loss may be different in different populations. Changes in bone mass and calcium 
metabolism are evident during this 'perimenopausal transition'. Oestrogen is the most 
important hormone in terms of skeletal integrity although progesterone and ovarian 
testosterone may play a role (Reid, 2008). This may also have ethnically diverse 
patterns (Aspray et al, 2005). 
Peak bone mass attained earlier in life is a major determinant of subsequent bone mass 
and fracture risk in later life (Compston, 1997). In contrast, Reid states that prior to the 
menopause transition there is virtually no bone loss in most regions of the skeleton and 
fracture rates are stable (Reid, 2008). The menopause "ushers in a period of bone loss 
that extends until the end of life and ... [is]. .. the central contributor to the development 
of osteoporotic fractures in older women" (Reid, 2008). 
The, rate and onset of bone loss varies by skeletal site. The greater metabolic activity 
and large surface area-to-volume ratio of trabecular bone mean that losses exceed those 
of cortical bone. It is estimated that 50% of trabecular and 35% of cortical bone mass is 
lost during the life time of an average woman, this compares with about a two-thirds 
loss of these amounts in men (Compston, 1997). 
The most obvious effect of menopausal bone loss is the increase in fracture incidence (at 
the forearm and vertebrae, the trabecular rich sites of the skeleton), which is already 
demonstrable in the first decade following the menopause (Reid, 2008). 
2.2.3.2 Oestrogen deficiency 
It is the oestrogen deficiency seen at menopause that plays a central role in the 
pathogenesis of postmenopausal bone loss (Compston, 2000; Raisz et al, 2008). It 
appears that oestrogen-induced bone effects are two-fold; by direct effects on bone cells 
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and indirectly via changes in the production of cytokines (e.g., TNFa) and growth factors 
by intramedullary cells (Compston, 2000). However the precise role of specific cytokines 
is unclear; that is, their pathophysiological role may not be definitively and directly 
linked to bone loss (Raisz et al, 2008). 
Studies in osteoporosis have demonstrated an increase in Receptor Activator of NFKB 
Ligand (RANKL) activity (see Sections 2.3; 2.2.4.1). RANKL induces preosteoclasts to 
become mature osteoclasts and therefore results in bone resorption (see Section 2.2.4). 
RANKL concentrations rise in the context of oestrogen deficiency (Raisz et al, 2008) and 
so this may be one of the central mechanisms of oestrogen deficiency-associated bone 
loss. Even in women many years past their menopause, the small amounts of 
endogenous oestrogens still produced have a beneficial effect on aBMD. Hip and 
vertebral fracture rates are significantly higher in those with undetectable blood 
concentrations of oestradiol compared with those with measurable, albeit low, 
concentrations. These findings "challenge the . . . belief that endogenous oestrogen 
production in postmenopausal women does not have physiologically relevant skeletal 
effects" (Compston, 2000). In men it is probable that the skeletal effects of testosterone 
are, in part, mediated by the conversion of testosterone to oestradiol, by aromatase, in 
bone (ibid.) and therefore, in part, accounts for decreased rates of bone loss compared 
to women. 
2.2.3.3 Osteoporosis and obesity 
Obesity is usually associated with decreased fracture risk although this association may 
be changing with observations of lower leg fractures in obese individuals; in contrast 
decreased physical activity, which often accompanies· obesity, increases risk of 
osteoporosis (Compston et al, 2011; Compston, 2013b). However the picture is mixed; 
there may be site specific pattern of fractures associated with obesity and fracture-
associated morbidity may be increased but mortality may be reduced in obese compared 
to non-obese individuals (Compston, 2013a). How this combination of risk factors 
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translates into fracture risk in countries such as South Africa, with its increases in 
obesity and decreases in physical activity, remains to be seen. 
The relatively new area of research of adiposity and bone health may provide clues into 
the possible future epidemiology of fracture risk in obese populations such as those in 
the UK and USA. Raisz et al (2008) frame the research in three ways. 
,-
1. That low 'body weight' is a clear risk factor for osteoporosis and that increased 
body weight has a positive effect on bone mass, though not necessarily on 
fracture (see Compston 2011, 2013). There is uncertainty about the relative roles 
of fat and lean mass in determining aBMD and it seems likely both play a role . A 
mechanism by which increased body mass affects bone is via mechanical loading 
as explained by the Mechanostat model (Ward, 2012) (see Figure 2-7). Also, high 
fat mass could increase oestrogen production via enhanced aromatase activity in 
adipose tissue. 
Figure 2-7 The Mechanostat 
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A summary diagram of the Mechanostat model : the grey boxes indicate non-mechanical factors, including 
nutrition , and where they may interact with the Mechanostat. These interactions may be through alterations 
in the ability of muscle to generate forces (load), the bone ability to detect or respond to changes in load . For 
example, vitamin D causes proximal muscle weakness, which would reduce loading to bone and from this 
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result in changes in bone phenotype and strength. 
(Ward, 2012) [Reproduced with permission] 
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2. 'Adipogenesis' in bone marrow increases with age and seems to be more 
pronounced in those with osteoporosis. Factors that promote adipogenesis may 
inhibi t osteoblast formation, so decreasing bone formation (Webb, 2008). 
3. 'Hormonal and neural factors' appear to play a role in determining bone mass. 
Sympathetic nerve fibres innervate bone and a number of neuropeptides act on 
bone, typically by increasing resorption. The observation that leptin deficient mice 
had high bone mass despite hypogonadism and that the leptin appeared to be 
acting centrally led to the postulation that the brain is involved in bone mass 
homeostasis (Raisz et al, 2008). 
2.2.4 Bone biology and metabolism 
The skeletal system is essential for normal bodily functioning; bone is one of its principal 
components and a metabolically active organ system responsible for vital functions. 
Bone is a "dynamic mineralised connective tissue with multiple physiological functions" 
(Grabowski, 2009). Three main functions are to provide the body with mechanical 
support, form a reservoir for calcium and phosphate, and to facilitate the production of 
haematopoietic cells by the bone marrow. Bone remodelling is the process by which old 
bone is removed and replaced by new bone as part of a coordinated process of skeletal 
maintenance that allows bone to respond to the body's requirements for calcium, 
phosphate, and acid-base homeostasis. Bones are dependent on other organs for their 
growth and maintenance, especially those of t he gut and the kidneys through which 
minerals, such as calcium, are absorbed, reabsorbed and excreted, and vitamins, such 
as vitamin D, are metabolised . Other body systems such as skin, pituitary, muscle, fat, 
and gonads are important, directly or indirectly, for skeletal integrity (ibid .). 
Macroscopically, bones can be described as either cortical or trabecular. Cortical , or 
cancellous, bone is the major bone type found in t he shafts of long bones and is made of 
dense tissue penetrated by blood vessels and canaliculi t hat surround osteocytes. 
Trabecula r bone is found at the end of long bones, nea r joint surfaces and in t he 
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vertebrae; it consists of a network of thin plates and connecting 'struts' surrounded by 
bone marrow. Cortical and trabecular bone are similar in their cellular properties but 
differ in function and rnechanical properties (Seeman, 2008; Grabowski, 2009; Anderson 
et al, 2012). 
Bone tissue is made of a mineralised matrix (osteoid) produced by osteoblasts, which 
synthesise and mineralise the organic matrix, thereby laying down new bone. The 
collagen fibres of the osteoid matrix are mineralised by hydroxyapatite (Ca1o(P04)5(0Hh) 
to form a rigid structure. In addition to type 1 collagen, proteins such as osteocalcin and 
alkaline phosphatase (ALP) are secreted by osteoblasts into the organising matrix 
(Seeman, 2008; Grabowski, 2009) . When their matrix-producing phase ends some 
" osteoblasts undergo apoptosis while others differentiate into flat bone-lining cells that 
line the bone surface or become enclosed in the bone matrix in lacunae (osteocytes). In 
adults, 80% of trabecular and 95% of intracortical bone surfaces are covered by lining 
cells. The remaining surfaces are populated by osteoblasts and osteoclasts (Aubin et al, 
2002). 
Ostepblasts, osteocytes, and bone-lining cells arise from a multipotent precursor of 
mesenchymal origin (Figure 2-8), which also gives rise to ad ipocytes and fibroblasts. In 
contrast, osteoclasts originate from a shared haemopoetic precursor lineage with 
macrophages. 
Osteoblasts control the differentiation of osteoclast precursors. Osteoclasts are large, 
multinucleated cells found in close proximity to bone surfaces undergoing resorption. 
When apposed to bone, osteoclasts form a region of contact with the bone surface; this 
'sealing zone' creates an area wherein bone resorption takes place via the action of 
secreted acid and proteolytic enzymes (Compston, 1997; Chen et al, 2000; Grabowski, 
2009). Bone is, therefore, dynamic and undergoes constant formation and resorption, 
resulting in continuously modelled and remodelled bone. Bone remodelling depends on 
"the tightly integrated activity of two major cell types, osteoblasts and osteoclasts. 
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Therefore, the balance between the number and activity of osteoclasts and osteoblasts is 
crucia l in determining bone mass, which is directly related to bone fragility and fracture 
risk" (Pan et al, 2006). 
Figure 2-8 Osteoclast and osteoclast pathways 
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Wnt, Wingless-type MMTV integration site family, member 1; DKK-1, Dickkopf-1; TNFa, Tumour necrosis factor 
alpha; OPG, Osteoprotegerin . (Gold ring et al, 2007) [Reproduced with permission] 
Skeletal remodelling can be measured using a number of bone turnover markers (BTM) 
as depicted in Figure 2-9; markers of bone formation include ALP and osteocalcin and 
markers of resorption include collagen type 1 telopeptides (CTx). 
Figure 2-9 Schematic of bone formation and resorption 
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When rates of resorption are greater than formation then the bone matrix is disrupted 
and bone mass decreases and fracture risk increases. It is speculated that HIV infection 
has the effect of 'uncoupling' the normal formation: resorption process (Paccou et al, 
2009). 
Osteocytes are the most abundant cell type in bone. It is estimated that osteocytes 
outnumber osteoblasts in the region of 10: 1. Their function is suggested by the strategic 
position within bone; they are spaced regularly throughout the mineralised matrix rather 
than on the bone surface and interconnect via long cell processes, within the canaliculi, 
giving them a typically stellate appearance (Klein-Nulend et al, 2008). Klein-Nulend 
asked if osteocytes are analogous with nerve cells elsewhere in the body and can sense 
mechanical loading and translate this into biochemical stimuli that regulate bone 
modelling and remodelling (Compston, 1997; Klein-Nu lend et al, 2008). Osteocytes are 
also seen as central to the homeostasis of calcium and phosphate (see Section 2.3.8) 
(Klein-Nulend et al, 2008) and may be one of the target cells for the anti-resorptive 
bisphosphonate drugs (Chapurlat et al, 2000). 
2.2.4.1 Cellular pathophysiology of osteoporosis 
At a molecular and cellular level, two important processes influence bone loss. The most 
important, in terms of quantity, is increased bone turnover that is facilitated by an 
increase in number of activated remodelling units on the bone surface. The result is an 
increase in bone remodelling units undergoing resorption at any given time. The second 
process is the down regulation of bone formation within individual remodelling units, so 
that there is a 'remodelling imbalance' whereby bone is lost because of increased 
resorption, decreased formation, or a combination of the two (Compston, 2000) (see 
Figure 2-10). 
It is these alterations in bone remodelling that determine the changes in cortical and 
trabecular bone architecture in osteoporosis. The deterioration in architecture is what 
decreases bone strength and increases fragility, hence fracture risk. The underlying 
mechanism by which strength is affected in trabecular bone is two-fold; bone loss is 
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associated with either trabecular thinning or penetration. Decreased activation results in 
trabecular thinning and increased activation (i.e., erosion depth or frequency) of the 
remodelling unit predisposes to penetration of the trabeculae (Croucher et al, 1996). 
These two states are intimately _related as increased thinning will increase the likelihood 
of penetration. Trabecular thinning is associated with better maintenance of architecture 
than penetration so bone strength is not so adversely affected by decreased, compared 
to increased, activation of remodelling (Compston, 2000). 
Figure 2-10 Bone remodelling unit 
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(Turner et al, 2001) [Reproduced with permission] 
The main mechanism of post-menopausal bone loss is via increases in bone resorption. 
Th is process can be reversed by oestrogen or other a_ntiresorptive agents such as 
bisphosphonates. These therapies improve bone density by filling in resorption cavities. 
At the level of the bone remodelling unit it is possible that both an increase in the depth 
of erosion and reduced wall width may contribute to bone loss. It is unresolved as to 
whether the pathophysiology of postmenopausal bone loss differs qualitatively from age-
induced bone loss. Even postmenopausal bone loss cannot be viewed homogeneously in 
terms of bone turnover; Compston suggests that it may "represent the lower and higher 
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extremes, respectively, of peak bone mass and/or age-related bone loss in t he normal 
population" (Compston, 2000). 
The net effect of increased osteoclast activity, uncoupled from osteoblast bone formation 
is skeletal fragility (Raisz et al, 2008). The microarchitectural deterioration underpinning 
th is probably reflects an increase in the number of osteoclasts formed and in their 
duration and intensity of action; RANKL can prolong osteoclast lifespan and oestrogen 
can decrease it. The interplay between different cytokines that may stimulate (e.g. 
TNFa, IL6) and inhibit (e.g. IL4) osteoclast function is very complex; they may influence 
each other so that a change in a single cytokine may not equate to its true physiological 
role in vivo (Ra isz et al, 2008). 
1 2.2.S Bone health assessment techniques 
The non-invasive assessment of bone health, strength, and mineralisation in vivo can be 
undertaken using many techniques including radiological imaging (e.g. radiographs, 
pQCT, ultrasound and DXA) to assess for presence of recent bone fractures, and for 
assessment of aBMD and bone age. Sampling of blood and urine can also provide 
important clues into overall bone health, particularly when the analytes measured in 
these body fluids give an indication of bone turnover (such as alkaline phosphatase) or 
concentration of metabolites and hormones essential for bone health and integrity (e.g . 
25(0H)D and PTH). 
DXA assessment is recognised as being clinically the most useful of the available bone 
assessment too ls. It allows for the estimation of bone mass and density , and provides a 
basis on which to predict future fracture risk at clinically relevant sites. However, DXA 
measurement gives only a stat ic v iew. I n contrast, measures in biological samples can 
give a more dynamic assessment of bone health, which when used longit udinally can be 
used to measu re cha nge. Together, DXA-based and laboratory-based tech niques give a 
more complete analysis of current bone status and possibly future bone outcomes 
(Section 2.2.3) than one technique alone. 
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These techniques are indirect measures of bone health . Direct analysis of bone structure 
and activity can be achieved by assessing bone biopsy materia l, for example with 
tetracycl ine labelling. However this is invasive and may not give a representative sample 
of the skeleton as a whole, rather the specific site of biopsy. 
2.2.6 Measures of bone strength and determinants of fracture risk 
In 1994 the WHO proposed four categories to describe aBMD and fracture risk, these are 
expressed in re lation to the young, adult reference range (i.e. aBMD T-score) (see 
section 1.2.1). They comprise of: i) normal, ii) low bone mass or osteopaenia, iii) 
osteoporosis, and iv) severe osteoporosis. These criteria were updated in 2008 and now 
specify t hat the reference site for diagnosis is the femoral neck. The young adult 
reference data are from the USA's NHANES III study based on young women aged 20 -
29 years w ith accompanying reference data for men (Hough, 2010). 
2.2.6.1 Peak bone mass 
Bone strength is predominantly determined by bone mineralisation, which is a feature of 
attained peak bone mass (Figure 2-11), age-related bone loss, and total duration of 
bone loss; aBMD measured by DXA is a marker of bone strength. 
Figure 2-11 Typical bone mass and changes with age 
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Peak bone mass is mediated by several factors including genetics, gender, body size, 
physical activity, and nutrition while involutional loss results largely from oestrogen 
deficiency (2.2.3.2), which increases bone resorption, and ageing, which is associated 
with decreased bone formation. 
Bone strength is also mediated by the structural and functional properties of bone and 
overall bone quality. These can be separated into: 
1. Macroarchitectural properties: bone size and geometry; 
2. Microarchitectural properties: cortical thickness, cortical porosity, trabecular size, 
number and connectivity; 
3. Bone turnover: i.e., dynamic between resorption and formation; 
4. Material properties: collagen composition and cross linkage, mineralisation of 
collagen (primary and secondary) and repair of micro-damage. 
These measures of bone quality are much more difficult to quantify than aBMD (Hough, 
2010). A full discussion about risk factors for osteoporosis is beyond the scope of this 
thesis; a detailed examination is available (Abrahamsen, 2010). In brief, risk factors 
include lifestyle, genetic, nutritional, disease specific (e.g. of the endocrine system), 
age.!related, toxic, qualitative factors (e.g. abnormal bone turnover) and a host of 
miscellaneous factors (Hough, 2010) (see Section 1.2.1). 
2.2.7 Assessment of bone health by DXA 
2.2.7.1 What is DXA? 
DXA imaging is a non-invasive x-ray technique and is an "extremely accurate and precise 
method for quantifying ... BMD" (International Atomic Energy Agency, 2010). It allows 
differentiation of materials of different atomic mass (fat, lean and bone tissue) when 
they are in proximity to another material. This is possible because each material will 
have a unique X-ray attenuation at different energies (International Atomic Energy 
Agency, 2010). As X-rays pass from the source through the body, the physical properties 
of different tissues prevent the X-rays exiting the body to be detected by the X-ray 
detector (Figure 2-12). This process of attenuation is caused by the result of scatter, 
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that is, the deflection of X-rays away from the detector and absorption of X-rays into the 
body's molecules via ionisation (the transfer of electrons) (Webb, 2008). Denser tissues 
such as bone attenuate X-rays more than less dense tissue; heavier calcium and 
phosphorus atoms present in hydroxyapatite attenuate X-rays to a much greater degree 
tha n soft tissue. In 'soft tissue', protein-based lean tissue is denser than fat so 
attenuates X-rays to a greater degree (ibid.). This gradient of attenuation produces DXA 
images that are made from attenuation of low and high average X-ray energy. The X-ray 
densities used in DXA machines are optimised for bone density assessment. 
DXA is accurate and precise in quantifying aBMD and body composition (International 
Atom ic Energy Agency, 2010). DXA software has to quantify the amount of attenuation 
due to bone by correcting for the amount attenuated by lean and fat mass. It achieves 
this by projecting X-rays at two different intensities through the body. Different radiation 
energies produce a distinct pattern of attenuation depending on the composition of 
tissue through which it passes. To provide an estimation of attenuation the DXA software 
makes assumptions about the ratio of fat and lean mass overlying and next to the 
skeletal region of interest (Webb, 2008; International Atomic Energy Agency, 2010). The 
assumptions are made using soft tissue area that is adjacent to the area of interest so 
assumptions can be generated on the basis of bone and non-bone. In some regions, e.g . 
the trunk, it is not possible for the software to discriminate between muscle and 
abdominal organs. The combination of assumptions about fat and lean ratios with that 
produced by the attenuation of the two X-ray energies allows the software to produce 
attenuation values for fat, lean and bone. Any change in these proportions, e.g. as a 
result of a disease state, may result in inaccuracies in the quantification of bone. 
Attenuation constants for each tissue type are applied to give mass values present in 
each pixel (i.e., unit area). Bone mineral for a region, e.g., lumbar spine, is the sum of 
the values for each pixel in the region scanned (Webb, 2008; International Atomic 
Energy Agency, 2010). 
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DXA creates a 2-dimensional image that combines low and high density attenuations. 
However, it is limited by the fact that it quantifies areal rather than volumetric bone size 
and density. As a result, bone size is also important when interpreting DXA generated 
assessments of density, and size needs to be considered when interpreting measurement 
of mineral, especially when comparing individuals or populations of different size. 
Methods are available to try and minimise error caused by 2-dimensional measures of 
bone (Prentice et al, 1994). In addition, volumetric density can be measured using other 
imaging techniques, e.g. peripheral Quantitative Computed Tomography (pQCT). 
The measure of radiation exposure is the 'effective dose' in Sieverts (Sv). This is 
generally used in preference to measures of absorbed dose in Grays (Gy) per kilo of 
{ issue. This is because the effective dose controls for the susceptibility of different 
tissues to radiation damage and the type of radiation used. Effective dose is used in 
assessing occupational and public exposure to radiation. It is also useful in characterising 
the dose typically received by a patient from a given X-ray procedure (International 
Atomic Energy Agency, 2010) (Table 2-2). The radiation dose from DXA is low when 
compared with other general X-ray techniques, such as chest radiography, or bone-
specific imaging techniques such as those required for the Singh index (see Section 
2.2. 7 .2). It is rare for the radiation dose from a set of DXA scans for an individual to 
exceed 5µSV (0 .005 mSv); this compares with a UK background daily dose radiation of 
7µSv. 
Table 2-2 Typical effective radiation dose from diagnostic X-ray - single 
exposure (in mSv) 
Examination; effective dose (mSv) 
Chest radiograph 0.04 
Pelvis radiograph 0. 7 
Lumbar Spine radiograph 0. 7 
Mammogram (four views) 0.7 
Dental radiograph (panoramic) 0.09 
Hip radiograph 0.8 
Abdomen radiograph 1.2 
Barium Enema ( 10 images, 137 sec. fl uoroscopy) 7.0 
CT Pelvis 10.0 
Coronary Ang iogram 4.6-15.8 
Adapted from 'Radiation exposure from medical diagnostic imaging procedures' (American College of 
Radiology, 2012) 
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There are three types of DXA system; pencil, narrow fan beam, and fan beam. Fan beam 
DXA scans require brief scanning time. For example, the time taken for a whole body 
scan is in t he region of 6 minutes . The measurement 'precision' (%CV, that is the 
reproducibility of the scan) of DXA is also high with intra-machine CVs less than 3% 
(Mazess et al, 1990; Mazess et al, 1995) and accuracy (% difference from 'true' 
measurement) in the region of 3 - 8% (Blake et al, 1999). 
Figure 2-12 Schematic diagram showing the components of a DXA system 
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(International Atomic Energy Agency, 2010) [Reproduced with permission] 
The three bone values evaluated by DXA are: 
Bone Mineral Content (BMC): the mineral component of bone i.e., hydroxyapatite, 
Ca1a(P04)G(OH)i. It is expressed in grams (g) and does not include mass of the other 
organic components of bone such as marrow and collagen. 
Bone Area ( BA) : the projected area of bone onto the image plane, it is expressed in 
cm2 • 
Areal BMD ( aBMD): the mineral mass of bone per unit image area in g/cm2 ; 
aBMD==BMC/BA (g/cm2) (I nternational Atomic Energy Agency, 2010). 
DXA also measures and calculates lean mass (kg) and fat mass (kg) and percentage 
body fa t. 
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DXA is widely used in both clinical and research settings and normative values have been 
collated to ascertain an individual's aBMD, which can be used to diagnose low bone mass 
and evaluate the success of treatment of, e.g., antiresorptive therapy. For osteoporosis 
diagnoses, the lumbar spine, proximal hip, and sometimes the distal forearm sites are 
used when measurements at other sites are not appropriate (e.g. bilateral hip 
replacement). The whole body site is used to determine whole body bone mass and body 
composition i.e., fat and lean tissue. 
The clinical and research utility of DXA in the diagnosis of low aBMD has several caveats; 
its role in diagnosising osteoporosis in children, men, and pre-menopausal women has 
not been clearly defined (Brown et al, 2006a) and normative data for developing world 
populations, and different ethnic groups in the developed world, are lacking. T-scores 
(1.2.1) therefore have limitations and need to take into account size, race, and gender 
(Prentice, 2004). Despite these limitations, DXA definitions of osteoporosis and fragility 
fracture risk have generally been accepted in all adult populations. 
2.2.7.2 Advantages of DXA 
DXA is non-invasive, uses low dose radiation and is relatively quick to perform because 
of high photon flux from the X-ray tube. It is designed to measure important sites 
I 
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vulnerable to osteoporosis (hip and spine). It has been used to predict fracture such 
that, in postmenopausal women, the odds ratio for risk of hip fracture is 2.6 for every SD 
decrease in aBMD (Marshall et al, 1996). Therefore, DXA has utility as a diagnostic tool 
in identifying individuals at high risk of bone fracture. Whilst its precise role in fracture 
prediction has been disputed (Nielsen, 2000) it remains the 'gold standard' tool for 
assessing aBMD and fracture risk as defined by the World Health Organisation (WHO, 
2003). The use of DXA to define osteoporosis in terms of T-scores <-2.5 is simple to 
interpret and prompts a set of clinical decisions to initiate investigation and treatment of 
low bone mass (Compston et al, 2009; Kanis et al, 2011). 
DXA has clear advantages over other methods of assessing bone density. Other methods 
such as plain radiographs of the hip have been used in the assessment of bone; the 
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Singh index assesses trabecular patterns as an index for osteoporosis. However, these 
requi re X-rays of high resolution and therefore high radiation doses. Further, it is 
estimated that there needs to be a 30% change in trabecular pattern before a general 
diagnosis of osteopenia can be identified by visual inspection of radiographs. 
2.2.7.3 Disadvantages of DXA 
DXA-associated radiation exposure is low; none-the-less it is additive to background 
radiation dose. Its use, and the pros and cons of scanning, have to be considered and 
only performed where justifiable in accordance with Ionising Radiation (Medical 
Exposure) Regulations (IRMER) guidance (Department of Health, 2000). 
Whilst DXA aBMD results have been adopted to influence diagnostic and treatment 
decisions regarding osteoporosis, they do not fully account for differences in bone 
strength. It is estimated that differences in aBMD account for 70% of variations in bone 
strength and consequent fracture risk. Other factors, notably bone size and geometry, 
and the relative contributions of cortical and trabecular compartments play an important 
role (Laskey et al, 2010; Kanis et al, 2012; Li et al, 2013). 
2.2.7.4 WHO classification of low aBMD 
While the WHO classification (2.2.3) provides a practical basis to identify those at 
increased fracture risk it is limited by the following factors: 
1. A single aBMD assessment is specific (±85%) for predicting fracture but has poor 
sensitivity. As a result, less than half of those with a known osteoporotic fracture 
will have a aBMD T-score value of -2.5 or less (Wainwright et al, 2005); 
2. WHO criteria are based on DXA data of the axial skeleton (i.e. spine and hip) 
from healthy postmenopausal women. Therefore extrapolation of these criteria to 
different populations, using different scanning techniques (e.g. QCT) of non-axial 
and/or axial sites is not correct; 
3. The aBMD-based WHO diagnostic guidelines do not include non-skeletal risk 
factors (e.g. fall risk) or qualitative risks (e.g. bone turnover) which affect bone 
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strength. A low aBMD may result from metabolic bone disease other than 
osteoporosis, e.g. osteomalacia; 
4. The four discrete diagnostic categories developed by the WHO should not be used 
to determine intervention (e.g. antiresorptive agents) in all cases (Hough, 2010) 
without reference to further guidelines (Compston et al, 2009). 
There are also technical limitations to using DXA to provide information on bone area 
and density as measures of bone strength, and therefore using DXA to extrapolate 
information on bone strength and fracture risk may not be clear cut. There are several 
reasons for this including: 
1. The bone volume is not known: DXA is a projectional technique and measures 
density in g/cm2 as it is not able to measure tissue thickness. For this reason DXA 
cannot discriminate between small, high density bone and large, low density 
bone; 
2. Fan beam magnification: Fan beams magnify BA via a factor proportional to the 
height of the scan table. Therefore, bone size can vary according to the body 
diameter (or body 'thickness'). Generally, there is a reciprocal demagnification in 
bone mass algorithms such that aBMD remains stable; 
3. Two compartments: As mentioned above, DXA can only resolve 2 material 
densities simultaneously. Therefore soft tissue can only be resolved into fat and 
lean tissue in areas exclusive of bone whereas bone mass can only be determined 
by making assumptions about the proportion of fat to lean in the overlying soft 
tissues. Bone is contained in approximately 40% of the image pixels so soft tissue 
composition has to be estimated from that of neighbouring tissues. Where there 
is inadequate soft tissue outside of the bone projection (e.g., the head), 
manufacturers use proprietary methods to take account of soft tissue; 
4. Standardisation: aBMD values generated by instruments from different 
manufacturers cannot generally be directly compared and are not interchangeable 
without cross calibration. There are several reasons for this including: 
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a. Known differences in relative accuracy in aBMD; e.g., between Hologic and 
Lunar systems there are 8% and 20% differences in aBMD and BMC 
respectively because of differences between pencil versus narrow fan 
beam versus fan beam technologies, and different software assumptions. 
b. Lack of standardisation on placement of regions of interest (RO!). 
As a result, T-scores generated using different imaging modalities cannot be used 
interchangeably (Binkley et al, 2005; Kiebzak et al, 2007). Furthermore, the long 
term precision of individual devices should be considered. 
5. Degenerative change: Degenerative change, vascular calcification, and fractured 
vertebrae may be difficult to visualise and cause significant, false, higher aBMD 
results. Disc degeneration and fracture reduce BA, increasing aBMD whilst 
calcification (especially in the aorta) projects more mineral into the pixels. These 
conditions increase with advancing age (International Atomic Energy Agency, 
2010); 
6. Inappropriate normative standards: Data outputted by different DXA systems 
may not be appropriate for the population studied. For example, using African-
American data to generate DXA T- or Z-scores (Tothill, 1995) or Caucasian data 
using other imaging techniques (Laskey et al, 2010) for black Africans may be 
misleading and result in high rates of low aBMD. Reference methods such as the 
use of phantoms and analysis of porcine material post-scanning can provide some 
information but are not definitive for human comparisons (Tothill et al, 1994; 
Toth ill et al, 1998); 
7. Longitudinal study: Inter- and intra-individual results may be compromised even 
when using a single machine. This is pertinent to situations where weight loss or 
gain may be a feature because of assumptions made about distribution of non-
bone material, especially fat (Yu et al, 2011). Animal fat (lard) to simulate weight 
gain was used in a study looking at the effects of gains in adipose tissue. The lard 
was placed over the subject's abdomen and the software was able to accurately 
measure the fat mass but also recorded an increase in BMC (Svendsen et al, 
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1993). Other factors such as menopause status (Movsesyan et al, 2003) and ART 
exposure may also influence fat mass; 
8. Measurement error in DXA is equivalent to the average rate of bone loss per 
annum in peri menopausal women at a 1 - 3%. It is impossible therefore to 
discriminate if this magnitude of loss, should it occur, is due to 'real' bone loss or 
measurement error (Gluer, 1999; Shepherd et al, 2011); 
9. Volumetric measurement: DXA calculates aBMD i.e., the mass of mineral per 
projected pixel. This does not equate to true density ( =mass/volume), which is in 
fact volumetric (v) density. Given that it is impossible to measure a mass per 
volume using a projectional technique, aBMD is used as a proxy for vBMD. As 
larger individuals have larger bones, so they have higher BMC than smaller 
individuals (if aBMD is the same). This depth of bone is the dimension that is not 
corrected for by dividing BMC by BA to generate aBMD, and is why full correction 
for BA is essential for studies comparing individuals of different size. 
2.2.7.5 Adjusting DXA BMC and aBMD for size effects 
Generally, data from absorptiometry are expressed in terms of areal measurements such 
as aBMD; these are derived by dividing BA by BMC in order to correct for size. This size 
correction assumes a linear and proportional relationship between BA and BMC when in 
fact this is not usually the case as the relationship depends on multiple factors including 
population being assessed and body size. Using a predefined index (BMD) may fail to 
fully correct BMC for skeletal size and lead to spurious associations of BMC with other 
size-related variables such as calcium intakes. In order to overcome some of these 
limitations, size adjusted-BMC (SA-BMC) has been calculated. This adjustment uses 
regression models to adjust BMC for BA, weight and height (Prentice et al, 1994 ). Such 
an approach does not detract from the importance of aBMD as a predictor of fracture risk 
but rather adds a further dimension for assessing differences in BMC between individuals 
by controlling for the effects of bone and body size on bone mineral status. 
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2.2.s Osteoporosis assessment in non-Caucasian populations 
one limitation of DXA is the difficulty of comparing low aBMD and fracture risk across 
populations. The majority of reference data are generated in developed countries and 
extrapolated to developing populations. Prentice has examined aBMD and subsequent 
fracture risk in different populations and demonstrated that aBMD is strongly influenced 
by body size (Prentice, 2004). Therefore, populations with traditionally shorter stature, 
who may be smaller and lighter, such as some African populations, "have lower bone 
mineral status than Western populations but do not have higher rates of osteoporotic 
fracture" (Prentice, 2004); this observation still is not fully understood. Nelson and 
colleagues have suggested a nuanced appraisal of various nutritional, anthropometric, 
geographi cal, dietary, and behavioural factors when comparing data and fracture rates 
across populations (Nelson et al, 2008). Whilst there is a paucity of data on osteoporosis 
in Sub-Saharan Africa, it is estimated that an increasing fracture risk is likely to be 
particu larly prominent in the developing world with its adoption of a more westernised 
lifestyle (Harvey et al, 2010). This is likely to be important in a country such as South 
Africa, undergoing rapid nutrition transition with high rates of overweight and obesity 
(Mayosi et al, 2009; Hall et al, 2011) and decreasing levels of physical activity partly 
because of urbanisation. 
Some African populations have been noted to have fewer fragility fractures compared to 
their Western counterparts than might be expected from aBMD measurements (Aspray 
et al, 1996; Zebaze · ~t al, 2003). This may be due to differences in muscle strength, 
bone geometry and decreased propensity to falling in the elderly rather than simply a 
reflection of aBMD differences per se. 
It is notable that bone data (and other risk factors for non-communicable disease), may 
also be significantly different between ethnic groups within a single country (Chantler et 
al, 2012) and therefore potentially problematic when compared across regions, e.g. 
diasporic Europeans or Africans, and Europeans or Africans residing in Africa (Rush et al, 
2007). 
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2.3 Vitamin D 
2.3.1 What is vitamin D? 
Vitamin D is a group of fat-soluble secosteroids primarily responsible for intestinal 
absorption of calcium and phosphate. In humans, the most important related compounds 
of vitamin D are vitamin D2 (ergocalciferol) and vitamin D3 (cholecalciferol) (Figure 
2-13) and both can be ingested from the diet and/or supplements. The body can also 
synthesize vitamin D3 (from cholesterol) when UVB sun exposure is adequate. 
Therefore, although vitamin D is commonly called a vitamin, it is not an essential dietary 
vitamin in the strict sense, as it can be synthesized in adequate amounts by most 
mammals, including humans, exposed to sunlight. 
Figure 2-13 Molecular structures of vitamin D2 and D3 
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Source: http://www.cyberlipid.org/vitd/vitdOOOl.htm 
Vitamin D plays a central role in calcium homeostasis and skeletal health throughout the 
life course. As described in 1.2.3, it is a hormone that is essential for skeletal health; 
rickets and osteomalacia being the classical diseases of deficiency (Holick, 2008; 
Pettifor, 2008). There is some evidence that vitamin D is important in the 
pathophysiology of osteoporosis and non-skeletal disease and of potential adverse health 
outcomes at greater concentrations of 25(0H)D than seen in rickets and osteomalacia 
(Holick, 2007; Martineau et al, 2011; Coussens et al, 2012). The Institute of Medicine 
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(IOM 2010) reported that there is good evidence supporting the role of vitamin D (and 
calcium) in bone health, but evidence is lacking, especially from RCTs, in terms of non-
skeletal health. The 2010 report stated that there is sufficient evidence to support the 
conclusion that an average blood level of 25(0H)D of above 20 ng/ml (i.e., SOnmol/1, 
(see section 1.3.4)) is needed for good bone health for practically all individuals (Ross, 
2010) but there was not sufficient evidence to set blood levels with respect to non-
skeletal disease. 
Some authors challenge the IOM position on vitamin D status and predisposition to non-
skeletal disease, as described above. There is controversy over definitions of vitamin D 
deficiency and insufficiency, the serum concentrations of 25(0H)D that equate to these 
terms and how this marker of status relates to disease outcome or risk (Heaney et al, 
2011 ; Holick, 2011). It may be that higher thresholds need to be set in certain situations 
and relating to specific disease entities to define risk of these associated with these 
conditions. 
2.3.2 Vitamin D epidemiology 
The prevalence of clinical vitamin D deficiency is high in many parts of the world, 
including temperate and tropical countries, and all ethnic groups may be affected 
(Prentice, 2008). It is sometimes assumed that those living in tropical or subtropical 
countries will not have poor vitamin D status because of year-round UVB radiation but 
behaviours, habits, and other medical conditions can affect that ability to synthesise 
vitamin D in the skin. There has been a resurgence of vitamin D deficiency in Northern 
Eu ropea n countries, particularly in ethnic minority groups (Prentice, 2008). Risk factors 
for poor vitamin D status include prolonged exclusive breastfeeding, dark skin 
pigmentation, lack of direct sun exposure, residing in a northern latitude, and winter 
season (Huh et al, 2008). Poor vitamin D status can affect people at every stage of the 
li fe course, from foetal life through to old age (see Section 1.2.3.1). 
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2.3.3 Vitamin D production 
It is estimated that in Western Europeans in the region of 90% of vitamin D is obtained 
from dermal synthesis, although this may be different in different populations (Prentice 
et al, 2008). In tropical climates, with year round exposure to appropriate UVB 
wavelengths, vitamin D deficiency is uncommon providing that the skin is exposed to 
sufficient sunlight. This is in contrast with temperate regions, such as the UK, where 
there are seasonal variations in dermal vitamin D synthesis. Dietary sources of vitamin D 
are largely limited to oily fish and fish oils, egg yolks and animal organs. Dietary 
supplements and fortified foodstuffs are important sources in some populations. 
Solar UVB radiation of wavelength 290 to 315 nm (Olds et al, 2008) with an optimum 
wavelength thought to be 295-300 nm (Maclaughlin et al, 1982), penetrates the skin 
and converts 7-dehydrocholesterol to previtamin D3, in the epidermis (specifically in the 
stratum basale and stratum spinosum). Previtamin D spontaneously isomerises to 
cholecalciferol and diffuses out of the cells of the epidermis into the circulation. Vitamin 
D intoxication is avoided because any excess previtamin D3 or vitamin D3 is degraded 
by the action of sunlight. Therefore exposure to sunlight is a closed system preventing 
excess production of vitamin D. Since few foods naturally contain vitamin D (see above), 
synthetic vitamin D is manufactured commercially through ultraviolet irradiation of either 
7-dehydrocholesterol in lanolin (D3) or ergosterol in yeast (D2) for use in supplements 
and fortified foods. 
2.3.4 Vitamin D metabolism 
The parent vitamin D compound is generally present in very low concentrations in blood 
and along with vitamin D from the diet, is transported to the liver by vitamin D binding 
protein (DBP). In hepatocytes, vitamin D is metabolised to 25(0H)D, facilitated by 
cytochrome P450 (CYP) pathways (CYP 2RI and 27AI) (Figure 2-14 ). 25(0H)D is 
secreted from hepatic cells into the circulation bound mainly to DBP. It is 25(0H)D that 
is used to assess a person 's vi ta min D st atus because it is a stable met aboli te, present in 
nanomolar concentrations with a long half-li fe (t!-2) of several weeks, which is relatively 
easi ly measured in blood. 25(0H) D acts as a reservoir and may undergo a furt her 
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hydroxylation step in the proximal renal tubule to its active form: 1,25-dihydroxyvitamin 
D (1,25(0H)zD), by the enzyme 25-hydroxyvitamin D-1-a-hydroxylase (CYP27B1), or to 
the catabolic form 24,25-dihydroxyvitamin D (24,25(0H)zD). The renal production of the 
active com pound is under very tight control by PTH, and calcium and phosphate 
concentrat ions as outlined in Section 2.3.8. 1,25(0H)zD also induces its own degradation 
by stimulating expression of 25-hydroxyvitamin D-24-a-hydroxylase (CYP24), which 
catabolises 25(0H)D and 1,25(0H)zD into inactive calcitroic acid (Holick, 2007). 
24,25(0H)zD also circulates bound to DBP and its production is an early step in the 
degradation of 25(0H)D thereby preventing intoxication. The fact that it can be found in 
signi ficant amounts even in those with vitamin D deficiency suggests that it may have a 
distinct physiological role yet to be fully understood (Prentice et al, 2008). 
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It is estimated that in Western Europeans in the region of 90% of vitamin D is obtained 
from dermal synthesis, although this may be different in different populations (Prentice 
et al, 2008). In tropical climates, with year round exposure to appropriate UVB 
wavelengths, vitamin D deficiency is uncommon providing that the skin is exposed to 
sufficient sunlight. This is in contrast with temperate regions, such as the UK, where 
there are seasonal variations in dermal vitamin D synthesis. Dietary sources of vitamin D 
are largely limited to oily fish and fish oils, egg yolks and animal organs. Dietary 
supplements and fortified foodstuffs are important sources in some populations. 
Solar UVB radiation of wavelength 290 to 315 nm (Olds et al, 2008) with an optimum 
wavelength thought to be 295-300 nm (Maclaughlin et al, 1982), penetrates the skin 
; and converts 7-dehydrocholesterol to previtamin D3, in the epidermis (specifically in the 
stratum basale and stratum spinosum). Previtamin D spontaneously isomerises to 
cholecalciferol and diffuses out of the cells of the epidermis into the circulation. Vitamin 
D intoxication is avoided because any excess previtamin 03 or vitamin 03 is degraded 
by the action of sunlight. Therefore exposure to sunlight is a closed system preventing 
excess production of vitamin D. Since few foods naturally contain vitamin D (see above), 
.synthetic vitamin D is manufactured commercially through ultraviolet irradiation of either 
7-dehydrocholesterol in lanolin (03) or ergosterol in yeast (02) for use in supplements 
and fortified foods. 
2.3.4 Vitamin D metabolism 
The parent vitamin D compound is generally present in very low concentrations in blood 
and along with vitamin D from the diet, is transported to the liver by vitamin D binding 
protein (DBP). In hepatocytes, vitamin D is metabolised to 25(0H)D, facilitated by 
cytochrome P450 (CYP) pathways (CYP 2RI and 27AI) (Figure 2-14 ). 25(0H)D is 
secreted from hepatic cells into the circulation bound mainly to DBP. It is 25(0H)D that 
is used to assess a person's vitamin D status because it is a stable metabolite, present in 
nanomolar concentrations with a long half-life (tv,) of several weeks, which is relatively 
easily measured in blood. 25(0H)D acts as a reservoir and may undergo a further 
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2412 s(OHhD also circulates bound to DBP and its production is an early step in the 
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Figure 2-14 Vitamin D metabolism 
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During exposure to sunlight, 7-dehydrocholesterol in the skin is converted to previtamin D3. PreD3 immediately converts by 
a heat dependent process to vitamin D3. Excessive exposure to sunlight degrades previtamin D3 and vitamin D3 into inactive 
photoproducts. Vitamin D2 and vitamin D3 from dietary sources is incorporated into chylomicrons, transported by the 
lymphatic system into the venous circulation. Vitamin D (D represents D2 or D3) made in the skin or ingested in the diet can 
be stored in and then released from fat cells. Vitamin D in the circulation is bound to the vitamin D binding protein which 
transports it to the liver where vitamin D is converted by the vitamin D-25-hydroxylase to 25-hydroxyvitamin D [25(0H)D]. 
This is the major circulating form of vitamin D that is used by clinicians to measure vitamin D status. It is biologically inactive 
and must be converted in the kidneys by the 25-hydroxyvitamin D-la-hydroxylase (1-0Hase) to its biologically active form 
1,25-dihydroxyvitamin D [1,25(0HhD]. Serum phosphorus, calcium, fibroblast growth factors (FGF-23) and other factors can 
either increase ( +) or decrease (-) the renal production of 1,25(0H)2D. 1,25(0HhD feedback regulates its own synthesis and 
decreases the synthesis and secretion of parathyroid hormone (PTH) in the parathyroid glands. 1,25(0HhD increases the 
expression of the 25-hydroxyvitamin D-24-hydroxylase (24-0Hase) to catabolize 1,25(0H)2D to the water soluble biologically 
inactive calcitroic acid which is excreted in the bile. 1,25(0HhD enhances intestinal calcium absorption in the small intestine 
by stimulating the expression of the epithelial calcium channel (ECaC) and the calbindin 9K (calcium binding protein; CaBP). 
1,25(0HhD is recognized by its receptor in osteoblasts causing an increase in the expression of receptor activator of NFKB 
ligand (RANKL). Its receptor RANK on the preosteoclast binds RANKL which induces the preosteoclast to become a mature 
osteoclast. The mature osteoclast removes calcium and phosphorus from the bone to maintain blood calcium and phosphorus 
levels. Adequate calcium and phosphorus levels promote the mineralization of the skeleton. 
(Holick, 2010) [Reproduced with permission] (N.B. Milk is fortified with vitamin Din the USA but not in 
the UK or South Africa. In the UK only margarine and spreading fats are statutorily fortified with vitamin D) . 
79 
Renal 1,25(0HhD is secreted into the circulation and binds to DBP and circulates to 
tissues involved in calcium and phosphorus supply (e.g., bone, gut and parathyroid 
glands), where it acts as an endocrine modulator. In contrast to 25(0H)D, 1,25(0HhD is 
present in picomolar concentrations in the circulation and has a very short tv,, of 4 - 6 
hours. 1,25(0HhD produced in extra renal tissues (e.g., macrophages) acts in a local 
autocri ne or paracrine fashion to exert its effect and does not appear in the systemic 
ci rcu lation except in rare circumstances, such as sarcoidosis, in which CYP27B1 in 
act ivated macrophages is capable of generating enough 1,25(0HhD to be measurable in 
the blood (Adams et al, 2012). The function of 1,25(0HhD in these target tissues is to 
prompt genomic responses via interactions with the vitamin D receptor (VDR). The VDR, 
upon binding to 1,25(0HhD, heterodimerizes with other nuclear hormone receptors, in 
pa rti cular the family of retinoid X receptors (RXR). This VDR-RXR complex then binds to 
special DNA sequences called vitamin D response elements (VORE) in the promoters of 
genes which it regulates. This is in contrast to vitamin D or 25(0H)D which do not 
read ily bind to VDRs (Prentice et al, 2008; Dowd et al, 2010). 
PTH concentration is an important marker of vitamin D and calcium metabolism. An 
elevated PTH is a risk factor for osteoporosis in the elderly (Prentice et al, 2008) and 
supplemental vitamin D can lower it (Malabanan et al, 1998). PTH is also found to be 
raised in HIV-positive patients receiving the ARV drug, tenofovir (Masia et al, 2012), 
however it is not clear if this is the result of increased production or decreased excretion. 
It may be that impaired renal function associated with HIV infection disrupts the normal 
PTH axis. The secretion of PTH into the bloodstream is stimulated by a decrease in 
plasma ionised calcium (iCa), and PTH acts to regularise iCa which, in health, is 
maintained w ithin a very narrow range. A decrease in iCa, below this narrow 
physiological range, may be the result of low dietary calcium intake, poor calcium 
absorption or low vitamin D. High dietary phosphorus intakes or high serum phosphate 
concentrations (such as in renal failure) may induce PTH secretion via effects on FGF23 
and 1,25(0HhD (see Section 2.3.8.) 
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The inverse relationship between PTH and 25(0H)D has suggested its use as a proxy for 
vitamin D status. However, the non-specificity of PTH, the lack of consistency between 
studies, and the inter- and intra-individual variability limits its use as a biomarker of 
vitamin D status. Furthermore, since most studies of PTH in this context have been in 
Caucasian populations it is not possible to define adequately its role, if any, as a proxy 
vitamin D status marker in non-Caucasian populations. However, studies from China and 
The Gambia (Yan et al, 2003; Aspray et al, 2005) have demonstrated elevated PTH 
concentrations in populations with low-moderate calcium intakes, and that the inverse 
relationship with aBMD and fracture found in Caucasians is not replicated. Therefore, the 
relationship between PTH, vitamin D status, and calcium intake in different population 
groups needs to be better understood (Prentice et al, 2008). 
.,-
There is a negative relationship between vitamin D status and adiposity, with some 
speculation that vitamin D and its metabolites may be permanently sequestered in 
adipose tissue and therefore unavailable (Wortsman et al, 2000; Sulistyoningrum et al, 
2012). Others regard the negative association to be a volumetric dilution effect rather 
than a manifestation of vitamin D sequestration into adipose tissue per se (Drincic et al, 
201i) .' There is some evidence that vitamin D mobilises following rapid weight loss, such 
as post-bariatric surgery, suggesting the liberation of vitamin D from adipose tissue (Lin 
et al, 2011). There is a debate about whether this mobilisation of vitamin D has potential 
effects on individuals who experience rapid changes in adiposity. 
VDR are present in many different cell types including those of the breast, muscle, and 
immune cells such as macrophages. Because of the widespread distribution of VDR, 
1,25(0HhD acts, or has the potential to act, on a wide range of target tissues and 
organs. Therefore, vitamin D supply has the potential to affect the body systems other 
than musculoskeletal (Figure 2-15) and has been increasingly recognised for potential 
effects on non-skeletal health. 
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There are questions about the optimal ways of ensuring appropriate vitamin D status in 
populat ions. Sunlight has both UVA and UVB components (UVC is mostly filtered out by 
the Earth's ozone layer); only the UVB wavelengths can generate the reactions for 
endogenous vitamin D synthesis (Section 2.3.1). However, both act as drivers of dermal 
carcinogenesis via inducing DNA-damage (Sage et al, 2012) and there are concerns 
about advocating sunshine exposure as a means to ensure population vitamin D 
adequacy. It has been argued that the global burden of disease caused by excess 
ultraviolet exposure, most notably skin cancer, is far outweighed by diseases associated 
with poor vitamin D status (via low UV exposure) (Lucas et al, 2008). In terms of 
estimated disability-adjusted life years (DALY) this equates to a loss of 1.6 million with 
respect to over-exposure to UV compared to 3.3 billion with under-exposure (Lucas et al, 
2008). 
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Figure 2-15 Non-skeletal functions of vitamin D 
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When a monocyte/macrophage is stimulated through its toll-like receptor 2/1 (TLR2/1) by an infective agent such 
Mycobacterium tuberculosis (TB), or its lipopolysaccharide (LPS) the signal upregulates the expression of vitamin D rece 
(VDR) and the 2'5-hydroxyvitamin D-1-hydroxylase (1-0Hase). 2S(OH)D levels> 30 ng/ml provides adequate substrate forth! 
OHase to convert it to 1,25(0H)2D. 1,25(0H)2D returns to the nucleus where it increases the expression of cathelicidin ( 
which is a peptide capable of promoting innate immunity and inducing the destruction of infective agents such as TB. It is 
likely that the 1,25(0H)2D produced in the monocytes/macrophage is released to act locally on activated T (AT) and activate: 
(AB) lymphocytes which regulate cytokine and immunoglobulin synthesis respectively. When 25(0H)D levels are ::::30 ng/lll 
reduces risk of many common cancers. It is believed that the local production of 1,25(0H)2D in the breast, colon, prostate, 
other cells regulates a variety of genes that control proliferation including p21 and p27 as well as genes that inhibit angioge 
and induced apoptosis. Once 1,25(0H)2D completes the task of maintaining normal cellular proliferation and differentiatiOI 
induces the 25-hydroxyvitamin D-24-hydroxylase (24-0Hase). The 24-0Hase enhances the metabolism of 1,25(0H)2D 
calcitroic acid which is biologically inert. Thus, the local production of 1,25(0H)2D does not enter the circulation and has 
influence on calcium metabolism. The parathyroid glands have 1-0Hase activity and the local production of 1,2S(OH)2D inh 
the expression and synthesis of PTH. The production of 1,25(0H)2D in the kidney enters the circulation and is able to d 
regulate renin production in the kidney and to stimulate insulin secretion in the (3-islet cells of the pancreas 
(Holick, 2010) [Reproduced with permission] (N.B. there are many other putative effects of vitamin D such 
as in multiple sclerosis). 
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2.3.5 Vitamin D, the bone and muscle unit 
As described above, vitamin D is essential for good bone health. An adequate supply and 
the body's ability to appropriately utilise available vitamin D is key to preventing rickets 
in children and osteomalacia in children and adults. Vitamin D is also essential for the 
prevention of osteoporosis in older adults, and also plays a key role in muscle function, 
potentially decreasing the rates of falls and fragility fractures. Skeletal muscle integrity is 
required to facilitate posture and ambulation, a disruption in this integrity can increase 
the risk of falling. Skeletal muscle possesses VDR and may require vitamin D for 
maximum function via myocyte calcium handling and muscle cell proliferation (Ceglia et 
al, 2013). A metanalysis of 5 trials comprising 1237 older subjects showed that 
increased vitamin D intake reduced falls by 22% when compared with calcium alone or 
placebo (Bischoff-Ferrari et al, 2006; Holick, 2007). In contrast, a 2012 Cochrane review 
found that in older people living in the community vitamin D supplementation did not 
reduce the "rate of falls (RR 1.00, 95% Cl 0.90 to 1.11; seven trials; 9324 participants) 
or risk of falling (RR 0.96, 95% Cl 0.89 to 1.03; 13 trials; 26,747 participants), but may 
do so in people with lower vitamin D levels before treatment" (Gillespie et al, 2012). The 
authors state that lower blood 25(0H)D concentrations, rather than lower intakes, prior 
to vitamin D supplementation was most likely to increase falls rate and risk. 
2.3.6 Vitamin D and fracture 
Indirectly, aBMD is a strong predictor of fragility fracture risk in older people from 
countries at high risk, and possibly in adolescents although this is not proven. Several 
RCTs have demonstrated the beneficial effects of vitamin D supplementation on aBMD; 
therefore it might be assumed that good vitamin D status will decrease fracture risk via 
effects on aBMD and possibly on suppression of PTH (Bischoff-Ferrari et al, 2006), and 
muscle function. However the evidence is mixed. 
Data from the UK Randomised Evaluation of Calcium OR vitamin D (RECORD) study did 
not demonstrate an anti-fracture effect (with supplements of 800 IU/day of 
cholecalciferol) (Grant et al, 2005). Similarly, a study by Porthouse et al did not report a 
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decrease in fracture risk with 800 IU/d of vitamin D plus 1000 mg calcium/d in women at 
high risk (Porthouse et al, 2005). 
In addition, the DIPART (Vitamin D Individual Patient Analysis of Randomized Trials) 
Group in a pooled analysis of 68,500 individuals demonstrated that "10-20 mcg (of 
vitamin D) is not effective in preventing fractures. By contrast, calcium and vitamin D 
given together reduce hip fractures and total fractures, and probably vertebral fractures, 
irrespective of age, sex, or previous fractures" (Abrahamsen, 2010; DIPART Group, 
2010). Other studies support the role of supplemental vitamin D with calcium but not 
vitamin D alone in reducing fracture risk (Ott, 2012a). Therefore the role of vitamin D 
supplementation in the prevention of fracture is controversial, although it is plausible 
that good vitamin D status has a beneficial effect on aBMD and therefore an indirect 
1· 
effect on reducing fracture risk. 
Bischoff-Ferrari et al have attempted to determine the 'antifracture efficacy' of oral 
vitamin D supplementation (Bischoff-Ferrari et al, 2006). In a meta-analysis of 5 RCTs 
looking at hip fracture rates (n=9294) and 7 RCTs of non-vertebral fracture, vitamin D 
intakes of 700-800 IU/day (17.5-20 mg/day) decreased the relative risk (RR) of hip 
fract~re by 26% and non-vertebral fracture by 23% when compared with calcium or 
placebo. On the basis of these findings the authors suggested that "optimal fracture 
prevention occurred in trials with mean achieved 25(0H)D ~100 nmol/1" by high dose 
supplementation i.e., 700-800 IU/d (Bischoff-Ferrari et al, 2006) which is at variance 
with the IOM's recommendation (see Section 2.3.1). Figure 2-16 illustrates the relative 
risk (RR) of hip and non-vertebral fracture at different serum concentrations of 25(0H)D. 
The top graph is the RR for hip and the bottom for non-vertebral fracture. These show 
that the Women's Health Initiative (WHI) and RECORD studies had RR values with Cis 
that crossed one, and that those studies with an RR demonstrating a protective effect 
were supplementing with 700-800 IU/day, which equates to serum 25(0H)D 
concentrations of approximately 70- 110 nmol/1. 
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Figure 2-16 Relative risks of hip and non-vertebral fracture 
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(Bischoff-Ferrari et al, 2006) [Reproduced with permission] 
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In a 2012 pooled analysis of 11 RCTs including 31,022 persons (mean age, 76 years; 
91 % women) with 1111 incident hip fractures and 3770 non-vertebral fractu res, 
Bischoff-Ferrari et al described a non-significant, 10% decrease in hip and 7% decrease 
in the risk of non-vertebral fracture in those randomised to receive vitamin D ( +/-
calcium) . When actual intake of v itamin D was analysed, reduct ion in fracture risk was 
seen in those with the highest intakes of vitamin D (median 800 IU daily). This was 
associated with a 30% reduction in the risk of hip fracture and a 14% reduction in the 
risk of any non-vertebral fracture. The authors concluded that, "high-dose vitamin D 
supplementation (~800 IU daily) was somewhat favourable in the prevention of hip 
fracture and any nonvertebral fracture in persons 65 years of age or older" (Bischoff-
Ferrari et al, 2012). Methodological flaws in this analysis have been suggested, including 
the 
1 fact that sunlight exposure, hence endogenous vitamin D synthesis, was not 
determined thereby weakening assertions made about the utility of vitamin D 
supplementation for reducing fracture risk (Ott, 2012b). 
There are currently no specific data regarding vitamin D status and fracture end point in 
HIV-positive individuals. In the largest population-based study of HIV-associated 
fracture, ,Triant et al do not present data on the vitamin D status of the fracture cases or 
controls (Triant et al, 2008). In her review of HIV-associated bone fracture in recent 
cohort studies, Hoy comments that vitamin D deficiency is common in the cohorts 
examined, but that the prevalence was no different to the general population, and no 
association with aBMD was noted in cross-sectiona l studies. She also commented that 
cross-sectional data from the 'Study to Understand the Natural History of HIV and AIDS 
in the Era of Effective Therapy' (SUN) cohort matched with NHANES data revea led within 
the HIV-positive populat ion a "high prevalence (70% ) of vitamin D insufficiency and 
deficiency which was comparable with the general population (79%)", the definition of 
deficiency was based on the SUN study and was set at 7Snmol/l. "However, t here was 
no association between aBMD and vitam in D insufficiency or deficiency" (Dao et al, 
2011; Hoy, 2011). These findings have been replicated in a cross-sectional study of HIV-
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posit ive and negative Hispanic and African-American postmenopausal women (Rodriguez 
et al, 2009; Stein et al, 2011). However, none of these studies had fracture endpoint 
data in HIV-positive patients. 
2.3.7 Vitamin D and non-skeletal health 
A detailed analysis of the evidence for the non-skeletal role of vitamin D is beyond the 
scope of th is thesis; for a summary see Halick (2007) and Martineau et al (2007a). 
These reviews detail the evidence of the relationship between vitamin D status and non-
skeletal outcomes from in vitro, preclinical, animal and epidemiological studies. Non-
skeletal outcomes examined include malignant, infectious, autoimmune, endocrine, and 
psychiatric condi t ions. 
I n recent years, a burgeoning body of research has examined the effect of vitamin D on 
immune function and its importance in conditions as diverse as tuberculosis and 
psoriasis (Wilkinson et al, 2000; Mathieu et al, 2002; Cantorna et al, 2004; Halick, 
2006; Stoffels et al, 2006; Halick, 2007; Martineau et al, 2007a; Martineau et al, 2007b; 
Adams et al, 2008; Alagarasu et al, 2009) as well as neoplastic diseases (Halick, 2007; 
Prentice et al, 2008). These data suggest that vitamin D may have a particular role in 
protection from infectious disease (Coussens et al, 2012; Khoo et al, 2012). 
1,25(0HhD has paradoxical effects on the immune system suggesting that it is what 
Cantorna calls a "selective regulator" of immune function (Cantorna et al, 2004). 
1,25(0HhD can be seen either as immune-suppressive or immune-stimulating 
depending on t he type of immune response elicited (infectious vs. autoimmune) . Th is is 
almost certainly a consequence of altered transportation and conversion of 25(0H)D as 
well as differences in VDR and intracellular effects of 1,25(0HhD. It is not clear how 
these effects of 1,25(0HhD relate to v itam in D status, as measured by 2S(OH)D, and it 
is conceivable that the immune-modulat ing mechanisms are diffe rent. The role of T-
helper (Th) cells is key to antigen-specific immune responses, it is also t hese cells that 
are the major target for HIV infection (see Section 2.1.1). Thl cells secrete the 
inflammatory cytokines interleukin 2 (IL2), interferon gamma (IFNy) and tumour 
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necrosis factor alpha (TNFa). Such Thl responses are required for strong cell-mediated 
immunity (Cantorna et al, 2004) . In contrast, Th2 lymphocytes secrete IL4 and ILS; 
these are key to humoral (antibody) mediated responses in concert with B-lymphocytes. 
Both Thl and Th2 lymphocytes are targets for 1,25(0HhD so express VDR; CD4 positive 
T-lymphocytes also express VDR. Further work on innate immunity suggested that 
vitamin D and VDR play a role in human defence against pathogens. "In innate immune 
responses, activation of Toll-like receptors (TLRs) triggers direct antimicrobial activity 
against intracellular bacteria ... We report here that TLR activation of human 
macrophages up-regulated expression of the vitamin D receptor and the vitamin D-1-
hydroxylase genes, leading to induction of the antimicrobial peptide cathelicidin and 
killing of intracellular Mycobacterium tuberculosis" (Liu et al, 2006). Halick has stated, 
1· 
"when serum levels of 25-hydroxyvitamin D fall below 20 ng per millilitre (SO nmol per 
liter), the monocyte or macrophage is prevented from -initiating this innate immune 
response" (Halick, 2007). This may have direct implications in terms of control of other 
intracellular pathogens such as HIV, and indirect effects, e.g. on TB since it is a major 
cause of pathology in HIV-infected patients. 
Patien~s , with, or at risk of, diseases such as HIV infection, may require 25(0H)D 
concentrations above that needed to maintain bone health. HIV-positive individuals may 
have higher demands for vitamin D to meet the increased immune cell turnover, and as 
a result of co-morbidities such as TB. Those with lower vitamin D status may have 
decreased mucosa l immunity, so are at increased risk of infection . However, such 
hypotheses have not been proven; controlled studies with disease end points are 
required. It remains to be seen if the associations observed between vitamin D status 
and non-skeletal disease are causal, or indeed if poor status predisposes to infectious 
disease or if good status is protective (Ross, 2010) . 
2.3.8 Regulation of calcium and phosphate homeostasis 
Vitamin D has an essential role in maintaining calcium and phosphate homeostasis 
(Figure 2-17). Calcium and phosphate metabolism is under classical hormonal feedback 
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control. Each element of the system interacts to maintain optimal extracellular calcium 
and inorganic phosphate concentrations. Bone provides an abundant supply of these ions 
and also acts as a buffer against an excessive supply of these minerals entering the 
extracellular fluid from dietary sources. 
Figure 2-17 A schematic of the calcium-phosphate-vitamin o homeostatic 
system 
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(Prentice et al, 2008) [Reproduced with permission] 
The renal system is central to the control of calcium and phosphate homeostasis through 
the excretion of calcium and phosphate in the urine and the conversion of 25(0H)D to 
l,25(0HhD (under action of PTH), which is responsible for regulating calcium absorption 
in the small intesti ne. The kidneys have the capacity to filter 20% of cardiac output per 
minute and produce in the region of 180L of filtrate each day, 99% of which is 
reabsorbed, resulting in approximately 1.4L of urine excreted daily. This urine contains 
metabolic waste as well as appropriate calcium and phosphate to maintain extracellular 
fluid balance of these ions. During times of fast, the kidneys reabsorb 99% of filtered 
calcium and 95% of phosph~te ions. Most of this reabsorption occurs at the proximal 
convoluted renal tubule; at this site calcium reabsorption is coupled with sodium 
reabsorption . Postprandially this reabsorptive capacity falls dramatically and as a result 
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there is renal loss of these ions in order to maintain physiological concentrations in the 
extracellular fluid (Anderson et al, 2012). 
2.3.8.1 Calcium 
Calcium is the most abundant mineral in the body. A 70 kg adult contains approximately 
1.2 kg of calcium. It is estimated that 99% of the body's calcium is present in bone in 
the form of hydroxyapatite. The remaining 1 % is distributed between body fluids and 
tissue . Calcium has numerous physiological functions; key ones include neuromuscular 
conduction and regulation of skeletal and cardiac muscle. Serum calcium is 
approximately 40% albumin-bound and the concentration of the ionised fo rm is tightly 
regulated. This keeps total calcium within 2.02-2.65 mmol/1. It is regulated primarily by 
PTH and 1,25(0HhD; increases in which result in a rise in serum calcium (and fall in 
.,. 
phosphate) due to increased calcium and phosphate reabsorption from bone, decreased 
renal calcium excretion, and increased phosphate excretion from the renal tubule. 
The diet is the only source of calcium; under low calcium intake conditions there is 
increased intestinal absorption to ma intain ca lcium balance. Rich dietary sources are 
dairy products and fortified cereals with smaller contributions by seeds, beans, and 
green leafy vegetables. Calcium intakes vary widely between popu lations and at different 
stages of the lifecycle, and absorption of ingested calcium differs depending on prevailing 
physiological requirements and dietary factors. There is obligatory loss of calcium in 
sweat, urine, and faeces. The adaptive response to low calcium intake is increased 
conversion of 25(0H)D to 1,25(0HhD in the kidney via the actions of PTH. PTH responds 
to low iCa via calcium sensing receptors that are located in t he ce ll membranes of the 
parathyroid gland. Under low calcium intake conditions, there are slight decreases in iCa 
in t he extracellular f luid, which st imulates PTH production and increased synthesis of 
1,25(0HhD (via 1-alpha-hydroxylase, CYP27B1) in the prox imal rena l tubule. Calcium 
uptake from the gut is by active absorption mediated by 1,25(0HhD, I n t imes of high 
calcium intakes there is non-regulated paracellula r d iffusion of calcium from the gut, 
between enterocytes. The rena l th reshold for calcium is in the region of 4mg/kg lean 
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mass/day. If calcium intake exceeds approximately 2300mg/day, renal thresholds may 
be exceeded with resu ltant soft tissue calcification (Klemmer et al, 2012). 
Calcium homeostasis is regulated by a complex interaction between the kidneys, gut, 
parathyroid glands, and skeleton (see Figure 2-18). As well as regulating gut absorption 
of calciu m (via production of 1,25(0HhD) the kidneys also reabsorb calcium present in 
the glomerular filtrate via tubular reabsorption. They filter in the region of 10g calcium 
per day, only 200 or 120 (men and women) mg of which passes into the urine. Urinary 
calcium concentrations are maintained across a wide range by modulation of gut calcium 
absorption, so that in young adults the net amount absorbed in the small intestine 
equals that excreted in urine. Even small decreases in glomerular filtration rate (GFR) 
may result in decreased urine calcium excretion (Klemmer et al, 2012) . Expansion of the 
extracellular space by increased sodium intake increases obligatory urinary calcium 
excretion, which facilitates urinary excretion of sodium ions. However, it not established 
if high sodium intakes results in net bone loss (Blackwood et al, 2001). The tight 
regulation of serum calcium concentration is facilitated by the effect of PTH on bone. The 
calcium in hydroxyapatite is not able to buffer minute-by-minute changes in extracellular 
calcium concentration; the calcium present in the fluid compartment of the bone serves 
this purpose. Increased concentrations of PTH promote the release of ion ic calcium from 
the bone envelope. In contrast, after calcium ingestion, the skeleton buffers the rise in 
iCa from extracellular fluid by removing it from the circulation (Klemmer et al, 2012). 
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Figure 2-18 Calcium homeostasis 
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(University of Birmingham at Alabama) [Reproduced under auspices of 
http: //creativecommons.orq/licenses/by-sa/3 .0/] 
2.3.8.2 Phosphate 
Phosphate homeostasis differs from that of calcium because it is mostly regulated at the 
site of the proximal renal tubule rather than at the small intestine. Dietary phosphorus is 
readily available especially in Western diets where phosphorus is added to processed 
foods in the form of buffers. Rich food sources are milk, gr~ins, and protein-rich foods . 
Of the 1 kg of phosphorus conta ined in the body, approximately 80% is in the form of 
the calcium phosphate salts comprising the inorganic component of bone. The remainder 
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is distributed throughout the cells of the body, mainly in the form of organic phosphorus 
forming part of phospholipids and phosphoproteins. In serum the majority of inorganic 
phosphorus exists in free form (phosphate) with approximately 15% protein bound. 
Measurements of inorganic phosphate in serum and urine are used in the diagnosis of 
various conditions such as parathyroid disease and renal disease. In the context of HIV-
disease, serum phosphate is an important analyte; it has been associated with exposure 
to tenofovir which can result in renal phosphate wasting and subsequent effects on bone 
health. 
A typical phosphorus intake of 1400mg/day results in 900mg renal and 500mg stool 
excretion. As intake and output are almost equal, healthy adults are in zero phosphate 
balance. Between 60-70% of phosphorus uptake takes place in the small intestine via 
the sodium/phosphate transporter. Phosphate homeostasis is largely independent of 
vitamin D but depends on actions of PTH and Fibroblast Growth Factor 23 (FGF-23). 
FG F-23 is a phosphatonin hormone produced by osteocytes that promotes urine 
phosphate excretion. FGF-23 also reduces the activity of the renal 1-alpha-hydroxylase 
and hence the production of 1,25(0HhD. Following a phosphate load, PTH and FGF-23 
concentrations increase in extracellular fluid resulting in a reduction in proximal tubular 
reabsorption of the ion. This has the net result of increasing urinary phosphate excretion. 
The osteocyte-related, noncollagenous matrix protein Dentin Matrix Protein! (DMPl) and 
phosphate-regulating gene with homology to endopeptidases on the X chromosome 
(PHEX) regulate phosphate metabolism through degradation of FGF-23 (Martin et al, 
2011). 
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Figure 2-19 Phosphate homeostasis 
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(Sapir-Koren et al, 2011) [Reproduced with permission] 
Ionic phosphate concentration, in extracellular fluid, is less tightly regulated tha n calcium 
and ranges in adults between 0.83 - 1.5 mmol/1 in the fasting state (Anderson et al, 
2012). Other factors such as elevated concentrations of insulin, glucose and 
catecholamines, and rapid bone mineralisation also play a role in the redistribution of 
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phosphate between extracellular and bone or cell components, resulting in decreased 
plasma concentrations (Drezner, 2008). 
2.4 Effects of HIV infection, ART, and associated conditions on bone 
health 
As discussed at the beginning of this thesis (Section 1.1), there is a growing clinical 
perception of, and experience with, HIV-associated bone disease. Many clinical and 
observational studies correlate HIV infection with bone loss. This section will explore 
these issues and, where possible, the mechanisms underpinning them and isolating, 
where possible, effects of HIV infection, ART exposure and non-direct, HIV-related 
factors on bone health, although overlap is inevitable so sometimes these factors will be 
considered together. 
2.4.1 HIV and bone health 
The Gilead 903 study (Powderly et al, 2005) has provided important information on pre-
ART bone data in HIV-infected individuals. In 600 HIV-positive, ART-na"ive individuals, 
the baseline rates of DXA-defined osteopaenia at the lumbar spine (LS) were 23% and 
28% in each pre-treatment arm (tenofovir vs. stavudine). Respective LS osteoporosis 
ra tes at baseline were 3% and 4% respectively. The lower LS T-scores correlated with 
male sex and the 'traditional' risk factors of lower weight and advancing age (Bruera et 
al, 2003; Brown et al, 2006a). These baseline low aBMD data suggest HIV infection may 
itself contribute to bone loss because low aBMD pre-dated ART exposure; however this 
study lacked a control group. 
Low (Z-score <-2.0) aBMD has been observed in 46% of patients with untreated HIV 
infection and high HIV RNA concentrations in plasma (Fausto et al, 2006), and was also 
associated w ith HIV infection of a longer duration compared to those with more recent 
infection (Mondy et al, 2003). Conversely, patients with low HIV RNA and high CD4 
counts have higher aBMD, compared to those with lower CD4 counts (Dolan et al, 2006), 
although one confounding factor, in such observations, is the co-exposure of such 
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patients to ART. In another study, low level HIV- viraemia was associated with a greater 
risk of osteoporosis using WHO criteria (Cazanave et al, 2008). 
An influential meta-analysis of 20 trials by Brown and Qaqish in 2006 demonstrated that 
67% of the HIV-positive individuals (n=884) studied had low aBMD; 15% of these had 
osteoporosis. These pooled data gave odds ratios of 6.4 and 3. 7 of low aBMD and 
osteoporosis respectively compared with HIV-negative controls (n=654) . The main 
methodological problem with all these studies, and doubtless accounting for many of the 
discrepancies in the data, is that they are all observational and therefore causality 
cannot be assigned (Post et al, 2011). 
It has not been conclusively demonstrated in well-designed studies that low aBMD 
~-redicts fracture risk in HIV-positives although evidence is emerging to support this 
proposition (Collin et al, 2009; Grund et al, 2009). Cross-sectional studies have reported 
increased vertebral fractures in HIV-positive compared to HIV-negative controls (26.9% 
and 12.9% p=0.002) (Torti et al, 2012) but causality cannot be inferred from these 
studies. 
In th~ context of HIV, a study by Arnsten et al, in older men (mean age 55 years) noted 
HIV infection was independently associated with modestly reduced aBMD in ageing men, 
and decreased aBMD was associated with increased fracture risk but did not see an 
association between ART use and aBMD loss (Arnsten et al, 2007). Moreover, in this 
study the negative relationship between HIV and aBMD was only present in overweight 
or obese individuals. This suggests that a higher BMI, also associated with slower HIV 
progression, may lessen the effect of HIV on aBMD (ibid.). This raises the important 
issue of the role of body weight in skeletal and non-skeletal disease in HIV-infected 
patients. A 2010 study from Johannesburg has shown that obesity was associated with 
less TB-associated mortality in a HIV-positive population (Hanrahan et al, 2010; Hurley 
et al, 2011), these data challenge notions of 'healthy' BMI applied to African HIV-positive 
individuals and warrant further exploration . 
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2.4.1.1 Age, gender, and lifestyle 
HIV-positive individuals, in the West at least, have higher rates of traditional risk factors 
for osteoporosis, e.g. smoking and lower plasma 25(0H)D concentrations (Carr et al, 
2001; Mondy et al, 2003; Dolan et al, 2006; Prior et al, 2007). Advanced HIV disease is 
associated with immobility (Terzian et al, 2009), malnutrition (Jacobson et al, 2003), 
and altered gut function (Martineau et al, 2007a; Wejse et al, 2007; MacPherson et al, 
2009). These factors may be associated with reduced aBMD through negative effects on 
bone loading and nutrient intake and/or absorption. 
Comorbid conditions, associated with HIV, often have shared predisposing factors with 
poor bone health, such as the use of medications that may influence bone directly or 
indirectly (via effects on calcium or vitamin D metabolism). 
Some authors have reported higher prevalence of low aBMD in HIV-positive men than 
women (Fernandez-Rivera et al, 2003). The mechanisms underpinning this observation 
are not clear but may relate to gonadal dysfunction and low testosterone production, as 
measured by free testosterone (Dube et al, 2007). Despite the cited increased risk of low 
aBMD in HIV-positive men, women with HIV infection are twice as likely to have low 
aBMD compared to their HIV-negative peers (Brown et al, 2006a). 
As the global HIV-positive cohort ages (Yin et al, 2009) age and gender will be key 
determinants of bone loss in these patients. However, few studies have specifically 
addressed the issue of aBMD in elderly HIV patients. Jones et al compared 57 HIV-
positive with 47 HIV-negative subjects aged over 55 years in a cross sectiona l study. 
The mean age was 61 years in HIV cases and 62 in HIV-negative controls (Jones et al, 
2008). This study found that aBMD at the hip was significantly lower in HIV-infected 
patients versus controls, and that tenofovir use was particularly associated with low 
spine aBMD (PI use was associated with low hip aBMD) and the authors speculated that 
the loss of trabecular bone in the lumbar spine and cortical bone of the hip represent 
different mechanisms by which Pis and tenofovir affect bone turnover. 
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Differences in leptin and adiponectin concentrations, and their relationships with 
adiposity and bone, in the context of HIV infection and/or ART exposure, may also be 
involved and require exploration although published studies suggest that there is an 
inverse relationship between leptin and bone mass in HIV-positive patients t reated with 
ART (Madeddu et al, 2009) . This may be mediated by disturbances in fat distribution and 
integrity seen in association with HIV-associated lipodystrophy (Rao et al, 2012) 
Injection drug use (IDU) (Madeddu et al, 2004) and associated methadone replacement 
in men and women is also associated with reduced aBMD (Arnsten et al, 2006; Arnsten 
et al, 2007), however, these associations may be primarily related to low BMI. Smoking 
and alcohol excess, and decreased mobility have been associated with low aBMD in HIV-
infected patients as well as in the general population (Mondy et al, 2003; Dolan et al, 
2006; Collin et al, 2009; Lo Re 3rd et al, 2009) . These findings are not, however, 
replicated in all studies (Prior et al, 2007). IDU is anecdotally reported to be low in 
Southern Africa but firm data are lacking. Nevertheless, recreational, non-IDU drug use 
is thought to be increasing generally and may disproportionately affect women (Parry et 
al, 2009). There are anecdotal reports of smoking crushed-up ARV tablets in South 
Africa. This so called 'Whoonga' is used as a recreational drug to promote hallucinations 
(Fihlahi, 2011). 
2.4.1.2 Pathophysiological mechanisms 
The normal process of bone remodelling is disrupted in HIV infection by uncoupling bone 
formation and resorption, indicated by increased markers of bone resorption and stable 
markers of formation over time (Aukrust et al, 1999). The pathophysiological 
mechanisms of HIV-associated increases in bone turnover, and related 
histomorphologica l changes of HIV and/or ART-associated bone loss, and effects on 
aBMD have yet to be fully elucidated. The relationship between HIV infection and 
osteoporosis is multifactorial. Some authors have speculated t hat specific components of 
t he HIV coat and v ira l proteins (such as gp120, (see Figure 2-2) or pSS gag (Walker-
Bone, 2012)) may increase osteoclast act ivi ty (Brown et al, 2006a). This direct effect 
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may explain why duration of HIV infection appears to be a better predictor of low aBMD 
(Bruera et al, 2003) than specific ART regimes (Seminari et al, 2005). HIV has direct 
apoptot ic effects on osteoblasts via up- regulation of TNFa (Gibellini et al, 2008). Other 
studies suggest that certain Pis induce bone loss by preventing inhibition of RANKL 
(Fakruddin et al, 2003). However, the underlying effects of HIV and/or ART exposure on 
the bone remodelling unit requires clarification as it may provide insights into how to 
abrogate the associated bone loss. It is also worth considering that the cells of the 
immune system, directly influenced by HIV (namely T and B lymphocytes), are involved 
in the action of oestrogen on the skeleton (Raisz et al, 2008). This may suggest a 
potential common mechanism underpinning HIV-associated bone loss. 
Inflammatory conditions such as Immune Reconstitution Inflammatory Syndrome (IRIS), 
associated with rapid immune recovery after introduction of ART, may require a 
prolonged course of high-dose corticosteroids and bed rest, both of which result in bone 
loss. Brown has suggested that low aBMD is associated with other HIV-associated 
metabolic abnormalities such as lipodystrophy and glucose intolerance (Brown et al, 
2004; Brown et al, 2006a). However, it is difficult to establish any causa l link between 
these associations, and they may have been the result of ART use or chronic HIV 
infection and associated cytokine dysregulation leading to greater tissue TNFa 
concentrat ions, or to disturbances of acid-base homeostasis. A reduction in extracellu lar 
pH, from whatever source, directly enhances osteoclastic activ ity and increases 
resorption pit formation. The alkaline skeleton acts as a buffer to maintain acid-base 
homeostasis and has parallels wit h t he dietary 'ash ' hypothesis which postulates t hat 
chron ic, low-level acidosis results in increased bone resorption and urinary calcium 
excretion (New, 2002; New et al, 2004; Fenton et al, 2011). 
2.4.1.3 Osteoporosis diagnosis and treatment in HIV 
Algorithms for investigation . and t reat ment of low aBMD to prevent fracture in HIV-
infected subjects are required to fill "one of the most important knowledge gaps in the 
field" (Brown et al, 2006a). However at present, the International AIDS Society USA 
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does not support routine screening for low aBMD (Schambelan et al, 2002). The UK and 
South Africa do not have screening programmes. Furthermore, as yet it is unclear if HIV 
infection is considered a sufficient additional risk factor to warrant screening for low 
aBMD in premenopausal women. Anecdotally, some UK clinicians use HIV infection 
instead of rheumatoid arthritis, to predict need for treatment or DXA, in the FRAX 
questionnaire (http ://www.shef.ac.uk/FRAX/), however this strategy is not validated. 
In HIV infection specific data are lacking on the best strategies to predict and prevent 
fracture in those with known or suspected low aBMD (Hoy, 2011; Walker-Bone, 2012). 
Alendronate (with calcium and vitamin D supplementation) has been shown to be safe in 
treating osteoporosis in HIV-positive patients (Mccomsey et al, 2007). Zoledronic acid 
l'}as been demonstrated to increase aBMD for at least five years after administration in 
HIV positive men (Bolland et al, 2012a). However, the optimal duration of 
bisphosphonate therapy has not been established (Pollock et al, 2009) and it is not 
known if it is as efficacious at reducing fracture as in HIV-negative adults. The use of sex 
hormones, calcitonin and teriparatide are far less well documented in HIV-infected cases 
than the general population but may be considered on an individual basis (Clay et al, 
2.4.2 ART and bone health 
2.4.2.1 Fracture 
The need to manage HIV infection with long-term ART has resulted in the recognition of 
potential toxicities of ART exposure, and particularly, a negative effect on bone health. 
Current evidence shows that the prevalence of osteoporosis (Mallon , 2010; Stone et al, 
2010; Walker-Bone, 2010; Post et al, 2011), and fracture (Triant et al, 2008) is higher in 
HIV positive individuals. There are case reports (Guarald i et al, 2001; Forsyth et al, 
2002) of minimal trauma fractures in patients on ART. The important Strategies for 
Management of ARV Therapy (SMART) study used both DXA (hip and spine) and 
quantitative computed tomography (qCT) (spine) to measure BMD annually. SMART was 
designed to compare the effects of interrupted ART treatment, guided by CD4 count, and 
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continuous ART treatment. This was a multicentre study following patients in the USA, 
Australia, and Europe, the median age of participants was 44 years and 19% were 
female. Patients were randomised to either continuous- or interrupted-ART. In the 
continuous-ART arm aBMD declined more than in the intermittent group, which was 
stable or increased at one year. In the continuous group hip and spine aBMD declined by 
0.8% and 0.4%, and vBMD by 2.4% (measured by qCT) up to one year. After 12 
months, aBMD at both sites appeared to decline at similar rates to each other in the 
continuous-ART group (Grund et al, 2009). The hazard ratio for 'serious' fractures was 
4.9 in the continuous-ART compared with the interrupted-ART groups. Whilst this study 
adjusted for factors associated with aBMD loss, such as sex, they did not define 'serious' 
fracture. 
Figure 2-20 Changes in bone measures in the SMART trial 
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In a French cohort study by Collin et al (Collin et al, 2009) following patients (n=l,281) 
who had been on ART for 10 years, the incidence of fracture was 3.3 per 1000 patient 
years. This may be an underestimate but is not different to the expected age-adjusted 
fracture rate in the general European adult population; these data suggest fracture rates 
were not increased in patients exposed to ART for a decade. The rate was 2.9 fold higher 
in those with excessive reported alcohol intake (defined as ~5 glasses/day). Only 5/26 
patients with a fracture in this study underwent bone densitometry; of these, four had 
osteoporosis (Collin et al, 2009). Other studies have reported an increase in fracture rate 
in HIV-positive women compared to controls despite similar aBMD (Prior et al, 2007). 
Attempts have been made to estimate the risk of HIV-associated fracture through large, 
retrospective hospital record reviews (Triant et al, 2008), in the context of drug trials 
:;· 
(Powderly et al, 2005), and in cohort studies (Arnsten et al, 2007). These studies 
demonstrated increased risk of fracture in HIV-positive patients but were limited by 
either cross-sectional or retrospective design or lack of a control group. More recently, 
Yong and colleagues demonstrated that fracture risk was strongly associated with a low 
CD4 count, although these data were in a predominantly white, male population (Yong et 
al, 20\1). The use of ART or degree of HIV suppression was not associated with fracture 
risk. 
In a 2011 publication from the 'A5224s Trial', HIV-positive patients, exposed to different 
ART combinations, fracture was observed in 5.6% of participants. In this RCT of 
treatment na'ive patients, the median age was 38 years, 85% were men and 47% were 
white. Subjects were randomised to receive different combinations of ART (See section 
2.1.2). All of these fractures (n=15) were the result of trauma. The probability of "on 
study" (incident) bone fractures and time to first fracture were not different across 
different ART-components (Mccomsey et al, 2011). Similarly in the parent 'ACTG A5202 
Study', 80 participants (4 .3%) reported at least one bone fracture on study. Among 
these, 10 ( 12. 7%) were atraumatic. Fracture rates were balanced across the study 
arms, with no statistically significant differences between the NRTI (p=O. 73) or the 
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NNRTI and PI components (p=0.57). No statistically significant difference in time to first 
bone fracture was seen between the NRTis (p=0.71) or the NNRTI and PI components 
(p=0.49 ). Similarly, fracture incidence rates were similar across arms (Table 2-3). 
Table 2-3 'ACTG A5202 Study' summary 
ART regime Fracture rates during Fracture incidence /100 
studv (%) patient-vears 
ABC/3TC & EFV 4.7 1.9 
ABC/3tC & ATZ/r 3.5 1.4 
TDF/FTC & EFV 4.5 1.8 
TDF/FTC & ATZ/r 4.5 1.8 
Adapted from Mccomsey (Mccomsey et al, 2011). 
2.4.2.2 ART and aBMD 
To better understand the relationship between ART use and aBMD the next section 
presents the literature on different classes of ART and aBMD. There are numerous 
reports of the effect of different ART regimes on bone and aBMD (Brown et al, 2009). 
While these studies provide important insights into HIV-related bone loss, there remains 
a paucity of well designed, controlled studies. Studies are divided into those that showed 
positive and those that demonstrate negative effects of ART exposure on bone health. 
Although long-term ART exposure seems to decrease aBMD, it is difficult to 
independently assign and quantify the effects of ART exposure in relation to those of HIV 
infection, and traditional risk factors for bone loss. 
An important observat\onal study by Mondy et al demonstrated elevated bone turnover 
markers during 72 week follow up in 93 HIV-infected patients on ART. In this study 85% 
were male and 14.7% were black, with a mean age of 41 . years in those with normal 
aBMD. In those with low BMD 88% were male, 18% black, with a mean age of 42 years. 
Alterations in bone turnover markers (BTMs) appear to reverse with ARV treatment, at 
least initially, suggesting a · temporary positive effect of ART on BTMs (Mondy et al, 
2003). ART may simply improve bone health by decreasing the body's HIV burden, and 
therefore the deleterious effects of ART on bone may finally be outweighed by the 
benefits of lim iting the effects of HIV on bone through ART. 
104 
In a study by Aukrust et al it was posited that ART exposure might improve markers of 
bone formation, with increases in osteocalcin over 24 months, compared to low 
osteocalcin and high CTx concentrations prior to the introduction of ART. ART exposure 
may cause a resynchronising of bone formation and resorption that became uncoupled 
(with increases in resportion) during untreated HIV infection (Aukrust et al, 1999). 
Bolland et al concluded that aBMD remains relatively stable over two years despite use 
of ART. In fact, in their small study of 23 HIV-positive men on ART, lumbar spine aBMD 
increased by 2.6% from baseline compared to a 1.4% increase in 26 HIV-negative 
controls. aBMD at total hip and whole body remained stable in both groups. These aBMD 
differences occurred even though HIV-positive men were significantly more likely to 
smoke and had a non-significantly lower BMI than controls. While 25(0H)D and 
te$tosterone concentrations were similar at baseline, data on physical activity and drug 
and alcohol use were not gathered (Bolland et al, 2006). This study contrasts with most 
that describe decreasing aBMD with ongoing ART use and the authors considered BMI to 
be a more powerful determinant of aBMD loss than ART. However, once again, HIV 
and/or ART-associated differences in aBMD disappeared after correction for BMI. The 
authors speculated that it was weight loss associated with advancing HIV infection that 
was ,re'sponsible for decreasing aBMD, and which is corrected by the weight gain 
associated with ART (Fernandez-Rivera et al, 2003). However, changes in size can cause 
body composition artefacts in DXA data and therefore also need to be explored. 
Carvalho et a/'s systemic review of aBMD in HIV-positive women taking ART focused on 5 
studies published between 2001 - 2009, using DXA to evaluate aBMD, concluded that 
femoral neck aBMD was more than 3% lower in women on PI-based-ART (PI-ART) . 
When comparing women using PI-ART and not using PI-ART (i.e. non-PI-based-ART) 
there was no difference noted at the lumbar spine (Carva lho et al, 2010). Fou r out of 
five of these studies were cross sectiona l and conducted in the USA and one examined 
data from North America, UK, France, and Spain . The orie randomised study of different 
ART regimes (Brown et al, 2009) did not have a HIV-negative control group (see Figure 
105 
2-2 1) . None examined bone loss in women in the developing world, although the 
majorit y of women were classified as non-white, i.e. of "African American or Hispanic 
origins" (Carvalho et al, 2010). 
f igure 2-21 Systematic review of HIV and bone health studies 
Table 1. Selected studies: focation, ran uage, study design and objectives 
Aulllor/year Location 
Brown and cols (3S) 2009 United Sta1es. Canada. 
France, Spain and United 
Kingdom 
A/lastos and cols. (2B). 2007 Uni led S1a1es 
Yin and cols. (33). 2005 United States 
Dolan and cols. ('.>4), 2004 United States 
Huang and cols (35), 200i United States 
Language Study design/follow up 
English Randomized Clinical trial 
open label/96 weeks 
English Cross-sectional 
English C ross-s~tional 
English Cross-sectional 
English Cross-sectional 
Objectives 
E•,aluate ct\lnges in BMD prospecti vely in antiretroviral-
r0ive persons in itiating a PI versus a NNRTl-based 
regimen; determine whether removal of ZD\/13TC backbone 
irnpac s BMD; identify fac1ors associated with BMD toss 
over 96 wooks, including systemic inflammation 
Ve rify association of BMD wi1h HtV infection and HIV 
therapy in women enrolled in he Women's lnteragene>/ HIV 
Study (WfHS) 
.&ssess risk factors for ostropo,osis and measured BMD 
and b1ocllemical indices of mineral metabo lism in a group 
of HIV-infected post-menopausal women 
Investigate bone density and associated factors in normal 
weight. ambulatory HIV-inf~~ted wcimen 
Determine 1he risk iactors for osteoperna in androgen-
deficient women wi1h Aids s ndrome wastmg 
BMD: ~ooe minerJI density: NNR11: non-nucloos1de re•,ersal lransr:npla<,e 11ll11b1tD1; ZD\/: 11dovud11l:l: 31C. 1am1vudlne, HIV: human immunodEliciem::y virus: 1\ids: acqrnre!l 11mnunooehde1~ysy11drome. 
Summary table of systematic review of published studies HIV and aBMD (up to 2010) 
(Carvalho et al, 2010) [Reproduced with permission] 
2.4.3 Effects of different classes of ART on bone health 
Various different classes of ART have also been correlated with increased rates of 
osteoporosis and osteopaenia wherein ART-exposed HIV-positive patients had a 2.5-fold 
increased odds of low aBMD compared to those not exposed to ART (Tebas et al, 2000; 
Brown et al, 2009). 
I n an important study by Brown et al (2009), in a majority male population, n=106 aged 
40 years or less, there· were overall rates of whole body (WB) aBMD decline of -2.3% 
(NNRTI) and -2.5% (PI) over 96 weeks on ART; 15% of patients in both treatment arms 
lost >5% aBMD. This higher rate of loss was positively associated with lower CD4 count, 
higher fasting glucose, and non-black race (Brown et al, 2009). These figures compare 
with estimated annual aBMD losses of 0.5-1 % in adults aged over 35 years (Powderly et 
al, 2005) and 1-2% loss in. t he early postmenopausal years (Hodgson et al, 2003) . 
Mallon et al studied 40 HIV-positive, t reatment-naive men, just beg inning ART. There 
was an init ial r ise in WB aBMD after starting ART up to 24 weeks afte rwhich the T-score 
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fell below that at baseline by week 144. Whole body DXA T-scores <-1.0 in these ART 
initiated men increased from 13% at baseline to 22% at week 144 (Mallon et al, 2003). 
The utility and clinical relevance of using WB aBMD T-score as a measure of bone loss is 
questionable because WB DXA is not used to diagnosis osteoporosis or response to anti-
resorptive treatment. 
Dolan et al followed up 100 female patients in Boston, USA along with age-, BMI- and 
race-matched controls (mean age 41 years) for two years. Historical low weight, 
duration of NRTI use and low follicle stimulating hormone (FSH) concentrations were 
positively associated with low LS aBMD. Duration of HIV infection, BMI, historical low 
weight, smoking, N-terminal telopeptides of type-I collagen (NTx), HIV viral load, 
o~teocalcin and low plasma 25(0H)D were positively associated with low total hip (TH) 
aBMD at baseline. Whilst aBMD remained lower in HIV-positive women than controls, 
despite controlling for BMI, race, and menstrual function, the rate of aBMD loss was not 
different in cases and controls. In the HIV-infected group longitudinal aBMD loss was not 
associated with ART use but baseline aBMD, CD4 count, and NTx (Dolan et al, 2006). 
2.4.3.1 Nucleoside reverse transcriptase inhibitors 
Nucleo::;ide reverse transcriptase inhibitors (NRTI) are the most common class of ART 
used worldwide. Older studies have found cumulative NRTI use to predict decreases in 
aBMD. However, cumulative NRTI use may be a surrogate for duration of HIV infection 
rather than represent an independent risk factor (Gold et al, 2002). Other studies have 
examined the role of thymidine analogue NRTis in the aetiology of reduced aBMD. The 
thymidine analogues stavudine (d4T) and zidovudine (AZT) are associated with 
metabolic complications, particularly the lipodystrophy syndrome (Mallal et al, 2000), as 
well as the development of decreased aBMD. In vitro and an in-vivo mouse model data 
have demonstrated that AZT stimulates osteoclasts (Pan et al, 2006). A further indirect 
effect of thymidine analogues may be mitochondrial toxicity that results in lactic 
acidaemia (Shahmanesh et al, 2002) and , consequently, reduced aBMD via disruptions 
in acid -base homeostasis (Carr et al, 2001; New, 2002). 
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2.4.3.2 Tenofovir 
The NRTI tenfovir (TDF) is the ARV most associated with bone loss and has also been 
shown to reduce aBMD. The large "Gilead 903 study" showed that patients receiving 
tenofovir had significant decreases in aBMD at 144 weeks. Compared with thymidine 
analogues those receiving tenofovir had a -2.2% loss of LS aBMD vs. -1.0% (p=0.001, 
between groups) with non-significant differences at the hip (-2.8% tenofovir, -2.4% 
stavudine, p=0.06, between groups). These changes occurred during weeks 24 - 28 and 
then plateaued to week 144 (Gallant et al, 2004). The mechanism by which tenofovir 
induces bone loss is not fully understood but seems to be a consequence of its action on 
the proximal renal tubule, increasing phosphate wasting (Woodward et al, 2009). 
Macaques treated with high-dose tenofovir develop an osteomalacia-like appearance on 
bone histological examination (Castillo et al, 2002). It is also thought that tenofovir may 
have a direct inhibitory effect on renal 1-alpha hydroxylase thereby decreasing 
1,25(0HhD and, hence, disrupting calcium/phosphate homeostasis (Brown et al, 
2006a). 
A fascinating insight into the effects of tenofovir is provided by the 2011 trial by Liu et al 
which measured longitudinal aBMD change in HIV-negative men using daily tenofovir 
(vs. placebo) as part of a HIV-prevention strategy, the so-called Pre-Exposure 
Prophylaxis (or PrEP). In the intention to treat (ITT) longitudinal analysis, there was a 
1.1 % net decrease in mean aBMD in the tenofovir vs. the placebo group at the femoral 
neck (95% CI 0.4-1.99~0 p = 0.004) , 0.8% net decrease at the total hip (95% CI 0.3% p 
= 0.003), and 0.7% decrease at the LS (L2-L4) (95% CI -0.1-1.5% p = 0.11). At 
baseline, there were higher than expected rates of low aBMD in these men and by 24 
months, 13% vs. 6% of participants had experienced >5% aBMD loss at the femoral 
neck in the tenofovir vs. placebo groups (p = 0.13) (see Figure 2-22). These changes 
were most marked in the first 12 months of tenofovir exposure (Liu et al, 2011) and are 
in keeping with data from Hansen et al and Mccomsey et al, which demonstrated that 
most ART-re lated bone loss occurs in the first 12 months of exposure (Hansen et al, 
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2011; Mccomsey et al, 2011), although other authors have not reported bone loss 
during the same period (Bolland et al, 2012b). 
I 
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figure 2-22 aBMD loss after exposure to tenofovir 
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(Liu et al, 2011) [Content under open content licenses may be reused without any need to contact the licensor. See: http://creativecommons.org/licenses/by/2.5/] 
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A bone sub-study of the 'ACTG A5202' tria l showed that tenofov ir is associated with 
greater bone loss than other NRTI treatment as demonstrated in the 'A5224s' trial (see 
Section 2.4.2). In this trial of ART-na"ive patients, at week 96, the mean percentage 
changes from baseline in spine and hip aBMD for Abacavir-lamivudi ne (ABC-3TC) versus 
tenofovir-emtricitabine (tenofovir-FTC) were -1.3% and -3.3% (p= 0.004) and -2.6% 
and -4.0% ( p= 0.024), respectively (Mccomsey et al, 2011). 
2.4.3.3 Protease inhibitors 
An important early cross sectional study by Tebas et al (Tebas et al, 2000) demonstrated 
that men receiving PI-based ART had a relative risk of osteoporosis and osteopaenia of 
2.19. Half of men on PI/ART were classed as osteoporotic or osteopaenic compared with 
non-PI/ART and controls. However, the men on PI were significantly older and other 
inJportant factors such as vitamin D status, and alcohol or steroid use were not reported 
, 
(Tebas et al, 2000). A cross-sectional study by Bruera et al (Bruera et al, 2003) 
comparing HIV-infected patients on different ART regimes and HIV-negative controls 
found no difference in rates of low aBMD by ART class (PI vs. non-PI) but noted a 
significantly lower proportion with a T-score of greater than -1.0 in HIV-infected patients 
compared with controls at femoral neck (35 - 54% and 58% respectively) and lumbar 
spine ,(19 - 31 % and 85% respectively) (Bruera et al, 2003). More PI studies have 
confirmed Tebas' early finding (Amiel et al, 2004; Brown et al, 2004) . Amiel et al 
examined 148 HIV-positive men, mean age 40 years and 81 HIV-negative controls; 
100/148 of the HIV-positive men were receiving ART. Of HIV-positive men, 16% had any 
site z-score less than -2.5 compared with 4% of controls. Low BMI and raised bone 
resorption markers were positively associated with low aBMD irrespective of ART use 
(Amiel etal, 2004). 
In a review article by Pollock et al, those treated with a PI compared to those treated 
wi t h a non-PI-based ART regime had increased odds of red uced aBMD and osteoporosis 
(1.5 and 1.6 respectively). However, since aBMD assessment did not generally predate 
the use of ART, the low aBMD may reflect the effects of HIV infection rather than choice 
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of ART (Pollock et al, 2009). In a French trial by Duvivier et al (Duvivier et al, 2009) 
patients were randomised to receive different ART regimes, and those assigned to either 
of the PI-based arms (PI/NNRTI or PI/NRTI) had the greatest percentage decrease in LS 
aBMD at 48 weeks compared to baseline when compared to those in the NNRTI/NRTI 
arm (-4.4%, -5.8%, and -1.5% respectively). This contrasts with a study by Brown et al 
that did not show a difference in loss of Whole Body aBMD in PI vs. non-PI treated 
patients (Brown et al, 2009), though these data are not directly comparable with LS 
aBMD. A potential explanation for the close correlation between PI use and lower aBMD 
is suggested by the in vitro data linking Pis and increased osteoclastogenesis and 
decreased osteogenesis via direct inhibition of osteoprotegerin (OPG) (Pan et al, 2006). 
What is more, in ex-viva experiments, different Pls have opposing effects: indinavi r 
increases bone loss by effects on osteoblast recruitment, and ritonavir blocks 
osteoclastogenesis, reducing bone loss. The authors concluded that their results 
"suggest that bone and fat formation ... may be coordinately down-regulated by some 
but not all Pls" (Jain et al, 2002). 
PI-based ART study results may also contradict one another because of different study 
designs, and because of a difference in the Pis employed. Also, since Pis are often used 
together and in combination with NRTI, it is difficult to separate the individual drug 
effects (Pan et al, 2006; Avenell et al, 2012). Because data on the effects of particular 
ART on aBMD are so conflicting there is a need for further investigation. The lack of 
consistency across trials and studies suggests that there is a complex, multifactorial 
association between speci fic PI t reatment and bone disease, and fo r which studies have 
not yet been well-enough designed to elucidate. 
2.4.3.4 Non-Nucleoside Reverse transcriptase inhibitors 
The balance of evidence suggests that NNRTI use has less detrimental skeletal effects 
than Pls. PI-based reg imes tend to be reserved for those with prev ious virological 
failu re, and therefore are used in patients with longer duration of infection ; also it is 
impossible to factor out the effects of HIV infection in these studies. A study of PI vs. 
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NNRTI based regimes in HIV-positive young adults/adolescents and adults (Mulligan et 
al, 2012) recruited 199 HIV-positive men, of these 52 were taking NNRTI-based and 42 
PI-based ART. These were compared with 53 HIV-negative controls; t he subjects were 
aged between 14 - 25 years. The study demonstrated that those exposed to ART had 
lower mean aBMD and Z-scores than controls with the lowest aBMD in the PI-exposed 
group. The bone sub-study of 'ACTG A5202' also demonstrated a less marked loss of 
bone with efavirenz (NNRTI) than Atazanavir/ritonavir (PI). Because this was a RCT, 
there was less inherent bias potentially seen in observational studies. At week 96, the 
mean percentage changes from baseline in spine and hip aBMD for efavirenz vs. 
atazanavir/ritonavir were -1.7% and -3.1% (p= 0.035) and -3.1% and -3.4% (p= 0.61), 
respectively. These results could also be interpreted as not so much a negative effect of 
th;se two regimes, but rather as NNRTI 'protecting' against spine but not hip aBMD loss 
(Mccomsey et al, 2011). 
2.5 HIV/ ART and vitamin D 
There are complex interactions between HIV infection, risk of osteoporosis and fracture, 
and poor vitamin D status. In a review, Brown and Mccomsey (Table 2-4) listed potential 
factors associated with low aBMD in patients with HIV infection and describe HIV-
' 
associated bone loss in terms of ART medication and viral factors. These included ART, 
HIV, and patient factors. Patient factors are those that may, or may not, be related to 
HIV-status. Some, e.g. smoking, alcohol use and poor vitamin D status, which are 
present in the genera l population may be more prevalent in HIV-positive patients, at 
least within developed countries (Mondy et al, 2003; Dolan et al, 2006; Prior et al, 
2007). 
113 
Table 2 - 4 Risk factors for reduced aBMD in HIV infection 
I Antiretroviral medications: 
Proteases inhibitors (PI) * 
Reverse transcriptase inhibitors 
Thymidine analogues* 
Tenofovir 
HIV disease factors: 
Duration of infection 
HIV disease severity 
Viral load Patient-:f=-a-c-:-t-o-rs_: __________ _ 
Low body weight/body mass index (BMI) 
Smoking 
Hypogonadism 
Vitamin D deficiency 
Glucocorticoid use 
Body fat changes* 
Immobility 
Drug and alcohol misuse 
Race 
Sex 
Age 
* controversial 
Adapted from Brown and Mccomsey (Brown et al, 2006a) 
In a 2012 review, Walker-Bone highlights the HIV-specific, secondary and traditional risk 
factors for HIV-associated low bone mass, which illustrates the different potential 
negative effects of these factors on aBMD (Figure 2-23). What remains unknown is if HIV 
infection may make individuals more susceptible to certain 'patient' or 'secondary' 
facto rs e.g. poor vitamin D status. 
HIV and ART, separately, and in combination have been associated with poor vitamin D 
status. In addition, other drugs commonly used in HIV-positive patients may have 
deleterious effects on vitamin D status (see Section 2.3). For example, potent CYP450-
inducing drugs, such as rifabutin (used to treat TB), can induce osteomalacia via its 
catabolism of 25(0H)D in the liver (Bolland et al, 2008). There may also be a 
cumulative, negative effect on vitamin D status of using drugs such as rifabutin in 
combination with ART. 
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Figure 2-23 Traditional, secondary, and HIV-related effects on aBMD 
Traditional HIV-related 
• Female gender • Antiretroviral therapy (e.g. Pls, NRTls) 
• Smoking • Viral factors (e.g. p55 gag, gp 120) 
• Caucasian • Immunologic effects (e .g. cytokines: TNF, IL-6) 
• Family history • Premature ageing 
• Increasing age 
• Alcohol 
• Decreased physical activity 
Bone mineral density • Decreased bone acquisition 
• Amenorrhoea/premature menopause 
• Opiates 
Secondary 
• Chronic diseases (e.g. hyperthyroidism, hyperparathyroidism, liver disease, 
meumatological conditions, eating disorders, etc.) 
• Hypogonadism 
• Renal dysfunction 
• Malnutritron/low BMI 
• Medications (e.g. glucocorticoids, anticonvulsants, anticoagulants) 
• Vitamrn D deficiency 
(Walker-Bone, 2012) [Reproduced with permission] 
Seminari et al described an observational study of 68 mainly male Italian patients with a 
median age of 41 years. Of these patients, 81 % had 25(0H)D <45nmol/l (18ng/ml), 
with secondary hyperparathyroidism in 26%, which negatively correlated with 25(0H)D 
as expected. However there were no healthy controls in the study (Seminari et al, 
2005). In a 2010 paper, Mueller et al describe a prevalence of 25(0H)D of <30nmol/l in 
42% of their Swiss HIV-infected patients in spring months (Mueller et al, 2010). 
In their 2012 paper, Sudfeld et al observed that 
"To date no longitudinal studies of vitamin D and HIV disease progression have 
been conducted among adults receiving ART in sub-Saharan Africa or for men and 
non-pregnant women in a resource-limited setting. Examining the relationship 
between vitamin D and HIV disease progression in this population is essential 
given over one million adults initiated ART in sub-Saharan Africa in 2010 and 
coverage is rapidly expanding. Furthermore, no studies have investigated the 
impact of vitamin D on change in CD4 T-cell count in HIV-infected individuals 
receiving ART in a resource-limited setting where individuals start ART at low CD4 
T-cell counts, which will give valuable insight to the mechanism of vitamin D on 
mortality." 
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The authors conducted a prospective cohort study of Tanzanian adults initiating ART to 
address these specific issues and concluded that "deficient (defined as <50 nmol/1) 
vitamin D levels may lead to increased mortality in individuals receiving ART and this 
relationship does not appear to be due to impaired CD4 T-cell reconstitution" (Sudfeld et 
al, 2012) (Figure 2-24) . 
Figure 2-24 Vitamin D status and mortality 
Number at Risk 
Deficient <20 n~ml 
Insufficient_ 20 - 30 n 
0.30..------------------. 
0 
8 
C 
GI 
0.25 
j 0.15 
i 
"3 § 0.10 
0 
0.05 
0.00 
0 
521 
481 
~ 
,r 
, . 
. , 
I 
-
-
3 6 9 12 15 18 21 24 
Months Post ART Initiation 
463 433 370 299 232 
425 383 323 265 199 
;~lationship between incidence of deat~ and vitamin D status, post ART-initiation (Sudfeld et al, 
. 12) (Content under o~en content licenses may be reused without any need to contact the 
licensor. See: http://creatrvecommons.org/licenses/by/2. SI] 
Mehta et al's 2010 paper from Tanzania found that in HIV-positive pregnant women, not 
in receipt of ART, those with the highest concentrations of serum 25(0H)D, mean value 
was 107 ±23 nmol/1, had a 42% less all-cause mortality when compared with those in 
the lowest quarter of vitamin D status (Mehta et al, 2010) . A large international study, 
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with data from 1985 participants, from Europe, Israel, and Argentina, described HIV-
positive patients > 73% male, and >80% white (most of whom were receiving ART) with 
the highest vitamin D status (25(0H)D >50nmol/l) having 0.56 times rates of mortality 
compared with those in the lowest third ( <30nmol/l) (Viard et al, 2011). 
A 2008 Dutch study demonstrated low 25(0H)D concentrations ( <25nmol/l) in 29% of 
252 patients with HIV infection, during the winter months (Van Den Bout-Van Den 
Beukel et al, 2008a) but there was not a HIV-negative control group to compare these 
to. Certain classes of ART were more associated with low 25(0H)D concentrations than 
others; specifically NNRTI compared to PI-containing ART. In this study, patients dark 
skin colour was the only other independent risk factor for low 25(0H)D. 
Other markers of vitamin D metabolism, such as 1,25(0HhD, have been studied in an 
attempt to assess the correlation between vitamin D metabolites and HIV-associated 
prognosis. A study carried out before the advent of modern combination ART 
demonstrated the positive correlation between symptomatic HIV disease, reduced 
survival, reduced CD4 count, and low plasma 1,25(0HhD concentrations (defined as 
<25pg/mL) compared with HIV-negative controls and those without symptoms. 
' Interestingly low 1,25(0HhD concentrations were more closely correlated with reduced 
survival than even CD4 count, which is the most commonly used proxy measure of HIV 
disease progression. The mechanisms for this effect are not known but it is speculated 
that it may be the result of altered antimicrobial activity by the cellular immune system, 
which utilises 1,25(0HhD to effect some of its antimicrobial effects (Haug et al, 1994). 
This, with other studies (Aukrust et al, 1999), provides an intriguing insight into the 
interaction between HIV infection and vitamin D metabolism and HIV disease 
progression. It suggests that HIV, possibly along with AIDS-related conditions, interferes 
with renal vitamin D hydroxylation or 1,25(0HhD consumption or catabolism (e.g. 
metabolism to 1,24,25(0HhD), and a potential interplay between raised TNFa and 
depressed 1,25(0HhD concentrations. As intracellular 1,25(0HhD has been shown to 
enhance the effect of killing of mycobacteria in human macrophages, Haug et al 
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speculate that low plasma 1,25(0HhD may contribute to impaired anti-mycobacterial 
defence thereby predisposing HIV-positive patients to mycobacterial infections (Haug et 
al, 1994). 
The mechanism for this observed low plasma 1,25(0HhD is elusive as 25(0H)D is taken 
up by immune cells and converted into 1,25(0H)iD. Therefore the process resulting in 
depleted plasma 1,25(0HhD may be distinct from its intracellular action. Low plasma 
1,25(0HhD may not reflect the intracellular environment, so it cannot be assumed that 
low plasma concentrations equate to low intracellular concentrations, with attendant 
suppressed antimicrobial effects. A study in the post-ART era examined 1,25(0HhD 
concentrations and it was also noted that they are low; and seen in conjunction with low 
PTH, and low or normal calcium, however, vitamin D status was not described. It was 
speculated that the low observed 1,25(0HhD was due to the inhibitory effects of TNFa 
on PTH secretion and renal hydroxylation of 25(0H)D to 1,25(0HhD (Aukrust et al, 
1999). 
2.5.1.1 Vitamin D supplementation in HIV infection 
In small trials, vitamin D supplementation in HIV-positive adults (n=20 - 74) (Van den 
Bout-van den Beukel et al, 2008b; Childs et al, 2009) and children (n=29) (Arpadi et al, 
2009) has been evaluated. These have demonstrated short-term safety, by not inducing 
hypercalcaemia, and efficacy by increasing 25(0H)D concentrations from baseline. One 
study included daily doses of vitamin D3 of up to 2800 IU/d (70 mcg/d) for HIV-positive 
men with initial concentrations of 25(0H)D of <25 nmol/1 (Childs et al, 2009) without 
toxicity. 
Small -scale studies in HIV-positive patients to assess the effect of supplemental vitamin 
Don bone health have been carried out. In an open label, non-randomised Dutch study, 
after 48 weeks of vitamin D supplementation (1000 - 2000 IU/d (25 - 50 mcg/d)) there 
was no significant difference in whole body aBMD. However the mean femoral neck T-
score was significantly lower at 48 weeks suggesting on-going loss at this site despite 
supplementation with vitamin D (Van den Bout-van den Beukel et al, 2008b). This may 
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suggest that loss of bone mineral was independent of vitamin D status or that a 
suboptimal dosing schedule was used. In this study, vitamin D supplementation resulted 
in decreases in PTH and increases in 25(0H)D and 1,25(0HhD, but when the dose was 
reduced from 2000 to 1000 IU/d after 14 weeks, as per study design, only 25(0H)D was 
significantly raised from baseline. Supplementation had no effect on CD4 count or HIV 
viral load at either dose (Van den Bout-van den Beukel et al, 2008b). 
2.5.1.2 ART and vitamin D metabolism interactions 
Many enzymes of the cytochrome P (CYP) 450 family involved in vitamin D metabolism 
are thought to interact with both NNRTI and PI drugs. Examples are hepatic CYP27A, 
CYP2Rl, and CYP3A4 enzymes involved in 25-hydroxylation and renal CYP27Bl in 1,25-
hydroxylation (see Sections 2.3.8 and 2.3.3). There are also in viva demonstrations of 
tht inhibitory effects of the Pls ritonavir, indinavir, and nelfinavir on CYP450 enzymes 
with net decreases in 25(0H)D in studies that have associated ART exposure with poor 
vitamin D status (Figure 2-25). In 211 HIV-positive patients in Switzerland (Mueller et 
al, 2010), NNRTI use was associated with lower 25(0H)D concentrations and tenofovir 
use associated with higher 1,25(0HhD concentrations. This study retrospectively 
assessed 25(0H)D status of 211 HIV- infected patients at baseline, pre-ART and 12 and 
18 mb~ths post-ART initiation. Only data from patients who were strictly virologically 
suppressed were analysed; the study was limited by lack of a control group, and dietary 
or supplementary vitamin D intake data. The level of 'sufficiency' was set at > 75nmol/l. 
The patients were predominantly white (88%) and male (75%). 43% were treated with 
NNRTI and 53% a PI-based ART regime . As anticipated 25(0H)D concentration was 
higher in autumn after peak sun exposure than in spring (post winter), but not 
significantly affected by ART. 'Sufficient' 25(0H)D concentrations (> 75nmol/l) were 
reached in 4% in the autumn compared with 5-10% measured in the spring. Black 
patients did not demonstrate increased 25(0H)D concentrations in the autumn compared 
with ' non-black' . In mu lt ivariate analysis NNRTI use was associated with a significant 
decrease in 25(0H)D concentrations from 46 (IQR 30-67) to 39 (IQR 21 -60) nmol/1; PI 
use was associated with a non-significant rise from 42 to 43 nmol/1. It was suggested 
119 
that 6-15% of the general Swiss population have 25(0H)D concentrations <75nmol/l 
during winter (Mueller et al, 2010). 
several enzymes have been associated with t.he hydroxylation of 25(0H)D, including 
mitochondrial CYP27A and microsomal CYP2Rl (Wikvall, 2001), the 1-alpha-hydroxylase 
CYP27B and the 24-hydroxylase CYP24 (Pascussi et al, 2005). CYP3A4 has been 
demonstrated to be a human microsomal vitamin D 25-hydroxylase (Gupta et al, 2004), 
efavirenz is a potent inducer of this enzyme and reduces the plasma area under the 
curve (AUC) of other CYP3A4 metabolised drugs, such as methadone, by >50%. CYP3A4 
is important clinically because it is the most abundant CYP enzyme and is involved in the 
metabolism of more than half of the drugs currently on the pharmaceutical market as 
well as potential effects on vitamin D metabolism. Therefore, efavirenz, one of the most 
commonly used ARV, may act in two distinct ways: limiting the 'supply' of 25(0H)D (via 
CYP3A4 in the liver) and increasing the 'breakdown' of 1,25(0HhD (via CYP24) 
(Gyllensten et al, 2006) . 
Tenofovir may induce hyperparathyroidism through effects on renal phosphate hand ling 
(Chi lds et al, 2008; Rosenvigne et al, 2010). As well as inducing renal hydroxylation 
pathways it is also possible that some ARV induce the hepatic and gastrointestinal 
cytochrome enzyme CYP450 3A4. Both commonly used NNRTI ART (efavirenz and 
nevirapine) induce CYP450 3A4, mediating degradation of 1,25(0HhD (Xu et al, 2006). 
I n a case report, Gyllensten had described an African male patient in Sweden (590N) 
developing undetectable (i.e. < 18nmol/l) 25(0H)D 18 months after commencing 
efav irenz-containing ART. This was associated with raised P~H and alkaline phosphatase 
(ALP) and low LS and FN aBMD by DXA (T-score -3.13. and -3.84 respectively). All 
parameters improved after treatment w ith calcium and vitamin D supplementation; after 
nine months of wh ich aBMD had improved by 4% at the LS and 11 % at the femora l neck 
(Gyllensten et al, 2006). 
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Interest in the relative roles of different classes of ART on vitamin D metabolism 
continues. As described above some studies suggest an association between PI and 
others to NNRTI use, and low plasma 25(0H)D concentrations (Cozzolino et al, 2003; 
Gyllensten et al, 2006; Brown, 2009) . Both PI and NNRTI have potent enzymatic effects 
that result in complex and often idiosyncratic effects on drug concentrations in 
particular. It has been suggested that Pis not only reduce 1,25(0HhD production by 
suppressing 25-and 1- alpha hydroxylases but also mildly suppressing 24-hydroxylase 
and therefore have comparatively less influence on the catabolism of 1,25(0HhD 
(Cozzolino et al, 2003; Halick, 2007; Bolland et al, 2008). A similar effect on cytochrome 
P450 has been mooted as responsible for inhibition of oestrogen-synthesizing aromatase 
thereby contributing further to ART-related bone loss through oestrogen depletion 
(Coi;zolino et al, 2003) (see Section 2.4.1). 
Figure 2-25 Interaction of ART with vitamin D. 
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2,6 Micronutrient intakes related to HIV, vitamin D, and bone health 
I n South Africa there are high rates of under- and over- nutrition, so macronutrient 
intake is an important area of research for general health. However since the focus of 
this thesis is bone health and HIV this section will focus on micronutrient intake , 
pa rticularly those relating to bone health and HIV infection. Some micronutrients such as 
calcium, phosphorus, boron, and magnesium are important for bone health and others, 
such as zinc, are important for immune function and bone formation. The sources of 
calcium and phosphorus in the diet have been described in Section 2.3.8. 
Villamar suggests that 90% of HIV-infected people live in areas of the world where 
nutritional deficiencies are prevalent (Villamar, 2006). Data on the role of micronutrient 
deficiencies and the use of supplementation are well described in the context of HIV 
infection, largely in Western populations (Coutsoudis et al, 1995; Tang et al, 1996; 
Baum et al, 1997). In the pre-ART era, studies examined the role of different 
micronutrients on HIV-associated mortality. In a US study by Tang et al (Tang et al, 
1996) data were collected at baseline in 1984 via a semi-quantitative food frequency 
questionnaire, and micronutrient intakes were correlated with subsequent mortality in an 
eight-year follow-up. The highest quarter of B group vitamins intake was positively 
associated with improved survival, whereas the highest zinc intake was associated with 
poorer survival; a finding that appears counter intuitive given zinc's role in immune 
function. This suggests that there is not always a predictable correlation between 
micronutrient intakes and health outcomes. High intakes of some nutrients such as iron - , , 
may decrease host survival by providing disease-causing microorganisms with essential 
nutrients for growth (Smith et al, 1989). On the other hand; Allard has described the 
favourable effects of supplements containing vitamins C and E in HIV-infected patients 
on plasma viral load (Allard et al, 1998). This was a Canadian double blind RCT in which 
patients (n=49) were randomised to receive 1000 mg of vitamin c and 800 IU of alpha-
Tocopherol per day versus placebo. However, more recently well-conducted 
supplementation studies have associated high dose multiv itamin supplements with 
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increased liver function abnormalities in Tanzanian HIV-positive patients (Isanaka et al, 
2012), as well as clinical mastitis and increased HIV-transmission via breast milk 
(Arsenault et al, 2010; Villamor et al, 2010). Such data challenge the validity of the 
notion that high-dose supplements improve outcomes even in populations likely to be 
habituated to chronic nutrient insufficiency. Because ART remains limited in many parts 
of the world, low-cost, health-promoting interventions, including nutritional 
supplementation, to decrease communicable and non-communicable diseases may have 
an important role for those who are unable to access ART or who do not yet require it 
(Fawzi et al, 2004). Clearly, studies in different population groups need to be carried out 
before general or specific recommendations about nutrient supplementation can be 
made. 
I 
2.7 Concluding remarks 
A consensus is evolving linking HIV infection and ART exposure with premature 
osteoporosis (Grund et al, 2009; Nachega et al, 2009), "sounding the alarm that we may 
expect an epidemic of fragility fractures in the future" (Amorosa et al, 2006). 
When considering the interplay between vitamin D status, bone health, and 
' 
comm~nicable disease, such as HIV infection, it is important that populations are studied 
when undertaking their habitual activities and habits (which might include supplement 
use). This is particularly pertinent in tropical countries where it is easy to assume that 
vitamin D status is not affected by season and vitamin D deficiency will be absent. In 
subtropical African countries, such as South Africa, there are distinct seasons with a cold 
winter during which there is decreased or absent UBV radiation and people tend to cover 
their skin to protect against the cold, thereby reducing their opportunity for vitamin D 
synthesis (Pettifor et al, 1978; Pettifor et al, 1996). 
In parts of the world where the HIV epidemic is evolving along with a shift from under-
to over-nutrition such as in South Africa, and ongoing obesity epidemics such as in the 
USA, the possibility of permanent sequestration of plasma 2S(OH)D into adipose tissue, 
obesity per se (Wortsman et al, 2000; Lenders et al, 2009) and HIV-associated 
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li podystrophy may be important factors in determining vitamin D status in HIV-positive 
patients. Whilst these findings might not be applicable to all patients, they do suggest 
that there is a need to conduct studies that will answer the questions: is poor vitamin D 
status a problem in particular populations? If so, would vitamin D supplementation in 
HIV-positive individuals, both on and off ART, improve measures of morbidity and 
mortality as well as bone health? At present there are a lack of RCT data supporting the 
routine supplementation of HIV-positive individuals, particularly those commencing ART. 
As discussed (see Section 2.2. 7 .5), historically, some black African populations have 
lower rates of fracture, however the protective effect African ethnicity seems to afford 
against fracture may be reduced in populations with high rates of HIV infection. If HIV 
and/or ART results in negative effects on muscle function, peripheral nerves, the 
autonomic nervous system as well as bone, all of which are important contributors to 
fracture risk, the fracture rates may increase in these populations. So it is important to 
describe aBMD in populations who may be at increased fracture risk (HIV-positive 
women), particularly in those with less well defined skeletal phenotypes (black Africans). 
Once described, preventative measures can be investigated if appropriate: 
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3 Study design 
The aims of the study were detailed in Section 1.5: 
1. To compare baseline bone mineral status in ART-na"ive HIV-positive Sout h Africa n 
women and compare with HIV-negative controls. To compare baseline 
anthropometry, body composition and serum concentrat ions of 25(0H)D in HIV-
positive women and HIV-negative women; 
2. To evaluate the changes in bone mineral status, anthropometry, body 
composition and vitamin D status in HIV-positive South African women with 
preserved and low CD4 counts with controls, at 12 months after baseline; and to 
compare those HIV-positive women who progressed to ART during the year with 
those who did not. 
3.1 Study location 
The study took place at the Developmental Pathways for Health Research Unit (DPHRU), 
which is a joint MRC (South Africa) and the University of the Witwatersrand unit. DPHRU 
has two main sites, one at the University of the Witwatersrand's Medica l School in 
central Johannesburg and the other at the Chris Hani Baragwanath Hospital in Soweto, 
approxi:-nately 13 kilometres south of central Johannesburg (see Figure 3-1). All 
reference to DPHRU pertains to the Soweto site. 
Figure 3-1 Soweto 
[Source : https://www.google.eo.uk/search?hl-en&q-soweto+south+africa&tbm] 
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DPHRU was formally established in 2011 after reconfiguration of the previous Mineral 
Metabolism Unit and is host to the longitudinal birth cohort, the Birth to Twenty Study 
(Richter et al, 2007) (see Figure 3-2) . 
Figure 3-2 The DPHRU building at the Chris Hani Baragwanath Hospital 
The Chris Hani Baragwanath Hospital is the only government hospital providing care to 
the population of Soweto (see Figure 3-3). This comprises approximately 1.3 million 
individuals, depending on time of year and seasonal changes in internal migration. The 
hospital is mostly used by the most disadvantaged patients for their health needs. 
Poverty is a major problem, with high rates of HIV infection, unemployment, and low 
educational attainment (Willey et al, 2009; Guateng: City of Johannesburg, 2013). 
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Figure 3-3 The Chris Hani Baragwanath Hospital 
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3,2 Setting up the study in South Africa 
After planning discussions with potential collaborators in South Africa I travelled to 
Johannesburg in March/April 2010 during which time I met several key collaborators; 
these included Professors John Pettifor and Shane Norris at the University of the 
Witwatersrand. I also had meetings with Dr Neil Martinson at the Perinatal HIV Research 
Unit (PRHU) at the University of the Witwatersrand and Dr Alan Karstaedt, Head of 
I nfect ious Diseases at the Chris Hani Baragwanath Hospital. These four individuals were 
very supportive of the project and expressed a wish to be involved in the collaboration. 
I nitial ideas about study design were revised and improved after this trip. Development 
of the study benefitted from close collaboration with laboratory and technical staff at the 
DPHRU facilities in Johannesburg; and this was agreed as the site for the study. 
Logistical considerations were discussed and incorporated in the study design (e.g. 
provision of transport costs) . It was suggested that in addition to the PhD project that a 
follow-up of two and three years be incorporated in the study protocol to ultimately allow 
for t he description of longer-term changes in bone and vitamin D status. 
3.3 Study protocol: submission to Ethics and Scientific Committees 
After approvals within MRC Human Nutrition Research, the protocol was submitted to 
MRC HNR Scientific Coordinating Committee (SCC) and to the University of the 
Witwatersrand Ethics Committee for scientific and ethical approval (Ethics Committee 
reference: HREC Number, M101525) . The study protocol and supporting documentation 
were also submitted to, and approved by, the Gauteng Department of Health (see 
Appendix 8); this is required fo r all studies involving patients in this province. Approvals 
included scrutiny of patient-held records for cli nical information if these were avai lable. 
During the study, 4 m inor amendments were made to the study design and successfully 
submitted to t he University of t he Wi twatersrand Human Resea rch Ethics Committee. 
3.4 Study design 
The study enrolled urban South African adult, premenopausal women who were over 18-
years old. 
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The women were assigned to one of 3 groups: 
HIV-negative controls (Nref); • 
• 
• 
HIV-positive with preserved CD4 counts (2::350 x106/I) (Ppres); 
HIV-positive with low CD4 counts (~200 x106/I), due to start ART in the near 
future (Plow). 
Nref had had recent (within 12 weeks) HIV tests, showing them to be negative. The 
women entered Ppres or Plow depending on the CD4 count criteria set using South 
African eligibility thresholds for commencing ART. Local clinic staff sometimes 
commenced a woman on ART at a higher CD4 count depending on clinical judgement. 
The justification for the target numbers in each group is described in Section 3.5. 
Subjects were selected based on meeting the baseline inclusion and exclusion criteria 
(Table 3-1 and Table 3-2). An exclusion criterion was current or planned pregnancy. 
Women consented to undergo pregnancy testing at baseline and prior to each further 
study visit. The primary reason was to avoid recruiting women who would be ineligible to 
undergo DXA scanning. Lactating and postmenopausal women were not enrolled to avoid 
the confounding associated with rapid changes in skeletal mineralisation seen during 
lactation and the menopause. Women who became pregnant, who commenced lactating 
' 
(following a pregnancy) or became climacteric after baseline remained in the study. 
Pregnant women did not undergo DXA scanning. 
Table 3-1 Study inclusion criteria 
General baseline inclusion criteria: 
No current AIDS defining illness (WHO or CDC definitions) 
No known current chronic kidney, liver, thyroid , or bone disease 
No current fracture (i.e. being actively treated) 
Not currently pregnant, lactating or planning a pregnancy 
No recent prolonged bed rest (i.e. >50% of day spent in bed for >2 weeks) 
No use of the following medication: 
- Steroids (i.e. >5 mg prednisolone/day (or equivalent) for >21 days in past 6 months. Inhaled 
and topical steroids were permitted) 
- Bone specific medication (systemic chemotherapy in past 6 months, prior use of drugs to 
increase bone formation e.g. bisphosphonates) 
- Drugs that may disrupt vitamin D metabolism, e.g. phenytoin 
No complaints of persistent fever, cough, or severe pain · in the past week. Other clinical or 
laboratory parameter deemed significant by study clinician 
Not taking part in another research study 
Expecting to be resident in Johannesburg area for 12 months post-enrolment 
Black, premenopausal, and aged > 18 years 
Recent CD4 count if HIV-positive 
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Table 3-2 Study exclusion criteria 
General baseline exclusion criteria: 
Current AIDS defining illness (WHO or CDC definitions) 
Known current chronic kidney, liver, thyroid, or bone disease 
Current fracture (i.e. being actively treated) . 
Current pregnancy or lactation o·r planning pregnancy 
Prolonged bed rest (i.e. >50% of day spent in bed for >2 weeks) 
Use of the following medication: 
- Steroi_ds (i.e. >5 mg prednisolone/day (or equivalent) for >21 days in past 6 months. Inhaled 
and topical steroids were permitted) 
- Bone specific medication (systemic chemotherapy in past 6 months prior use of drugs to 
increase bone formation e.g. bisphosphonates) ' 
- Drugs that may disrupt vitamin D metabolism, e.g. phenytoin 
Complaints of persis~en~ ~ever, cough, or severe pain in the past week. Other clinical or laboratory 
parameter deemed s1gnif1cant by study clinician 
Taking part in another research study 
Not expecting to be resident in Johannesburg area for 12 months post-enrolment 
The study was an observational longitudinal investigation. Details of the methods 
employed are provided in Chapter 4. At baseline, anthropometry, DXA scans, 
questionnaire data, and fasting blood and urine samples were collected. These were 
repeated at 6 and 12 months post baseline. Women in the Nref group were offered 
repeat HIV-testing at 6- and 12-month visits to ascertain current HIV status. 
The study was designed so that the three study visits would be during summer (summer 
and autumn), winter (winter and spring) and summer (summer and autumn) in order to 
evaluate the effect of season, particularly on vitamin D status. 
The study protocol was designed with a focus on subject safety and wellbeing. Strict 
inclusion and exclusion criteria (Table 3-1 and Table 3-2) were employed in order to 
enable timely access to ART and medical care for those HIV-infected women requiring 
ART-i nitiation. The exclusion criteria were intended to ensure that those with acute 
illness did not enrol in the study. Only those Plow women were recruited who did not 
exhibit advanced AIDS since this is associated with general frailty, profound weight loss, 
and associated effects on endocrine function and aBMD. In order to have 
immunologically similar groups, the initial upper CD4 count limit for enrolment into Ppres 
was 500 x106/I, and the lower cutoff of 250 x106/I. A limitation of the study was that 
duration of HIV infection was generally not known as most HIV positive women had not 
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previously been tested. After the inception of the study and prior to completion of 
recruitment, the South African Department of Health amended the threshold for ART 
initiation from a CD4 of $200 x106/I up to $350 x106/I (see Section 1.3.3). In order to be 
able to complete recruitment, an amendment was submitted to the Ethics Committee to 
allow greater flexibility in using CD4 count cutoffs so that subjects could be recruited 
from a much larger pool of potential subjects. It was agreed that Ppres subjects would 
have a CD
4 
count in the region of >350 x106/I and ideally $500 x106 /I wherever 
practical. Plow subjects would have CD4 counts, wherever practical, in the region of 
$200 x106/I but ideally not <50 x106/I. 
CD
4 
and other clinical indicators for receiving ART followed prevailing South African 
guidelines and ART followed current South African standards of care. The study team did 
n~t initiate ART in the research clinic and encouraged all women to continue to attend 
their local clinical services for medical follow up. 
To satisfy research and clinical governance, women gave written informed consent and 
were made aware that the study site did not provide clinical care; if clinical input was 
required during the course of the study, participants were referred to the appropriate 
facilities. Generic health advice was always offered to women if requested, and an 
experienced nursing sister (Thokozile Lephoto) was available to discuss social and 
general health issues. Those women who were initially in the Ppres group, who had an 
unanticipated fall in CD4 count, or who developed symptoms of signs of progressing 
disease and so subsequently required ART initiation, were encouraged to seek medical 
care as soon as possible. 
3.5 Sample size 
Before this study the extent of low aBMD and rate of bone loss (as measured by DXA) 
and low serum 25(0H)D concentrations in this population were unknown. To detect a 
difference of 2% (0.4 SD) change in aBMD over 12 months, allowing for 5% SD, with 
95% confidence and 80% power, 100 cases and 100 controls (n=200) were required. 
After discussion with a senior statistician (Dr Tony Fulford, MRC International Nutrition 
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Group), a more balanced study design across the three groups was adopted to better 
allow discrimination between the two HIV-positive groups. To this effect, and in order to 
account for losses to follow-up of 10%, the minimum number required in the HIV-
positive group was increased to 146 whilst the number in the HIV-negative group was 
reduced to 95 (n=241). 
These sample sizes would enable differences of 0.4SD to be detected in the primary 
outcomes as significant at 5% significance and 80% power. A difference of 2% change in 
lumbar spine aBMD over 12 months would provide a clinically pertinent measure of bone 
loss in this population of women. Such a rapid loss, associated with HIV infection and 
ART exposure would be analogous to aBMD loss in early menopause (1-2%) and would 
be measurable by DXA and clinically significant as a measure of increased future fracture 
risk. 
In the SMART trial (see Section 2.4.2), Grund et al described an annual aBMD decline of 
0.8% hip, 0.4% (spine DXA), and 2.4% (spine QCT) in the continuous ART group (Grund 
et al, 2009). Conversely other studies such as Dolan et a/'s prospective cohort study, 
aBMD remained lower but stable in HIV-positive women compared with controls over two 
years (Dolan et al, 2006). Mondy et al described an increase in aBMD over the 72 week 
follow-up period in 90 patients. There was a small but statistically significant mean 
percentage increase in the subset of subjects who agreed to be followed up; at the LS 
this was 2.6 ±0.6%. This was independent of ART and HIV infection duration but was 
associated with an undetectable HIV viral load at baseline (Mondy et al, 2003). In this 
study>95% of subjects were already receiving ART at baseline so the relative effects of 
ART and other risk factors are difficult to disentangle. 
In South Africa, HIV studies reported dropout rates between 2-10% . (Maskew et al, 
2007 ; MacPherson et al, 2009; Boulle et al, 2010). In this population of mobile, urban 
women we anticipated that loss to follow-up might be greater than the typical upper limit 
of 10% because of death, illness (particularly in HIV-positive subjects), and the potential 
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for relocation (away from Soweto). Since these women were premenopausal we 
anticipated either pregnancy or the onset of menopause in some subjects would limit the 
ability to ascribe bone changes to HIV/ART rather than these life stage events during the 
duration of follow up. To prevent this, prior to enrolment, each woman was asked if she 
was actively planning a pregnancy in the next 12 months and if yes, she was excluded. 
We also tried to ensure that subjects were having regular menses. Attempts to minimise 
attrition included providing transportation costs and provision of a meal after visit 
attendance; transportation costs have been identified as a common cause of losses to 
follow up (Maskew et al, 2007). Public transport around Soweto is limited; most people 
travel by privately operated 'taxi' minibuses that carry multiple passengers at relatively 
low cost. Permission from the Ethics Committee was granted to recruit up to 10 further 
;1· 
subjects per group to account for potential attrition or loss to follow-up. 
In January - February 2011, before the study commenced, an internal 'run through' of 
the protocol procedures took place in order to identify logistical bottlenecks and areas for 
improved volunteer flow. As a result, minor changes were made to the study protocol 
prior to the commencement of the study proper. 
I 
3.6 Study protocol 
Baseline evaluation took place on day O and involved (Table 3-3): 
1. Fasting blood sampling; 
2. Fasting urine sampling; 
3. Dietary evaluation; 
4. Questionnaires: Physical activity, sunlight exposure, and medical/clinical history; 
5. Anthropometry, blood pressure (BP), and grip strength; 
6. DXA (whole body, lumbar spine, hip, and vertebral morphometry); 
7. pQCT (radius and tibia). 
Whi lst the aim was to complete all the evaluation with in one day, the extensive natu re 
meant that t his sometimes extended. Most subj ects completed the evaluation in one 
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day, although several who had forgotten to fast were asked to re-attend to provide 
fasting blood and urine samples on a day close to the first day. 
Those in groups Ppres and Plow had immunological measures (CD4 count, and HIV viral 
loads if available) measured at their normal clinical appointments and the most recent 
resu lts were collected from patient-held records and used in the analysis. Those in Nref 
were asked to repeat HIV antibody testing if their negative result was >3 month prior to 
study entry. 
Table 3-3 Summary of investigations at each study visit 
Time point months/ 
Investigation 
DXA whole body less head 
• Bone, fat mass and lean mass 
DXA regional 
• Lumbar spine 
• Hip 
DXA vertebral morphometry# 
pQCT#** 
• Radius 
• Tibia 
Fasting blood and urine samples 
• Fasting lipid profile & glucose#"' 
Anthropometry 
• BP# 
• Grip strength# 
Questionnaires: 
• Medical/clinical history 
• Physical activity# 
• Dietary# * 
• Sunshine exposure# 
• Socio economic status measures 
0 
...; 
...; 
...; 
...; 
...; 
...; 
...; 
...; 
X 
6 
X 
X 
X 
...; 
...; 
...; 
...; 
...; 
...; 
...; 
...; 
...; 
...; 
...; 
...; 
X 
* Dietary data were collected at each time point and are forming part of an add-on study 
with Dr Alison Feeley, Stephanie Wrottesely and others. 
* *pQCT data were collected at 2 time points and are forming part of an add-on study 
with Dr Kate Ward and others. 
"' Add-on study with Dr Shane Norris 
# data not presented in this thesis 
# # This visit constituted the final visit for the PhD component of the study 
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The 6- and 12-month study visit took place as close to the time as possible with some 
built in flexibility in the protocol (± 6 weeks) to allow participants to be seen at 
convenience to them (see Table 3-3). 
At 6 and 12 months Nref were offered, and underwent, voluntary repeat HIV-testing to 
detect incident HIV infection. Ppres and Plow subjects had their CD4 count and HIV viral 
loads recorded from their patient-held records (if available) as they were measured at 
their usual clinical facilities . The most recent result was used for the midpoint data. 
3.7 Recruitment 
All subjects were assessed for eligibility and provided informed written consent before 
enrolment. The study information sheet was written in English; those who were not 
fluent_,- in English .had the information translated into their own language by one of the 
research staff prior to informed consent being given. Care was taken at the initial 
screening visit to ensure that potential subjects satisfied the inclusion criteria and did not 
satisfy any of the exclusion criteria . 
Time was taken to explain to participants, and their families if appropriate, the purpose 
of the study and the safety of unfamiliar technologies such as DXA scanning. This was, in 
' part, to ·counteract several misconceptions about the nature of biomedical research. 
Some participants believed that the blood samples would be sold for nefarious purposes 
and one participant was under the impression that DXA scanning involved the sampling 
of bone tissue. These concerns could generally be dealt with by careful explanation of 
the rationale behind the study and various scanning technologies. Many participants had 
no experience of medical research and great pains were taken to ensure that their 
consent was fully informed prior to enrolment in the study. 
The vast majority of HIV-negative and HIV-positive subjects were recruited via the ZAZI 
volunta ry counselling and testing (VCT) clinic within the Perinatal HIV Research Unit 
(PHRU) at the Chris Hani Baragwanath Hospital. ZAZI is an open access, free, 
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confidential VCT service provided by PHRU (http://www.phru.co.za/zazi-vct-centre). 
Patients attend the clinic, are registered, and undergo pre- and post-test counselling for 
HIV infection. HIV status is ascertained using a standard, validated point of care test 
(POCT), the results of which are available in the clinic within approximately 30 minutes, 
obviating the need for return clinic visits for results. Those who test HIV-positive 
automatically have further blood samples taken for the measurement of CD4 count. HIV-
positive patients are instructed to attend for their CD4 count result after 7 days, at which 
point a decision is made about any referral for ART initiation, lifestyle advice, and further 
counselling if required. ZAZI is run by an experienced social worker and staffed by a 
team of nurses and counsellors. 
I undertook a series of formal and informal training exercises with the ZAZI staff 
expla ining the purposes of the study, the inclusion criteria, and the potential benefits to 
participants. These training sessions involved a PowerPoint presentation, question and 
answer sessions, and small group discussions. 
To advertise the study, A4 size posters were posted in the waiting room of the clinic and 
more widely around the hospital site alerting patients to what was called 'The Women's 
Bone Study' (WBS). In addition, ZAZI staff informed their patients of the WBS study 
pending the result of their HIV-test result. If a patient expressed interest they were 
given a written information sheet and told that they would be telephoned by a member 
of the WBS study staff to discuss the study further and, if appropriate, to arrange a visit 
to the DPHRU office for informed consent and enrolment into the study. 
Those who tested HIV-negative at the VCT clinic were able to be screened for the study 
as soon as they received their HIV-test result. Those who tested HIV-positive had to 
await the results of the CD4 count to ascertain their eligibility for Ppres or Plow groups. 
There is a strong history of biomedical research in Soweto where HIV-negative 
ind ividuals, in particula r, are sought after by research groups for HIV-prevention studies, 
and retention in WBS was clearly affected (see results : Table 6-2 and Table 6-10) . 
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Recruitment for WBS was initially complicated by a large US-funded vaginal, topical 
microbicide trial recruiting HIV-negative women from the ZAZI clinic at the same time . 
W ·ith this HIV-prevention study for HIV-negative Initially, WBS was competing 
m·1crob·1c·1de gel may have contained tenofovir (or volunteers. Furthermore as the 
placebo) and undergone systemic absorption there was a potential effect of this gel on 
bone. However, the overall numbers of women using the VCT clinic, as well as the 
reluctance of many to take part in a study that required insertion of a vaginal gel, meant 
that the Nref recruitment targets were met. Another complication that affected Ppres 
women was the closure of the 'Wellness' clinic at the PHRU, which saw patients with 
preserved co4 counts who had not yet commenced ART. USAID funding was withdrawn 
from this service in September 2010 and the several hundred patients attending the 
cli ~;c were redirected to their local community clinics for ongoing clinical care. The 
Wellness clinic maintained a database of patient contact telephone numbers, however, 
and eligible patients were contacted by the Wellness staff and asked if they would be 
willing to consider taking part in WBS. So although this initially threatened to affect 
recruitment, the target number was reached well within the allotted period. 
There, was, finally, an unanticipated difficultly recruiting Plow patients. Since there is 
such a high prevalence of HIV infection in Soweto, any difficulty in recruiting patients 
requiring ART, prior to initiation of therapy was not anticipated. However, since many 
patients in this community do not attend for medical assistance until they have advanced 
disease with pronounced symptoms, it was much more difficult to find patients with low 
co4 counts, eligible for ART but who were not yet acutely unwell. We had anticipated 
f th adult HIV clinic at Baragwanath recruiting the majority of Plow patients rom e 
Hospital; however patients referred to 1s service th . · were generally too unwell to be 
considered for the study since ART initiation could not be delayed whilst baseline 
evaluations for WBS were being conducted. The problem was overcome, however, by 
seeking permission from the Gauteng Department of Health to recruit HIV-positive 
patients from local, community clinics in Soweto. Patients attending these clinics tended 
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to have less advanced disease and were, therefore, eligible to take part in the study. 
Sensitisation work along with a multilingual research assistant was carried out with 
clinical staff at community clinics to inform them of the study and to encourage them to 
inform their patients. Information sessions were also offered to the patient support 
groups. However, as a result, Plow subject recruitment was completed approximately 4 
weeks later than the other two groups. Plow therefore had 25 (OH)D measurements 
later than the other groups. This is important since it may have an effect on vitamin D 
status. 
Once women expressed an interest in taking part and were provisionally found to meet 
the inclusion criteria via telephone interview, they were invited to the DPHRU research 
offices to undergo a formal screening process by a clinician and enrolment if appropriate. 
Enrolment was considered complete after the subject had completed the baseline 
evaluation, described in detail in Chapter 4. As the Chris Hani Baragwanath Hospital is 
spread over a very large area most women were met at the ZAZI clinic, by a research 
assistant with whom they were familiar, who accompanied them to the DPHRU building. 
Each participant was reimbursed ZAR 50.00 ( ~£3.50) per study visit, in line with local, 
South African Ethics Committee standards. Since participants had to arrive fasted they 
were also given refreshments, (tea, coffee or fruit juice, and cheese and salad 
sandwiches), following collection of blood and urine samples. At each study visit, 
participants also had their BP measured, finger prick glucose testing, and had their BMI 
calculated. If any of these tests were abnormal by South African standards the 
participant was referred for further assessment to the releva.nt health care professional 
(4.10). Given that access to any type of healthcare service is difficult in poor 
communities in South Africa, this type of opportunistic screening was viewed in a very 
positive light by participants. 
Prior to each study visit, participants were contacted by telephone to remind them of 
their appointment. Attempts were made to maximise retention by ensuring that each 
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study visit did not take too long to complete. Since it is common for mobile telephone 
numbers to be changed frequently in South Africa, not only were participants' mobile 
telephone numbers collected but also the names and contact numbers of next of kin and 
of two other friends or family. As a result it was possible to contact participants 
unavailable on their own contact number. Physical addresses were recorded wherever 
possible, although this was difficult for more informal settlements because street and 
bu ilding numbers are not always readily available. 
All participants were provided with the DPHRU toll-free number so that they could call 
the office without cost. Appointments were made up to 2 weeks in advance; participants 
were then called the day before their appointment as a reminder. A specific WBS mobile 
phone was also used to send a text message the evening before each study visit as 
another form of reminder. This message also reminded the participant to fast overnight. 
Mobile phone usage in urban South Africa is extremely high and virtually all participants 
had access to a mobile telephone. However, even with these intensive attempts to 
encourage attendance, it was very common for women to fail to attend on the appointed 
day, so visits often had to be rescheduled three or more times. Letters provided to 
employers explaining that a participants was absent from work because of participation 
' 
in a study often succeeded in allowing participants to take time off work without being 
penalised. 
Every effort was made to make the experience of each study visit as pleasant as 
possible. For many poor black South Africans their experience of a health care facility 
involves several hours of waiting in crowded circumstances in order to be seen by a 
clinician. Patients often have to give up an entire day to be seen at a clinic or in hospital. 
The experience can be very stressful and is perceived to lack privacy and care. Whilst I 
made it clear to participants that they were attending a research and not a clinical 
facility, they clearly appreciated the professional and courteous manner in which they 
were treated by various members of the study staff. This is likely to have increased 
retention in the study. Each participant was offered a written copy of her relevant study 
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visit results (BP, glucose, weight, and BMI) and this was also generally very well 
received. 
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4 Methods 
4.1 Selection of methods 
The following methods were chosen to try and best answer the specific research 
questions outlined in the aims and objectives. 
Anthropometry was used to measure height, weight, and waist and hip circumferences. 
To compare baseline aBMD and body composition the method of choice was DXA, which 
allows for measurement of bone mineral content, area and density. It also allows for 
estimation of body fat and fat free mass. Laboratory analysis of blood and urine allowed 
for measurement of 25(0H)D and biochemical markers of bone metabolism. 
Questionnaires allowed for assessment of medical/clinical history, socio-economic status 
.,-
(SES), physical activity, sunshine exposure, and dietary intake. pQCT measurements of 
tibia and radius were conducted as part of an add-on study, separate from my PhD 
research. 
4.2 Study team and responsibilities 
The team who were involved in data collection and sample processing were as shown in 
Tabl~ 4'-1. 
Table 4-1 Study staff in South Africa 
Individual Role Duties 
Matthew Hamill# Principal • Study physician 
investigator • Clinical oversight 
• Consent 
• Phlebotomy 
• Fasting blood glucose 
• HIV-antibody testing 
• Medical/clinical history (Appendix 2), 
Physical activity, socioeconomic status 
questionnaires 
Dimakatso Mafokwane* Research • Consent 
assistant • Phlebotomy 
• Fasting blood glucose 
• DXA, pQCT 
• Telephone appointments 
Mary Mokhale Research • Phlebotomy 
nurse • Fasting blood glucose 
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Thokozile Lephoto Research • Consent 
sister • Phlebotomy 
• Fasting blood glucose 
• DXA,pQCT 
Eliza Tsoeu** Research • DXA, pQCT 
assistant 
Thabile Sibiya Research • DXA, pQCT 
assistant 
Mantoa Langa Research • Food Frequency Questionnaire (baseline) 
assistant • Telephone appointments 
Meike Hlalele*** Research • Anthropometry 
assistant • Dietary questionnaires (6 and 12 months) 
Nomses Baloyi Research • All questionnaires 
assistant • Anthropometry 
Zandile Lephoto Research • All questionnaires 
assistant 
Mampho Ratshihule Domestic • Food and beverage preparation 
worker 
Usanda Puta Laboratory • Laboratory analysis 
technician 
Machuene Poopedi Laboratory • Laboratory analysis 
technician 
Jackson Mabasa Research • Biological sample processing and storage 
assistant 
Alison Feeley Post-doctora I 
scientist 
• Dietary analysis 
Stephanie Wrottesley Research • Dietary analysis 
assistant 
*Was a member of the study team until August 2011 
#carried out >90% of consent and phlebotomy 
**Carried out >90% of DXA/pQCT 
***Carried out >90% of anthropometry measures 
Figure 4'-1 Some of the study team members in South Africa 
Left to right: Nomses Baloyi, Mantoa Langa, Zandile Lephoto, Dimakatso Mafokwane, Eliza Tsoeu, 
Mampho Ratshihule, Thokozile Lephoto, Meike Hlalele 
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All the procedures described below were conducted in accordance with DPHRU operating 
procedures. 
4.3 Anthropometry 
Anthropometry was undertaken by a trained, female research assistant who carried out 
the measurements in the vast majority (>90%) of subjects. These measures were 
undertaken in a room used exclusively for anthropometric measurements to ensure that 
the participants had privacy and to ensure that the equipment used was not tampered 
with. The DXA whole body scan was used to provide measures of fat and lean mass and 
to estimate percentage(%) body fat (see Section 2.2.7.1). 
4.3.1 Height 
Height was measured to the nearest 0.1 cm using a permanent wall-mounted 
stadiometer (Holtain, Crosswell, UK) (see Figure 4-2). Subjects were asked to remove 
' 
footwear and to stand erect with the posterior aspect of the heels and shoulders against 
the wall, keeping knees and back straight with the Frankfort plane (i.e. the line between 
the left eye and superior border of the external auditory meatus) in the horizontal 
position. In subjects who wore irremovable, sewn-in wigs or hair weaves the moveable 
portion of the hair piece was flattened and compressed as close to the skull as possible 
without ,causing the subject discomfort. Where buttock adiposity prevented the subject 
from holding the shoulders against the wall without standing upright, she was asked to 
stand as close to the wall as was feasible. 
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Figure 4-2 Volunteer having her height measured 
4.3.2 Weight 
Weight was measured to the nearest 0.1kg using an electronic digital scale (Tanita, TBF-
410 MA Body Composition Analyzer, Tanita Corporation of America, Inc., Illinois, USA) 
with participants wearing light clothing and no shoes. 
4.3.3 BMI 
Body Mass Index (BMI) was calculated as the participant's weight in kilograms divided by 
the square of their height in metres (kg/m2). Underweight, normal, · overweight, and 
obese were defined as BMI < 18.5, 18.5-24.9, 25-29.9, >30.0 respectively (WHO, 2006) . 
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A BMI of >25 or <18.5 triggered a referral onwards to the dietetic clinic at Chris Hani 
Baragwanath Hospital for on-going advice and management. 
4.3.4 Hip and waist circumferences 
Hip and waist circumferences were measured to the nearest 0.1cm. The tape measure 
used was plasticised and non-stretchable and the same measure was used for all 
subjects. The tape measure was held as tightly as possible to the skin without causing 
depression of the underlying skin. Measurements were taken over the minimum amount 
of clothing; asking subjects to expose their abdomen could have been considered 
intrusive. Any bulky item was removed prior to measurement. The research assistant 
ensured that there was no concealed padding as it was anecdotally reported common 
practice that women who consider themselves to be underweight use towels or other 
f;bric padding under their clothes to give the impression of accentuated buttock 
contours. 
Waist measurement was obtained with the subject standing and in a relaxed pose at the 
minimum circumference between the bottom of the rib cage and the tip of the iliac crest. 
Where adiposity made this difficult to visualise, the torso was gently palpated to 
ascertain the area of minimum circumference. 
Hip measurement was taken at the maximum circumference between the waist and top 
of the thighs. 
W aist: Hip ratio was calculated by dividing waist by hip circumferences (Wcirc/Hc;rc) . 
4.4 Assessment of bone health 
4.4.1 Dual-energy X-ray absorptiometry (DXA) 
DXA was performed using an Hologic QDR 4500A dual-energy X-ray absorptiometer 
(DXA) (Model : Discovery w (S/N 71201) software version 12.5:7 Hologic, Inc., Waltham, 
MA, USA) according to standard procedures, see Section 2.2.7 . This DXA machine 
provided measurement of the following sites : whole body (WB) , lumbar spine (LS) , total 
hip (TH) and femora l neck (FN ) . Manufacturer's instructions were fo llowed for correct 
position ing for hip, lumbar spine, and WB scans. Scans were conducted with subjects 
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wearing light clothing having removed metal objects such as jewellery, belts and clothes 
conta ining metal. Scans were performed using the automatic scan mode, i.e. 'array', 
'fast array ' or 'slow array', depending on the weight of the subject. DXA was used to 
measu re BMC (g), BA (cm 2) and aBMD (g/cm 2) of WB, TH, FN and LS (L1-L4). A full set 
of DXA scans was obtained at both basel ine and 12 months, only a WB scan was carried 
out at the six month visit. The reason for this was that it was felt to be unlikely that 
changes in TH, FN, and LS would be detectable at six months. DXA measurements of WB 
were analysed using the 'WB- less head' mode (WBLH) as many women wore wigs and 
hair weaves t hat could not be removed pri or to scanning. This artificial hair was of 
simi lar density to soft tissue and therefore would affect DXA measurements of the head 
region . Total fat and lean body mass (g) were also measured by DXA. aBMD SO-scores 
(SDS) were derived using the HIV-negative controls as the reference popu lation. 
Based on a set of the manufacturer's unpublished assumptions, the bone edges are 
automatically delineated from soft tissue using the attenuation profiles generated. The 
Hologic software (Hologic QDR 4500A (Model: Discovery W (S/N 71201) software version 
12.5:7 Hologic, Inc., Waltham, MA, USA) defines BA, and BMC and aBMb are measured 
with in this area. This is a fanbeam scanner that uses a broad X-ray beam and multiple 
detectors to allow the measurement of attenuation in a row of pixels simultaneously. 
Rad iation doses used in DXA are low and deemed to be safe. They represent little over 
normal background radiation doses (UNSCEAR, 2000; NESCA, 2009; Radiological Society 
of Nort h America Inc. (RSNA), 2010). A set of scans was ca rried out three times during 
the 12-month study period, calculated to be 0.0202 mSv (Radiological Society of North 
America Inc. (RSNA), 2010), this compares with 0.04 mSv for a chest radiograph (Table 
2-2). The global annual , background radiation is measured at 2.4 mSv and South Africa's 
average is close to t his although Johannesburg's is likely to exceed this amount due to 
the presence of gold mining activity and associated uranium deposits in surface soil 
(personal communication, James Larkin). Therefore the DXA radiation dose for each set 
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of scans was equivalent to approximately one day's background rad iation dose and for 
the whole set much less than annual background exposure. 
Prior to scanning, the subject's biographical details were checked to ensu re the correct 
individual was being scanned, and name, date of birth, weight, and height were entered. 
Prior to each DXA scan, the woman was asked if she might be pregnant and a pregnancy 
test performed; the scan was only conducted if the pregnancy test was negative (see 
Section 3.4). 
4.4.1.1 The hip scan 
The left hip scan was acquired with the subject lying on her back and with foot positioner 
between her ankles (see Figure 4-3). This was then aligned with the subject's midl ine. 
The hip was internally rotated 25° and the medial edge of the foot placed against the 
triangle of the foot positioner with the foot held in plantarflexion . The foot was secured 
on the foot brace with a strap. The femur was aligned to be parallel to the table edge to 
provide adequate rotation to ensure correct positioning of the neck box fo r analysis. The 
leg was then abducted from the midl ine in order to straighten the femur. The scanner 
was positioned with the laser light guide positioned over the middle of the left thigh, 
approximately 7 cm below the level of the greater trochanter. The machine then 
automatically carried out the measurement. 
Figure 4-3 A participant undergoing a hip DXA scan 
Reproduced with permission MRC Keneba. Used to illustrate positioning for a TH DXA 
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4.4.1.2 The lumbar spine scan 
The lumbar spine scan was acquired by laying the subject on her back with the body 
positioned so that the spine was straight on the table mattress and the shoulders at the 
upper scan limit line (see Figure 4-4). The pelvis and shoulders were aligned in a straight 
line and centred on the marks on the table pad. The knee positioner was then placed 
under the subject's legs and positioned until the femurs were parallel with the edge of 
the block creating a 45 - 90° angle at the knees, reduci·ng the lumbar lordosis and so 
reducing projection errors in the scan. Finally the subject was instructed to place her 
arms above her head or by her sides, whichever was the most comfortable, and asked to 
breathe normally while remaining still. 
Vertebral assessment via lateral DXA was carried out to determine vertebral fracture 
and/or deformity prevalence within this cohort and to serve as a baseline on which to 
investigate incident osteoporotic fracture in the future. 
Figure 4-4 A participant undergoing a lumbar spine DXA scan 
Reproduced with permi ssion MRC Keneba. Used to illust rate positioning for a LS DXA 
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4.4.1.3 The whole body scan 
This scan was obtained with the subject lying on her back and instructed to keep looking 
at the ceiling while remaining still (see Figure 4-5). The body was straight on the table 
using the centre lines at the head and feet ends of the table as a gauge. The body was 
positioned within the scan limit area whenever possible. Arms were placed by the sides 
with arms pronated and separated from the thighs; the feet were held in plantarflexion 
and held together using a fabric tie. 
The high rates of adiposity in the study participants meant that a large number of 
subjects were unable to fit within the scan field. For those individuals who were too wide 
to fit all of their body into the scan field for the WB scan, initially the individual was 
positioned slightly to the right to try and fit in all of the body except the most lateral 
aspect of the right arm. As a result a number of subjects were scanned so that a portion 
; · 
of their right arm was not within the scan field and a correction applied based on left arm 
values (Micklesfield et al, 2007). The main reason was that gluteal adiposity caused the 
arms to be splayed away from the body (Figure 4-6). During the baseline data collection 
time period there were problems with the mattress slipping on the DXA table resulting in 
a shift of the body marginally to the right. As a result of these 2 combined factors a 
decisi9n was made to systematically replace the right arm measures with those of the 
left in all subjects' data. This technique is known as "whole body result by imputation 
from shifted scans" (International Atomic Energy Agency, 2010) and used the following 
equation (in this example for BMC): 
BMC total imputed=BMC total shifted - BMC right arm + BMC left arm (modified from 
(International Atomic Energy Agency, 2010) 
This process was applied also for BA, and aBMD was recalculated using the new BMC and 
BA values. In order to compare all scans consistently the method was continued for the 
6 and 12 months scans (see Figure 4-7). 
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Figure 4-5 Volunteer undergoing whole body DXA 
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Figure 4-6 Example of right sided 'over-positioning' for WB DXA scan 
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Figure 4-7 DXA operator at DPHRU 
(Eliza Tsoeu) 
4.4.2 Quality assurance (QA) 
Throughout the course of the study daily quality checks were conducted using spine 
phantoms to test scanner performance and are demonstrated in Figure 4-8, Figure 4-9, 
and Figure 4-10. 
Typically, the coefficients of variation for measurements of the manufacturer's phantom 
were 0.39%, 0.34%, and 0.23% for bone mineral content (BMC), bone area (BA) and 
bone mineral density · {BMD) respectively. The coefficients of variation for the DXA 
operator (2 repeat measures on 10 volunteers) of the lumbar spine and proximal femur 
BMD were 0.65% and 0.97% respectively (personal communi·cation, Prof Shane Norris). 
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Figure 4-8 Lumbar spine BMC QA 
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Figure 4-10 Lumbar spine BMD QA 
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4.4.3 Scan quality 
All scans were assessed by me after training by an experienced senior research scientist 
at MRC HNR (Dr Kate Ward). The scans were reviewed and graded each day and where 
possible scans that were technically poor were repeated. 
Scan acquisition: Post-analysis, each scan was graded from one to three, as is 
standard practice in Nutrition and Bone Health (NBH) MRC HNR, according to the ability 
to extract valid data from the scan, taking into account: the positioning of the subject 
and consequently the ability to correctly position the regions of interest; artefacts in the 
scan caused by clothing and jewellery or the presence of metallic joint material. Grade 
three scans were those in which one or more of the above considerations were deemed 
to have affected the scan quality and the ability to generate valid data. Grade two scans 
were those in which one or more of the considerations was in effect but where the effect 
was judged less likely to affect the resultant data. Grade one scans were those 
unaffected by the above considerations. A small number of spine scans were excluded 
from data analysis due to severe problems preventing the scans from being analysed, 
such as visible evidence of soil in the gut lumen due to geophagy. Scans graded as a 
three were repeated whenever practicable. 
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Scan analysis: After analysis, each scan was graded from one to three, as is standard 
practice in NBH, according to the clarity of the scan image, based on the ability of the 
person grading and the analysis program to correctly identify bone edges in the scan. 
Reductions in image clarity occur as a result of subject movement during the scan and 
lead to a reduced confidence in the data extracted. Scans graded as three were those in 
which movement by the subject was deemed to have substantially affected the ability to 
extract valid data. Grade two scans were those in which movement was discernible but 
not considered extensive enough to affect data validity. Grade one scans were those 
where little or no movement was evident. Other reasons to grade a scan as a grade two 
would include the inability to completely separate arm from torso on WB scan due to 
overlying fat or the inclusion of T12 rather than L1 on LS scan. Grade 2 scans would be 
rec:1nalysed by the DXA technician (ET) in order to improve the detection of the correct 
bone edge whenever feasible . They were then re-evaluated by me as the Principal 
Investigator. 
Whilst the grading of scans was subjective it was carried out by the same investigator 
and was therefore consistent. If a scan was of uncertain quality it was discussed with 
Professor John Pettifor and a decision made about its quality and whether it was suitable 
• 
to be included in the analysis. 
4.5 Collection of biological samples 
4.5.1 Fasted blood collection 
Blood was collected in the vast majority of cases by me (see Section 4.2) using standard 
procedures with the subject sitting in a comfortable position on a couch. A suitable vein 
was identified using inspection and palpation, the skin cleaned using an alcohol swab, 
allowed to dry and then blood drawn using the Becton Dickinson vacutainer system and 
blood collection tubes (BD, Plymouth UK). After the needle was withdrawn the area was 
dressed with a cotton wool pad and sticking plaster. The reason to measure fasting 
samples is to avoid any circadian or post-prandial variation in serum concentration. All 
laboratory measurements were carried out by two trained laboratory technicians (see 
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Section 4.2) in the on-site DPHRU laboratory. The samples obtained are shown in Table 
4-2. 
Table 4-2 Blood samples 
serum 
Plasma 
Plasma 
Pla in CAT 
tubes (3 x 10 ml) 
EDTA K2E 7.2 mg 
tubes (4 ml) 
FX lOmcg, 8 mcg 
tubes (4 ml) 
WBS analysis 
25(0H)D 
Routine chemistry : 
Calcium 
Phosphate 
Albumin 
Creatinine 
ALP 
(see section 5.8) 
*Beyond the scope of this thesis 
Planned later 
analysis* 
CTx 
Osteocalcin 
BALP 
FSH 
Lipid profile 
PTH 
Glucose 
Lactate 
4.5.1.1 Fasting blood glucose 
How sample 
processed 
Allowed to clot at 
room temperature 
for 20-60 minutes 
Centrifuged within 
3 hours 
On ice immediately 
Spun within 3 
hours 
Centrifuged within 
3 hours 
On ice immediately 
Centrifuged within 
3 hours 
Samples storage 
-20 oc (4 weeks), 
thereafter -sooc in 3ml 
polypropylene storage 
tubes 
-20 oc (4 weeks), 
thereafter -sooc in 3ml 
polypropylene storage 
tubes 
-20 oc ( 4 weeks), 
thereafter -sooc in 3ml 
polypropylene storage 
tubes 
A fi nger prick blood glucose test was undertaken at each study visit. There were two 
reasons for this. Firstly to alert the study team to previously undiagnosed diabetes 
mellitus and secondly, to confirm that the subject was likely to have undertaken an 
overn ight fast. The use of finger prick glucose monitoring has historically. been used for 
research studies at Bt20/DPHRU to provide evidence of appropriate fasting state. A value 
of ::;; 7 .0 mmol/1 was considered consistent with an overnight fast. Finger prick blood 
sampling was obtained following operators instructions using the Roche, Accutrend® GCT 
(153762) (Roche, Basel, Switzerland) . A blood glucose reading of >11.1 mmol/1 
triggered an immediate referral onwards to the subject's local clinic facility for checking 
and treatment as necessary. A result between 7.0-11.0 mmol/1 triggered a routine 
referral to the subject's local clinical fac ility for repeat testing and appropriate 
management. 
4.5.2 Fasted urine collection 
Urine was collected after an overnight fast, though water was permitted to be drunk. The 
first urine of the day was voided and the second was collected into a sterile universal 
container ( 4. 7 .1). The spot urine sample was collected just before or immediately after 
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phlebotomy. Approximately 20 - 30 ml of urine were collected into a sterile universal 
container and divided into 2 samples in the onsite DPHRU laboratory. 5 ml of urine was 
acidified with 1 drop (=50µ1) of concentrated (38%) hydrochloric acid (HCI). Another 5 
ml of unacidified urine was stored for future analysis. The samples obtained are shown in 
Table 4-3. 
Table 4-3 Urine samples 
WBS 
analysis 
Universal Urinary 
sterile container J3HCG 
Universal Creatinine 
sterile container Calcium 
Phosphate 
(see Section 
4.7 
Planned later 
analysis* 
RBP 
Protein: 
Creatinine ratio 
*Beyond the scope of this thesis 
How sample 
processed 
Refrigerated within 
3 hours then stored 
Acidified and 
refrigerated within 3 
hours then stored 
Samples storage 
-20 oc (4 weeks), thereafter 
-sooc in 5ml polypropylene 
storage tubes 
-20 oc (4 weeks), thereafter 
-sooc in 5ml polypropylene 
storage tubes 
4.Sd HIV-antibody testing . 
At the 6-month and 12-month visits, Nref subjects were offered repeat HIV antibody 
t t t' at a local community facility testing if they had not already undergone repea es mg 
within 6 weeks prior to the visit. HIV-testing used the Alere Determine™ rapid HIV-
antibody test (Alere San Diego, Inc. San Diego, CA). For convenience this test was taken 
at the same time as the fasting blood samples but did not require the subject to be in a 
fasted state. This technique uses point of care technology, the results of which were 
' 
available in approximately 15 minutes. Additional full verbal consent was obtained prior 
to the test being carried out. The consent was taken, and result given, by a trained 
research assistant translating for the Principal Investigator if the subject was unable to 
communicate well in English. The whole blood sample was obtained by finger prick blood 
testing and testing algorithms were followed as per manufacturer's instructions. Each 
test had an internal control to ensure quality control. If the test was reactive then the 
subject was referred to the ZAZI clinic for confirmatory serological testing and CD4 
count. http://www.who.int/diaqnostics laboratory/documents/quidance/determine.pdf). 
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4.6 Laboratory methods (blood) 
4.6.1 25-hydroxyvitamin D 
Blood was collected for 25(0H)D analysis, measured by chemi-luminescent 
immunoassay (Liason) kit DiaSorin Inc., Stillwater, MN, USA). The blood samples were 
allowed to clot for a minimum of 20 min at room temperature, and the serum was 
aliquoted and stored at -20 C until analysed. All samples were run in duplicate. The 
inter-assay CV for low and higher 25(0H)D controls was 10 and 9 %, respectively, 
whereas the intra-assay CV was 8 and 6 %, respectively. The DPHRU laboratory 
participates in the International Vitamin D External Quality Assessment Scheme and 
holds the certificate of proficiency. 
4.6.2 Calcium 
Serum calcium was corrected for serum albumin using the following formula (Ramrakha 
et al, 2010): 
Corrected calcium = measured calcium+ {[40 - serum albumin (g/L)] x 0.02} 
Serum (and urinary (see section 4. 7)) calcium was measured using a colorimetric 
method, whereby the reagent (Arsenazo III) specifically binds to calcium forming a 
coloured complex measured at 660 nm. The amount of calcium present in the sample is 
directly proportional to the intensity of the resulting coloured complex. The assay was 
performed using a Randox Daytona analyser with a 660 nm optical analyser using 
Randox calibration serum level 3 for calibration. Randox assayed multi-sera, levels 2 and 
3 were used for daily quality control, if the values obtained fell outside of the specified 
range then the analysis was repeated. The normal range specified is 2.02-2.65 mmol/1 
for serum, the minimum level of detection for calcium has been determined as 0.20 
mmol/1. 
The following data listed in tabular form in the remainder of this chapter are those 
provided by information in the manufacturers kit inserts. 
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The intra-run precision was as follows: 
Serum calcium Level 1 
Mean (mmol/1) 1.81 
SD 0.01 
CV(% ) 0.88 
N 20 
The inter-run precision was as follows: 
Serum calcium Level 1 
Mean (mmol/1) 1.66 
SD 0.07 
CV(%) 4.35 
N 20 
4.6.3 Phosphate 
Level 2 
2.28 
0.03 
1.51 
20 
Level 2 
2.13 
0.06 
2.99 
20 
Level 3 
4.02 
0.03 
0.83 
20 
Level 3 
3.98 
0.09 
2.16 
20 
Ser6m phosphate was measured using a Randox UV method whereby the inorganic 
phosphorus binds with ammonium molybdate in the presence of sulphuric acid forming a 
phosphomolybdate complex measurable at 340 nm. The assay uses an endpoint method 
and single point calibration. 
The manufacturers determined normal range for serum is 0.87 to 1.45 mmol/1; the 
minimum detectable concentration of inorganic phosphorus, with an acceptable level of 
' 
precision, was 0.144 mmol/1. 
The intra-assay precision was as follows: 
Serum phosphate 
Mean (mmol/1) 
SD 
CV(%) 
N 
Level 1 
0.492 
0.011 
2.25 
20 
The inter-assay precision was as follows: 
Serum phosphate 
Mean (mmol/1) 
SD 
CV(%) 
N 
· Level 1 
0.482 
0.017 
3.52 
20 
Level 2 
1.20 
0.022 
1.83 
20 
Level 2 
1.72 
0.027 
1.59 
20 
Level 3 
2.18 
0.013 
0.61 
20 
Level 3 
2.64 
0.031 
1.16 
20 
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4.6.4 Creatinine 
Creatinine is the product of breakdown of creatinine and creatinine phosphate in muscle 
and is a nitrogenous waste product. Creatinine is not further metabolised but excreted in 
the urine via the kidney. It is produced and excreted in a constant fashion that is 
proportionate to body muscle mass. Because of its constant excretion characteristics it is 
used mainly as a proxy for renal function or to correct for urine dilution. The advantages 
of measuring creatinine as a marker of renal function is that it is relatively independent 
of protein and water intake, exercise and rate of urine production. Since its rate of 
production is constant, elevation of serum creatinine is indicative of renal under-
excretion although it is limited in situations of extremes of muscle mass and differs 
between ethnic groups. 
Measurement of serum creatinine was by Randox colorimetric method whereby 
creatinine in alkaline solution reacts with picrate to form a coloured complex; it is the 
rate of formation of complex that is measured. 
The minimum detectable concentration of serum creatinine with an acceptable level of 
precision was determined as 26µmol/l. The manufacturer's determined normal range 
was 44 - 80 µmol/1 for women. 
The within-run precision was as follows: 
Serum creatinine Level 1 
Mean (µmol/1) 65.3 
SD 2,64 
CV (%) 4.0 
N 88 
The total-run precision was as follows: 
Serum creatinine Level 1 
Mean (µmol/1) 65.3 
SD 3.27 
CV(%) 5.0 
N 88 
Level 2 
131.4 
3.38 
2.6 
87 
Level 2 
131.4 
4.29 
3.3 
87 
Level 3 
384.2 
8.35 
2.2 
88 
Level 3 
384.2 
14.8 
3.8 
88 
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Serum creatinine assays for all samples collected at baseline were conducted at the 
same time with the same kit batch; those collected at the 6 and 12 months timepoints 
were performed some months later using a different kit batch, which had slightly 
different quality characteristics. All urine samples from each of the three timepoints 
were analysed together using the second kit batch. All baseline values for serum 
creatinine were therefore corrected using the formula x78.55/69.2 in order to ensure 
consistency across the longitudinal series and in the calculation of TMP/GFR without 
affecting any observed between-group differences at each timepoint. 
4.6.5 Estimated glomerular filtration rate 
Estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet 
in Renal Disease (MDRD) study formula. It estimates the glomerular filtration rate (GFR) 
using the serum creatinine, age, gender, and ethnicity, i.e.: eGFR (ml/min/1.73m2 ) = 
175 X ((serum Creatinine (1,1mol/l)/88.4r1·154) X age (yearsr0 ·203 X 0.742 if 
female and x 1.21 if African-American (Levey et al, 2006; Stevens et al, 2010). 
However, as per South African guidelines, the African-American multiplier was not 
applied to black African subjects as it tends to lead to an underestimate of eGFR in this 
population when compared with African-Americans, using plasma clearance of 
chrorniu'm-51-EDTA ((51)Cr-EDTA) as a gold standard method of measuring GFR (van 
Deventer et al, 2008). 
4.6.6 Albumin 
Albumin is the most abundant serum protein accounting for 55 - 65% of total protein. It 
is hepatically synthesised and has a half-life of 2 - 3 weeks. The principal biological 
functions of albumin are to maintain water balance in serum and plasma and to 
transport and store a variety of ligands such as calcium, fatty acids, drugs, and 
hormones such as thyroxine. Albumin also provides a source of endogenous fatty acids. 
In catabolic disease states, such as under-nutrition, cancer, and untreated HIV infection, 
albumin synthesis may fail to keep pace with its metabolism resulting in low serum 
albumin concentrations. 
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serum albumin was measured using the Randox Bromocresol Green assay. This 
tech nique is based on albumin's quantitative binding to the indicator 3,3', 5,5'-
tetra bromo-mcresol sulphonophthalein (Bromocresol Green (BCG)). The albumin-BCG-
complex absorbs maximally at 578 nm. 
The minimum detectable concentration of albumin in serum with an acceptable level of 
precision was determined as <4. 7 g/1. The manufacturer's determined normal range for 
adults is 38-44 g/1. 
The within-run precision was as follows: 
Serum albumin Level 1 
Mean (g/1) 14.6 
SD 0.24 
CV(%) 1.62 
N 20 
The between-run precision was as follows: 
Serum albumin Level 1 
Mean (g/1) 14.0 
SD 0.49 
CV(%) 3.48 
N 20 
4.6.7 Alkaline Phosphatase (ALP) 
Level 2 
35.6 
0.43 
1.20 
19 
Level 2 
30.6 
0.67 
2.19 
20 
Level 3 
43.1 
0.53 
1.23 
20 
Level 3 
45.4 
0.79 
1.74 
20 
Measurements of alkaline phosphatase (ALP) activity are used in the diagnosis and 
investigation of hepatobilary disease and bone disease associated with increased 
osteoblastic activity. total ALP activity cannot distinguish between that produced by 
bone and liver, however, it remains a useful adjuvant in assessing bone health and bone 
formation . Bone ALP (BALP) is the bone-specific isoenzyme that can identify ALP 
liberated from osteoblasts and is therefore an important biomarker of bone formation. 
Serum ALP was measured using the Randox optimised standard colorimetric method at 
37°C. The substrate p-nitrophenyl is hydrolysed by alkaline phosphatase from the 
sample, in the presence of magnesium ions, to form p-nitrophenol, which is yellow in 
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colour and can be read at 405 nm. The intensity of colour produced is proportional to the 
alkaline phosphatase activity in the sample. 
The minimum detectable concentration of ALP in serum with an acceptable level of 
precision was determined as 18 U/1. The manufacturer's determined normal values for 
adult females aged less than 60 years are 30 - 80 U/1 at 30°C and 30 - 120 U/1 at 37°C. 
The within-run precision was as follows: 
Serum ALP Level 1 
Mean (U/1) 34.1 
SD 0.45 
CV(%) 1.31 
N 20 
The between-run precision was as follows: 
Ser!Jm ALP Level 1 
Mean (U/1) 56.2 
SD 1.54 
CV(%) 2.74 
N 20 
4.7 Laboratory methods (urine) 
Level 2 
79.6 
1.64 
2.05 
19 
Level 2 
103 
1.72 
1.67 
20 
Level 3 
469 
7.55 
1.61 
20 
Level 3 
406 
2.95 
0.73 
20 
The following analyses were conducted on acidified urine samples (4.5.2), with the 
exception of f3HCG. 
4 .7.1 Urine pregnancy test 
After the urine samples were divided, a commercially available, over-the-counter, 
pregnancy test for measurement of urinary BHCG, was carried out in order to exclude 
pregnancy prior to DXA scanning. 
4.7.2 Calcium 
The same assay was used to calculate urine calcium concentrations as described above 
for serum calcium. 
The intra-assay precision was as follows: 
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Uri ne calcium Level 1 
Mean (mmol/1) 1.57 
SD 0.041 
CV (%) 2.28 
n 20 
The inter-assay precision was as follows: 
Uri ne calcium 
Mean (mmol/1) 
SD 
CV (%) 
n 
4.7.3 Phosphate 
Level 1 
1.75 
0.039 
2.23 
20 
Level 2 
2.16 
0.021 
0.91 
20 
Level 2 
2.23 
0.023 
1.04 
20 
Level 3 
3.90 
0.031 
0.79 
20 
Level 3 
3.77 
0.058 
1.54 
20 
The same assay was used to determine urine phosphate concentration as described for 
serum phosphate (4.6.3). The manufacturers determined normal range is 0.4 - 1.3 
mmol/d 24-hour urine collection. The urine samples for this study were spot urines, i.e. 
t he urines were collected after an overnight fast and were the 2nd void urines of the day. 
The minimum detectable concentration with an acceptable level of precision was 1.14 
mmol/1. 
The intra-assay precision was as follows: 
Urine phosphate · 
Mean (mmol/1) 
SD 
CV (%) 
N 
Level 1 
9.65 
0.27 
2.78 
20 
The inter-assay precision was as follows: 
Urine phosphate 
Mean (mmol/1) 
SD 
CV (%) 
N 
Level 1 
9.15 
0.21 
2.34 
20 
Level 2 
32.65 
0.81 
2.49 
20 
Level 2 
28.8 
0.84 
2.93 
20 
Level 3 
63.43 
1.59 
2.52 
20 
Level 3 
55.1 
1.55 
2.82 
20 
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4.7.4 Creatinine . . 
The same assay was used to determine urine creatinine concentration as described for 
serum creatinine (4.6.4). The manufacturer's determined normal range was 8.84 - 13.3 
mmol/24-hours for 24-hour urine collection. As with urinary phosphate measurements, 
the urine samples for this study were spot urines, i.e. the urines were collected after an 
overnight fast and were the 2nd void urines of the day. 
The minimum detectable concentration with an acceptable level of precision was 
determined as 310 µmol/1. Urine was diluted with 1+8 with 0.9% NaCl solution; this was 
performed automatically using the urinary creatinine programme. 
The within-run precision was as follows: 
Urine creatinine 
Mean (mmol/1) 
SD 
CV(%) 
n 
Level 1 
4.46 
0.10 
2.1 
88 
The total-run precision was as follows: 
Urine creatinine 
Mean (mmol/1) 
SD , ' 
CV(%) 
n 
4.7.5 TmP/GFR 
Level 1 
4.46 
0.13 
3.0 
88 
Level 2 
8.93 
0.18 
2.1 
87 
Level 2 
8.93 
0.26 
3.0 
87 
Level 3 
17.75 
0.27 
1.5 
88 
Level 3 
17.75 
0.50 
2.8 
88 
The ratio of renal tubular maximum reabsorption rate of phosphate to glomerular 
filtration rate (TmP/GFR) is a measure of maximum renal tubular phosphate reabsorption 
I f ·1t t It is independent of other factors in mass per unit volume of glomeru ar I ra e. 
influencing plasma phosphate concentra ion, 1.e. t . · rate of phosphate efflux from gut, 
bones, and cells into the extracellular space, and the GFR. As plasma phosphate 
concentration increases so does the appearance of the ion in urine. When the nephrons 
have reached their maximum capacity to reabsorb phosphate there is a linear 
relationship between increase in plasma phosphate and rate of urine excretion. 
165 
The Mayo Clinic defines measurement of phosphate reabsorption as the most convenient 
way to evaluate renal phosphate transport and set the 'theoretical renal phosphate 
threshold '. This threshold corresponds to the theoretic lower limit of plasma phosphate 
below which all filtered phosphate would be reabsorbed in the renal tubule. Although 
direct measurements of parathyroid hormone (PTH), which increases renal phosphate 
excretion have replaced much of the utility of TmP/GFR measurements, it may still be 
useful in assessing renal reabsorption of phosphate in a variety of pathological conditions 
(Mayo Clinic, 2012). 
Algorithms derived by Kenny and Glen are used to calculate TmP/GFR in this analysis 
(Payne, 1998). 
Urine and blood phosphate (Up and Sp) concentrations are measured, as are blood and 
urine creatinine measurements (Ver and Ser). 
The ratio of phosphate clearance to creatinine clearance gives the fraction of filtered 
phosphate that is not reabsorbed so appears in the urine (e.g. 0.15 or 15%). When 
subtracted from 1.0 this gives the fractional tubular reabsorption of phosphate (TRP) 
(e.g. of 0.85). In general, a low TRP in the presence of hypophosphatemia is indicative 
of a renal defect in phosphate reabsorption. The equation for TRP is: 
TRP=l-[{Up/Sp) x (Scr/Ucr)] 
A value less than, or equal to, 0.86 indicates a value lying in the linear part of the 
excretion curve, suggesting maximum phosphate reabsorption. 
Assuming serum (or plasma) phosphate is equal to that found in glomerular filtrate then 
TRP multiplied by Sp gives the maximum reabsorption per unit volume of filtrate, i.e.: 
TmP/GFR=TRP X Sp 
If, however, TRP is greater than 0.86 then the value lies on the non-linear part of the 
derived curve and a different formula is used to calculate TmP/GFR. The assumptions of 
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Kenny and Glen's algorithms are that Sp = Up, and that Ser is a close proxy of creatinine 
clearance (Payne, 1998; Bagga et al, 2005). The normal tubular reabsorption of 
phosphate is >80% and the TmP/GFR 2.6 - 4.4 mg/dl (0.80 - 1.35 mmol/1). 
4.8 Dietary assessment 
The full background, design, and results of the dietary assessment component of this 
study are located in Appendix 6. A summary of baseline key nutrient intake data is 
presented in Section 5.4. The dietary assessment tool used in this study was the South 
African MRC Food Frequency Questionnaire (FFQ). This dietary intake tool has been 
devised to assess dietary intakes of South Africans and is linked to the food composition 
database called 'Food Finder' dietary analysis programme previously used to estimate 
habitual dietary intake in metropolitan Johannesburg populations (MRC South Africa, 
2002; Zingoni et al, 2009). This tool was used at the baseline visit and all participants 
underwent assessment of dietary intake by FFQ. At the six and 12-month visits, 
participants were asked a modified dietary questionnaire that enquired into changes in 
dietary intake, appetite, and dietary habits since the last visit. The aim of this was to 
identify changes in appetite and dietary, and seasonal, intake patterns and in particular, 
changes associated with exposure to ART. 
4.9 ·Measures of socio-economic status 
Given the high rates of unemployment, it was felt that employment status or occupation 
would not be a good discriminator of socio-economic status (SES). Therefore, at the six 
month visit the women were asked questions about their educational attainment, (i.e. 
which school grade they finished) and the household ownership of certain material items 
such as mobile telephones or microwave ovens; these were then used as a proxy 
measure of SES. Measures of SES are notoriously difficult to equate to actual living 
standards in terms of the economic and social components (Sheppard et al, 2009). The 
brief, 10-point measure of household SES used in this study largely mirrors that used in 
previous South African studies and allowed group compa risons in terms of household 
assets (ibid.). A further proxy for SES was an assessment of educational attainment to 
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evaluate if there were group differences. This evaluation of SES was thought to be 
important as measures of SES are associated with different health outcomes (Griffiths et 
al, 2012) and may influence skeletal health. 
4.10 Clinically reportable data 
Those subjects who had a clinically relevant result, for example a positive HIV-antibody 
test or a BMD Z-score of <-2.0, were referred to the most appropriate clinical service for 
ongoing management. Other reportable data included any abnormal biochemical result 
that was considered clinically relevant. As previously mentioned, underweight and 
overweight participants were offered dietetic referral (Section 4.3.3), and those with a 
blood glucose measurement of >11.1 mmol/1 (Section 4.5.1.1) were immediately 
referred to their local clinical service for follow-up. 
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4.11 Data handling and statistical analysis 
4.11.1Data handling 
All original source documents were examined by me, after completion of each study visit 
and before the participant left the department, so that any implausible or missing data 
and discrepancies could be rechecked or collected. On the rare occasion that I was 
unable to complete this task it was conducted by a trained research assistant 
(Dimakatso Mafokwane) and then the completed forms rechecked by me within one or 
two days. This process of 'check out' was an integral part of the study visit and took 
place with the participant in the room and prior to her being given money for transport. 
The person completing this process signed and dated the paperwork to ensure that all 
data had been checked. 
A cor;nputer database was established at DPHRU by Mat Mainwaring, data manager. All 
data were singly entered from the primary source material (paper forms) into a Microsoft 
Access™ 2010 database by experienced data coder research assistants (Jackson Mabasa, 
Nomses Baloyi, Zandile Lephoto, and Eliza Tsoeu) at DPHRU. Each coder concentrated on 
a specific questionnaire or data set (e.g. anthropometry) until the whole of that dataset 
had been entered into the Access database. Further quality checks were carried out by 
me, wh[ch involved cross-checking 20% of all entered data against the primary source 
material. Any mistakes were passed back to the original data entry research assistant for 
appropriate correction. Regular meetings were held with the research assistants to 
explain the rationale of the study and the reason certain data were being collected. All 
research assistants were encouraged to freely enquire about perceived discrepancies in 
any document so that these could be addressed immediately as well as to provide an 
opportunity for ongoing training. Data was emailed to me by Mat Mainwaring and then 
imported into Microsoft Excel™ 2010 for ease of scrutiny fo r outliers and obvious erro rs, 
then the data were imported into DataDesk. 
4 .11.2Data transformation 
Al l continuous variables were expressed in their original units (Chapters 5 and 6) and 
discrete variables were coded as O or 1. Continuous variables apart f rom age were also 
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tra nsformed into natural logarithms (Ln) to allow for the exploration of proportional 
re lationships between continuous and discrete variables (Chapters 7 and S). Conversion 
to Ln is a convenient way of expressing proportional differences between groups. It also 
allows for a regression analysis in which coefficients provide information about the 
relative influence of each factor on the dependant variable. A sympercent is derived 
when the change in dependant variable is expressed in Ln and then multiplied by lOO, a 
difference between groups or timepoints corresponds closely to the percentage 
difference between them, i.e. (difference/mean) x 100 (Prentice et al, 1994; Cole, 2000; 
Ja rjou et al, 2010). If the independent variable is continuous the coefficient x 100 
corresponds to the percentage increment per 100% change in the variable. The 
transformation of data into Ln also normalises skewness. 
Baseline data are presented in absolute terms for ease of interpretation of actual values. 
For all longitudinal analysis data are presented in absolute terms (e.g. mmol/l) and as % 
difference from baseline. 
4.11.3 Statistical analysis 
All data were analysed using DataDesk 6.1.1 (Data Description Inc, .Ithaca, NY). 
or median Summary statistics were presented as mean (±standard deviation (SD)) 
(i nterquartile range (!QR)), depending on the distribution. Categorical data were 
compared using Chi 2 where appropriate using STATA 11.1 (STATACorp LP, Texas) . When 
there was low cell frequency Freeman-Halton extension to 3*2 tables of Fisher exact 
probability test was use~ instead of Chi 2 • Comparisons were made between the three 
groups of women using hierarchical linear models; ANOVA (or ANCOVA) and Scheffe post 
hoe tests were used to compare group means (standard error. (SE)) . Bone mineral data 
were fully adjusted for age, weight, height, and bone area where appropriate (see 
Sections 4 .11.4, 2.2.7.5 ). A p value of :50.05 was considered to . be statistically 
sign ificant. 
To evaluate individual SA-BMC values, a res idua l value fo r each subject was obtained 
from the relevant model and added to the group mean value. 
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Preliminary plots of the relationship between fat mass and lean mass in this sample 
population demonstrated non-linearity. Regression of fat mass on lean mass in the HIV-
negative control group with data in natural logarithms gave a power exponent of 2.05 ± 
0.14 (SE), indicating that fat mass-to-lean mass2 best described the relationship in this 
population. The exponent was similar when the entire data set were included in the 
model; 1.98± 0.14. The exponent did not change significantly at the 6- and 12-month 
time points; 2.25± 0.14, 2.08± 0.16 respectively. Consequently, a fat mass-to-lean 
mass2 term was used to describe differences in body composition between the groups, 
and logarithmic regression was used to adjust fat mass for lean mass in statistical 
models. 
so-scores (SOS) for aBMO were generated using Nref as the reference population (ref) 
I 
against which the SOS for each individual HIV-positive woman (i) was derived as follows: 
[(aBMOi - mean aBMOref )/SOref.] 
Some women acquired HIV infection during the course of the study. Some in Ppres 
group did commence ART, and some in Plow group did not commence ART as planned 
(see Section 6.1.2). However, as this was an observational study and not a trial, a 
decisiofl was made that subjects should be analysed based on the original group that 
they were assigned to. However, as the major hypothesis (see Section 1.6) was based 
on ART exposure a decision was made to also analyse the data based on exposure to 
ART in a binary No/Yes fashion. To consider a possible association with ART exposure a 
post hoe division of HIV-positive women into those ART-exposed and ART-unexposed 
was performed. These formed two approximately equal groups. This division allowed 
consideration of the question 'did ART exposure influence outcomes such as change in 
bone mineral, body composition or vitamin O status?' The nature of the division was 
dichotomous (Yes or No). Including duration of exposure did not provide further 
discrimination, largely because most that were exposed to ART initiated had ART close to 
baseline, and this variable was excluded in the models presented in Chapter 8 
171 
4.11.4 Model design 
The effect of HIV status and exposure to ART treatment on bone mineral status at each 
site measured, (i.e. total hip, femoral neck, lumbar spine, and whole body) was 
examined in the following ways: 
a. Effect on BMC over time; 
b. Effect on bone area (BA) over time; 
c. Effect on aBMO (aBMO= BMC/BA) over time; 
d. Effect on BMC (and so aBMO) after full correction for age, height, weight, and BA, 
i.e. size adjusted BMC (SA-BMC), to allow for effects on the skeleton independent 
of bone and body size (Prentice et al, 1994); 
e. Where appropriate, effect on BA after correction for age, height, and weight. 
Weight and height were included in the models separately rather than using derived 
measures such as BMI as these, separately, better discriminate effects of body 
composition on bone than when used as a composite measure (Cole et al, 1992). This is 
because both BMC and aBMO are positively and independently associated with height 
and weight (ibid.). The effect of HIV-status and exposure to ART treatment on body 
composition and vitamin O status at each time point was examined. 
Comparisons of changes in BMC, BA, aBMO, and SA-BMC, body composition and 
25(0H)O between the 3 groups were examined using simultaneous, multiple, linear 
regression. For consistency, all variables of interest were included in an initial full model 
for the regression analisis, followed by backward elimination for non-significant factors 
(p> 0.05) (see Figure 4-11). The least significant factors were removed first to produce a 
fina l parsimonious model. Interaction terms (see Section 4.11.4.6) remained in the 
model regardless of their significance. Where appropriate, baseline values of the 
independent variable were induded in the regression model to adjust for regression 
towa rd the mean. 
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4.11.4.1 Regression analyses 
Regression analysis is a statistical technique for estimating the relationships among 
variables. It includes many techniques for modelling and analysing several variables, 
when the focus is on the relationship between a dependent variable and one or 
more independent variables. Regression analysis demonstrates how the typical value of 
the dependent variable changes when any one of the independent variables is varied, 
while the other independent variables are held fixed. 
In order to examine observed changes in variables a series of regressions, and linear 
regressions and group-by-variable interactions were scrutinised. This was intended to 
allow exploration of predictors of key variables such as the ability of fat mass to predict 
vitamin D status (see Section 5.7.1). 
;· The linear models illustrated in Figure 4-11 to Figure 4-14 combined features of 
regression, ANOVA and ANCOVA. ANCOVA is a mix of ANOVA and regression analysis. 
173 
Figure 4-11 An example of a full linear model in DataDesk 
DESIGN 
Dependent variables 
Name Code 
ABMCNeck ABk 
Type of analysis: OLS ANOVA 
Factors 
Name Code Nested in 
Agroup Agp () 
Aage Aag () 
Aheight Ahl () 
Aweight Awl () 
A Area Neck ANk () 
Partial <Type 3) Sums of Squares 
Interactions up to 1 - way 
No Modifications 
RESULTS 
General Results 
F/R 
Fix 
Fix 
Fix 
Fix 
Fi x 
247 total cases of which 5 are missing 
ANOVA 
Analysis of Variance For 
No Selector 
247 total cases of which 5 are missing 
Source df Sums of Squares 
Const 1 4633.76 
Agp 2 1.23086 
Aag 0 .537258 
Ahl 0 . 123123 
Awl 17 .6075 
ANk 7.34337 
Error 235 59 .6652 
Total 241 93 .4349 
Results for factor Agp 
Kind 
Disc 
Cont 
Cont 
Cont 
Cont 
ABHCNeck 
Hean Square F-ratio 
4633.76 18251 
0.61543 2.424 
0.537258 2.1161 
0 . 123123 0.48494 
17.6075 69.35 
7.34337 28.923 
0 .253895 
Prob 
5 0.0001 
0.0908 
0.1471 
0.4869 
5 0 .0001 
5 0.0001 
(Data_Des_k model to examine SA-BMC of the femoral neck. This linear model (i.e. ANCOVA) is a combination of ANOVA and regression analysis) 
4.11.4.2 - Analyses of variance {ANOVA) 
Analysis of variance (ANOVA) was used to ascertain whether two or more groups had the 
same mean value (i.e. as tests for uniformity of mean values). ANOVA is a parametric 
method based on an assumption of normality, i.e. that data are from normally 
distributed populations with uniform variance even in the face of different mean values. 
In reality the ANOVA works well even when the normality assumption is imperfectly 
satisfied (Kirkwood et al, 2005). 
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This comparison statistical testing follows an F distribution. The F-statistic tests the null 
hypothesis of the means of the groups being equal against an alternative hypothesis of 
at least one group mean not being equal. Larger F-values suggest that the mean values 
vary more than anticipated for measures between different groups. Conversely, smaller 
F-values support the null hypothesis that the mean group values are not discernibly 
different between groups (Stear, 1998). The p value for the ANOVA shows the 
probability of observing an F-value as large as the one observed if the null hypothesis is 
true. A small p value suggests that the F-value observed did not occur by chance. In this 
study ANOVA was used to test for differences between the different study groups, i.e. 
Nref, Ppres, and Plew. 
4.11.4.3 Scheffe post hoe testing 
Thes1;i post hoe tests examine differences between the predicted values of the dependant 
variables in pairs of groups by comparing group means. Multiple testing involves a high 
probability of generating type 1 errors, i.e. those that appear to meet the criterion of 
significance by chance. Scheffe post hoe testing has the advantage of controlling for and 
minimising the occurrence of type 1 errors. In this study the type 1 error rate was set at 
5%. When comparing group means of 3 or more groups that are not ordered there is no 
'best approach' for comparing group means (Altman, 1999). One possibility is to 
compare each pair of means ·in turn; the problem associated with this approach is that 
multiple significance testing gives a high probability of finding a significant result by 
chance. Each test has a 5% chance of a false positive result. Scheffe is aimed at 
controlling this overall type 1 error rate and was chosen because of its conservative 
nature (Altman, 1999). It is preferable in comparison with other tests such as the 
Tukey-Kramer method, which examines pairwise differences, as it tends to give 
narrower confidence limits. 
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Figure 4-12 An example of Scheffe post hoe 
DESIGN 
Dependent variables 
Name Code 
ABMCNeck A Bk 
Type of analysis: OLS ANOVA 
Factors 
Name Code Nested in F/R Kind 
Agroup Agp () 
Aage Aag () 
Aheight Aht () 
Aweight Awt () 
A Area Neck ANk () 
Partial <Type 3) Sums of Squares 
Interactions up to 1 - way 
No Modifications 
RESULTS 
General Results 
Fix 
Fix 
Fi x 
Fix 
Fi x 
247 total cases of which 5 are missing 
ANOVA 
Analysis of Variance For 
No Selector 
Disc 
Cont 
Cont 
Cont 
Cont 
ABHCNeck 
247 total cases of which 5 are missing 
Source df 
Const 1 
Agp 2 
Aag 
Aht 
Awt 
ANk 
Error 
Total 
235 
241 
Sums of Squares 
4633.76 
1.23086 
0.537258 
0 . 123123 
17.6075 
7.34337 
59.6652 
93.4349 
Results for factor Agp 
Coeffic ients 
Expected Cel I Means 
Scheffe Post Hoe Tests 
2 - 1 
3 - 1 
3 - 2 
Difference 
-0.0538466 
0. 131994 
0 . 18584 
std. err. 
0.08086 
0.08461 
0.08617 
Hean Square 
4633.76 
0 .6 1543 
0 .537258 
0 . 123123 
17.6075 
7.34337 
0 .253895 
Prob 
0 .801322 
0.298019 
0.0999831 
F-ratio Prob 
18251 ! 0.0001 
2.424 0 .0908 
2 . 1161 0. 1471 
0.48494 0.4869 
69.35 . i 0.0001 
28.923 ! 0.0001 
~=~~~)model in DataDesk (to examine SA-BMC of the femoral neck) de~onstrating Scheffe post hoe 
4.11.4.4 Analysis of covariance (ANCOVA) 
Continuous variables are described as covariates. ANCOVA allows for analyses of both 
discrete and continuous factors, whereas ANOVA is limited to discreet factors. ANCOVA is 
similar to ANOVA but allows the independent, predictor, variable to be a combination of 
discrete and continuous. Where binary variable are used (0/1) ANCOVA is similar to 
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regression analysis. ANCOVA enables the examination of linear trends in dependant 
variables across the range of the covariate (continuous factor). For instance, I was able 
to investigate the influences of continuous variables, e.g. weight or BMI, and discrete 
groups (e.g. subject group) on change in aBMD or vitamin D status. DataDesk sets all 
factors to be discrete by default, therefore the covariates have to be amended to 
'continuous' prior to analysis. 
4.11.4.5 Nesting 
The experimental design of this study included nested factors; these are factors whose 
levels are different for each level of some other discrete factor. Nested factors are 
ordinarily random and this allows separation of the, in this case, individual effect from 
the group effect. Nesting refers to the design wherein each main effect can be nested in 
the,- previous one so that the nesting forms a hierarchy. DataDesk has a function that 
allows nesting of repeated measures so that one factor is linked to another factor. In this 
analysis, individual subject identification (ID) can be nested within the group (Nref, 
Ppres, or Plow). This ensures that linked factors (e.g. individual subject ID and group) 
are controlled for in the analysis. 
Figure 4-13 An example of nesting 
DESIGN 
Dependent variables 
Name Code 
hl25Dnmol /L h2L 
Type of analysis: OLS ANOVA 
Factors 
Name Code Nested ;n F/R 
TpT0..-tL12 T02 () Fix 
IDh IDh <GRh > Ran 
GRPh GRh () Fix 
Partial ( Type 3) Sums of Squares 
Interact ions up to 1 - way 
No Modifications 
RESULTS 
General Results 
741 total cases of w hich 69 are missing 
ANOVA 
Analysis of Variance For 
No Sel@ctor 
Kind 
Disc 
Disc 
Disc 
hL25Dnmol /L 
741 tota l cases of w hich 69 are missing 
Source df Sums of Squares Hean Square 
Const 1 10814.2 10814.2 
T02 2 5 .40137 2 .70069 
IDh 244 57.712 0 .236525 
GRh 2 0 .0604749 0 .0302374 
Err"or 423 26.2791 0 .0621256 
Tota l 671 89.3295 
Re-suits for factor T02 
F-rotio 
45721 
43.471 
3 .8072 
0 . 12784 
(ID (IDh) nested within Group (GRPh)) 
Prob 
i 0 .0001 
! 0 .0001 
i 0 .0001 
0 .8801 
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4.11.4.6 Interactions 
An interaction refers to the combined effect of two or more factors unaccounted for by 
individual factors. An interaction assesses whether the response, as measured by one of 
the variables, changes at different levels of the other factor. 
In DataDesk's linear model function a command allows for interaction terms to be 
created in ANOVA or ANCOVA models. In this study, the relationship between the groups 
(Nref, Ppres, or Plow or ART-unexposed/exposed) and the different time points was the 
main interaction assessed (0, 6, and 12 months) in order to determine whether this 
interaction was more important than each factor individually. This made it possible to 
determine whether the group effect influenced the time effect on the variables of interest 
or vice versa, that is if the time effect influenced group effect. 
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Figure 4-14 An example of an interaction term 
DESIGN 
Dependent variables 
Name Code 
hL25Dnmol /L h2L 
Type of cincilysis : OLS ANOVA 
Factors 
Name Code Nested in F/R Kind 
TpT0....5-12 T02 () 
IDh IDh <GRh) 
GRPh GRh () 
Pcirticil ( Type 3) Sums of Squcires 
Custom intercictions 
Source F/R max df 
Const 1 
T02 F 2 
IDh R 738 
GRh F 2 
T02*GRh F 4 
Error R (5) 
Totcil 740 
No Modifications 
RESULTS 
General Results 
Fi x 
Rein 
Fix 
EMS 
Disc 
Disc 
Disc 
IDh+Const 
T02 
IDh 
GRh+IDh 
T02*GRh 
741 totcil ccises of which 59 cire missing 
ANOVA 
Ancilysis of Vciricince For 
No Selector 
741 totcil ccises of which 59 cire missing 
Source df Sums of Squares 
Const 10814.2 
T02 2 5 . 1915 
IDh 244 57.7317 
GRh 2 0 .0489007 
T02*GRh 4 0 .744959 
Error 419 25.5342 
Totcil 571 89 .3295 
Results for factor T02 
F-Denom 
IDh 
Error 
Error 
IDh 
Error 
hL25Dnmol /L 
Hean Square 
10814.2 
2.59575 
0.235505 
0.0244504 
0.18524 
0.0509407 
(Timepoint (T02)*Group (GRh) interaction term) 
F-ratio 
45705 
42.595 
3.8825 
0 . 10334 
3.0551 
Prob 
S 0.0001 
S 0.0001 
S 0.0001 
0.9019 
0 .0158 
4.11.4.7 Per protocol and post hoe analysis . 
The analysis of the effect of HIV infection on bone mineral status at each site measured 
D Status Was Conducted on a Per Protocol Analysis, so that each as well as on vitamin 
individual was analysed in the original group to which she was assigned. Furthermore, as 
described above (Section 4.11.3) a post hoe analysis was conducted to examine the 
potential effect of ART exposure on bone, body composition, and vitamin D measures. 
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This meant that all subjects were compared according to their original group allocation 
as well as by their ART exposure status in the HIV-positive women. 
Since this study was designed to detect differences between groups in change over time, 
the main reason for this approach was to preserve the original study design that was 
powered to detect differences in changes between groups. Even in these exceptional 
cases subjects were kept in the group that they were originally assigned to for analysis 
to maintain the integrity of the study. Since this was not a clinical trial, it was 
appropriate to track changes in individuals in all the complexities of their circumstances. 
To overcome any bias introduced by this approach, data were analysed in several 
different ways to see if reordering the grouping affected the significance of the results. 
The data were reanalysed based on, for example, CD4 counts less than or greater than 
200 x106/I or 350 x106/I and based on exposure to ART or not. Reanalysing the data in 
these ways did not alter the interpretation of the results, so a decision was made to 
present the data as a Per Protocol Analysis with a further post hoe analysis of the HIV-
positive women. The effect of ART exposure was analysed as a binary variable (see 
Section 4.11.3). Using ART exposure as a continuous variable to represent cumulative 
dose of ART did not affect the interpretation of results. 
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5 Baseline results 
The results of this cross-sectional analysis are in press in Osteoporosis International 
(MM Hamill, KA Ward, JM Pettifor, SA Norris, and A Prentice (Appendix 7)) and Public 
Health Nutrition (SV Wrottesley, LL Micklesfield, MM Hamill, GR Goldberg, A Prentice, JM 
Pettifor, SA Norris, and AB Feeley (Appendix 6)). 
5 .1 Overview 
Weight, BMI, waist circumference, fat mass, and fat:lean2 ratio were significantly greater 
in Nref and Ppres than Plow women. Hip circumference was significantly greater in Nref 
and Ppres than Plow. Nref had a significantly smaller waist: hip ratios than Ppres and 
Plow. The percentage overweight was 65% (in Nref and Ppres) compared to 44% in Plow 
.--(Table 5-6 and Table 5-8). 
There were no significant differences in measures of bone mineral status before or after 
fully correcting for weight and height between the three groups (Table 5-10). Likewise, 
there were no significant between-group differences in vitamin D status (Table 5-12). 
Plow women had significantly lower serum albumin, higher serum phosphate, and 
greater,TMP/GFR than Ppres and Nref (Table 5-13). Nref and Ppres were not different in 
any measure of body composition, bone mineral, or vitamin D status, but Ppres had 
lower serum albumin and higher serum phosphate and TMP/GFR than Nref. 
5.2 Recruitment 
The initial power calculations were based on a total of 241 but the number recruited was 
greater to allow for potential loss to follow-up (see Section 3.5). In order to account for 
a dropout rate of greater than 10%, whilst still retaining the necessary power, the study 
recruited n=247; 98 controls (Nref) and 149 HIV-positive subjects. The HIV-positive 
group comprised 74 .Ppres and 75 Plow. Ppres were women with a CD4 count ~350 x10
6 
cells/I , who underwent regular clinical review and were not anticipated to require ART 
during the course of the study. Plow were women with low CD4 counts (::::;200 x10
6 
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cells/I) who were due to commence ART as soon as feas,·ble v,·a their regular clinical 
provider. 
It was hoped that the three groups would be recruited in parallel, however, in practice 
the Nref women group finished recruitment first, followed by the Ppres and the Plow. 
5.3 Subject characteristics 
Table 5-1 describes the subject characteristics of the women at baseline. As expected 
from the study design, mean ±SD CD4 count (x 106 cells/I) in the Ppres group was 
respectively, significantly higher than that in the Plow group ( 412 ±91 and 161 ±69 · 
p<0.0001). 
· years with HIV-positive women being significantly older Mean age ±SD was 32.1 ±7 2 
on average than HIV-negative women (p <0.01) although th 
· . 
, e age ranges were s1m1lar 
in the three groups (18-49, 22-48 and 19-47 years in Nref, Ppres and Plow respectively). 
Median (IQR) gravidity was 2 (1;3) with both Ppres and Plow having a higher median 
gravidity compared to Nref (p::::;0.0001). Current hormonal contraception usage was 
similar across the groups with about a third of women reporting current usage. 
Table 5-1 Subject characteristics 
Group Nref 
n =98 
Ppres 
n=74 
Plow 
n = 75 
CD4 count x 106 cells/I ~~O <8·1) 33.5 (6.ll 33.4(6.5)6 Min NA 412 (91)3 161 (69t 
Age (years) 
M 
240 18 
ax NA Gravidity median (IQR) 1 (0,· 2) 604 275 Rang 2 (2;3) 2 (1;3) e 0-5 1 0-6A 
Group 
effect 
ANOVA 
p 
0.001 
<0.0001 
NS 
Cu t h 0-6
6
•
3 
rren ormonal contraceptive use (%) 34.0 (35.4)2 26.0 (36 _6)4 All values are Mean ±SD unless stated IQR . . 
_ _ 25.0 (33.3) 0.92 determined; NS, non-significant . ' interquartile range; NA, not applicable; ND, not 
Letters are used to indicate significance of b t · : S!gnif!cantly different from Nref p $O.Ol. e ween-group differences as tested by ANOVA/Scheffe 
c S~gn~f~cantly different from Nref p $0.01. 
· 
1 
S1gnif1cantly different from Ppres p $0.001. 
n=97, 2n=96, 3n=74, 4n=71 
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5 3 1 Socio-economic status/lifestyle factors . . . 
I~di.vidual socio-economic status was evaluated at the 6-month study v1s1t but 1s 
presented here as baseline characteristics for context. Data are presented for 220/247 
participants (89%) (Table 5-2). The number in each group reflects the number returning 
for the 6-month visit, i.e. 84%, 99%, and 87% for groups Nref, Ppres, and Plow 
respectively (see Sections 6.1 and 6.2). 
Table 5-2 Measures of household assets 
Group Nref Ppres Plow p 
n 82 n 73 n-65 
Cellular telephone 
No/Yes (%N;Y) 1/81 (9; 81) 0/73 (O; 100) 1/64 (1; 99) 0.8* 
Microwave 
No/Yes (%N;Y) 13/69 (16; 84) 13/60 (18; 82) 19/46 (23; 71) 0.1 
Video machine 
No/Yes (%N;Y) 13/69 (16; 84) 16/57 (22; 78) 12/53 (19; 82) 0.6 
Telephone 
No/Yes (%N;Y) 66/16 (80; 20) 63/10 (86; 14) 59/6 (91; 9) 0.2 
Washing machine 
No/Yes (%N;Y) 34/48 ( 41; 59) 31/42 (43; 57) 37/28 (57; 43) 0.1 
Fridge 
No/Yes (%N;Y) 1/80 (1; 99) 5/68 (7; 93) 13/52 (20; 80) 0.0003* 
Car 
No/Yes (%N;Y) 
Radio 
52/30 (63; 37) 53/19 (74; 26) 42/23 (65; 35) 0.4 
No/Yes (%N;Y) 
TV 
No/Yes (%N;Y) 
Electricity 
3/79 ( 4; 96) 
3/79 (4; 96) 
4/69 (6; 94) 
2/71 (3; 97) 
No/Yes (%N;Y) 2/80 (2; 98) 2/71 (3; 97) 
N are different from baseline because data obtained at 6_ mon~hs. 
5/60 (8; 92) 
1/64 (2; 98) 
4/60a (6; 94) 
0.6* 
0.9* 
0.5 
"Less than number in the group as item missed on quest1onna1re. . . . _2 
• indicates use of Freeman-Halton extension to 3*2 tables of Fisher exact probability test instead of chi test 
due to low cell frequency. 
Table 5-3 Individual educational attainment 
Level/school grade Nref Ppres % Plow % Educational % 
completed n 82 n-73 n=65 achievement 
2 Nil 0 0.0 0 0.0 1 1.5 
3 1 - 2 1 1.2 2 2.7 0 0.0 
4 3-5 1 1.2 1 1.4 3 4.6 
5 6-7 1 1.2 5 6.8 4 6.2 
6 10 7 8 .5 8 11.0 12 18.5 
7 11 14 17.1 27 37.0 21 32.3 
8 12 (matriculation) 53 64.6 28 38.3 22 33.8 
9 Post matriculation 4 4;9 1 1.4 1 1.5 
10 Diploma 1 1.2 1 1.4 1 1.5 
183 
There were no significant differences between groups in measures of household 
possessions except for possession of a fridge, which was significantly lower in Plow. 
There were group differences in educational attainment Chi2=23.1, p=0.001. This was 
significantly higher in Nref compared with Ppres and Plow, because the control group had 
many more subjects who had attained a matriculation qualification. Educational 
attainment for the Chi 2 test was collapsed into 4 groups (2 - 5, 6, 7, 8 - 10). 
There were no significant differences in self-reported current smoking, current alcohol 
use, or history of ever-fracture (Table 5-4 ). 
Table 5-4 Smoking, alcohol intake, and fracture history 
Nref Ppres Plow 
n=98 n=74 n=75 
Current smoker y 10 13 8 
N 88 87 92 
ND 2 0 0 Current alcohol use y 20 26 16 
N 80 74 84 
ND 0 0 0 
History of fracture y 24 26 13 
N 72 73 85 
ND 4 1 2 
All values are percentages. 
n= number; N, No; ND, Not documented; Y, Yes. 
There were no significant group differences by Chi2 testing . 
5.4 Dietary data 
At baseline there were no significant group differences in the intakes of macronutrients 
and micronutrients relevant to bone health (Table 5-5). United States Dietary Reference 
Intake (DRis) for energy and macronutrients were selected for assessing the intakes of 
the groups compared to recommendations as these are most commonly used in South 
Africa and therefore are the most useful for comparison with other published data 
(Trumbo et al, 2002). The data from the women in the study were therefore compared 
With the US Estimated Energy Requirement (EER) and the Recommended Dietary 
Allowance (RDA) for protein and carbohydrate in adult women aged 19 to 50 years. The 
med ian intakes for carbohydrate, protein, fat, and fibre as proportions of total energy 
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intake were calculated and compared with the Acceptable Macronutrient Distribution 
Ranges (AMOR). 
Energy, carbohydrate, and protein intakes were high across the groups when compared 
to DRis of 10.1 MJ (EER), 130g (ROA) and 46g (ROA) respectively (Trumbo et al, 2002). 
None of the components of dietary intake were different between the three 
groups. Dietary intake exceeded the EER, the ROA for carbohydrate and protein across 
all three study groups. Carbohydrate, protein, fat, and fibre contributed to 
approximately 54%, 11 %, 30%, and 4%, respectively of total energy intake across all 
three groups. Intakes, as percentages of total energy intake, were therefore within the 
AMOR for carbohydrate (45 - 65%), protein (10 - 35%), and fat (20 - 35%) for all 
groups. Approximately 8%, 5%, and 21 % of subjects in the sample had carbohydrate, 
,t· fat, and protein intakes, respectively, below the acceptable range, while 5% and 19% 
had carbohydrate and fat intakes, respectively, above the acceptable range. Alcohol 
contributed to less than 1 % of total energy intake in all groups (Wrottesley et al, 2013). 
Median intakes of calcium and vitamin D were below the recommended intakes of 
1000mg (ROA) and 15mcg (ROA) respectively (Institute of Medicine, 2010). Intakes of 
phosphorus, magnesium, and zinc exceeded the recommended intakes of 700 mg, 
310 - 320 mg, and 8 mg (RDAs) respectively (Institute of Medicine, 2001). 
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5.5 Anthropometry 
There were no significant differences in height between the three groups, although Nref 
tended to be shorter. Nref and Ppres were significantly heavier than Plow but not 
different from each other. Median (!QR) BMI (kg/m2) was 27.3 (23.1 ;31.7), 27.8 
(23.3;32.3), and 23.5 (20.5;27 .0) in Nref, Ppres, and Plow respectively with Plow being 
significantly lower than the other groups. The percentage overweight and obese (BMI> 
25 kg/m2) in Nref, Ppres, and Plow were 65%, 65%, and 44%. The percentage 
underweight (BMI<18.5 kg/m2) was 4%, 1%, and 11% respectively; Plow had a 
significantly lower prevalence of overweight and/or obesity, and higher prevalence of 
underweight than the other groups (Table 5-6). 
Plow had significantly smaller waist circumference than Ppres, and smaller hip 
;· 
circumference than Nref and Ppres. However, the mean waist: hip ratio (WHR) was 
lowest in the Nref group compared with Ppres and Plow suggesting that both Ppres and 
Plow had different fat distri_bution compared to Nref. It is important to recognise this 
difference in WHR was in ART-na'ive women, as frank lipodystrophy and subtle changes 
in body composition are most often attributed to ART. Table 5-7 demonstrates the size 
effect differences in anthropometric measures between the three groups. 
Table 5-6 Anthropometry 
Nref 
n=98 
All values are Mean (SD) unless indicated. 
Height (cm) 157 .6 (5.9) 
Weight (kg) 69 .7 (17.0) 
BMI (kg/m2) median (IQR) 27.3 (23.1;31.7) 
~25 (%) 65 
>24.9, <30 (%) 35 
>30 (%) 30 
<18.5 (%) 4 
Waist circumference (cm) 86.5 (14.2) 
Hip circumference (cm) 107.4 (13.8) 
Waist: Hi ratio cm/cm 0.80 0.07 
Ppres 
n=74 
159.4 (5.9) 
72.0 (17.4) 
27 .8 (23.3;32.3) 
65 
28 
37 
1 
90.2 (15.2)1 
107.5 (13.9) 1 
0.84 0.08 A,l 
Plow 
n=75 
159 .2 (5.3) 
62.3 c15.2l· 8 
23.5 (20.5;27.0l'8 
44 
28 
16 
11 
83.1 (13.9)8 ' 2 
98.4 (13.4l'8 '2 
0.84 0.06 A,2 
cm, centimetres; IQR, interquartile range; kg, kilograms. 
Letters are used to indicate significance of between-group differences as tested by ANOVA/Scheffe. 
A Significantly different from Nref P '.$0.01. 
6 Significantly different from Ppres P '.$0.01. 
1 n=73 
2 n=74 
Group 
effect 
ANOVA 
P= 
0.06 
0.0009 
0.0002 
0.01 
<0.0001 
0.0003 
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Table 5-7 Percentage differences in anthropometric measures 
Variable 
Weight (Kg ) 
Med ian BMI (kg/m2) (IQR) 
Wa ist circumference (cm) 
Hip circumference (cm) 
Wa ist: Hip ratio (cm/cm) 
All values are %(SE) differences. 
Group 
Ppres-Nref 
Plow-Nref 
Plow-Ppres 
Ppres-Nref 
Plow-Nref 
Plow-Ppres 
Ppres-Nref 
Plow-Nref 
Plow-Ppres 
Ppres-Nref 
Plow-Nref 
Plow-Ppres 
Ppres-Nref 
Plow-Nref 
Plow-Ppres 
% (SE) difference 
3.4 (3.6) 
-11.2 (3.5) 
-11.6 (3.8) 
1.1(3.4) 
-13.4 (3.4) 
- 14.5 (3.6) 
4.1 (2.5) 
-4.0 (2.4) 
-8.1 (2.6) 
0.2 (2.0) 
-8.8 (1.9) 
-9.0 (2.1) 
4.0 (1.3) 
4.8 (1.3) 
0.8 (1.4) 
cm, centimetres; IQR, interquartile range; kg, kilograms; m, metres. 
5.5.1 Body composition 
There were significant differences in fat mass with Nref and Ppres women having 
significantly higher fat mass than Plow women (p<O 001) Although I - · . ean mass was also 
higher in Ppres than Plow women (p=0.005), Nref and Ppres had a higher fat mass to 
lean mass2 ratio than the Plow group (p=0.003) (Table 5-8). When fully adjusting for 
lean mass using log-log regression, the Plow group had significantly lower fat mass for 
their lean mass than the other two groups; for each unit of lean mass the Plow group 
had a mean difference ±SE of 16 ±5% less fat than the Ppres group, (p=0.02), and 21 
±5% less fat than the Nref group, (p=0.0002) (see Section 4.11.3). The size effect 
differences in fat mass, lean mass, and fat : lean2 between the three groups is 
demonstrated in Table 5-9. There were no significant differences in Ppres from Nref in 
any measure of body composition. 
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Table 5-8 DXA derived measures of body composition 
Nref Ppres Plow Group effect 
n=98 n=74 n=75 ANOVA 
P= 
WBLH fat (kg) 26.1 (11.5) 26.1 (9.8) 1 19.7 (9.3) A,B,2 <0.0001 
WBLH lean (kg) 38.3 (60.8) 39.5 (62.4)1 36.4 (48.1)8' 2 0.005 
2 9 (4 6)1 14.6 (5.5)A,C,2 0 02 Fat:lean2 (kg/kg ) 17.3 (4.8) 15. . 
_ _ · 
All values are Mean (SD) unless indicated. WBLH, whole body less head. . Letters are used to indicate significance of between-group differences as tested by ANOVA/Scheffe. 
A Significantly different from Nref P S0.001. 
8 Significantly different from Ppres P s0.01 . 
c Significantly different from Ppres P s0.05. 
1 n=73 
2 n=74 
Table 5-9 Percentage differences in fat mass, lean mass, and fat:lean
2 
Variable 
Fat (kg) 
Lean (kg) 
Fat: lean2 
All values are %(SE) differences. 
5.6 Bone mineral status 
I 
Group 
Ppres-Nref 
Plow-Nref 
Plow-Ppres 
Ppres-Nref 
Plow-Nref 
Plow-Ppres 
Ppres-Nref 
Plow-Nref 
Plow-Ppres 
% (SE) difference 
1.2 (6.8) 
-30.3 (6.8) 
-31.4 (7 .2) 
3.3 (2.3) 
4.7 (2.3) 
-7.9(2.5) 
-5.3 (5 .0) 
-20.9 (5.0) 
-15.6 (5.4) 
The bone values at all sites measured at baseline are presented in Table 5-10. As 
described in Section 4.11.4, these were bone mineral content (BMC, g), bone area (BA, 
cm2 ), bone mineral density (BMD g/cm2 ), and size-adjusted BMC (SA-BMC, g). 
The influence of HIV status, age, and anthropometric variables were investigated using 
linear models. Models were built up to examine the effects of potential influences on 
BMC, BA, BMD, and SA-BMC for each variable. Additionally, the effects of current 
cigarette smoking, current alcohol use, and previous history of fracture were built into 
the model. Therefore results are expressed as: 
1. Unadjusted comparisons between three groups (Nref, Ppres, Plow) ~ th 
2. After full size-adjustment (age, height, weight, and BA) between t e ree groups 
(see Section 4.11.4). 
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No significant differences in mean BMC, BMD, or SA-BMC at the TH, FN, LS and WBLH 
were found between groups (Table 5-10). Unadjusted BA was significantly lower in Nref 
compared to Plow at the total hip {TH) (3.9 ±1.5%). At the lumbar spine {LS), Nref BA 
was significantly lower than Ppres and Plow (-3.7 ±1.4% and -4.2 ±1.4% respectively). 
Plow BA was significantly (-3.9 ±1.5%) lower than Ppres at whole body less head 
(WBLH). These differences in BA did not remain significant (p>0.05) when adjusted for 
age, height, and weight. Adjusting the BA values for stature and age removed the 
differences at TH and LS but not WBLH; however, after further adjustment for weight, 
these differences were no longer significant (p>0.05). There were no significant group 
differences in BMD SO-scores for any site measured (p>0.05) {Table 5-11). 
Sequentially adding current cigarette smoking, current alcohol use, and personal history 
of bone fracture, or a combination of these into the models, did not alter the group 
comparisons of bone variables. 
Table 5-10 Total hip, femoral neck, lumbar spine, and whole body bone 
measures 
Total hip 
BMC*(g) 
Area (cm2) 
BMD (g/cm2) 
Femora l neck 
BMC*(g) 
Area (cm2 ) 
BMD (g/cm2 ) 
Lumbar spine 
BMC*(g) 
Area (cm2) 
BMD (g/cm2) 
WBLH 
Nref 
n=98 
Mean (SD) 
31.4 (5.3) 
31.0 (3.08) 
1.013 (0.131) 
4.38 (0.59) 
4.71 (0.34) 
0.930 (0.114) 
55.0 (9.0) 
54.1 (4.84) 
1.018 (0.118) 
Ppres 
n=74 
Mean (SD) 
31.2 (5.1) 
31.7 (3.30) 
0.985 (0.124) 
4.38 (0.63) 
4.79 (0.33) 
0.916 (0.125) 
57.5 (9.5) 
56 .1 (5.06) A 
1.021 (0 .109) 
Plow Group effect 
n =75 ANOVA 
Mean (SD) p-
31.7(4.8) 0.84 
32.2 (3.18)A 0.04 
0.988 (0.125) 0.30 
4.37 (0.66) 0.99 
4.76 (0.37) 0.31 
0.923 (0.131) 0.75 
56.8 (9.4) 0.21 
56.3 (4.43) A 0.003 
1.006 (0.128) 0.72 
BMC*(g) 1606 (232) 1621 (241) 1564 (224) 0.30 
Area(cm2 ) 1670 (145) 1714 (160)· 1647 (142) 8 0.02 
BMD(g/cm2) 0.958 (0.079) 0.943 (0.071) 0.947 (0.080) 0.41 
Area, bone area; BMC, bone mineral content; BMD, bone mineral density; SD, standard deviation; WBLH, whole body less head. 
Letters are used to indicate significance of between-group differences as tested by ANOVA/Scheffe . 
A Unadjusted value significantly different from Nref P :50.05 but not significantly different after size 
adjustment. 
6 Unadjusted value significantly different from Ppres P :50 .05 but not significantly different after 
size adjustment. * No significant differences after full size adjustment (SA-BMC) . 
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Table 5-11 DXA BMD SOS relative to Nrefa 
Ppres Plow 
n=74 N n=75 N 
Total hip -0.211 (0.953) 73 -0.193 (0. 953) 74 
Femoral neck -0.122 (1.096) 73 -0.063 (1.147) 74 
Lumbar spine 0.026 (0.923) 73 -0.099 (1.081) 74 
WBLH -0.194 (0.898) 73 -0.144 (1.009) 73 
All values are Mean ±SD. 
DXA, dual-energy X-ray absorptiometry; SDS, standard deviation score. 
WBLH, whole body less head (see Sections 4.4.1, 4.11.3). 
a SDS for groups Ppres & Plow derived using Nref as the reference population. 
There were no significant group differences. 
5.7 Vitamin D status 
Mean (SD) 25(0H)D for the whole cohort was 60.1 ±18.4 nmol/1 and there were no 
significant differences between groups (p>0.05). 25(0H)D concentration was <50 nmol/1 
in 29.6% of individuals; with similar proportions in each of the groups in this category 
(26.5%, 29.7%, and 33 .3% in Nref, Ppres, and Plow respectively). Very few subjects 
had a 25(0H)D concentration <25 nmol/1 (1.0%, 2.7%, and 5.3% in the three groups 
respectively), despite the slightly greater number of Plow subjects whose blood samples 
for 25(0H)D measurement were obtained during the autumn and winter months (see 
I 
Section 3.7) (Table 5-12). 
Table 5-12 Baseline vitamin D status 
25(0H)D (nmol/1) 
25(0H)D (nmol/1) >50 (%) 
25(0H)D (nmol/1) <50 (%) 
25(0H)D (nmol/1) <25 (%) 
Nref 
n=98 
59.7 (16.5) 
73.5 
26.5 
1.0 
There were no significant group differences. 
5.7.1 Vitamin D status and fat mass 
Ppres 
n=74 
59.2 (16.5) 
70.3 
29.7 
2.7 
Plow 
n=75 
61.6 (22.3) 
66.7 
33 .3 
5.3 
Group effect 
ANOVA 
P= 
0.69 
Fat mass did not predict 25(0H)D concentration in the group as a whole (n=247) at 
baseline; adjusted R2 = 0.1%, coeffic ient -99.5x10-5 (SE 271x10-6), p=0.37. In ART-
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exposed subjects the pattern was similar; adjusted R2=-0.8%, coefficient 170.8xlo-6 
(271. 3x10-6), p=0.53. 
5.8 Biochemistry results 
Serum phosphate was significantly higher in both the HIV-positive groups than HIV-
negative women (p<0.0001) and higher in the Plow compared to Ppres (p=0.05). The 
magnitude of differences was: Ppres-Nref = 12.7 ±2.9%; Plow-Nref = 20.3 ±2.9% and 
Plow-Ppres = 7.6 ±3.1%. 
TmP/GFR was significantly higher in the Ppres and Plow compared to Nref (11.2 ±3.2%; 
27 .4 ±3.2 % respectively) and higher in the Plow compared to Ppres 16.2 ±3.4%, 
(p=0.0002). 
There were highly significant differences (p<0.005) in serum albumin at baseline 
between the groups with the HIV-negative women having significantly higher albumin 
concentrations that the HIV-positive women. Ppres and Plow were 6.5 ±1.3% and 12.3 
±1.3% lower than Nref respectively. Plow was significantly lower, 5.8 ±1.4%, than 
Ppres. 
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Table 5-13 Baseline biochemistry 
Group -Analyte/ Nref Ppres Plow 
effect derived value 
n=74 n=75 ANOVA n=98 
P= 
78.5 (20.8)1 77.7 (17.7)3 74.1 (22.1)3 0.35 Serum Cr (µmol/1) 
81.6 (27.1)1 78.9 (21.1)3 87.6 (34.4) 3 0.16 eGFR 
Serum albumin (g/1) 40.1 (2.27)1 37.6 (2.83l 35.6 (3.94l'6 <0.0001 
Corrected calcium (mmol/1) 2.20 (0.17) 2.24 (0.13) 2.20 (0.08) 0.12 
1.06 (0.16)1 1.21 (0.24l 1.32 (0.34l·c <0.0001 Serum Pi (mmol/1) 
61.3 (24.3)1 57.4 (17.7) 66.8 (27.3) 0.05 Serum ALP (U/1) 
0.17 (0.40)2 0.18 (0.27)4 0.18 (0.36)6 0.06 Urine P/Cr 
1.20 (0.27)1 1.35 (0.34)D,S 1.60 (0.49l'E'4 <0.0001 TmP/GFR 
:~pva!~::li~~e p~~!~~!t~~~; Cr, creatinine; eGFR, estimated glomerular filtrntion rate; P, phosphate; TmP/GFR, ren~I tubular maximum reabsorption rate of phosphate to glomerular filtration rate. 
Letter;, are used to indicate significance of between-group differences as tested by ANOVA/Scheffe. 
A Significantly different from Nref P ::,0.001. 
8 Significantly different from Ppres P ::,0 .001. 
c Significantly different from Ppres P ::,0.05. 
0 Significantly different from Nref P =0.001 - 0.01. 
E Significantly different from Ppres P =0.001 - 0.01. 
1n=97, 2 n=95, 3 n=73, 4 n=72, 5 n=71, 6 n=70 
s.9 Factors influencing renal phosphate handling 
The significance of the difference in serum phosphate results was not augmented by the 
addition of serum creatinine or eGFR into the linear models. Inclusion of age in the 
• 
ANOVA' model for serum phosphate resulted in a marginal decrease in the difference 
between Ppres and Plow (3.6 ±3.0%) (p=0.54). However, the differences between Nref 
and Ppres and Plow remained significant (p<0.05). 
The significance of the difference in TmP/GFR was not augmented by the addition of 
serum creatinine or eGFR into the linear models. 
s.10 summary of groups differences at baseline 
Nref and Ppres subjects were not different in any measure of body composition apart 
from WHR but both were different from Plow. Plow weighed significantly less (p$0.02) 
and had significantly lower BMI (p$0.002) than Nref and Ppres. Nref had significantly 
smaller WHR than Ppres and Plow (p$0.0l), suggesting a possible difference in fat 
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distribution phenotype in HIV-positive women associated with greater risk for cardio-
metabolic disease, even before initiation of ART. Plow had significantly less body fat than 
Ppres or Nref (p$0.001), and significantly less lean mass than Ppres (p=0.005). When 
expressed as fat:lean 2, which best described the relationship between fat and lean 
masses in all the women, Plow had significantly less fat per unit lean mass than Nref and 
Ppres (p$0.02). 
There were no significant differences in BMC, aBMD, or SA-BMC between the three 
groups. Unadjusted BA was significantly lower in Nref compared to Plow at the TH and in 
LS, and lower than Ppres at the LS. WBLH BA was significantly lower in Plow than Ppres 
(p<0.05). These differences in BA did not remain significant (p>0.05) when adjusted for 
age, height, and weight. Adjusting for current cigarette smoking, alcohol intake, and 
history of a previous fracture did not alter any differences in bone status between the 
groups. Examination of HIV-status, bone measures, and vitamin D status, revealed no 
significant correlations. 
There were no significant differences in 25(0H)D between the three groups. There were 
highly significant differences in serum albumin concentrations (p$0.005) with 
Nref>Ppres>Plow, and differences in serum phosphate and TmP/GFR 
(Nref<Ppres<Plow). Both Ppres and Plow had significantly higher serum phosphate than 
Nref. 
The lack of difference in bone and vitamin D status between the groups, which is at 
variance from previously reported studies, may be the result of true lack of effect of HIV 
infection or reflect important differences in bone response to HIV between black Africans 
and Caucasians. The study design in which two distinct groups of HIV-positive women, 
based on South African eligibility criteria for ART-treatment, plus the inclusion of a HIV-
negative control group strengthens the finding that HIV infection with varying degrees of 
immunosuppression does not appear to be driving alterations in BMD or vitamin D status 
in these young, urban women. The high rates of overweight may be masking an effect 
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Table 5-13 Baseline biochemistry 
Analyte/ Nref Ppres Plow Group 
derived value effect 
n=98 n=74 n=75 ANOVA 
P= 
Serum Cr (µmol/1) 78.5 (20.8)1 77.7 (17.7)3 74.1 (22.1)3 0.35 -
eGFR 81.6 (27.1)1 78.9 (21.1)3 87.6 (34.4)3 0.16 
Serum albumin (g/1) 40.1 (2.27)1 37.6 (2.83l 35.6 (3.94l• 6 <0.0001 
Corrected calcium (mmol/1) 2.20 (0.17) 2.24 (0.13) 2.20 (0.08) 0.12 
Serum Pi (mmol/1) 1.06 (0.16)1 1.21 (0.24l 1.32 (0.34t·c <0.0001 
Serum ALP (U/1) 61.3 (24.3)1 57.4 (17.7) 66.8 (27.3) 0.05 
Urine P/Cr 0.17 (0.40) 2 0 .18 (0.27)4 0.18 (0.36)6 0.06 
TmP/GFR 1.20 (0.27)1 1.35 (0.34)D,S 1.60 (0.49t,E,4 <0 .0001 
All values are Mean (SD). 
ALP, alkaline phosphatase; Cr, creatinine; eGFR, estimated glomerular filtration rate; P, phosphate; TmP/GFR, 
renal tubular maximum reabsorption rate of phosphate to glomerular filtration rate. 
Letters are used to indicate significance of between-group differences as tested by ANOVA/Scheffe. 
A s fg nificantly different from Nref P S0.001. 
6 Significantly different from Ppres P S0.001. 
c Significantly different from Ppres P SO.OS. 
0 Significantly different from Nref P =0.001 - 0.01. 
E Significantly different from Ppres P =0.001 - 0.01. 
1n=97, 2 n=95, 3 n=73, 4 n=72, 5 n=71, 6 n=70 
5.9 Factors influencing renal phosphate handling 
The significance of the difference in serum phosphate results was not augmented by the 
addition of serum creatinine or eGFR into the linear models. Inclusion of age in the 
ANOVA model for serum phosphate resulted in a marginal decrease in the difference 
between Ppres and Plow (3.6 ±3.0%) (p=0.54). However, the differences between Nref 
and Ppres and Plow remained significant (p<0.05). 
The significance of the difference in TmP/GFR was not augmented by the addition of 
serum creatinine or eGFR into the linear models. 
5.10 Summary of groups differences at baseline 
Nref and Ppres subjects were not different in any measure of body composition apart 
from WHR but both were different from Plow. Plow weighed significantly less (p::50.02) 
and had significantly lower BMI (p::50.002) than Nref and Ppres. Nref had significantly 
smaller WHR than Ppres and Plow (p::50.01), suggesting a possible difference in fat 
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distribution phenotype in HIV-positive women associated with greater risk for cardio-
metabolic disease, even before initiation of ART. Plew had significantly less body fat than 
Ppres or Nref (p::50.001), and significantly less lean mass than Ppres (p=0.005). When 
expressed as fat:lean2, which best described the relationship between fat and lean 
masses in all the women, Plow had significantly less fat per unit lean mass than Nref and 
Ppres (p::50.02). 
There were no significant differences in BMC, aBMD, or SA-BMC between the three 
groups. Unadjusted BA was significantly lower in Nref compared to Plow at the TH and in 
LS, and lower than Ppres at the LS. WBLH BA was significantly lower in Plow than Ppres 
(p<0.05). These differences in BA did not remain significant (p>0.05) when adjusted for 
age, height, and weight. Adjusting for current cigarette smoking, alcohol intake, and 
history of a previous fracture did not alter any differences in bone status between the 
groups. Examination of HIV-status, bone measures, and vitamin D status, revealed no 
significant correlations. 
There were no significant differences in 25(0H)D between the three groups. There were 
highly significant differences in serum albumin concentrations (p~0.005) with 
Nref>Ppres>Plow, and differences in serum phosphate and TmP/GFR 
(Nref<Ppres<Plow). Both Ppres and Plew had significantly higher serum phosphate than 
Nref. 
The lack of difference in bone and vitamin D status between the groups, which is at 
variance from previously reported studies, may be the result of true lack of effect of HIV 
infection or reflect important differences in bone response to HIV between black Africans 
and Caucasians. The study design in which two distinct groups of HIV-positive women, 
based on South African eligibility criteria for ART-treatment, plus the inclusion of a HIV-
negative control group strengthens the finding that HIV infection with varying degrees of 
immunosuppression does not appear to be driving alterations in BMD or vitamin D status 
in these young, urban women. The high rates of overweight may be masking an effect 
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and more dramatic differences in aBMD and vitamin D might have been seen in women 
with advanced clinical HIV-disease not included in this study. The baseline data from this 
study provide an insight into bone health, body composition, and vitamin D status in 
African women living with HIV. They challenge the original hypotheses of this study, 
which was based on previously reported differences in aBMD and vitamin D status in 
HIV-positive subjects living in developed countries, and highlight the importance of 
studying subjects prior to ART exposure. 
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6 Follow-up results 
6.1 Consort diagram for study 
Baseline HIV-negative (Nref) 
N=98 
Death: n=O 
Pregnancy: 
n= O 
Lactation: 
n= 0 
W/NA: n= 
16 
Agreed to be contacted 
N = 313 
Number agreed to attend for screening 
N= 297 
Excluded at screening visit 
N=16: 
Postmenopausal: n=2 
Did not complete screening visit: n=14 
Enrolled into study 
N= 247 
Preserved CD4 count 
(Ppres) 
N= 74 
Death: n=O 
Pregnancy: 
n= 5* 
Lactation: 
n= 0 
W/NA: n= 1 
Did not wish to 
attend for screening 
N=16 
Did not attend for 
screening 
N=34 
Baseline HIV-positive 
N=149 
Low CD4 count (Plow) 
N= 75 
Death:n=l 
Pregnancy: 
n= 1 * 
Lactation: 
n= O 
W/NA: n= 7 
I 
Attended for 6- Attended for 6-Attended for 6-
month visit (Ppres) month visit (Plow) 
month visit Seroconversion: 
(Nref) 7 n= 1* N= 73 N= 67 
N= 82 t t 1' 
Attended for 6-month visit N = 222 (90%) I 
t t t 
Death: n= 0 Death: n=l Death: n= 0 
Pregnancy: Pregnancy: ? Menopause: Pregnancy: 
n= S* n= 3* n= 2* n= S* 
Lactation: Lactation: Lactation : 
n= 0 n= 0 n= 2* 
W/NA: n=4 ' W/NA: n=4 W/NA: n= 6 
1 \V w 
Attended for 12- Attended for 12-Attended for 12-
month visit (Ppres) month visit (Plow) 
month visit 
(Nref) 
N=76 (78%) 
t 
Death: n= O 
Pregnancy: 
n= S* 
Lactation: 
n= 2* 
Nref 
p,, 
' 
Seroconversion: 
n= 3* N=69 (93%) 
t 
Total attendees at 12 months N= 208 (84%) 
Death: n= 0 
Pregnancy: 
n= 10* 
Lactation: 
n= 0 
Ppres 
N= 63 (84%) 
t 
Death: n= 2 
Pregnancy: 
n= 3* 
Lactation: 
n= 1 * 
? Menopause: 
n= 3* 
Plow 
cumulative events (by Group) . 
W/NA = withdrawal/non-attendance. *These participants remained in the study in the group assigned at 
baseline 
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6.1.1 HIV seroconversion and changes in CD4 count 
Nref women consented to HIV-testing at the six and 12 month study visits. The uptake 
of this was excellent with only one participant declining the test at six months. Over the 
cou rse of the study, four (4.1%) participants seroconverted from HIV-negative to HIV-
positive. This equates to 5.3% incidence rate (4/76) using the number of participants 
seen at 12 months as the denominator. One seroconversion occurred between baseline 
and 6 months, and three between the six and 12-month visits. Each woman was referred 
for confirmatory HIV-testing to the ZAZI clinic, PHRU and for CD4 count measurement 
and entry into cl inical care. 
South African guidelines for initiating ART changed from a CD4 count of S200 x106/I, to 
S350 x106/I during the course of the study. Some women in the Ppres group had falls in 
their CD4 counts and were therefore initiated on ART, which had not been anticipated at 
the inception of the study to be likely before 12 months. Some women in the Plow 
group either had an increase in CD4 or, more commonly, had not commenced ART as 
adv ised. There was therefore some switching between the predefined groups, according 
to CD4 count status. Despite th is, there were the predictable significant differences in 
CD4 count between Ppres and Plow at the 6- and 12-month visits. 
Table 6-1 Changes in CD4 counts from baseline 
Ppres 
CD4 count x106 cells/I 
Min 
Max 
Plow 
CD4 count x 106 cells/I 
Min 
Max 
SE, standard error 
6 Months 
Mean (SD) 
N= 69 
398 (116) 
99 
800 
N=64 
183 (114) 
18 
780 
% change 
from baseline 
SE 
-4.8 (0.05) 
11.6 (0 .05) A 
12 Months 
Mean (SD) 
N= 64 
421 (163) 
160 
1328 
N= 62 
256 (133) 
, 28 
600 
% change 
from baseline 
SE 
-2.6 (0.05) 
42.0 (0.05) A 
Letters are used to indicate significance of between-group differences as tested by ANOVA/Scheffe. 
A Significantly different from Ppres P ~0 .001. 
6.1.2 Group designation 
As th is was an observationa l study and not a clinical t rial, a decision was made that data 
should be analysed based on the original group that subjects were assigned to. The 
numbers involved and the di rection of movement are represented in Figure 6-1. As 
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previously discussed, a post hoe analysis of the data based on exposure to ART, was also 
performed; these data are presented in Chapter 8. 
I 
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Figure 6-1 Group changes 
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6.2 6 month time point 
6.2.1 Retention at 6 months . 
h t d · ·t 10 101 (25/247) participants did not attend for their follow-At the 6-mont s u y v1s1 , . 10 
up, resulting in data on 222 women being collected for analysis. 
Table 6-2 Losses to follow-up at 6 months 
Group/ Nref Ppres Plew 
reason N (%) N (%) N (%) 
Loss to follow up 17 (17.3) 0 (0) 8 (10. 7) 
Death 0 (0) 0 (0) 1 (1.3) 
No longer willing/able to take part 2 (2.0) 0 (0) 0 (0) 
Moved away 1 (1.0) 0 (0) 0 (0) 
Joined another study 4 (4.1) 0 (0) 0 (0) 
Not contactable 10 (10.2) 0 (0) 7 (9.3) , 
The reasons for non-attendance were death, no longer willing/able to take part, moved 
away, or joined another study and was ascertained in 32%; the remainder of 
participants were not contactable, despite several telephone calls and home visits where 
feasible (Table 6-2). Table 6-3 shows the mean (SD) duration from baseline to the 6-
month vis.it 'for each of the three groups. 
Table 6-3 Mean (SO) duration of follow-up at 6-month visit 
Group N (%) 
Nref 82 (84) 
Ppres 73 (99) 
Plew 67 (89) 
Baseline to 6-month visit 
days mean (SD) 
173 (32) 
164 (26) 
166 (25) 
There were no significant group differences. 
Similarly, not all of the HIV-positive participants commenced ART at the same time after 
their baseline visit. Table 6-4 illustrates the mean duration of ART exposure. 
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Table 6-4 Mean (SO) duration of ART exposure at 6-month visit 
Group N(%) Duration of ART exposure* 
at 6-month visit days mean (SD) 
Nref NA NA 
Ppres 9 (12) 93 (93) 
Plew SO (67) 140 (39) 
NA, not applicable. * refers only to those who started ART. 
The majority of patients who initiated ART were prescribed the South African standard, 
first line, triple combination of lamivudine, tenofovir, and efavirenz. Table 6-5 and 
Figure 6-2 describes the types of ARV drugs prescribed to Plew and Ppres women from 
baseline until they were reviewed at their 6 month visit. Figure 6-4 represents the 
proportions of different combination therapies in Plew and Ppres as a % of those 
exposed to ART in each group. 
Table 6-5 ART usage at 6-month visit 
ART drug/Group Ppres N (%) 
AZT: Zidovudine 2 (2. 7) 
3TC: Lamivudine 7 (9.6) 
TDF: Tenofovir 6 (8.2) 
D4T: Stavudine 1 ( 1.4) 
ABC: Abacavir 0 (0) 
NVP: Neviripine 1 ( 1.4) 
EFV: Efavirenz 6 (8.2) 
Figure 6-2 ART usage at 6-month visit 
60 
._ 40 
.8 
E 
:, 
Z 20 
6MARV 
ARV 
Plow N (%) 
0 (0) 
50 (74.6) 
48 (71.6) 
1 (1.5) 
0 (0) 
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44 (65.7) 
CJ Ppres 
~ Plow 
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Figure 6-3 ART combinations in Ppres at 6 months 
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Figure 6-4 ART combinations in Plow at 6 months 
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6.2.2 Pr,egnancy 
Figure 6-1 shows the number of pregnancies, after baseline and before the six month 
visit. There were 5 pregnancies (6.8%) in Ppres and 1 (1.5%) in Plow. 
6.2.3 Anthropometry 
At 6 months (Table 6-6) the mean weight in all groups had increased since baseline 
(Table 5-6) by 0.9, 0.3, and 1.8 kg (Nref, Ppres, and Plow respectively). Weight 
remained significantly less in Plow than Ppres and Nref. Weight in Ppres was non-
significantly higher than in Nref. The median BMI was significantly lower in Plow than 
Nref and Ppres which were the same. Mean waist circumference was non-significantly 
greater in Nref and Ppres compared with Plow, and hip circumference was statistically 
lower in Plow compared to the other groups. There were non-significant differences in 
WHR (Table 6-6) . 
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Fat mass remained significantly lower in Plow than Nref and Ppres. Lean mass was 
significantly lower in Plow than Ppres, and fat: lean2 was significantly lower in Plow than 
Nref (Table 6-6). 
Table 6-6 Anthropometry at 6 months 
Nref Ppres Plow Group effect 
n=82 n=74 n=67 ANOVA 
p 
Weight (kg) 70.6 (17.1) 72.3 ( 16. 7)1 64.1 (15.4/ 0.01 
BMI (kg/m2) median (IQR) 27.4 (23.7;32.4) 27.4 (24.2;32.3) 1 24.4 (21.4;27.9/•8 0.003 
>24.9 kg/m2 (%) 63 65 48 
>30 kg/m2 (%) 34 38 18 
<18.5 kg/m2 (%) 5 1 9 
Waist circumference (cm) 88.0 (15.2) 88.0 (19.8)2 83.4 (17.4) 0.21 
Hip circumference (cm) 109.0 (14. 7) 109.1 (13. 7)1 101.7 (12.6/•8 0.002 
Waist: Hip ratio 0.81 (0.06) 0.79 (0 .17)1 0 .82 (0 .12) 0.52 
Fat mass (kg) 26.6 (11.8} 26.4 (10 .1)3 21.2 (9.1/•8 •4 0.04 
Lean mass (kg) 38.6 (5.7) 39.9 (5.7)3 36.9 (5.0/·4 0.01 
Fat: lean2 (kg/kg2 ) 17 .3 (4 .7) 16.3 (4 .7)3 15.1 (4.6)8·4 0.02 Values are mean (SO). 
Letters are used to indicate significance of between-group differences as tested by ANOVA/Scheffe. A Significantly different from Ppres P $0.01. 
8 Significantly different from Nref P $0.01. 1n=72, 2n=71, 3n=67, 4n=65 
6.2.4 Bone measures 
At the 6-month study visit, subjects had whole body DXA scans but no other skeletal 
sites because it was deemed unlikely to see changes in TH, FN, and LH after 6 months 
(see Section 4.4.1). There were significant differences in BA with Plow being significantly 
lower than Ppres, and in SA-BMC with Ppres significantly lower than Nref (Table 6-7). 
Table 6-7 Bone minera_l status at 6 months 
Nref Ppres Plow Group Mean (SO) Mean (SO) Mean (SO) effect 
n=82 n=66 n=65 ANOVA 
p 
WBLH 
BMC (g) 1608 (232) 1637 (247) 1561 (237) 0.18 
BA (cm 2) 1662 (140) 1722 (165) 1647 (146l 0.01 
BMO (g/cm2) 0 .964 (0 .082) 0.947 (0.072) 0.944 (0.085) 0.29 
SA-BMC (g) 1622 (111)1 1574 (106) 8 1607 (125) 0.04 ; e~ter~_are use~ to indicate significance of between -group differences as tested by ANOVA/Scheffe. S1grnf1cantly different from Ppres P $0.05. 8 Significantly different from Nref p $0.05. 1 n=81 
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6.2.5 Vitamin D 
As at baseline, there were no mean differences between groups at 6 months (Table 6-8). 
However, all group mean 25(0H)D values were lower than at baseline, reflecting 
predictable decreases in vitamin D status during the winter and spring months. 
Table 6-8 Vitamin D status at 6 months 
25(0H)D (nmol/1) 
25(0H)D (nmol/1) >50 % 
25(0H)D (nmol/1) <50 % 
25(0H)D (nmol/1) <25 % 
Nref 
n=81 
51.1 (48.8) 
74 
26 
0 
Ppres 
n=73 
50.4 (48.6) 
70 
30 
3 
Plow 
n=67 
56.4 (21.5) 
67 
33 
4 
All values are Mean ±SD unless stated . 
25(0H)D, 25 hydroxyvitamin D. There were no significant group differences. 
Group effect 
ANOVA 
P= 
0.12 
6.2.6 Biochemistry 
At 6 months there were no significant differences in serum creatinine between groups by 
;· 
Scheffe post hoe testing, despite a significant group effect by ANOVA (p=0.02). As at 
baseline, there were significant differences in albumin across the groups with Nref being 
significantly higher than Ppres and Plow, and Ppres significantly higher than Plow. 
However, the difference between Plow and the other two groups had decreased over 
time. As at baseline, serum phosphate was significantly higher in Ppres and Plow 
comparep to Nref at 6 months. TmP/GFR was significantly lower in Nref than Ppres and 
Plow at six months reflecting the differences at baseline. 
There were increases in ALP activity in Plow compared to Ppres and Nref at the six-
month timepoint. In Nref and Ppres the ALP activity was marginally lower at six months 
compared to baseline, whereas in Plow it had increased from a mean (SD) value of 66.8 
(27 .3) U/1 to a mean of 80.0 (30.4) U/1. As this is a measure of total ALP activity it could 
suggest either hepatic or bone involvement. However, it is less common to see such 
large increases in hepatic ALP in response to ART treatment although this is possible. On 
balance, it probably $Uggests a skeletal origin for the rise in ALP in Plow, although this 
remains to be established. This difference in ALP was not materially affected when the 
few pregnant and lactating women were excluded from the analysis. 
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Table 6-9 Biochemistry at 6 months 
Analyte/ Nref Ppres Plow Group effect 
Derived variable n=82 n=73 n=67 ANOVA 
p 
Serum Cr (µmol/1) 79.8 (12.4) 74.0 (13.0)4 77.7 (13.6) 0.02 
eGFR 75.4 (14.2)1 81.8 (22.1)4 77.4 (19.4) 0.1 
Serum albumin (g/1) 42 .. 8 (2.9) 39.6 (3.8l·5 38.7 (4.4l•6 <0.0001 
Corrected calcium (mmol/1) 2.40 (0.13) 2.37 (0 .15)5 2.38 (0.14) 0 .39 
Serum P (mmol/1) 1.15 (0.17) 1.26 (0.24f•5 1.32 (0.29l 0.0001 
ALP (U/1) 59.2 (21.0) 52.4 (16.7)5 80.0 (30.4l•6 <0.0001 
Urine P/Cr 1.22 (0.62)2 1.23 (0.65)6 1.13 (0.54)7 0.53 
TmP/GFR 1.23 (0.27)3 1.40 (0.36/·4 1.49 (0.47t·8 0.0001 
All values are Mean (SD). 
ALP, alkalin~ phosphatase; Cr, creatinine; eGFR, estimated glomerular filtration rate· 
f
~'lt pht?sphate, TmP/GFR, renal tubular maximum reabsorption rate of phosphate to glomerular' 1 ra 10n rate. 
;e~ter~.are use~ to indicate significance of between-group differences as tested by ANOVA/Sch ff' 
8 
S1_grnf1.cantly different from Nref p S0.001. e e. 
c significantly different from Ppres p s0.001. 
1 
S1gnif1iantly different from Nref P SO.OS. 
n=81, n=76, 3n=78, 4 =n71, 5n=72, 6n=68, 7n=63, sn=66 
6.3 12-month time point 
6.3.1 Retention at 12 months 
At the 12-month study visit, 39/247 (15.8%) participants did not attend for their follow-
up visit. The reason for non-attendance was ascertained in 9/39 (23.1%) at 12 months; 
the remainder of participants were not contactable, despite several telephone calls and 
home visits where feasible. 
Table 6-10 Losses to follow-up at 12 months 
Reason/group Nref Ppres Plow 
Loss to follow up n (%) 22 (22.4) 5 (6.8) 12 (16.0) 
Death 0 0 1 
No longer willing/able to take part 4 0 2 
Moved away 0 0 1 
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Table 6-11 shows the mean duration from baseline to the 12-month visit: 
Table 6-11 Mean (SD) duration of follow-up at 12-month visit 
Group N (%) Baseline to 12-month visit 
days mean (SD) 
Nref 76 (76) 358 (24) 
Ppres 69 (93) 351 (25) 
Plew 63 (84) 343 (21l 
Letters are used to indicate significance of between-group differences as tested by ANOVA/Scheffe. 
A Significantly different from Nref P S0.01. 
As participants commenced ART at different times in relation to their baseline visit the 
mean duration of ART usage was calculated at the 12-month visit. In Ppres 20% (n=15) 
initiated ART during the study period. An almost equal proportion in Plew due to 
,· 
commence ART did not (Table 6-12). 
The vast majority of patients who initiated ART were prescribed the South African · 
standard, first line, triple combination of lamivudine, tenofovir, and efavirenz (Table 6-
13). At 12 months, one subject in Plew was treated with abacavir rather than tenofovir 
and this appeared to be because of concerns about her impaired renal function. 
Figures· 6-6 and 6-7 represent the proportions of different combination therapies in Plew 
and Ppres as a % of those exposed to ART in each group. 
Table 6-12 Mean (SD) duration of ART exposure at 12-month visit 
Group N (%) Duration of ART exposure 
at 12-month visit days Mean (SD) 
Nref NA NA 
Ppres 15 (20) 177 (98) 
Plew 53 (71) 293 (99) 
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Table 6-13 ART usage at 12-month visit 
ART drug/ Group Ppres N (%)* 
AZT: Zidovudine O (0) 
3TC: Lamivudine 14 (20.3) 
TDF: Tenofovir 15 (21. 7) 
D4T: Stavudine O (0) 
ABC: Abacavir O (0) 
NVP: Neviripine 1 (1.4) 
EFV: Efavirenz 14 (20.3) 
*Information missing on use of 1 ART drug 
Figure 6-5 ART usage at 12-month visit 
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Figure 6-7 ART combinations in Plow at 12 months 
• 3TC, TDF, & EFV • 3TC, ABC, & EFV • 3TC, TDF, & NVP 
% of each combination of ART as total of those exposed to ART 
6.3.2 Pregnancy, lactation, and menopause 
As Figure 6.1 illustrates, 12 women became pregnant and 2 were lactating at the 
12-
montii visit. Three women, all in Pfow, ceased their regular menses between 6- and 
12-
month visits. 
Table 6-14 Pregnancy, lactation, and menopause at 12 months 
Group Nref Ppres Plow 
N (%) N (%) N (%) 
Pregnancy 5 (6.6) 5 (7 .2) 2 (3.2) 
Lactation O 2 (2.9) O 
Menopause O O 3 ( 4.8f 
tPossible" menopause, last reported menses 3 - 6 months prior to visit 
6.3.3 Anthropometry 
At the 12-month visit the mean weights of Nref and Ppres were similar to each other
 and 
greater than Plow. Plow weighed 7kg less than Nref but this was no longer signifi
cant 
(p=0.06) . BMI followed the same pattern with similar size effects, although Plow 
remained significantly lower than Nref. At 12 months Plow was still different in term
s of 
weight from Nref and Ppres, which were similar to each other. Percentage overwe
ight 
and obese (BMI >24.9 kg/m2) were 73%, 65%, and 48% in Nref, Ppres, and Plow 
respectively. Waist circumference, waist:hip ratio, and lean mass were not significa
ntly 
different between the groups. Hip circumference and fat mass were lower in Plow t
han 
Nref and Ppres, which were similar to each other. Fat mass was different betwee
n the 
groups (p=0.05), Plow was lower than Nref and Ppres by -2.4 ±1.9% and -1.9 ±1.9% 
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respectively. Fat:lean
2 
were not significantly different between the groups, however 
Ppres and Plow were similar to each other and less than Nref (p=0.08). 
The differences in anthropometry at baseline are still evident at 12 months. 
Table 6-15 Anthropometry at 12 months by original grouping 
Nref Ppres Plow Group effect 
n==76 n==69 n==63 ANOVA 
Weight (kg) 
p 
73.0 (17.8)1 71.0 (16 .6) 66.2 (15.3) 0.06 
BMI (kg/m2 ) median (IQR) 28.2 (25.2;34.1)1 27.4 (22.9;31.4) 25.3 (21.4;29.l/ 0.01 
>24.9 kg/m2, (%) 73 65 48 
>30 kg/m2 (%) 34 35 19 
<18.5 kg/m2 (%) 5 1 8 
Waist circumference (cm) 90.4 (15.1)2 91.1 (16.1)4 87 .2 (13.6)6 0.34 
Hip circumference (cm) 110.8 (15.2) 1 107.9 (13.2)4 104.4 (12.1/·6 0.03 
Waist:hip ratio (WHR) 0.82 (0.07)2 0.84 (0.12)4 0.83 (0.06)6 0.11 
WBLH fat (kg) 28.4 (12.4)3 25.6 (10.0)5 23. 7 (lQ.6)6•6 0.05 
WBLH lean (kg) 38.5 (5.9)3 38.8 (5.6)5 37.2 (3.4)6 0.23 
Fat: lean2 (kg/kg2) 18.5 (5.0)3 16.8 (5.2)5 16.8 (5.3)6 0.08 
All values are mean (SD) unless stated. 
;e~ter_s_are use~ to indicate significance of between-group differences as tested by ANOV
A/Scheffe. 
S1gnif1cantly different from Nref P ~0 .01. 
8 Non significantly different from Nref P=O 055 
1
n=74, 2n=73, 3n=72, 4n=68, 5n=65, 6n=62 
· · 
6.3.4 Bone measures 
At 12 months there were no significant group differences in BMC, BMD, and SA-BMC
 at 
any site. TH BA was significantly higher in Ppres (4.4 ±1.7%, p=0.03) and Plow (4.9 
±1.7%, p=0.02) than in Nref. LS BA was also significantly higher in Ppres (4.4 ±1.5%, 
P=0.03) and Plow (3.9 ±1.6%, p=0.04) than in Nref (Table 6-16). The differences in 
bone measures (i.e. BA) at baseline are still evident at 12 months. However, the effect 
of group on BA disappeared on size-adjustment. From baseline ~o 12 months there was a 
decrease in lumbar spine aBMD SDS (Z-score) from -0.099 (1.081) to -0.292 (1.101) in 
Plow, that is constistent with the changes demonstrated in Chapter 7. 
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Table 6-16 Bone measures at 12 months 
Total hip 
BMC (g) 
Area (cm2) 
BMO (g/cm2) 
SA-BMC (g) 
SOS 
Femoral neck 
BMC (g) 
Area (cm2) 
BMO (g/cm2) 
SA-BMC (g) 
SOS 
Lumbar spine 
BMC (g) 
Area (cm2) 
BMO (g/cm2) 
SA-BMC (g) 
SOS 
Nref 
Mean (SO) 
n=72 
33.3 (6.3) 
33.1 (3.1) 
1.036 (0.153) 
33.9 (4.4) 
4.43 (0.69) 
4.78 (0.51) 
0.930 (0.139) 
4.39 (0.61) 
55.0 (9.0) 
53.4 (5.0) 
1.028 (0.125) 
55.5 (6.0) 
Ppres 
Mean (SO) 
n=65 
33.8 (5.3) 
33.5 (3.2t 
1.008 (0.130) 
33.3 (3.6) 
-0.180 (0.853) 
4.40 (0.67) 
4.82 (0.32) 
0.914 (0.131) 
4.39 (0.51) 
-0.113 (0.941) 
57.2 (9.4) 
55.7 (5.ot 
1.022 (0.109) 
55.9 (5.3) 
-0.046 (0.869) 
Plow 
Mean (SO) 
n=62 
33.6 (5.6) 
33.7 (3.5t 
o. 995 (0.127) 
33.4 (4.0) 
-0 .265 (0.831) 
4.33 (0.64) 
4.82 (0.33) 
0.902 (0.133) 
4.39 (0.58) 
-0.202 (0.958) 
55 .1 (9.8) 
55.4 (4.6t 
0.991 (0.138) 
54.7 (7.3) 
-0.292 (1.101) 
Group effect 
ANOVA 
P= 
0.89 
0.006 
0.23 
0.70 
0.70 
0.58 
0.47 
1.0 
0.33 
0.009 
0.20 
0.30 
WBLH 1614 (242) 1625 (231) 1574 (234) 0.45 BMC (g) 2 (141) 1701 (145) 1661 (146)1 0.21 Area (cm ) 2 166655 (0 086) 0 952 (0 072) 0.945 (0.081)1 0.34 BMO (g/cm ) 0.9 . 1591 (107) 1599 (1220)1 0.23 SA-BMC (g) 1624 (113) -0.150 (0.839) 0.238 (0.945)1 . 
6.3.5 Vitamin D status 
. . . At 12 months there were no significant between-group differences in vitamin D status, 
the majority had 25(0H)D concentrations greater than 50 nmol/1 (Table 6-17), and all 
group "m,eans were higher at 12 months compared to baseline and six months. The 
proportion with 25(0H)D concentrations <25nmol/l remained constant between groups 
over time suggesting that there was not a change in rates of those with lower vitamin D 
status. 
Table 6-17 Vitamin D status at 12 months 
Nref Ppres 
n=74 n=68 
25(0H)O (nmol/1) 63.3 (17.7) 66.0 (18.40) 
Plow Group 
n=62 effect 
ANOVA 
P= 
61.1 (20.1) 0.32 
25(0H)O >50 nmol/1, % 73 71 ~~ 25(0H)O <50 nmol/1, % 27 2; 5 25(0H)O <25 nmol/1, % 0 
. __ 
M (so) Unless stated 25(0H)O 25 hydroxyvitamin O. There were no s1gnif1cant All values are ean 
· , 
group differences. 
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6.3.6 Biochemistry 
The 12-month biochemistry data are presented in Table 6-18. At 12 months there were 
no significant differences in serum creatinine between groups by Scheffe post hoe 
testing, despite a significant group effect by ANOVA (p=0.009). There were no 
significant between-group differences in eGFR, corrected calcium or urine 
phosphate:creatinine ratio. There were significant differences in serum albumin and 
serum phosphate. Nref albumin was significantly higher than Ppres or Plow, which were 
similar. Serum phosphate was significantly lower in Nref than Ppres and Plow which were 
similar. The serum albumin and phosphate differences are similar to those at baseline. 
ALP activity was significantly higher in Plow than Nref and Ppres, which were similar, this 
also followed a similar pattern to baseline except the difference between Plow and Nref 
and Ppres were more pronounced (see Table 5-13). TmP/GFR was significantly lower in 
Nref than Ppres and Plow, which were similar to each other. 
Table 6-18 Biochemical analysis at 12 months 
Analyte/ Nref Ppres Plow Group effect derived variable n=75 n=69 n=63 ANOVA 
P= 
Serum Cr (µmol/1) 77.3 (11.7) 1 73.3 (11.0)3 74.9 (9.4) 0.009 
eGFR 78.1 (15.7)1 80.9 (15.1)3 78. 7 (12.5) 0.50 
Albumin (g/1) 40.7 (2.9)1 38.9 (3.4l·3 39.2 (3.6l 0.004 
Corr calcium(mmol/1) 2.36 (0.12)1 2.33 (0.13)3 2.34 (0.15) 0.39 
Serum P (mmol/1) 1.12 (0.19)1 1.28 (0.23)8·3 1.32 (0.31) 8 ~0.0001 
ALP (U/1) . -71.1 (41.6) 1 66.7 (26.6)3 90.0 (29.6l·c 0.0002 
Urine P/Cr 1.64 (5.6) 1.36 (0.7)3 1. 47 (1.2)4 0.89 
TmP/GFR 1.19 (0.55)2 1.38 (0.32t,3 1.45 (0.50)8 0.004 
All values are Mean (SO). 
ALP, alkaline phosphatase; Corr, corrected; Cr, creatinine; eGFR, estimated glomerular filtration rate; P, phosphate; TmP/GFR, renal tubular maximum reabsorption rate of phosphate to glomerular filtration rate. 
· 
Letters are used to indicate significance of between-group differences as tested by ANOVA/Scheffe. 
A Significantly different from Nref P ~0 .05. 6 Significantly different from Nref P ~0.001. 
c Significantly different from Ppres P ~0.001. 1n=74, 2n=72, 3n=68, 4n=62 
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6.4 Summary 
The subject retention rate at 6 months was 90% and at 12 months was 84% (see 
Consort diagram, Section 6.1). Attrition at 12 months was 22.4%, 8.6%, and 16.0% in 
Nref, Ppres, and Plow respectively; the reasons were given in Table 6-10. 
At six months, Plow were lighter than Nref and Ppres with lower BMI, waist, and hip 
circumferences, fat mass, lean mass, and fat: lean 2. As at baseline, Nref and Ppres were 
not different from each other at the six-month visit in any of these measures. The only 
significant difference in bone mineral status between the groups at six months was lower 
WBLH SA-BMC in Ppres compared with Nref, and a lower unadjusted BA in Plow than in 
Ppres. There were no differences in vitamin D status between the groups at six months. 
Serum albumin was significantly greater, and serum phosphate and TmP/GFR 
sig(Jificantly less, in Nref compared to Ppres and Plow. These differences were in the 
same direction as at baseline. ALP activity had become significantly greater in Plow than 
Nref and Ppres. 
At 12 months a similar pattern emerged with Nref and Ppres having greater weight, BMI, 
waist and hip circumferences, and fat and lean mass than Plow. At 12 months, Ppres was 
not different from Plow in fat:lean2 but had a greater WHR ratio than both Nref and Plow. 
At 12 ' months there were no group differences in BMC, aBMD, or SA-BMC. There were 
significant differences in unadjusted BA at TH and LS with Nref being lower than Ppres 
and Plow at both sites. Measures of BMC and aBMD at 12 months were similar to those 
found at baseline, that is, no significant differences between the groups. 
There were no significant differences in mean vitamin D status between the groups at 12 
months. At this time point Nref had significantly higher serum albumin than Ppres and 
Plow and lower serum phosphate, ALP, and TmP/GFR, as at six months. At 12 months, 
as at other time points, Nref and Ppres characteristics were closer to each other than 
either to Plow. 
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A key observation is that Nref and Ppres were similar in most measures and more similar 
to each other than to Plow. It confirms the need to view HIV-positive individuals with 
advanced disease as distinct from those with preserved immune function who may be 
more physiologically and phenotypically similar to their HIV-negative counterparts. 
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7 Longitudinal modelling 
7 .1 Overview 
This chapter explores longitudinal changes within individuals rather than comparing 
cross-sectionally the differences in groups at each of the three time points. I n order to 
evaluate the changes in bone measures, body composition, and biochemical variables 
over time, hierarchical models were constructed wherein data for each individual could, 
where available, be used to determine individual change over time, 'nested' within the 3 
groups assigned at baseline. Individual subjects were nested within their recruitment 
group and a time point-by-group interaction term derived (see Sections 4.11.4.5 and 
4.11.4.6). 
In order to best appreciate change over time, values were converted into natural logs, 
therftbY allowing changes over time and differences between groups to be presented as 
sympercentages (see Section 4.11.2). All longitudinal values discussed as percentage 
change in the following chapters refer to sympercentages (mean (SE)). The absolute 
values for each variable at each time point were given in Chapters 5 and 6. 
Table 7-1, Table 7-2, and Table 7-3 summarise the changes in body composition, bone 
and laboratory analysis from baseline to 12 months. The table is arranged to display 
differences by original grouping (Nref, Ppres, and Plow). Change was calculated from 
hierarchical linear models for each variable separately. 
The relationship between the groups (Nref, Ppres or Plow) and the different time points 
(0, 6, and 12 months) was t he main interact ion assessed in order to determine whether 
the change over time differed by group. An interaction assesses whether the response, 
as measured by one of the variables, changes at different levels of the other factor (see 
Sect ion 4 .11.4.6). 
In this section results are expressed in terms of percentage change from basel ine as 
mean (SE) , significances ~0.05 are given . Scheffe post hoe test were used for individual 
pairs of timepoint and group to construct the graphs (see Section 4 .11.4.3). 
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Table 7-1 Anthropometry: percentage change (SE) from baseline at 12 months 
Variable Nref Ppres Plow 
Weight (kg) +2.3 (0.8) 
-0.74 (0.8) +3.9 (0.9) <0.001 
BMI (kg/m2) +2.3 (1.1) 
-1.1 (1.1) +4.0 (1.2) 0.02 
Fat (kg) +5.3 (1. 7) 0.04 
-1.2 (1.8.) +10.2 (1.8) <0.001 
Lean (kg) +0.2 (0.5) 
-1.7 (0.6) 0.05 +0.3 (0.6) 
Fat:lean2 +5.0 (1. 7) +2.3 (1.8) +9.6 (1.9) <0.001 
~abluelds at re mweahn (SE) percentage change from baseline to 12 months in each group p= 
in o ype. ere no p value stated, p>0.05. ' 
Table 7-2 Bone measures: percentage change (SE) from baseline at 12 months 
Region/site Nref 
Total hip 
Ppres Plow 
BMC (g) +6.1 (1.0) <0.001 +7.4 (1.1) <0.001 
BA (cm2) +3 .6 (0. 6) <O.OOl +4.7 (1.1) <0.001 +5.5 (0. 7) <0.001 +4 3 (0 7) <O 001 
BMD (g/cm2) +2.5 (0.5) <0.001 . . . SA B +1.9 (0.6) 0.004 +O 4 (0 6) 
F - MIC (g) +0.8 (0.5) 
-0.3 (0.6) -1 .7 (0 °6) O 02 
emora n&k · · • 
~:~c~J) +f-~ (cg.9)) -0.1 (0.9) -0.8 (0.9) 
BMD ( 2 + . .6 0.03 +0.5 (0.6) +1 3 (0
 6) 
g/cm ) +0.6 (0.6) 2 ·4 (O '6 ) SA -0.5 (0.6) - 0 001 Lu m~~~~p~~! -0, 3 (0, 5) -o. 5 (0.6) -2:7 (0:7) <0.001 
~:~ (gJ +1.1 (0.6) -1.0 (0.6) -3 3 (0 7) <0 001 
BMDc(m ) 2 -O.l (0.3) -0.8 (0.3) 
-1·3 (0°3) <0°001 
g/cm ) +1.2 (0.5) o.os 2 ·0 (O · · 
w~~!Mc (g) +1.1 co.5) =~:f ~g:~~ =2:1 co:~~ g:g~2 
BMC (gJ +0.2 (0.4) -0.4 (0.4) -1 O (0 4) 
BA (cm ) -0.6 (0.3) -0 7 (0 3) · · 
BMD (g/cm2) +0.2 (0.3) +o· 6 o· 3 -0.3 (0.3) 
SA-BMC (g) -0 3(0 3 ) · ( · ) -0.7 (0.3) V I . - . - +0.5 (0.3) -0 5 (O 3) 
ina b~~~ ~re mweahn (SE) pe~centage cha nge from basel ine to 12 months i~ ea~h group p= 
ype. ere no p value stated, p . > 0. 05. ' 
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Table 7-3 Vitamin o and biochemistry: percentage change (SE) from baseline to 
12 months 
Analyte/ Nref Ppres Plow 
derived variable 
25{0H)D (mmol/1) +6.6 (4.0) +12.5 (4.2) +2.0 (4.4) 
Serum Cr (µmol/1) +0.9 (2.9) -4.4 (3.1) ~3-; (<;-;)) 
eGFR -1.9 (3.4) +4.5 (3.5) 4. · 
Albumin (g/1) +1.5 (1.0) +3.0 {1.0) +9.1 {l.l) <0.001 
Cor calcium (mmol/1) +6. 7 (0.9) <0.001 +3.8 (0.9) 0.002 +5.8 (1.0) <0.001 
Serum P (mmol/1) +7.0 (2.3) 0.05 +5.2 (2.4) +0.0 (2.5) 
ALP (U/1) +13 .1 ((3.5) 0.008 +14.4 (3. 7) 0.005 +29.6 (3.8) <0.001 
Urine P/Cr +17.4 {11.5) +10.3 (12.2) +52.0 (12.7) 0.001 
TmP/GFR +6.4 3.3 . +3.8 3.5 . -=~-2 3.6 0,05 
Values are mean (SE) percentage change from baseline to 12 months in each group, p- in bold 
type. Where no p value stated, p>0.05 . .. 
Car calcium, corrected calcium ; Cr, creatmme; P, phosphate. 
Figure 7-1 to Figure 7-8 illustrate percentage changes in body composition, bone 
mineral, vitamin D status, and biochemical data from baseline. Nref is the reference 
value at baseline (timepoint O) set at zero against which Ppres and Plow are set. 
.;· 
In the figures, Nref is represented in green, Ppres in orange and Plow in red. All data 
points are mean percentage change with error (SE) bars. The timepoint-by-group 
{Tp*Grp) interaction term is shown on each graph and describes the probability of a 
I · h. over t·1me within individuals. All interaction terms group difference in the re at1ons 1p 
described are timepoint-by-group interactions unless otherwise stated. 
i 
7.1.1' Anthropometric and body composition changes . 
0 At the 12-month visit the mean weight of Nref and Plow had increased (2.3 ±0.8 Yo and 
3.9 ±0.8% respectively), while it had fallen marginally in Ppres (-0.7 ±0.8%). Waist 
circumference had increased by 6.0 ±3.1% and 3.1 ±3.3% in Nref and Plow and 
decreased by 0.1 ±3.0% in Ppres. In contrast, hip circumference had increased most in 
Plow (4.1 ±1.7%), followed by Nref and Ppres (1.7 ±1.7% and 0.8 ±1.6% respectively). 
These changes in waist and hip circumferences translated into changes in waist:hip ratio 
(WHR) from ase me o . 11 b I. f 4 5 ±2.8010, -0.9 ±2.8%, and -1.0 ±2.9% in Nref, Ppres, and 
Plow respectively. There were changes in fat mass, significantly in Plow, 
Plow>Nref>Ppres of 10.2 ±1.8%, 5.3 ±1.7%, and -1.2 ±1.7% respectively. Lean mass 
also changed, significantly in Ppres, Ppres>Nref>Plow; -1.7 ±0.6%, 0.2 ±0.5%, and 0.3 
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±0.6%. Fat:lean
2 increased in the same direction as fat mass with increases of 9.5 
±1.8%, 5.0 ±1.7%, and 2.2 ±1.7% respectively (Table 6-15). Figure 7-1 illustrates the 
within individual changes in body composition from baseline to 12 months. There was a 
significant increase in weight, BMI, and fat mass in Plow but not in Nref and Ppres 
(Tp*Grp p=0.0004, p==0.002, and p=0.004 respectively). Plow demonstrated a 10% 
increase in fat mass. The increases in fat mass in Plow were not mirrored by increases in 
lean mass. There was a 9.6% increase in fat: lean2 in Plow subjects suggesting a 
preferential increase in fat rather than lean mass. In Ppres there was -1. 7% change from 
baseline in lean mass (p==0.05), consistent with the -1.2% non-significant decrease in fat 
mass. 
There were non-significant (p=>0.05) increases in waist and hip circumferences in Plow 
and in Nref and a non-significant decrease in waist and increase in hip circumference in 
Ppres. There were no significant changes in WHR from baseline to 12 months. 
Plow saw significant increases of 10% in fat mass and fat: lean2 and 4% increases in 
weight and BMI compared to Ppres, which demonstrated no significant change in these 
variables. Ppres had a significant decrease in lean mass over 12 months. The interaction 
terms for weight, BMI, and fat mass were significant confirming that the changes over 
time differ between groups. The interaction terms were not significant for waist and hip 
circumferences, WHR, lean mass and fat:lean2• 
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Figure 7-1 Changes in body composition 
Weight 
Ti mepoi nt* group 5 interaction 
0 p=0.0004 
G) 
CD 
~ 2.3°/o, p=0.07 C C'CI 
-5 
.c 
CJ 
~ ~ -0.74°/o, p=0.94 0 
-10 
~ 3.9°/o, p=<0.001 
-15 
~ $ .... ~ 
Timepoint 
., 
BMI 
5 Timepoint*group 
interaction 
0 p=0.002 
G) 
CD 
' -5 ; · ~ 2.3°/o, p=0.34 .c CJ 
-10 
~ 
~ -1.1 °/o, p=0.92 
0 
-15 
-20 ~ 4.0°/o, p=0.02 
~ $ .... ~ 
Timepoint 
Percentage changes from baseline to 12 months in weight and BMI (Nref in _green, Ppres in orange and Plow in 
red). Nref at baseline is set at zero and all others are expressed relative to 1t. 
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Fat mass 
10 Timepoint*group 
0 interaction 
G) p=0.004 CD 
-10 C 
C'CI 
.c 
CJ 
-20 }* ~ 5.3°/o, p=0.04 ~ 0 
-30 
~ -1.2°/o, p=0.98 
-40 
~ $ 
.... ~ ~ 10.2°/o, p<0.001 
*Difference between Ill II 
Timepoint Plow at O and 12 months 
10.2%, p<0.001 
Lean mass 
6 Timepoint*group 
4 interaction 
G) 2 p=0.07 
CD 
C ~ 0.19°/o, p=1.0 ~ 0 
CJ 
'$. -2 ~ -1.7°/o, p=0.05 
-4 
~ 0.33°/o, p=0.99 
-6 
~ $ 
.... ~ 
Timepoint 
Percentage changes from baseline to 12 months in fat mass and lean mass (Nref in green, Ppres in orange and 
Plow in red). Nref at baseline is set at zero and all others are expressed relative to it. · 
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Fat:lean2 
10 Ti mepoi nt*g rou p 
interaction 
0 p=0.09 Cl) 
C> 
C: 
ea 
-10 ~ 5.0°/o, p=Q.Q9 .&:. u 
~ 0 
~ 2.3°/o, p=0.82 -20 
-30 ~ 9.6°/o, p=<0.001 
~ ~ ... ~ 
Time point 
Percentage changes from baseline to 12 months in fat:lean2 (Nref in green, Ppres in orange and Plow in red). 
Nref at baseline is set at zero and all others are expressed relative to it. 
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C 
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~ 6.0°/o, p=0.45 
~ -0.14°/o, p=1.0 
~ 3.1 °/o, p=0.93 
Timepoint*group 
interaction 
p=0.47 
~ 1.7°/o, p=1.0 
~ 0.74°/o, p=1.0 
~ 4.2°/o, p=0.27 
Percentage changes from baseline to 12 months in waist circumference and hip circumference (Nref in green, Ppres in orange and Plow in red). Nref at baseline is set at zero and all others are expressed relative to it. 
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Waist: hip ratio 
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Percentage changes from baseline to 12 months in WHR (Nref in green, Ppres in orange and Plow in red). Nref 
at baseline is set at zero and all others are expressed relative to it. 
7.1.2 Bone mineral status 
Figure 7-2 to Figure 7-5 illustrate the within individual changes in bone measures from 
baseline to 12 months. These are expressed as percentage change from baseline to 12 
months. The BMC data were adjusted for weight and BA to create SA-BMC (as height did 
not change over time). The absolute longitudinal changes in mean bone variables BMC, 
BA, BMD, and SA-BMC are also given in Table 7-2 . 
7.1.2.1 Hip 
At the, total hip there were increases in BMC and BA in all groups but with non-significant 
timepoint-by-group interactions, meaning that the changes over time within an 
individual were not significantly different from each other between the groups. The 
increases in hip BA were unexpected as bone expansion of this magnitude was unlikely 
in these adult women. It is probably a technical artefact, which is described in the 
discussion. 
There were increases in hip aBMD in all groups, the largest increase was in Nref (2.5 
±0.5%, p<0.01) followed by Ppres 1.9 ±0.6% (p=0.004), and Plow 0.4 ±0.6% 
(p=0.74) with a sign ificant interaction term (p=0.03). However, there was a sign ificant 
decrease in hip SA-BMC of -1. 7 ± 0.6% (p=0.02) in the Plow group with a significant 
interaction term (p= 0.003) and a 4 .5% (p<0.001) difference between Nref and Plow 
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groups in SA-BMC (Figure 7-2). This showed that the bone mineral of Plow had not 
increased in proportion to their weight gain and increases in BA whereas for Nref the 
increases in BMC (and aBMD) were accounted for by their increased weight and BA. 
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Figure 7-2 Changes in total hip 
Total Hip BMC Timepoint*group 
10 interaction 
8 p=0.23 
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2 ~ 4.3°/o, p<0.001 
0 
(;)+ ..._$' 
Timepoint 
Percentage changes_ from baseline to 12 months in total hip bone measures (BMC & BA) (Nref in green, Ppres 
in orange and Plow in red). Nref at baseline is set at zero and all others are expressed relative to it. 
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Total Hip aBM D Timepoint*group 
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7.1.2.2 Femoral neck 
At the femoral neck (FN) there were non-significant changes in BMC and BA in all 
groups, with the exception of BA in Nref (p=0.03). There was an increase in BMC in Nref 
and decrease in Ppres and Plow but the interaction term was not significant. aBMD 
decreased significantly in Plow -2.4 ±0.6% (p=0.001), but changed little in the other 
groups, with a significant interaction term (p=0.01). Similarly, there was a -2. 7 ±0.7% 
(p<0.001) decrease in . SA-BMC in Plow and a significant interaction term (p=0.01) 
resulting in a 1.8% (p=0.1) difference between Nref and Plow groups in SA-BMC at 12 
months (Figure 7-3). 
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Figure 7-3 Changes in femoral neck 
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7.1.2.3 Lumbar spine 
There were small, non-significant changes in BMC in Nref (1.1 ±0.6%) and Ppres (-1.0 
±0.6) at the lumbar spine. However, in the Plow group there was a -3.3 ±0.7% decline 
in BMC (p<0.001) with a significant interaction term p<0.0001. In BA there were small, 
non-significant changes in Nref (-0.1 ±0.3%) and Ppres (0.8 ±0.3%) but a significant 
decrease in Plow -1.3 ±0.3% (p=0.001) with a significant interaction term p=0.05. In 
aBMD there was a -2.0 ±0.6% (p=0.002) decrease in Plow and a 1.5 ±0.5% (p=0.05) 
increase in Nref with a significant interaction term (p=0.0001). There was a -2.1 ±0.6% 
(p=0.002) decrease in SA-BMC in Plow and a significant interaction term (p=0.0002) 
with non-significant changes in Nref and Ppres, resulting in a 4.3% (p<0.001) difference 
between Nref and Plow groups in SA-BMC (Figure 7-4). 
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Figure 7-4 Changes in lumbar spine 
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7.1.2.4 Whole body less head 
There were small, non-significant changes in BMC and BA in all groups. There were non-
significant increases in WBLH aBMD and non-significant decrease in Plow but with a 
significant interaction term (p=0.03) showing that the changes were different between 
the groups. There were non-significant decreases SA-BMC in Nref and Plow and a non-
significant increase in Ppres. At 12 months there was a -2.4% (p<0.001) difference 
between Nref and Plow groups in SA-BMC (Figure 7-5). 
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Figure 7-5 Changes in whole body 
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7.1.3 Changes in vitamin D status 
The baseline visit (0) took place during the summer and autumn months (October -
Apri l) and the 12 month the following summer. By the 12-month visit serum 25(0H)D 
concentrations had not only increased from the 6-month (winter and spring, May -
October) visit but exceeded baseline concentrations. There were 6.6 ±4.0%, 11.2 
±4.0%, and 2.8 ±4.2% increases from baseline in Nref, Ppres, and Plow respectively at 
12 months (Table 6-17). 
Figure 7-6 illustrates the within individual changes in vitamin D status from baseline to 
12 months. There were significant, and predictable, decreases in mean winter and spring 
va lues from baseline in groups Nref, Ppres, and Plow of -16.8 ±3.9%, -20.4 ±3.8%, and 
-7.9 ±4.0% respectively. The winter decline in 25(0H)D concentrations in Ppres closely 
mapped that in Nref. Interestingly, the Plow group had a less steep winter decrease than 
Nref and Ppres. By 12 months there were non-significant increases from baseline but 
significant increases from six months. 
Figure 7-6 Changes in vitamin D status 
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7.1.3.1 Vitamin D and fat mass 
To explore percentage changes in 25(0H)D and any relationship to adiposity the 
following model was constructed: 
y variable: log 25(0H)D at 12 months - log 25(0H)D at baseline 
X variables: 
group 
log 25(0H) D at baseline (to prevent regression to the mean) 
log fat mass at 12 months - fog fat mass at baseline (I nfat12-lnfat0) 
mean (fog fat mass at 12 months + log fat mass at baseline) 
Also, fat mass did not predict 25(0H)D concentration in the group as a whole (all 
groups) at six or 12 months. Change in fat did not predict change in vitamin D status. 
Ther~ were non-significant coefficients and interaction terms (p>0.05) at both time 
points. The group*lnfat12-lnfat0 interaction was non-significant, p=0.5. 
7 .1.4 Changes in biochemistry 
At baseline there were significant differences between groups with Nref having 
significantly higher albumin concentrations than Ppres and Plow, and Ppres having 
significantly higher concentrations than Plow. Also, there were significant baseline 
' differences in serum phosphate with Plow having significantly greater concentrations 
than Nref and Ppres, and Ppres significantly higher than Nref. These serum phosphate 
differences were reflected in TmP/GFR (see Table 5-13). 
At 6 months compared to baseline (Table 5-13) there were significant increases in serum 
albumin in all groups; 6.7 ±0.94%, 5.2 ±0.94%, and 8.6 ±0.98% in Nref, Ppres, and 
Plow respectively. There were increases in serum albumin concentration from baseline in 
Pfow, 9.1 ±1.1% (p<0.001) and non-significant increases in Nref and Pfow over 12 
months. There were changes in ALP activity from baseline to 6 months; an increase in 
Pfow by 15.5 ±3.6% compared with a fall of 8.4 ±3.5% in Ppres (see Table 6-9). 
237 
There were significant increases in corrected calcium in all groups but a non-significant 
interaction term (p>0.05). Serum creatinine concentrations remained stable in all groups 
(between +3.7% to -4.4%, p>0.05). Predictably, changes in eGFR mirrored changes in 
serum creatinine and were non-significant. 
There were further increases in albumin in Pfow (0.5 ±1.0%) from 6 to 12 months, a 
decrease in Ppres (-2.1 ±0.96%), and larger decreases in Nref (-5.2 ±0.97%). The 
increases in al bum in in Pfow probably reflect improvements in nutritional status and 
decreased catabolism after the initiation of ART. There was a further 14.1 (3.6)% 
increase in ALP activity from 6 months to 12 in Plow. There were increases in serum 
phosphate in Nref. In Pfow there was a decline in TmP/GFR of 11.2% over the study 
period although serum phosphate remained constant. This possibly reflected increases in 
urinary phosphate loss with liberation of phosphate from bone in order to maintain 
serum concentrations and is supported by the markedly raised ALP activity (Table 6-18). 
From baseline there were large, significant increases in ALP activity in all groups, with 
t he largest increases seen in Pfow at 29.6 ±3.8% (p<0.001) at 12 months. 
Figure 7-7 illustrates the within individual changes in biochemistry from baseline to 12 
months. 
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Figure 7-7 Changes in biochemistry and derived variables 
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7.1.S Changes in markers of phosphate homeostasis 
At baseline, Plow had significantly higher mean serum phosphate concentrations than 
Nref or Ppres (p:::,0.05) and TmP/GFR was significantly higher in Plow, (see Section 5.8). 
By six months, serum phosphate increased in Nref and Ppres (by 9.6 ±2.2% and 3.9 
±2.2% respectively) and remained stable in Plow. 
At 12 months there was an overall increase in serum phosphate in Nref and Ppres; 7.0 
±2.3% (p=0.05), and 5.2 ±2.4% (p=ns) respectively. There was no change in Plow 0.0 
±2.5% (p=ns). At six months TmP/GFR increased in Nref and Ppres by 4.6 ±3.2% and 
4.4 ±3.5% respectively but declined by 7.3 ±3.6% in Plow. By 12 months there were 
non-significant increases in Nref and Ppres of 6.4 ±3.3% (p=0.45) and 3.8 ±3.5% 
(p=0.88), which was consistent with serum phosphate change. There was a significant 
decrease in TmP/GFR in Plow, -11.2 ±3.6% (p=0.05), which was consistent with 
changes in patterns of serum phosphate. At 12 months there was a 9.9 ±3.8% (p=0.14) 
difference in TmP/GFR between Nref and Plow. Figure 7-8 illustrates the within individual 
changes in phosphate handling from baseline to 12 months. 
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Figure 7-8 Changes in phosphate metabolism 
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7.2 Summary 
Longitudinal analysis of these data, using hierarchical models, provides a more detailed 
exploration of change within individuals over 12 months, and allows for an exploration of 
differences between groups in change over time that were not evident following cross-
sectional analyses. 
These analyses reveal a 3.9 ±0.9% increase in weight and a 10.2 ±1.8% increase in fat 
mass in Plow. Nref also gained weight and fat mass but half the amount compared with 
Plow. Ppres had decreases in weight, BMI, fat mass and lean mass over the course of the 
study. The large increases in weight and fat mass in Plow are important as they could 
indicate an increased risk of future metabolic disease such as impaired glucose tolerance 
and insulin resistance. 
i" There were significant increases in hip BMC in all groups (p<0.001) but no significant 
changes in femoral neck BMC. At the lumbar spine there was a 3.3 ±0.7% decrease in 
BMC in Plow with no significant changes in Nref or Ppres. There were also significant 
increases in hip BA in all groups. At the femoral neck there was a 1.5 ±0.6% increase in 
BA in Nref (p=0.03). At the lumbar spine there was a -1.3 ±0.3% decrease in BA in Plow 
( <0.001). There were no significant changes in any measure of WBLH. 
It is likely that total hip BA was affected by overlying fat and possibly by technical 
factors. The apparent increase in BA results in an increase in BMC and therefore may 
mask real changes in aBMD. The SA-BMC however corrects for changes in BA, and 
therefore provides a more representative analysis of changes in bone mineral at the total 
hip. 
At the femoral neck and lumbar spine there are decreases in aBMD of >2% in Plow. At 
total hip, femoral neck and lumbar spine there were decreases in SA-BMC of 2.1 % to 
2.7% over 12 months in this group of young women. This exceeds the rates of bone loss 
seen in menopause, which are in the order of 1 % per annum. The combination of rapid 
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increases in weight and significant decreases in bone mineral may increase the risk of 
lower limb fracture. 
Changes in aBMD and SA-BMC are demonstrated in Plow from baseline to 12 months: 
Plow 
Total hip aBMD +0.4 ±0.6% 
SA-BMC -1.7 ±0.6% 
Femoral neck aBMD -2.4 ±0.6% 
SA-BMC -2.7 ±0.7% 
Lumbar spine aBMD -2.0 ±0.6% 
SA-BMC -2.1 ±0.6% 
There were no differences in vitamin D status between the groups over 12 months 
although Plow had less of a winter nadir than the other groups. Corrected calcium 
increased in all groups while albumin increased by 9.1 ±1.1% (p<0.001) in Plow, 
decreasing the differences seen between the groups at baseline. Serum ALP activity 
increased in all groups but increased by the largest amount (29.6 ±3.8%) in Plow. 
Serum phosphate increased by 7.0 ±2.3% in Nref but non-significantly in Ppres and 
Plow; therefore the original, baseline group differences remained at 12 months. 
TmP/GFR declined by 11.2 ±3.6% in Plow (p=0.05), and increased by 6.4_ ±3.3% and 
3.8 ±3.5% in Nref and Ppres respectively. However at 12 months Nref had a 9.9% 
greater TmP/GFR than Plow (p=0.14). 
These analyses demonstrate that Plow is distinct from Nref and Ppres in measures of 
change in body composition, bone status, and markers of phosphate homeostasis. Plow 
had marked increases in weight and adiposity without commensurate increases in lean 
mass. The significant decreases in hip, femoral neck, and lumbar spine SA-BMC, and 
aBMD at the femoral neck and lumbar spine in Plow illustrate that Plow are losing 
mineral from these sites compared to the other groups. In contrast, Ppres and Nref are 
similar in most respects but distinct for serum phosphate and TmP/GFR. This is of 
interest because it might suggest that phosphate handling in Ppres is a precondition, 
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intermediate to Plow, and not yet reflected in other aspects of renal and bone 
homeostasis. 
At baseline and at 12 months there were no significant differences in bone status 
between the groups when examined cross-sectionally. This analysis serves as a reminder 
of the importance of longitudinal follow-up of subjects when considering change in 
skeletal mineralisation, the differences demonstrated over time would be overlooked if 
only cross-sectional analyses were performed. 
These observations suggest that Plow subjects are at a specific risk of metabolic and 
bone-related morbidity because of the rapid changes in body composition and bone 
mineral status. 
; 
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8 Post hoe analysis on ART exposure 
As indicated earlier (see Sections 4.11.3 and 4 .11.4.7), given that there were changes in 
the composition of the three groups over the course of the study, the data presented in 
this chapter are the result of post hoe analyses. The subjects were analysed according to 
whether or not they were exposed to ART during the study period, rather than Ppres or 
Plow (and Nref). This approach is a way of clarifying that any changes seen in the Plow 
group were associated with ART exposure rather than other confounding factors. 
Sections 8.1 to 8.2.2 present data consistent with the analysis in Chapter 6. Section 8.3 
examines the ART-unexposed and -exposed in a longitudinal, hierarchical analysis 
similar to that in Chapter 7. 
8.1 6-month visit 
8.1.1 Anthropometry 
At the 6-month visit the ART-unexposed group were significantly heavier (p=0.01) with 
greater median BMI (p=0.02) than ART-exposed. ART-unexposed had greater waist and 
hip circumferences (p::50.02) and greater fat and lean mass (p::50.05) compared with 
ART-exposed (Table 8-1). 
Table 8-1 Anthropometry at 6 months 
Weight (kg) 
BMI (kg/m2) Median (IQR) 
>24.9 kg/m 2 (%) 
> 30 kg/m 2 (%) 
<18.5 kg/m 2 (%) 
Waist circumference (cm) 
Hip circumference (cm) 
Waist: hip ratio 
WBLH fat (kg) 
WBLH lean (kg) 
Fat: lean2 (kg/kg2) 
ART-unexposed 
n=66 
72.1 (17.3) 
27.0 (23.7;32.4) 
67 
38 
2 
89.6 (15.1) 1 
108.9 (14.4) 
0.81 (0.12) 
26.1 (10.5) 2 
39.2 (5. 7)2 
16.4 (4.8)2 
ART -exposed 
n=73 
65.0 (15.2) 
24.9 (21.6;29.4) 
47 
19 
8 
82.4 (21.0) 
102.5'(12.2) 
0.80 (0.16) 
21.7 (8 .9)3 
37.5 (5.2)3 
15.0 (4.5)3 
Group effect 
ANOVA 
p 
0.01 
0.02 
0.02 
0.006 
0.75 
0.009 
0.05 
0.08 
All values are Mean (SD) unless indicated . cm, centimetres,· IQR · 1n =GS, 2n =G
4
, Jn=GS 
, interquartile range; kg , kilograms. 
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8.1.2 Bone measures 
WBLH BMC and BA were significantly greater in ART-unexposed (p~0.005), although 
after full size adjustment the differences in BMC were no longer apparent. There was no 
significant difference in aBMD (Table 8-2). 
Table 8-2 Bone mineral status at 6 months 
ART-unexposed ART-exposed 
n=64 n=67 
WBLH 
BMC (g) 1658 (249) 1544 (228) 
Area (cm2 ) 1724 (168) 1647 (142) 
BMD (g/ cm2) 0.958 (0.078) 0.933 (0.078) 
SA-BMCa (g) 1593 (123) 1588 (110) 
All values are Mean (SD). WBLH, whole body less head. 
• Adjusted for weight & BA. 
Group effect 
ANOVA 
P= 
0.007 
0.005 
0.07 
0.77 
8.1;3 Vitamin D status 
There were no significant group differences in vitamin D status at 6 months and the 
mean proportion with 25(0H)D greater or less than 50 nmol/1 were comparable (Table 
8-3). 
Table 8-3 Vitamin D status at 6 months 
25 (OH) D 
25(0H)D (nmol/1) 
25(0H)D (nmol/1) >50, % 
25(0H)D (nmol/1) <50, % 
25(0H)D (nmol/1) <25, % 
All values are Mean (SD) unless stated. 
25(0H)D, 25 hydroxyvitamin D. 
ART-unexposed ART-exposed 
n=66 n=74 
52.0 (18.6) 
67 
33 
5 
54.4 (21.7) 
70 
30 
3 
Group effect 
ANOVA 
P= 
0.5 
8.1.4 Biochemistry 
There were significant differences in ALP activity at 6 months (p~0.001) with ART-
exposed having almost 25% higher concentrations. Similarly, there were differences 
(P<0.0001) in TmP/GFR with ART-unexposed being significantly higher than ART-
exposed (Table 8-4). 
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Table 8-4 Biochemistry at 6 months 
Analyte/ ART-unexposed ART-exposed Group effect 
derived variable n=66 n=74 ANOVA 
p-
Serum Cr (µmol/1) 75.1 (13.1) 1 76.4 (13.7) 0.08 
eGFR 80.5 (19.8) 1 78.9 (21.9) 0.24 
Serum albumin (g/1) 39.8 (4.0)2 38.6 (4.1) 0.1 
Corrected calcium (mmol/1) 2.38 (0.11)2 2.36 (0.17) 0.4 
Serum P (mmol/1) 1.33 (0.25)2 1.25 (0.28) 0.08 
ALP (U/1) 54.1 (22.1)2 75.9 (28.6) <0.001 
Urine P/Cr 1.22 (0.7) 1.15 (0.5) 4 0.47 
TmP/GFR 1.50 (0.41)3 1.39 (0.42)4 <0.0001 
All values are Mean (SD). 
ALP, alkaline phosphatase; Cr, creatinine; eGFR, estimated glomerular filtration rate; P, phosphate; TmP/GFR, 
renal tubular maximum reabsorption rate of phosphate to glomerular filtration rate. 
1n=64, 2n=65, 3 n=64, 4n=73 
8.2 12-month study visit 
8.2.1 Anthropometry 
By the 12-month visit, baseline differences in weight and BMI between the groups had 
diminished and there were no significant differences in mean anthropometric measures. 
Fat and lean mass differences had also become non-significant (Table 8-5). 
Table 8-5 Anthropometry at 12 months 
ART-unexposed 
n=62 
ART-exposed 
n=70 
Group effect 
ANOVA 
P= 
Weight (kg) 71.1 (16.7) 66.6 (15.4) 0.1 
BMI (kg/m2 ) Median (IQR) 26.3 (22.7; 31.4) 25.5 (22.4;30.7) 0.2 
BMI >24.9 kg/m2 (%) 66 49 
BMI >30 kg/m2 (%) 35 20 
BMI <18.5 kg/m2 (%) 2 7 
Waist circumference (cm) 90.3 (16.2) 1 88.3 (14·.o)3 0.4 
Hip ci rcu mference (cm) 108.0 (13.6) 1 104.6 (11.9)3 0.1 
Waist:hip ratio 0.83 (0.07) 1 . 0.84 (0.07)3 0.5 
WBLH fat (kg) 25.6 (10.2) 2 23.9 (10.4)4 0.3 
WBLH lean (kg) 38.7 (5.6) 2 37.4 (5.5)4 0.2 
Fat:lean2 (kg/kg2 ) 17.0 (5.6)2 16.6 (4.9)4 0.7 
All values are Mean (SD) unless indicated. cm, centimetres; IQR, interquartile range; kg , kilograms. 1n=61, 2n=59, 3n=69, 4 n=68 
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8.2.2 Bone measures 
Table 8-6 demonstrates bone variables at 12 months. ART-unexposed had significantly 
greater BMC at the LS and WBLH and aBMD at TH and LS. SA-BMC was also greater in 
this group at LS (Table 8-6). 
Table 8-6 Bone mineral status at 12 months 
ART-unexposed ART-exposed Group effect 
n=59 n=68 ANOVA 
P= 
Total hip 
BMC (g) 34.2 (5.9) 33.2 (5.0) 0.3 
Area (cm2) 33.4 (3.4) 33.8 (3.2) 0.4 
BMD (g/cm2l 1.026 (0.139) 0.981 (0.115) 0.05 
SA-BMCa (g) 33.9 (4.2) 32.9 (3.3) 0.11 
Femoral neck 
BMC (g) 4.45 (0.67) 4.30 (0.63) 0.2 
Area (cm2) 4.78 (0.30) 4.85 (0.34) 0.2 
BMD (g/cm2l 0.932 (0.136) 0.887 (0.125) 0.06 
SA-BMCa (g) 4.46 (0.56) 4.33 (0.52) 0.18 
Lumbar spine 
BMC (g) 58.2 (9.8) 54.4 (9.1) 0.02 
Area (cm2) 56.0 (4.8) 55.2 (4.8) 0.4 
BMD (g/cm2l 1.036 (0.121) 0.982 (0.122) 0.01 
SA-BMCa (g) 56.6 (6.0) 54.2 (6.4) 0.03 
WBLH 
BMC (g) 1647 (238) 1559 (221) 1 0.03 
Area (cm2) 1708 (146) 1659 (144)1 0.06 
BMD (g/cm2l 0.962 (0.079) 0.937 (0.073) 1 0.07 
SA-BMCa (g) 1605 (119) 1585 (110) 1 0.33 
All values are Mean (SD). WBLH, whole body less head. 
• Adjusted for weight & BA. 
1n=67 
8.2.3 'Vitamin D status 
At the 12-month visit there were no significant group differences in mean vitamin D 
status (Table 8-7). 
Table 8-7 Vitamin D status at 12 months 
25 (OH) D 
25(0H)D (nmol/1) 
25(0H)D (nmol/1) >50, % 
25(0H)D (nmol/1) <50, % 
25(0H)D (nmol/1) <25, % 
Values are Mean (SD) unless stated . 
25(0H)D, 25 hydroxyvitamin D. 
ART-unexposed ART-exposed 
n=62 n=68 
66.4 (17.4) 
66 
34 
5 
61.1 (20.6) 
71 
29 
3 
Group effect 
ANOVA 
P= 
0.1 
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8.2.4 Biochemistry 
There were significant differences in serum ALP activity at 12 months with ART-exposed 
having 30% higher concentrations. Serum albumin concentrations were not significantly 
different between the two groups. Serum phosphate was non-significantly higher in ART-
unexposed. The resulting TmP/GFR was significantly reduced in the ART-exposed group 
(p=0.002), which was consistent with the pattern at six months (Table 8-8). 
Table 8-8 Biochemistry at 12 months 
Analyte/ ART-unexposed ART-exposed Group effect 
derived variable n=62 n=69 ANOVA 
p-
Serum Cr (µmol/1) 74.4 (10.1) 73.8 (10.4) 0.7 
eGFR 79.4 (13.2) 80.2 (14.6) 0.7 
Serum albumin (g/L) 38.5 (4.0) 39.6 (3.0) 0.08 
Corrected calcium (mmol/L) 2.34 (0.11) 2.33 (0.16) 0.6 
Serum P (mmol/L) 1.31 (0.26) 1.29 (0.28) 0.6 
ALP (U/L) 60.6 (21.5) 93.4 (28.8) <0.001 
Urine P/Cr 1.21 (0.68) 0.15 (0.11) 0.02 
TmP/GFR 1.47 (0.38) 1.36 (0.45) 0.002 
All values are Mean (SD) . 
ALP, alkaline phosphatase; Cr, creatinine; eGFR, estimated glomerular filtration rate; P, phosphate; TmP/GFR, 
renal tubular maximum reabsorption rate of phosphate to glomerular filtration rate. 
8.3 Longitudinal analysis 
The remaining analyses in this chapter examine changes in body composition, bone and 
biochemical variables from baseline to 12 months in ART-unexposed and -exposed using 
the hierarchical, longitudinal models (Section 7.1). In the figures in this section ART-
unexposed are represented in green, and ART-exposed in red. 
There was an increase in weight (3.9 ±0.81%) (p<0.001) and BMI (4.0 ±1.3%) 
(p=0.01) in ART-exposed, and non-significant decreases in ART-unexposed. Waist 
circumference was not significantly different from baseline, and while not significant, hip 
circumference had increased by 4.5 ±2.1% in ART-exposed. Corresponding WHR was -
2.8 ±3.0% lower in this group compared to baseline (p=0.66) (Figure 8-1). 
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ART-exposed had mean increases in fat mass of 10.1 ±2.0% (p<0.001), which was 
highly significant and different from ART-unexposed, -2.1 ±2.1%, this was mirrored in 
fat:lean2 ratios. ART-unexposed and ART-exposed had -1.9 ±0.6% (p=0.008) and 0.34 
±0.57 (p=0.8) changes in lean mass respectively (Figure 8-1). 
These body composition changes very closely map, as anticipated, those differences 
seen in Ppres and Plow with ART-exposed being analogous to Plow. 
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Figure 8-1 Changes in body composition 
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8.3.1 Bone measures longitudinal 
8.3.1.1 Total hip 
There were significant (p<0.001) increases in BMC and BA at the TH in both groups. In 
ART-unexposed there was a 2.0 ±0.68% (p=0.005) increase in aBMD with a non-
significant increase in ART-unexposed. There were decreases at the total hip in SA-BMC 
in ART-unexposed -0.80 ±0.73% (NS) and ART-exposed -2.2 (0.74)% (p=0.003) with a 
non-significant interaction term (p= 0.09). At 12 months SA-BMC in ART-exposed was 
4 .1 (0. 75)% (p<0.001) greater than ART-unexposed (Figure 8-2). 
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Figure 8-2 Changes in hip 
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8.3.1.2 Femoral neck 
At the FN there was a non-significant increase in BMC in ART-unexposed 0.33 ±1.0, and 
a non-significant decrease in ART-exposed -1.0 ±0.94%. There were increases in BA in 
both groups; 0.42 ±0.63% (NS) and 1.2 ±0.59% (p=0.04) in ART-unexposed and ART-
exposed respectively. There were decreases in aBMD in both groups with a significant 
decrease in ART-exposed -2.3 ±0.65% (p<0.001). There was a decrease in SA-BMC in 
ART-unexposed -0.32 ±0.70% (NS) and ART-exposed, -2 .7 ±0.70% (p<0.001). At 12 
months there was a 4.8% (p<0.001) difference between ART-exposed and ART-
unexposed in SA-BMC (Figure 8-3) . 
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Figure 8-3 Changes in femoral neck 
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8.3.1.3 Lumbar spine 
There were non-significant changes in BMC, BA, aBMD, and SA-BMC in ART-unexposed 
groups at the LS. The ART-exposed group had a -4.1 ±0.62% (p<0.001) decrease in 
BMC and a -1. 7 ±0.32% (p<0.001) decrease in BA. There was a significant decrease in 
aBMD in ART-exposed -2.4 ±0.57 ( <0.001). There was a decrease in SA...:BMC in ART-
exposed -2.8 ±0.65% (p<0.001). At 12 months there was a 5.2% (p<0.001) difference 
between ART-unexposed and ART-exposed in SA-BMC {Figure 8-4 ). 
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Figure 8-4 Changes in lumbar spine 
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8.3.1.4 Whole body less head 
There were non-significant changes in BMC and BA in both groups at WBLH. There was a 
significant increase in aBMD in ART-unexposed 0.90 ±0.31 % (p=0.02) and a significant 
decrease in ART-exposed -0.83 ±0.30 (p=0.02). ART-unexposed had a 0.89 ±0.32% 
increase (p=0.02) in SA-BMC and a significant interaction (p=0.05), there was a non-
significant decrease in ART-exposed. At 12 months there was a 2.8% (p<0.001) 
difference between ART-unexposed and ART-exposed in SA-BMC (Figure 8-5). 
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Figure 8-5 Changes in whole body 
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8.3.2 Vitamin D status 
In ART-unexposed and ART-exposed there were mean winter decreases of 25(0H)D of 
14.2 ±4.8% and 14.1 ±4.5% respectively. By 12 months (summer) the ART-unexposed 
had increased significantly from baseline by 14.5 ±4.9% (p=0.01) but with a non-
significant interaction (p=0.08). There was no significant change in 25(0H)D in ART-
exposed over 12 months (Figure 8-6). 
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Figure 8-6 Changes in vitamin D status 
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8.3.2.1 Vitamin D and fat mass 
To explore percentage changes in 25(0H)D and any relationship to adiposity the 
following model was constructed for ART-exposed: 
Y variable: log 25(0H)D at 12 months - log 25(0H)D at baseline 
' 
X variables: 
group 
log 25(0H) D at baseline (to prevent regression to the mean) 
log fat mass at 12 months - log fat mass at baseline (lnfat12-lnfat0) 
mean (log fat mass at 12 months + log fat mass at baseline) 
Also, fat mass did not predict 25(0H)D concentration at six or 12 months. Change in fat 
did not predict change in vitamin D status. There were non-significant coefficients and 
interaction terms (p>0.05) at both time points. The group*lnfat12-lnfat0 interaction was 
non-significant, p=0.5. 
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8.3.3 Biochemistry 
There were increases in serum albumin concentrations from baseline in ART-exposed, 
9.4 ±1.1% (p<0.001), with non-significant increases in ART-unexposed over 12 months. 
There were significant increases in corrected calcium in both groups but non-significant 
interaction terms (p>0.05). Serum creatinine concentrations and eGFR did not change 
significantly in either group. 
There were large, significant increases in ALP activity, with the largest increases seen in 
ART-exposed, 34.8 ±3.7% (p<0.001) (Figure 8-7). 
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Figure 8-7 Changes in biochemistry and derived variables 
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8.3.4 Changes in markers of phosphate homeostasis 
When analysed at baseline, ART-exposed had significantly hig~er mean serum phosphate 
concentrations than ART-unexposed (p::50.05). At 12 months there was an overall 
increase in serum phosphate in ART-unexposed, 7.9 ±2.7% (p=0.003), but no 
significant change in ART-exposed -1.9 ±2.5% (Figure 8-8). At baseline, ART-unexposed 
had a significantly lower TmP/GFR when compared to ART-exposed 1.37 ±0.35%, 1.58 
±0.49% respectively, (p= 0.003). At 12 months ART-unexposed had a 9.8 ±3.9% 
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increase in TmP/GFR (p=0.04) compared to a 15.4 ±3.7% decrease in ART-exposed 
(p=0.0002). These findings are consistent with the observed changes in serum 
phosphate concentrations (Table 8-9). 
Table 8-9 Changes in phosphate 
ART-unexposed Serum phosphate 
TmP/GFR 
ART-exposed Serum phosphate .J.,/~ 
TmP/GFR .J., 
Relative changes in markers of phosphate metabolism in ART-unexposed and ART-
exposed 
figure 8-8 Changes in phosphate metabolism 
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8.4 Summary 
In summary, the changes seen in body composition and bone variables were similar in 
the groups categorised post hoe as ART-unexposed and ART-exposed, when compared to 
the origina l allocation Ppres and Plow (see Section 7.1) . There were significant increases 
in weight, BMI, fat mass, and fat:lean 2 in ART-exposed. The ART-unexposed had a 
significant decrease in lean mass (Table 8-10) . 
Table 8-10 Changes in anthropometry and body composition 
Variable 
Weight (kg) 
BMI (kg/m2) 
Fat (kg) 
Lean (kg) 
Fat:lean2 
ART-unexposed 
-1.3 (0.9) 
-1.7 (1.4) 
-2.1 (2.1) 
-1.9 (0.6) 0.008 
ART-exposed 
+3. 9 (0.8) <0.001 
+4.0 (1.3) 0.01 
+10.1(2.0) <0.001 
+0.3 (0.6) 
+1.7 (2.2) +9.4 (2.0) <0.001 
Values are mean (SE) percentage change from baseline to 12 months in each group, p= in bold 
type. Where no p value stated, p>0.05. 
There were significant increases in hip BMC and BA in both groups; ART-unexposed had 
a significant increase in aBMD. However, when full size-adjustment was conducted ART-
exposed had a significant decrease in SA-BMC. At the femoral neck the ART-exposed 
group had increases in BA and decreases in aBMD and SA-BMC. At the lumbar spine 
there were significant decreases in all bone variables in ART-exposed. At WBLH there 
were increases in aBMD and SA-BMC in ART-unexposed, and a decrease in aBMD in ART-
exposed (Table 8-11). 
Table 8-11 represents the same data as Table 7-2 but for ART-unexposed and ART-
exposed groups. 
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Table 8-11 Changes in bone mineral status 
Variable 
Total hip 
BMC (g) 
BA (cm 2) 
BMD (g/cm2) 
SA-BMC (g) 
Femoral neck 
BMC (g) 
BA (cm2) 
BMD (g/cm2 ) 
SA-BMC (g) 
Lumbar spine 
BMC (g) 
BA (cm2 ) 
BMD (g/cm2) 
SA-BMC (g) 
WBLH 
ART-unexposed 
+7 .3 (1.2) <0.001 
+5.0 (0. 7) <0.001 
+1.95 (0.7) 0.005 
-0.80 (07) 
+0.33 (1.0) 
+0.42 (0.6) 
-0.46 (0.7) 
-0.32 (0.7) 
+0 .21 (0. 7) 
-0.24 (0.4) 
+0.44 (0.6) 
+0.43 (0.6) 
ART-exposed 
+5.0 (1.1) <0.001 
+4.5 (0.6) <0.001 
+0.5 (0.6) 
-2.2 (0.7) 0.003 
-1.0 (0.9) 
+1.2 (0.6) 0.04 
- 2.3 (0. 7) <0.001 
-2.7 (0.7) <0.001 
-4.1 (0.6) <0.001 
-1.7 (0.3) <0.001 
-2.4 (0.6) <0.001 
-2.8 (0.7) <0.001 
BMC (g) +0.55 (0.5) -0.96 NS 
BA (cm2) -0.85 (0.4) -0.13 (0.3) 
BMD (g/cm2 ) +0.90 (0.3) 0.02 -0.83 (0.3) 0.02 
SA-BMC (g) +0.89 (0.3) 0.02 -0.58 (0.3) 
Values are mean (SE) percentage change from baseline to 12 months in each group, p= in bold 
type ( Where no p value stated, p>0.05. 
In the ART-unexposed group there was a significant increase in 25(0H)D and serum 
phosphate over the course of the study period but no significant change in the ART-
exposed group. There were increases in corrected calcium and no significant change in 
serum creatinine and eGFR. In ART-exposed there were large increases in ALP activity 
and urine phosphate to creatinine ratio. TmP/GFR significantly increased by 9.8 ±3.9% 
in ART:unexposed and decreased by 15.4 ±3.7% in ART-exposed (p=0.0002) (Table 
8-12). Table 8-12 represents the same data as Table 7-3 but for ART-unexposed and 
ART-exposed groups. 
Table 8-12 Changes in vitamin D status and biochemistry 
Variable/ 
derived variable 
25(0H)D (mmol/1) 
Corrected calcium (mmol/1) 
Albumin (g/1) 
ALP (U/1) 
Serum P (mmol/1) 
Urine P/Cr 
Serum Cr (µmol/1) 
eGFR 
TmP/GFR 
ART-unexposed 
+14.5 (4.9) 0.01 
+5.1 (0.75) <0.001 
+1.0 (1.2) 
+7.1 (3.9) 
+7.9 (2.7) 0.003 
-1.4 (13.1) 
-4.6 (3.3) 
+4.7 (3.8) 
+9.8 (3.9) 0.04 
ART-exposed 
+1.1 (4.7) 
+4.5 (0. 71) <0.001 
+9.4 (1.1) <0.001 
+34.8 (3.7) <0.001 
-1.9 (2.5) 
+58.2 (12.3) <0.001 
+3.2 (3.1) 
-4.2 (3.6) 
-15.4 (3. 7) 0.002 
Values are mean (SE) percentage change from baseline to 12 months in each group, p= in bold 
type. Where no p value stated, p>0.05. 
ALP, alkaline phosphatase; Cr, creatinine; eGFR, estimated glomerular filtration rate; P, 
phosphate; TmP/GFR, renal tubular maximum reabsorption rate of phosphate to glomerular 
filtration rate. 
These post hoe analyses demonstrate a similar magnitude of change in terms of body 
com position when compared with the three group analysis comparing Ppres and Plow 
(and Nref). They also reveal a more pronounced change in bone status over time with 
greater declines in aBMD at the lumbar spine and greater declines in SA-BMC at the total 
hip and lumbar spine. 
This type of analysis also highlighted relative differences in vitamin D status at 12 
months with ART-u nexposed seeing a 14.1% (p=0.01) increase in 25(0H)D compared to 
a non-significant increase of 1.1 % in ART-exposed. There were also larger increases in 
serum albumin and ALP activity in ART-exposed compared to ART-unexposed. 
Signi ficant differences in TmP/GFR are revealed in this post hoe analysis, so that ART-
exposed saw a 15.4% decrease while ART-unexposed a 9.8% increase in this measure 
of renal phosphate handling. This result was accompanied by a non-significant decrease 
in serum phosphate in ART-exposed which is in keeping with the hypothesis of ART-
induced renal phosphate wasting. 
Therefore this post hoe analysis provides interesting insights into the differences in those 
exposed and unexposed to ART beyond those demonstrated by original grouping. 
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9 Discussion 
The study that forms the basis of this thesis was carried out in Soweto, an impoverished, 
urban area of Johannesburg, the largest city in South Africa. Soweto has a very high 
prevalence of HIV infection, ranging from 19.4% in the general population (Piwowar-
Manning et al, 2011) to >35% in pregnant women (Gounder et al, 2011). South Africa is 
described as being a hyper-endemic region for HIV infection with high rates of new 
infections. Historically, Soweto has seen high rates of under-nutrition and stunting, and 
malnutrition remains prevalent (Willey et al, 2009). Relatively recently there have been 
dramatic secular changes in Soweto, and urban South Africa more generally, with 
increases in childhood and adult obesity, and burgeoning non-communicable disease 
burden. These two epidemics overlap so that HIV infection may be partially associated 
,· 
with non-communicable disease or may be a direct cause, for example HIV-associated 
cardiomyopathy (Sliwa et al, 2012). 
In recent years, access to free ART treatment has dramatically improved life expectancy 
in South Africa with estimates of up to 11.3 years gained with the introduction of ART, in 
as little as 11 years since the roll-out of ART in 2000 (Bor et al, 2013). For this reason it 
can be pr,edicted that South Africa will continue to see rises in life expectancy in HIV-
positive populations, so much so that they are likely to survive for long enough to 
develop non-communicable disease, such as osteoporosis, seen with advancing age in 
other populations. If, as has been demonstrated in Caucasian populations, ART exposure 
is associated with poor bone health it is important to describe the history of this (in a 
South African population) in order to anticipate the magnitude of the problem and 
potential consequences for population and individual health within Africa (Bendavid et al, 
2012). 
The work described in this thesis has sought to gain insights into the associations 
between HIV infection, ART exposure, body composition, bone mineral, and vitamin D 
status in women in Soweto. It also sought to explore changes in body composition, bone 
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mineral, and vitamin D status over time. The study was designed to test several key 
hypotheses that were developed after scrutinising the existing literature on body 
composition, bone health, and vitamin D status in HIV-positive individuals. The data 
from these wide-ranging studies are mixed, particularly with respect to changes in bone 
density. 
The majority of published studies demonstrated low bone mass associated with HIV 
infection and ART exposure (Brown et al, 2006b), although some did not support these 
observations and indeed saw the opposite effect. Work by Bolland et al described either 
no bone loss associated with ART exposure or an increase, at least initially, of aBMD 
after initiation of ART (Bolland et al, 2006; 2011). Data generated from this study 
support the idea that tenofovir-exposure is most likely driving loss of bone mineral in 
these women. It supports other data such as that described in the PrEP study (Liu et al, 
2011) demonstrating loss of bone mineral following tenofovir-exposure in HIV negative 
men, and the 'ASSERT' study (Stellbrink et al, 2010) which described higher rates of 
bone loss with tenofovir- than abacavir-based ART in HIV-infected patients. Until 
recently there has been little attention paid to bone health in HIV-positive Africans living 
in Africa. At the time of writing this thesis there was only one paper examin.ing the effect 
of HIV infection on bone density in Africa; this was a 2012 publication from Senegal 
describing a cross-sectional study examining the association of ART-use (mean duration 
8.8 years, 45% were receiving a protease inhibitor-based regime) using QUS at the 
ca lcaneus. The HIV-positive patients in this study had lower bone density by QUS than 
controls (Figure 9-1). 
QUS has been used either alone or in conjunction with DXA to assess fracture risk (Chan 
et al, 2012; 2013). QUS gives a measure of microstructure of bone (particularly at the 
calcaneus) which closely correlates with BMD. It has the advantages of being relatively 
inexpensive and portable when compared with DXA and does not involve the use of 
ionising radiation. However, osteoporosis is defined by the WHO in terms of bone density 
measured by DXA. "There is currently no established, accepted definition of osteoporosis 
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based on QUS measurements, so QUS cannot currently be used to confirm the diagnosis 
of osteoporosis. Ultrasound cannot be used to monitor rates of bone loss or bone gain 
with treatment" (NOS, 2012). Studies in the elderly aged 65 - 76 years suggested that 
QUS might predict hip fracture risk as reliably as DXA (Moayyeri et al, 2009), and this 
finding was repeated in a wider age range, 42 - 82 years (Khaw et al, 2004 ). There is a 
lack of evidence of the utility of QUS predicting fracture in premenopausal women and 
men (NOS, 2012) and there is lack of standardisation between different QUS 
technologies, which makes its use as a screening and diagnostic tool problematic. 
Furthermore, the effects of pharmacological agents, such as bisphosphonates, on bone 
mineral density and fracture risk are based on DXA measurement rather than QUS, 
therefore QUS has not been validated to demonstrate effects of treatment on BMD and 
fracture risk. 
In the paper from Senegal cited, Cournil et al described a heterogeneous group of 
patients with a mean age of 47.0 years and a variety of different ART exposures; whilst 
an important study in assessing bone health in African subjects it is limited by design 
and choice of imaging modality. 
Figure 9-1 Differences in BMD in Senegalese subjects 
0.5 
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Women Men 
Controls 
"Mean QUS bone mineral density expressed as T-score (and 95% confidence interval) in HIV-infected patients 
and controls, separately for men and women" (Cournil et al, 2012) . [Content under open content licenses may 
be reused without any need to contact the licensor. See : http://creativecommons.org/licenses/by/2.5/] 
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The dearth of African studies examining the association of HIV infection and ART 
exposure with low bone mineral status aside, it seems reasonable to speculate that HIV-
positive African women experience low bone mineral or bone mineral loss. The results of 
t he study presented in this thesis certainly support an association between low CD4 
count, ART exposure, and bone mineral loss. There were rates of decline in aBMD and 
SA-BMC of 2:::2% at the lumbar spine over 12 months in Plow (as well as in ART-exposed) 
when compared with baseline. Indeed, at baseline there were no significant differences 
in bone status between any of the three groups (Nref, Ppres, and Plow) (see Section 
9. 2). 
In contrast to bone health, there are more published studies examining the effect of HIV 
infection and ART exposure on body composition in African subjects. A number of studies 
in children and adults with older, stavudine-containing ART combinations have 
associated ART use with accumulation of visceral fat and loss of limb fat (Innes et al, 
2012; Goedecke et al, 2013). Studies have also demonstrated comparatively lower lean 
mass in some HIV-positive Africans than expected (Mutimura et al, 2010; Mupere et al, 
2012). Some of these studies have used DXA to examine body composition but are 
cross-sectional and do not establish baseline body composition characteristics and 
change after ART-initiation. Awareness of the importance of examining body composition 
in HIV-positive African subjects and those exposed to ART is in part due to the 
appreciation of an increase in metabolic dysregulation associated with HIV infection 
(Boufassa et al, 2012) and the likely burden of associated cardio-metabolic disease. 
The studies examining vitamin D status in HIV-positive patients almost universally 
describe high rates of vitamin D deficiency (Van Den Bout-Van Den Beukel et al, 2008a; 
Childs et al, 2012). There have been many studies into the immune-modulating effects 
of vitamin D over recent years and a clinical perception that low vitamin D status is 
associated with increased risk for infectious disease and an impaired ability to combat 
these infections should they be acquired . For this reason, as well as those pertinent to 
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bone health, it was important to investigate vitamin D status in an urban, South African 
context. 
One of the key findings of the research presented in this thesis is that, at baseline, HIV-
positive women did not differ from HIV-negative women in measures of bone and 
vitamin D status, and only in Plow in weight and measures of fat. The same findings 
were also described at six and 12 months when examined cross-sectionally. However, 
the more detailed longitudinal analysis demonstrated within individual declines in aBMD 
and SA-BMC at the femoral neck and lumbar spine of ~2.0%, and SA-BMC at the hip of 
1.7% in Plow suggesting a rate of bone loss similar to, or greater than, at menopause. 
Similar results were obtained when the Ppres and Plow groups were reclassified as ART-
unexposed and ART-exposed. In ART-exposed there were complementary decreases in 
aBMD and SA-BMC at the femoral neck compared to Plow with decreases of -2.3% 
compared with -2.4% in aBMD and -2. 7% in Plow and ART-exposed in SA-BMC. At the 
lumbar spine there was a greater decrease in aBMD and SA-BMC in ART-exposed 
compared to Plow by -0.4% and -0.7% respectively. At the hip there was a decline in 
SA-BMC of 2.2% in ART-exposed compared to 1.7% in Plow. 
The post hoe analysis examining ART-unexposed and ART-exposed proved slightly more 
discriminating than examining differences over time using the baseline Ppres and Plow 
classification. The reason analysing subjects by ART exposure status allowed a more 
precise discernment of the effects of ART, or of declining health for those in Ppres who 
had falls in CD4 count, on body composition, bone, and vitamin D status than by original 
classification was cross-over between groups that occurred over the course of the study. 
This was due to several factors including: i) increases and decreases in individual CD4 
counts, which changed their eligibility for ART, ii) individuals due to start ART after the 
baseline visit not commencing therapy as planned, and iii) a change in South African CD4 
eligibility criterion for commencing ART from ~ 200 x106 cells/I to ~350 x106 cells/I. 
277 
This thesis adds to the body of knowledge on the subject of HIV infection, immune 
dysregulation, ART exposure, body composition, bone health, and vitamin D status in the 
following areas. 
9.1 Body composition 
At baseline, Plow was significantly lighter, with a lower BMI, than Nref and Ppres, 
although rates of overweight and obesity were generally high in all groups. Surprisingly, 
even at baseline the HIV-positive women with advanced HIV-disease (Plow) had high 
BMI, with a median of 23.5, 48% of whom were overweight or obese (BMI >25 kg/m2). 
Nref and Ppres had the same rates of overweight (65%) compared to Plow (44%). Ppres 
had the highest proportion of obese subjects (37%) compared to Nref (30%) and Plow 
(16%). Plow had smaller waist and hip circumferences than Nref and Ppres which were 
not different from each other. WHR was the same in Ppres and Plow (0.84) and greater 
than Nref (0.80), suggesting differences in distributions of adiposity between HIV-
positive and HIV-negative women. Lean mass, fat mass, and fat:lean 2 were all lower in 
Plow while Nref and Ppres were not different. These patterns suggest that Nref and Ppres 
are more similar than Ppres and Plow and indicate that it is not appropriate to conflate 
all women with HIV infection as there are significant differences depending oh the stage 
of disease. Usually lipodystrophy and alterations in body composition is attributed to ART 
exposure in the context of HIV infection. However, in this study the differences in body 
composition described at baseline were in ART-na"ive individuals. 
Weight in the Plow group increased by approximately 10% over the 12-month duration 
of the study and this increase was mostly due to the accrual of fat rather than lean 
mass. The high proportion of fat increase for a given increase in weight was unexpected; 
normally it would be anticipated that with weight gain the proportion of fat mass to lean 
was would be in the region of 55% to 45% respectively (Siervo et al, 2008). The women 
in the Plow group far exceeded these proportions; increases were 80% fat mass to 20% 
lean mass. A similar pattern was observed when HIV-positive women on ART were 
considered . Such a dramatic increase in adiposity in those with low CD4 counts, 12 
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months after initiation of ART, is of concern and may be a risk factor for future metabolic 
disease. At baseline, Nref had smaller waist:hip ratios than Ppres and Plow. However, 
the relative stability of WHR over time suggests that fat is being deposited and not 
particularly on the hips or centrally. A WHR of >0.80 has been associated with cardio-
metabolic risk, and is a more sensitive marker of central adiposity-induced pathology 
than BMI (Huxley et al, 2010; Coutinho et al, 2011). However, 2012 data from South 
Africa has suggested that the waist circumference used in Caucasian female populations 
{>80 cm) as part of the diagnosis of the metabolic syndrome is not appropriate for black 
South African women. Crowther et al suggest that the appropriate cut-off in this 
population is 91.5 cm and points to this as evidence of "a clear ethnic difference in the 
relationship between abdominal adiposity and metabolic disease risk" (Crowther et al, 
2012). This observation serves as a reminder that it may not be appropriate to 
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extrapolate Caucasian normative values onto black African populations with respect to 
body composition and measures of bone health. In a similar vein, a WHO report 
acknowledged that the "proportion of Asian people with a high risk of type 2 diabetes 
and cardiovascular disease is substantial at BMis lower than the existing WHO cut-off 
point for overweight" (WHO Expert Consultation, 2004). 
However, the burden of obesity in these women may contribute to increases in fracture 
risk as they age (Compston, 2013a; 2013b) although ongoing research is needed into 
the morbidity and mortality associated with fractures in obese patients, particularly in 
the developing world, the extent of which has not yet been defined. 
9.2 Bone status 
At baseline there were no differences in BMC, aBMD, or SA-BMC at any site between 
Nref, Ppres, and Plow. Differences in BA were not significant when adjusted for age, 
height, and weight. There were no differences in aBMD SDS at any skeletal site 
measured. These data are at variance with some published work but have the distinct 
advantage of having been derived from subjects prior to ART exposure and with the 
comparison of a HIV-negative control group. 
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Longitudinally, changes in BMC, aBMD, and SA-BMC were demonstrated over the 12-
month duration of the study in Nref, Ppres, and Plow (see Table 9-1). 
Table 9-1 Changes in BMC, aBMD, & SA-BMC (Nref, Ppres, & Plow) 
Site 
Tota l hip BMC i in all groups 
aBMD i Nref and Ppres 
SA-BMC +-+ Nref and Ppres 
! Plow (-1.70/o) 
Femoral neck BMC +-+ in all groups 
aBMD +-+ Nref and Ppres 
! Plow (-2.40/o) 
SA-BMC +-+ Nref and Ppres 
! Plow (-2.70/o) 
Lumbar Spine BMC +-+ Nref and Ppres 
! Plow (-3.30/o) 
aBMD i Nref 
! Plow (-2.00/o) 
SA-BMC +-+ Nref and Ppres 
! Plow (-2.1010) 
Whole body less head BMC +-+ in all groups 
aBMD +-+ in all groups 
SA-BMC +-+ in all groups 
Ch_anges in BMC and SA-BMC from baseline and magnitude of changes. 
j, increase; !, decrease; +-+, no difference 
There were decreases in aBMD at the femoral neck and lumbar spine, and SA-BMC at the 
hip, femoral neck and lumbar spine in Plow over the course of 12 months, i.e. after 
initiating ART. The magnitude of this decline reached -2. 7 ±0.68% at the femoral neck. 
The analogous changes in the ART-unexposed and ART-exposed are shown in Table 9-2. 
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Table 9-2 Changes in BMC, aBMD, & SA-BMC (ART-unexposed & ART-exposed) 
Site 
Total hip 
Femoral neck 
Lumbar Spine 
Whole body less head 
BMC 
aBMD 
SA-BMC 
BMC 
aBMD 
SA-BMC 
BMC 
aBMD 
SA-BMC 
BMC 
aBMD 
i in both groups 
i in both groups 
! ART-exposed ( - 2. 2 O/o) 
+-+ in both groups 
! ART-exposed (-2.30/o) 
! ART-exposed (-2.70/o) 
! ART-exposed ( -4.1 D/o) 
+-+ in ART-unexposed 
! ART-exposed (-2.40/o) 
! ART-exposed (-2.SD/o) 
+-+ in ART-unexposed 
+-+ in both groups 
i ART-unexposed 
! ART-exposed 
SA-BMC +-+ in both groups 
Comparison with 
Plow 
= 
> 
= 
= 
> 
> 
> 
> 
Changes in BMC and SA-BMC from baseline, magnitude of changes and comparison with Plow. 
j, increase; !, decrease; +-+, no difference; >, greater than; =, equal to 
The aBMD and SA-BMC changes, present in the post hoe analysis of ART exposure, 
ranged from -0.58 ±0.31 % (WBLH) to -2.8 ±0.65% (lumbar spine) and exceed those 
(2%) used in the sample size calculation (see Section 3.5). 
The importance of describing changes in BMC, aBMD and SA-BMC is due, in part, to the 
fact that the women are changing weight over the course of the study. This is 
particularly true in the Plow (and ART-exposed) subjects. BMC describes the actual 
mineral content changes over time and SA-BMC describes the changes in bone mineral 
after correction for weight. The change in aBMD will be between these values (BMC/BA) . 
If, for example, bone mineral had increased in proportion to weight gain then BMC would 
have increased but SA-BMC would stay the same, again aBMD would be intermediate. If 
bone mineral had gone up less than expected for the amount of weight change, BMC 
would have increased but SA-BMC would decrease, aBMD would again be in-between . 
At the hip, the latter pattern is evident in both Plow and ART-exposed suggesting less 
than expected increases in bone mineral for the amount of weight gained. At the femoral 
neck there were no changes in BMC but decreases in SA-BMC in Plow and ART-exposed, 
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suggesting an inappropriate increase in bone mineral for the amount of weight gained. 
At the lumbar spine there were significant decreases in BMC, aBMD, and SA-BMC in Plow 
and ART-exposed. It is feasible that that may have been even greater losses of bone 
mineral in Plow and ART-exposed had these losses not been partially compensated by 
increases in weight. There were no significant changes in BMC, aBMD or SA-BMC in Plow 
at WBLH although there were decreases in ART-exposed, and trends for SA-BMC 
reflected those in regions and the aBMD change at 12 months was significant. 
These changes are important with respect to the magnitude of change; they compare 
with estimated aBMD annual loss of 0.5 - 1.0% in HIV-negative adults aged >35 years 
(Powderly et al, 2005) and 1 - 2% loss in the early menopause years (Hodgson et al, 
2003) . In postmenopausal women the OR for hip fracture is 2.6 for every SD decrease in 
aBMD from mean hip aBMD at age 30 years (Marshall et al, 1996), however it is not yet 
known if the changes described in this thesis will continue over time or plateau. It is also 
unknown if these decreases in bone mineral, in premenopausal women will translate into 
increased fracture risk either in the near future or following menopause. 
The results presented in this thesis closely map the estimated rates of bone loss in 
Brown's ART study at 96 weeks, i.e. -2.3% and -2.5% for NNRTI and PI use respectively 
(Brown et al, 2009), a study of treatment-na"ive patients commencing ART. It should be 
noted that the bone loss in Brown's study was over twice the time period compared to 
the study presented in this thesis. Duvivier et al describe a mean change in aBMD from 
baseline of -4.1 ±3.9% at 48 weeks at the LS and as great as -5.8 ±4.5% in those on 
PI-based ART (Duvivier et al, 2009) (see Section 2.4.3.3), which exceeds those seen in 
this study of South African women. The large increases in ALP activity in Plow and ART-
exposed support the interpretation that bone loss is occurring in these groups and is 
accompanied by increased bone turnover (see Section 9.4). 
There were unanticipated increases in BA at the total hip and, to a smaller degree, the 
femoral neck by original grouping and by post hoe ART exposure classification. This was 
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unanticipated because subjects were adult women who were unlikely to be undergoing 
bone expansion to this extent in 6 - 12 months. The fact that the same Holog ic machine 
and software was used and operated by the same technician throughout this study with 
appropriate QC suggests that the results described are unlikely to be t he resul t of 
technical differences, movement, positioning, or machine error. As speculated in Section 
8.4, this is more likely to be due to a technical artefact because of overlying fat. The hip 
and femoral neck are the sites most likely to be affected by increases in gluteal and 
abdominal fat adjacent to, and overlying, the hip region (Tothill et al, 1997; Binkley et 
al, 2003). 
There was particular loss of bone mineral at trabecular-rich sites such as the femoral 
neck and lumbar spine, compared to more cortically-rich WBLH. Trabecular rich sites are 
the most metabolically active, as a result of their high surface area, so it could be 
,' 
predicted that, in a situation analogous to bone loss related to pregnancy and lactation 
(Olausson et al, 2012), that ART-associated bone loss occurs predominantly at 
trabecular-rich sites. The majority of studies in HIV-positive patients suggest that the LS 
is the site of the greatest bone loss. This is probably because of the increased 
susceptibility of metabolically active trabecular bone to the effects of ART. 
In the post 
1
hoc analysis there were decreases in BMC, aBMD, and SA-BMC at several 
skeletal sites in the ART-exposed group. There was increased urinary phosphate 
excretion and decreased tubular resorption of phosphate in ART-exposed also. This, in 
the context of good vitamin D status, and non-significantly different bone mineral status 
in HIV-positive women with high and low CD4 counts when ART-na"ive, supports t he 
hypothesis that ART exposure (specifically tenofovir) is associated with loss of bone 
mineral over 12 months. In this study there is such overlap between Ppres and Plew, 
and ART-unexposed and ART-exposed that it was not possible to look at Plew and ART-
unexposed (i.e . progressive HIV disease and bone loss in those w ith low C04 cou nts who 
did not receive ART) . In t his study premenopausal HIV-posit ive women with preserved 
CD4 counts and HIV-negative controls demonstrated no evidence of bone loss, which is 
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in contrast to those HIV-positive women with low CD4 counts who went on to be treated 
wi th ARTs. 
In order to distinguish the specific effects of ART on bone health from other factors 
studies must: i) have a HIV-negative control group, and a HIV-positive group not 
exposed to ART against which to compare bone outcomes, ii) control for the 'traditional ' 
osteoporosis risk factors (e.g. ethanol excess, poor vitamin D status) that are 
overrepresented in some HIV-positive cohorts, iii) involve cohorts large enough and with 
long enough duration of follow-up to determine both small changes in aBMD and clinical 
(namely fracture) outcome measures, and iv) allow for comparison of different ART drug 
combinations to look for differential effects on bone health. In such studies the "relative 
contributions of HIV infection, HIV viraemia and cART (combination-ART) to bone loss 
(which) remain poorly defined" will be better understood (Post et al, 2011). Such studies 
must also account for the relative difference in ages of the HIV-positive population and 
the population at large. While the HIV-positive population is ageing, it still remains 
relatively young, with a mean age several decades younger than the HIV-negative 
populations who develop osteoporosis and fracture their bones as a result of ageing. A 
germane observation is that even in individuals with relatively low peak bone mass, 
fragil ity fractures are uncommon before the age of 50 years. This is due, in part, to the 
probability that microarchitectural deterioration has yet to have developed (Raisz et al, 
2008). For this reason it is important to observe HIV-positive individuals as they age to 
gather evidence for HIV and/or ART-associated bone loss and fracture. 
9.3 Vitamin D status 
At baseline there were no group differences in 25(0H)D concentrations with group mean 
values well in excess of SOnmol/1, although there was a tendency for there to be more 
Plew subjects with 25(0H)D concentrations <25nmol/l (5.3%) , compared to 2. 7% in 
Ppres and 1.0% in Nref. 
Contrary to published findi ngs t here were no significant mean group differences in 
vitamin D status, at baseline or at 6 and 12 months with a similarly small percentage 
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with low 25(0H)D concentrations. The hypotheses that HIV-positive patients would have 
lower concen ra ions t t . of 25(0H)D than controls and would demonstrate significantly 
greater declines in vitamin D status over time, particularly after the introduction of ART 
with its potent CYP450, hepatic enzyme inducing effects were not borne out. These data 
provide reassurance that, in 12 months, ART exposure did not lead to significant 
decreases in 25 (OH)D in this ~roup of women living in Johannesburg. 
remal·ned well above thresholds for risk of skeletal disease, Mean vitamin D status 
including osteomalacia, in all groups throughout the study, and exceeded the IOM 
threshold of 50nmol/l deemed sufficient for bone health. The intriguing observation was 
that the Plow groups saw less marked wintertime decline in 25(0H)D compared with the 
other groups. It could be speculated that their relative lack of adiposity might mitigate 
again$t 25(0H)D sequestration into fat, however there was no significant relationship 
., 
between 25(0H)D concentration and fat mass in ART-exposed subjects (p=0.75) and the 
pattern of blunted winter decline in Plow subjects disappeared when looking just at HIV-
infected women (see Section 2.5). 
I · th s a greater increase in 25(0H)D in ART-unexposed In the post hoe ana ys1s ere wa 
compared to ART-exposed at 12 months. This may indicate a relative difference in 
vitamin n ' metabolism in those exposed to ART. The possibility of a 'relatively' poor 
vitamin D status in ART-exposed was supported by increases in ALP activity, although 
· · I d certainly higher than that mean 25(0H)D concentrations were in the norma range an 
usually associated with skeletal mineralisation defects ( <25nmol/l). However without 
supporting histopathological evidence and more detailed evaluation of renal tubular 
function to exclude renal tubular acidosis as a cause a mineralisation deficit cannot be 
completely excluded. Other explanations for the differences in vitamin D status could 
include increased dermal synthesis of vitamin D (or greater dietary intake) in the non-
exposed group. The combination of a raised ALP activity in the context of a relatively 
blunted increase in 25(0H)D in ART-exposed compared to ART-unexposed subjects may 
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suggest a perturbation in vitamin D metabolism that is too subtle to be reflected in gross 
serum 25(0H)D changes. 
Vitamin D is increasingly recognised as being important for non-skeletal health 
outcomes, in particular the possible negative effec_t of poor vitamin D status on infectious 
disease susceptibility, progression, and outcomes (Halick, 2007). This requires further 
investigation particularly in populations at high risk of infectious diseases. 
9.4 Mineral metabolism 
In baseline biochemical variables there were non-significant group differences in serum 
creatinine, eGFR, and corrected calcium. There were significant, and predictable, 
differences in serum albumin with Plow having lower values than Nref and Ppres, and 
Ppres lower than Nref. Serum phosphate and TmP/GFR were greater in Plow than Nref 
and Ppres, and greater in Ppres than Nref. At baseline, TmP/GFR was higher in Plow 
(ART-exposed) compared to Ppres (ART-unexposed). By 12 months, Ppres appeared like 
Plow at baseline but Plow looked like Ppres at baseline. These observations may suggest 
that there were pre-existing differences in renal phosphate handling in HIV-infected 
women compared to controls and that ART exposure (or low CD4 count) lowered renal 
thresholds for phosphate reabsorption. 
Longitudinally, the alterations in phosphate metabolism with decreases in TmP/GFR of 
11.2% in Plow and increases in Nref (6.4%) and Ppres (3.8%), coupled with increases in 
serum phosphate in Nref (7.0%) and Ppres (5.2%) but no change in Plow (0.0%) are in 
keeping with the a priort hypothesis of tenofovir-induced renal phosphate wasting and 
reflect the observations seen in other populations (Childs et al, 2008; Kinai et al, 2009; 
Bonjoch et al, 2012; Nishijima et al, 2012). It is plausible that the loss of bone mineral 
demonstrated in Plow and ART-exposed subjects was the result of renal phosphate 
wasting and subsequent leaching of phosphate from bone in order to maintain serum 
phosphate homeostasis. 
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The phosphate data support the observation that ART (specifically tenofovir) being 
associated with decreased bone mineral via urinary phosphate wasting when viewed in 
the context of tenofovir-exposure and a) decreased TmP/GFR, b) increased ALP, as a 
marker of osteoblast activity, and c) normal 25(0H)D concentrations. In the future it will 
be interesting to explore associations with PTH because of its positive associations with 
tenofovir exposure and with sodium chloride (salt) intakes. It is plausible that high salt 
intakes may have an additive effect on the kidney by promoting further phosphate loss 
in those exposed to tenofovir, as increased sodium intake results in decreased sodium 
and phosphate reabsorption in the proximal renal tubule. 
It is noteworthy and as yet unexplained from the analyses conducted so far, why Plow 
and Ppres maintained higher serum phosphate concentrations than Nref. The expectation 
might be that HIV-positive subjects have lower serum phosphate concentrations than 
,1· 
controls. The normal physiological range for serum phosphate is 0.87 - 1.45 mmol/1. 
These differences are marked and different between groups at each time point. At 
baseline the proportions of subjects with serum phosphate >1.4 mmol/1 were 2%, 20%, 
and 27% in Nref, Ppres, and Plow respectively. At six months and 12 months these 
proportions were similar at 2%, 21 %, and 28% (6 months) and 0%, 21 %, and 25% (12 
months) in Nr~f, Ppres, and Plow respectively. The proportions exceeding 1.4 mmol/1 in 
Ppres and Plow greatly exceed the 2.5% expected from mean serum phosphate 
concentration +3 SD. Nref and Ppres are similar in most respects except for differences 
in serum phosphate and TmP/GFR. It suggests that Ppres may be intermediate between 
Nref and Plow in terms of renal phosphate handling and that this might act as a marker 
of future bone loss. However, this is speculative and remains to be seen during longer 
follow up studies. There are no published data describing hyperphosphataemia in HIV-
positive ART-na"ive subjects; indeed most reports of are hypophosphataemia in the 
context of ART exposure (Woodward et al, 2009). The mechanisms underlying these 
observations of higher serum phosphate in this group of women have yet to be 
elucidated but might include higher bone resorption and therefore lower PTH because 
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serum calcium would be raised resulting in supressed PTH concentrations to maintain 
serum calcium within the normal range. An alternative, or co-existing, mechanism could 
be a deficit in renal clearance of phosphate as a result of HIV infection. 
The changes seen in serum albumin concentrations support established patterns seen in 
HIV infection and are in turn upheld by the demonstrated changes in weight. Lower 
serum albumin in HIV-positive patients is well described (Sudfeld et al, 2013) and is 
proportional to declining CD4 count (Bhowmik et al, 2012). In this study, the Plow group 
had significantly lower albumin and weight at baseline. After the introduction of ART, and 
presumably improvements in appetite, and food intakes (Hendricks et al, 2006) 
accompanied by improvements in hepatic synthetic function and decreased catabolism 
seen with control of HIV viraemia, serum albumin concentrations increased in the Plow 
group over time. Likewise, serum albumin mean concentration in the ART-exposed group 
exceeded that in the ART-unexposed at 12 months. It is possible also that there were 
improvements in occult HIV-associated nephropathy (HIVAN) in those treated with ART. 
This glomerular disorder, with accompanying tubular and interstitial lesions, is associated 
with urinary albumin loss so would be improved by ART (Wyatt et al, 2012). 
The measured increases in ALP activity in Plow over 12 months were for total ALP, 
however, given the change in bone mineral status it is likely to be of bone rather than 
hepatic origin, particularly when viewed in the context of phosphate results (see Section 
7.1.5). However, this needs to be confirmed by measuring BALP in stored samples. It 
remains a possibility that the deleterious effects of ART exposure on bone mineral status 
could be a direct t oxic effect of ART on bone, rather than the effect being mediated by 
renal phosphate loss. However, the balance of evidence would support the latter rather 
t han the former explanation. 
Plow could be demonstrating biochemical evidence of tenofovir induced . renal injury 
(Calza, 2012; Maggi et al, 2012; Calza et al, 2013) and this is supported by the changes 
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seen in renal phosphate handling, which suggests a tubular pathology. Further 
investigation and more detailed investigation of renal function are warranted. 
9.5 Participant retention 
There was overall good retention in the study over the course of 12 months. Potential 
explanations for loss to follow-up were examined when possible (see Sections 6.2.1 , 
6.3.1). Anecdotally, retention may have been influenced by traditional beliefs that blood 
taken at the study visit is not replaced by the body. Other beliefs around blood were that 
it would be sold to others or would be used to transfuse to other people. The study team 
endeavoured to dispel these misconceptions by carefully explaining the purpose of the 
laboratory tests and allowing subjects to decline blood collection should they wish. These 
observations are anecdotal and require specific, qualitative investigation to examine the 
extent of these beliefs and the degree to which they affect willingness to enrol into 
;j'· 
clinically-based studies. 
1.6% of participants who initially undertook to enrol in WBS then opted to join a 
different research study. This figure may well be an underestimate since this reason was 
only offered by those participants who actually explained why they did not wish to return 
for their follow-up visit. For subject safety reasons it was, in fact, a condition of taking 
part in the WBS, that participants were prohibited from taking part in another study 
(Table 3-2) . 
Whilst retention in the study was good, fewer subjects in Nref completed the study than 
Ppres or Plow. There are potential biases introduced by such non-response and non-
attendance. These types of bias may limit the way in which data generated from this 
study are generalisable to other urban, black women residing in Soweto. In particular, 
the potential non-attendance bias might skew the overall results if, for example, the 
women who did not attend their follow-up visits were those with higher aBMD, then 
there may have been a greater difference in aBMD at 12 months than demonstrated in 
the study. It wou ld appear from t he dist ribution of non-at tendance among t he groups 
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t hat this was not a systematic effect but such sources of potential bias need to be borne 
in mind when interpreting the study results. 
9.6 Future directions 
Future directions for studies of HIV-associated bone mineral loss and changes in vitamin 
D status can be informed by some of the observations made from the data presented in 
th is thesis and hypotheses generated as a result. These directions are divided into those 
that can be explored using existing data and stored samples and those that will require 
additional studies. 
Existing data and stored samples: 
1. HIV infection and ART may result in changes in bone geometry. These may be 
artefactual, such as that seen in increases in hip BA as a result of overlying fat in 
this study, or could potentially represent unanticipated periosteal apposition of 
bone in response to ART exposure. Analysis of serial pQCT scans will allow 
demonstration of changes in appendicular bone geometry and estimation of bone 
strength. Furthermore, pQCT may reveal insights into the associations between 
overweight and obesity and peripheral vascular calcification. The . analysis of 
vertebral morphometry assessment (VMA) will allow investigation of the presence 
of spinal degeneration and undiagnosed spinal fractures. 
2. The changes in body composition seen in this study warrant further exploration to 
examine why, and how, fat gain exceeds gains in lean tissue, and possibly bone, 
predicted from population studies. The use of DXA so~ware to examine the 
distribution of fat in the participants (android versus gynaeoid, and peripheral 
versus central) may reveal insights into the change in ri~k of metabolic syndrome 
and obesity-related fracture. This work is being supported by a metabolic add-on 
study (Prof Shane Norris) to examine the effects of weight gain on metabolic and 
inflammatory markers. 
3. I plan t o further explore ex isting data and generate new laboratory data from 
stored biological samples and investigate these in the context of changes in body 
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seen in renal phosphate handling, which suggests a tubular pathology. Further 
investigation and more detailed investigation of renal function are warranted. 
9.5 Participant retention 
There was overall good retention in the study over the course of 12 months. Potentia l 
explanations for loss to follow-up were examined when possible (see Sections 6.2 .1, 
6.3.1). Anecdotally, retention may have been influenced by traditional beliefs that blood 
taken at the study visit is not replaced by the body. Other beliefs around blood were that 
it would be sold to others or would be used to transfuse to other people. The study team 
endeavoured to dispel these misconceptions by carefully explaining the purpose of the 
laboratory tests and allowing subjects to decline blood collection should they wish. These 
observations are anecdotal and require specific, qualitative investigation to examine the 
extent of these beliefs and the degree to which they affect willingness to enrol into 
.~· 
clinically-based studies. 
1.6% of participants who initially undertook to enrol in WBS then opted to join a 
different research study. This figure may well be an underestimate since this reason was 
only offered by those participants who actually explained why they did not wish to return 
for their follow-up visit. For subject safety reasons it was, in fact, a condition of taking 
part in the WBS, that participants were prohibited from taking part in another study 
(Table 3-2) . 
Whilst retention in the study was good, fewer subjects in Nref completed the study than 
Ppres or Plow. There are potential biases introduced by such non-response and non-
attendance. These types of bias may limit the way in which data generated from this 
study are generalisable to other urban, black women residing in Soweto. In particular, 
the potential non-attendance bias might skew the overall results if, for example, the 
women who did not attend their follow-up visits were those with higher aBMD, then 
there may have been a greater difference in aBMD at 12 months tha n demonstrated in 
t he st udy. It would appear f rom t he d istribution of non-attendance among the groups 
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that this was not a systematic effect but such sources of potential bias need to be borne 
in mind when interpreting the study results. 
9.6 Future directions 
Future directions for studies of HIV-associated bone mineral loss and changes in vitamin 
D status can be informed by some of the observations made from the data presented in 
th is thesis and hypotheses generated as a result. These directions are divided into those 
that can be explored using existing data and stored samples and those that will require 
additional studies. 
Existing data and stored samples: 
1. HIV infection and ART may result in changes in bone geometry. These may be 
artefactual, such as that seen in increases in hip BA as a result of overlying fat in 
this study, or could potentially represent unanticipated periosteal apposition of 
bone in response to ART exposure. Analysis of serial pQCT scans will allow 
demonstration of changes in appendicular bone geometry and estimation of bone 
strength. Furthermore, pQCT may reveal insights into the associations between 
overweight and obesity and peripheral vascular calcification. The analysis of 
vertebral morphometry assessment (VMA) will allow investigation of the presence 
of spinal degeneration and undiagnosed spinal fractures. 
2. The changes in body composition seen in this study warrant further exploration to 
examine why, and how, fat gain exceeds gains in lean tissue, and possibly bone, 
predicted from population studies. The use of DXA software to examine the 
distribution of fat in the participants (android versus gynaeoid, and peripheral 
versus central) may reveal insights into the change in risk Qf metabolic syndrome 
and obesity-related fracture. This work is being supported by a metabolic add-on 
study (Prof Shane Norris) to examine the effects of weight gain on metabolic and 
inflammatory markers. 
3. I plan to further explore existing data and generate new la boratory data from 
stored biological samples and investigate t hese in the context of changes in body 
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composition, bone mineral, vitamin D status, and mineral metabolism. These will 
include evaluation of PTH concentrations, bone turnover markers, adipokine 
concentrations, and urine markers of renal tubular function such as retinol-
binding protein (RBP) and urine albumin/creatinine and protein/creatinine ratios. 
Another area of interest would be to explore genetic associations, in particular the 
rs2485209 single nucleotide polymorphism, which has been associated with 
changes in femoral neck BMC in black South African children (May et al, 2013). It 
would be interesting to explore the role of genetic determinants of HIV and ART-
associated differences in bone mineral. 
Additional studies: 
1. ART exposure is associated with bone loss in HIV-positive black South African 
I women. This may be due to direct effects of ART on bone, e.g. via impact on 
osteoclasts and indirectly through, for example, acid-base disturbance. This could 
be tested by detailed histomorphometric studies of bone tissue and detailed 
analysis of acid-base balance before and after the introduction of ART. A 
hypothesis underpinning the work presented in this thesis is that ART induces 
bone mineral to be preferentially lost from trabecular-rich sites because of 
increased metabolic activity in trabecular bone. Therefore, these sites are 
predisposed to the effects of ART-induced changes in mineral handling, the spine 
in particular may be a site vulnerable to rapid bone loss. This hypothesis could be 
evaluated further by examining changes in trabecular-rich sites using imaging 
techniques other than DXA, such as HRCT. 
2. HIV infection is associated with lower 25(0H)D concentrations despite adequate 
opportunity for skin synthesis. Vitamin D may be synthesised less efficiently 
and/or consumed more rapidly in HIV-positives vs. controls. ART use may 
accelerate metabolism of available vitamin D in HIV-positive black South African 
women. This may be due to induction of hepatic and renal CYP450 enzyme 
pathways by drugs that impact on CYP450 pathways. This could be tested more 
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accurately by carrying out detailed vitamin D turnover studies (Jones et al, 2012) 
in HIV-positive patients and HIV-negative controls. Ideally, any vitamin D 
turnover study would be carried out before and after the introduction of ARTs. 
3. In order to better understand the trajectory and magnitude of HIV- and ART-
associated bone loss the study presented in this thesis (WBS) has been funded to 
be extended to 24 months and a further round of data collection will take place in 
April - May 2013. The aim of this extension is to ascertain if there is ongoing loss 
of bone after two years in the Plow/ART-exposed women and to compare with 
age-related changes and effects of body weight in HIV-uninfected controls, and to 
investigate the determinants of this. The clinical significance of the findings 
detailed in this study can be further explored by examination of BMD Z-scores 
(SDS) at the study endpoint. Whilst Z-scores in this group of premenopausal 
women have not been validated against future fracture risk because they were 
generated from South African data, they will be none-the-less interesting to 
evaluate, and may provide useful data regarding changes in aBMD within this 
population. In particular it will be interesting to see if the decrease in lumbar 
spine Z-score at 12 months will continue to decline at 24 months . . Furthermore, 
it will allow me to chart further changes in body composition, particularly fat 
mass, and in renal function and markers of phosphate homeostasis. It will also 
provide evidence about changes in, or stability of, vitamin D status in those 
exposed to ART for 24 months. 
4. As part of my post-doctoral research I plan to expand my research into the 
skeletal effects of other chronic infections such as hepatitis B, and their 
treatment. I have recently (March 2013) submitted a research proposal 
examining the effects of hepatitis B, and its treatment, on bone health to MRC 
Gambia Scientific Coordinating Committee (SCC) for consideration. I plan to 
continue to examine the role of HIV infection and ART exposure on bone mineral 
status and ideally develop a study to include clinical end points such as fracture 
data. Ideally, in future studies, there would be provision to undertake 
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histomorphological examination of bone tissue in patients before and after the 
introduction of ART and to use more sophisticated imaging techniques, such as 
high resolution (HR) pQCT to delineate, more precisely, the nature of bone loss 
and to compare this to DXA and biopsy results. Also, more sophisticated 
measures of renal tubular dysfunction, such as urinary concentrations of RBP 
could be employed to better isolate the precise location of renal insult (Campbell 
et al, 2012), and collection of 24-hour urinary collections would allow a more 
detailed analysis of renal mineral handling, and 2-hour timed urine collections to 
estimate renal phosphate excretion. 
5. Another important area of research is to assess the effects of HIV infection and 
particularly ART exposure, at other times in the life course when women are 
vulnerable to mobilisation of skeletal mineral, such as during pregnancy and 
1· 
lactation. I have been working with Dr Gail Goldberg, Senior Investigator 
Scientist NBH, MRC HNR who has successfully secured funding for a Cambridge 
Gates PhD scholarship to investigate the effects of pregnancy and lactation on 
bone health in HIV-positive Ugandan women. 
6. Another key life course event is the menopause transition. If HIV infection and 
ART exposure, and menopausal bone loss result in cumulative loss of bone 
' 
mineral then it is possible that HIV-positive women in the early years following 
menopause could lose even more significant amounts of bone mineral, leaving 
them at higher risk of future fracture. This is particularly important because HIV 
infection is associated with premature ovarian failure and early menopause (Ohl 
et al, 2010; de Pommerol et al, 2011) which means that HIV-positive women may 
be relatively oestrogen deficient for significantly longer than their HIV-negative 
counterparts. The three subjects who probably were climacteric in WBS were in 
Plow (see Section 6.3.2) Likewise, HIV infection and ART exposure might 
augment the degree of pregnancy and lactational bone mineral loss and impair 
post-lactation gains in bone mineral. At present these are theoretical concerns 
but are important considerations when designing future studies of skeletal health 
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in HIV-positive women and those with other chronic infections such as hepatitis B 
and C. 
7. Finally, if the two year data suggest ongoing bone loss in the face of renal 
phosphate wasting it would be interesting to address the utility of switching from 
tenofovir to, for example, abacavir to establish if this strategy would halt, or 
reverse, declines in bone demineralisation. An alternative study could assess the 
effect of oral phosphate replacement on bone mineralisation in the context of 
ongoing tenofovir exposure. In order to achieve this it is likely to require a 
sufficiently powered RCT with a prolonged duration of followup to demonstrate 
the effects of different ART on bone health. 
9.7 Summary 
Data generated from this study have demonstrated that there were no significant 
differences, at baseline, in three groups of women with respect to bone measures and 
vitamin D status. The differences in body composition (weight, BMI, fat mass, lean mass, 
fat :lean2, and waist and hip circumferences) were all lower in Plow than Nref and Ppres, 
which were not significantly different from each other. At baseline only WHR was 
equivalent in Ppres and Plow, and greater than Nref, which might suggest that the 
proportions of adiposity were not changing. 
This PhD has made some novel contributions to knowledge, these include the first 
observation of ART-associated bone loss, measured by DXA, in African women. WBS has 
added to the literature on tenofovir effects on renal function and bone health. It has 
demonstrated that ART exposure is associated with decreases in bone mineral and 
TmP/GFR, and whilst it cannot be described as causal it is likely to be related to tenofovir 
use. The study has also largely refuted the observations made in Western settings that 
HIV infection and ART exposure are associated with poor vitamin D status and that HIV 
infection with preserved CD4 counts is associated with bone loss. 
Preliminary results of this study have been presented as an oral presentation at the 
National Osteoporosis Foundation South Africa (NOFSA) meeting in Cape Town (April 
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2012) and as a poster presentation at the National Osteoporosis Society (NOS) meeting 
in Manchester (July 2012). A paper is in press describing the baseline body composition, 
bone and vitamin D findings (Appendix 7) and a further paper, on the baseline dietary 
data, is under review (Appendix 6). 
In conclusion, the WBS has demonstrated that exposure to ART is associated with 
declines in bone mineral over time in urban, black South African women with immune 
compromise (as measured by CD4 count) when compared with HIV-negative controls and 
HIV-positive patients not exposed to ART. These changes are apparent, and statistically 
significant, when the subjects are analysed by the groups established in the study design 
(Plow group) and when the ART-exposed subjects are examined in a post hoe analysis. 
The magnitude of this change, ~2% over 12 months at the femoral neck and lumbar 
spi~J~, exceeds that seen in early menopause and therefore is likely to be clinically 
significant. This study was not designed, or powered, to examine estimation of future 
fracture risk but the results do justify further study to assess if this rate of loss continues 
or, plateaus or reverses, as ongoing bone loss at this rate is likely to predispose to poor 
bone outcomes. The two-year follow-up study will examine if there is ongoing bone loss. 
Unlike other studies in largely Caucasian populations, there were no significant 
' differences in vitamin D status, and the hypothesis that ART use would result in up-
regulation of vitamin D catabolism was not borne out although there are some subtle 
indications that exposure to ART may decrease winter declines in vitamin D status. 
However, there was no difference when split by ART-unexposed and ART-exposed. The 
ART-exposed 25(0H)D concentration were lower at 12 months and this observation 
requires longer duration of follow-up to ascertain longitudinal effects of ART exposure on 
vitamin D status. 
This study has demonstrated how ART exposure is associated with perturbations in 
phosphate homeostasis and this supports the hypothesis that loss of bone mineral is 
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being driven by loss of phosphate by the kidney as a result of tenofovir toxicity at the 
proximal renal tubule. 
The large (10%) increases in body fat in those women exposed to ART requires further 
exploration to see if this accumulation of adipose tissue continues and, if it does, what 
effect this will have on cardio-metabolic disease risk as well as on risk for increased rates 
of fracture. 
As the global prevalence of HIV infection continues to rise and because infected patients 
are living long enough to develop age-related, non-communicable conditions, such as 
osteoporosis, it is likely that there will be a continued need to undertake studies of bone 
health in these populations in the future. 
Much research is needed, not only to better understand the basic interrelationships 
between HIV, ART, body composition, bone health, and vitamin D status at an individual 
level but also to allow development of algorithms for prevention, treatment, and care 
pathways to be used in conjunction with those for screening for low aBMD and 25(0H)D 
in populations. Future research is required to ascertain, for example, how predictive low 
aBMD, measured by DXA, plasma 25(0H)D concentrations and calcium -intakes are of 
fu ture fragility fractures in Sub-Saharan African women with HIV infection. 
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Appendix 1 Full list of ART 
(http://www. fda .gov /ForConsumers/byAudience/ForPatientAdvocates/HIVandAI 
D5Activities/ucm1189l5.htm) (Accessed 30/2/2013) 
Non Nucleoside Reverse Transcriptase Inhibitors (NNRTis) 
Brand Generic Name Manufacturer Name* Approval Time to 
Name Date Approval 
Atripla efavirenz, Bristol -Myers Squibb and 12-July-06 2.5 months 
emtricitabine and Gilead Sciences 
tenofovir disoproxil 
fumarate 
Complera emtricitabine, Gilead Sciences 10-August- 6 months 
rilpivirine, and 11 
tenofovir disoproxil 
fumarate 
1Stribild elvitegravir, Gilead Sciences 27-August- 6 months 
cobicistat, 12 
I 
emtricitabine, 
tenofovir disoproxil 
fumarate 
Nucleoside Reverse Transcriptase Inhibitors (NRTls) 
' Brand 
Name 
1combivir 
Emtriva 
Epzicom 
Retrovir 
1
Trizivir 
Truvada 
Videx EC 
Generic Name Manufacturer Name* Approval Time to 
Date Approval 
lamivudine and 
zidovudine 
GlaxoSmithKline 27-Sep-97 3.9 months 
emtricitabine, FTC Gilead Sciences 
lamivudine, 3TC GlaxoSmithKline 
abacavir and GlaxoSmithKline 
lamivudine 
zalcitabine, Hoffmann-La Roche 
dideoxycytidine, ddC 
(no longer 
marketed) 
zidovudine, GlaxoSmithKline 
azidothymidine, 
AZT, ZDV · _ 
abacavir, GlaxoSmithKline 
zidovudine, and 
lamivudine 
tenofovir disoproxil Gilead Sciences, Inc. 
fumarate and 
emtricitabine 
enteric coated 
didanosine, ddI EC 
didanosine, 
dideoxyinosine, ddI 
Bristol Myers-Squibb 
Bristol Myers-Squibb 
02-Jul-03 10 months 
17-Nov-95 4.4 months 
02-Aug-04 10 months 
19-Jun-92 7.6 months 
19-Mar-87 3.5 months 
14-Nov-00 10.9 
months 
02-Aug-04 5 months 
31-0ct-00 · 9 months 
9-0ct-91 6 months 
-V- i-re_a_d----+j t_e_n_o_fo_v_i_r -d_-i_s_o -P_-r_o~x-~i-1_-_+-j'-G~i~le~a~d-----_--:~-+j 2_6 __  0_c_t-0-1===5- .-9- m_ o_n-th_s__,I 
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I Jfumarate, TDF I I I 
1z erit stavudine, d4T I Bristol Myers-Squibb 124-Jun-94 5.9 months 
IZiagen abacavir sulfate, I GlaxoSmithKline 117-Dec-98 5.8 months 
ABC 
I 
Non Nucleoside Reverse Transcriptase Inhibitors (NNRTis) 
)Brand Name Generic Name Manufacturer Approval Time to 
Name* Date Approval 
f Edu rant I rilpivirine Tibotec Therapeutics 20-May- 10 
I 
I 11 months 
1Intelence etravirine Tibotec Therapeutics 18-Jan- 6 months 
08 
I 
J Rescri ptor ldelavirdine, DLV I Pfizer 14-Apr-97 8.7 
months 
I 
lsustiva efavirenz, EFV Bristol Myers-Squibb 17-Sep- 3.2 
98 months 
r---
IViramune nevirapine, NVP Boehringer Ingelheim 21-Jun- 3.9 
(Immediate Release) 96 months 
Viramune XR(Extended nevirapine, NVP Boehringer Ingelheim 25-Mar- 9.9 
Release) 11 months 
Protease Inhibitors (Pis) 
JBrand Generic Name Manufacturer Name* Approval Time to 
Name Date Approval 
Agenerase amprenavir, APV (no GlaxoSmithKline 15-Apr-99 6 months 
longer marketed) 
I 
Jtipranavir, TPV J Boehringer Ingelheim Aptivus 22-Jun -05 6 months 
' Crixivan indinavir, IDV, Merck 13-Mar-96 1.4 months 
! I Hoffmann-La Roche Fortovase ' saquinavir (no 7-Nov-97 5.9 months 
longer marketed) 
1Invirase saquinavir mesylate, Hoffmann-La Roche 6-Dec-95 13.2 months 
I SQV 
1 
Kaletra lopinavir and Abbott Laboratories 15-Sep-00 3.5 months 
ritonavir, LPV/RTV 
I 
Lexiva Fosamprenavir GlaxoSmithKline 20-0ct-03 10 months 
Calcium, FOS-APV I 
Norvir ritonavir, RTV Abbott Laboratories 1-Mar-96 2.3 months 
I 
Jdarunavir JTibotec, Inc. Prezista 23-Jun-06 6 months 
! 
atazanavir sulfate, 120-Jun-03 16 months Rey:ataz Bristol-Myers Squibb 
I ATV 
I 
Viracept nelfinavir mesylate, Agouron Pharmaceuticals 14-Mar-97 2.6 months 
NFV 
· Fusion Inhibitors 
I 
Brand J Generic Name --~' M_a_n_u_fa_ct __ u_r_e_r_N_ a_m_e __ j~A_p_p_r_o_v_a_l __ ~j T_im_ e_t_o_~ 
I 
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fName I I jDate JApproval ' 
Fuzeon enfuvirtide, T-20 Hoffmann-La Roche & 13-Mar-03 6 months 
Trimeris 
Entry Inhibitors - CCR5 co-receptor antagonist 
Brand I Generic Name I Manufacturer Name Approval Time to 
Name Date Approval 
J Selzentry: Maraviroc Pfizer 06-August- 8 months 
07 
HIV integrase strand transfer inhibitors 
~: Generic Name Manufacturer Name Approval Time to e Date Approval 
i isentress Raltegravir Merck & Co., Inc. 12--0ct-07 6 months 
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A p p e n d i x  2  M e d i c a l / c l i n i c a l  h i s t o r y  q u e s t i o n n a i r e  
W O M E N ' S  B O N E  S T U D Y  ( W B S }  
C h a r a c t e r i s t i c s  a n d  h e a l t h  d a t a  c o l l e c t i o n  f o l l o w  u p  
W B S  n u m b e r :  M o n t h  o f  f o l l o w  u p  v i s i t  ( c i r c l e ) :  
D a t e : - - ~ - - - ~ - - -
G r o u p  
1 .  R e p e a t  H I V  t e s t  i n  p a s t  6  w e e k s  
R e s u l t  ( O = n e g a t i v e ,  l = p o s i t i v e )  
2 .  P r e g n a n c y  t e s t  N e g a t i v e  
( i f  p o s i t i v e  i n f o r m  D r  H a m i l l )  
3 .  P r e g n a n c y  s i n c e  l a s t  v i s i t ?  ( i f  Y e s  i n f o r m  D r  H a m i l l )  
- I f  c u r r e n t l y  p r e g n a n t :  E s t i m a t e d  d u r a t i o n  ( g e s t a t i o n )  i n  w e e k s  
( i n f o r m  D r  H a m i l l )  
4 .  C u r r e n t l y  b r e a s t f e e d i n g  ( i f  Y e s  i n f o r m  D r  H a m i l l )  
5 .  R e g u l a r  p e r i o d s  
6 .  R e a c h e d  m e n o p a u s e  ( i f  Y e s  i n f o r m  D r  H a m i l l )  
- I f  Y ,  w h e n  w a s  l a s t  p e r i o d  ( a g e )  Y r s  M n t h s  
- N o t e s :  
7 .  U s i n g  h o r m o n a l  c o n t r a c e p t i o n  
- I f  Y ,  w h a t  ( e . g .  t h e  p i l l ,  d e p o  p r o v e r a ) :  
8 .  S t e r i l i s a t i o n  
G r o u p  
1  
Y D  N D  
o D  1 D  
Y D  N D  
Y D  N D  
Y D  N D  
Y D  N D  
Y D  N D  
Y D  N D  
Y D  N D  
~ 
16  
I  1 2  I  2 4  I  3 6  
G r o u p  G r o u p  
2  
3  
X  X  
Y D  N D  Y D  N D  
3 2 7  
Y D  N D  
Y D  N D  
Y D  N D  
Y D  N D  
Y D  N D  
Y D  N D  
Y D  N D  
Y D  N D  
Y D  N D  
Y D  N D  
Y D  N D  
Y D  N D  
3 2 8  
9. Other family planning e.g. condoms 
YD ND YD ND YD ND 
.. ~ 
List here: 
-
10. Age in years & months e.g. 37Yrs 6 Mnths 
11. Current smoker 
YD ND YD ND YD ND 
12. Started smoking after last visit? 
YD ND YD ND YD ND 
13. Total month/years of smoking 
14. How many cigarette do you smoke per day 
15. New fracture since last visit (if 'No' go to Q. 19) 
YD ND YD ND YD ND 
16. Site of this fracture (e.g. left hip): 
17. Was it a traumatic 
YD ND YD ND YD ND 
If trauma please list (e.g. car crash, fall from stairs): 
329 
OR 
18. Was it non-traumatic 
YD ND YD ND YD ND 
If non-traumatic please describe (e.g. standing up): 
19. Current medication(s) & dose - list (if known). Other than ARV or 
vitamins 
1. Dose 
2. Dose 
3. Dose 
4 . Dose 
20 . Ask if subject takes: 
YD ND YD ND YD ND 
Calcium supplements, if Y 
- List preparations 
- Dose/number of tablets 
21. Vitamin D supplements, if Y 
YD ND YD ND YD ND 
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=J 
- List preparations 
- Dose/number of tablets 
' 
22. Vitamin/mineral supplements (e.g. mu lt ivitamins, BCom), if Y 
- List preparations 
- Dose/number of tablets 
23. History of steroid use since last v isit. If Y: 
- List preparations 
- Dose/number of tablets Number of months 
taken 
24. Liopodystrophy (clinician assessed) (If unsure discuss with 
Dr Hamill) 
25. Current diarrhoea per day (if any), in past 7 days 
25. Current (most recent) CD4 count 
26. Lowest CD4 count (if different) 
27. Bactrim (PCP) prophylaxis 
28. Current (most recent) HIV viral load (if available) 
29. Peak viral load, if different from previously recorded (if 
available) 
30. Current ARV - list ARVs and start date: 
!.~~~~~~~~~~~~~ 
Start date: 
2.~~~~~~~~~~~~~ 
Start date: 
3.~~~~~~~~~~~~~ 
Start date: 
31. Previous ARV regimes - list ARVs and start and stop dates: 
··~ 
YD ND YD ND YD ND 
YD ND YD ND YD ND 
YD ND YD ND YD ND 
X 
X 
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YD ND YD ND 
X 
X 
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~ 
1. 
Start date : Stop date: 
"'· 
~ 
2. 
St art date : Stop date: 
3. 
Start date : Stop date: 
32. Cumulat ive duration of ALL ARV ( in months) X 
33. Cumulat ive duration of NRTI e.g . d4T, 3TC, AZT ( in months) X 
34 . Cumulat ive duration of Tenofovir (TDF) ( in months) X 
35. Cumulative duration of NNRTI e.g. Efavirenz/Nevirapine (in X 
months) 
36 . Cumulative duration of PI e.g. Kaletra/ Alluvia (in months) X 
37 . Major illness since last visi t 
YD ND YD ND YD ND 
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I f maj or illness please list what & dates 
1. 
Start date : Stop date: 
2. 
Sta rt date : Stop date: 
3. 
Start date : Stop date: 
38 . CDC stage of disease e.g. Al X 
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Appendix 3 Dietary assessment 
Dietary intake can be assessed by a variety of methods such as weighed or estimated 
food records, 24-hour recalls, food frequency questionnaires (FFQ) or diet histories 
(Bi ngham et al, 1994, Prentice et al, 2009b). The method chosen depends on the 
characteristics of study subjects, respondent burden, study objectives and available 
resources. The decision for this study was to use a locally available dietary tool, a semi-
quantitative FFQ, which measured habitual food intake and allowed for inclusion of 
traditional, locally prepared food and recently available convenience items such as fast 
food. 
The aim was to investigate the potential role of diet on bone outcomes, in particular the 
role of dietary calcium intake. 
Food Frequency Questionnaire (FFQ) 
Dietary intake was assessed using a FFQ based on the South African Food Composition 
Tables (SAFCT) developed by the Nutritional Intervention Unit of the South African 
Medical Research Council (MRC) (Wolmarans et al, 2010). Although this FFQ has not 
been validated against other techniques for estimating dietary intake, an early version 
was used to assess eating patterns and the past 6 months' food intake in children aged 1 
to 9 years in the National Food Consumption Survey (Labadarios et al, 2005), and a 
modified version was then piloted in a sample of 92 adolescents from the University of 
Witwatersrand's Bt20 cohort and found to produce feasible estimates of energy intake 
(Zingoni et al, 2009). 
There were staff trained in deploying the South African MRC FFQ and software devised to 
handle the data generated (MRC (SA), 2002, MacKeown et al, 2007, Pedro et al, 2008). 
The food list on the questionnaire was based on an analysis of dietary surveys conducted 
in South African adults from 1983-2000. The list is comprehensive and includes all foods 
eaten by at least 3% of the population (Steyn et al, 2003) however it is recognized that 
336 
11111: 
I 
certain foods, such as Asian foods, are underrepresented. However is unlikely that 
underrepresentation of Asian dishes biased the results in the black population. 
South African Food Composition Database (SAFOODS) contains nutrient information from 
South African origin as well as from other international databases and scientific 
publications. The latest 1991 edition contained 18% South African values and therefore 
the South African Food Composition Data (SAFCoD) steering committee was formed in 
1995 to increase the South African values. This resulted in the 1998 vegetables and fruit 
and the 1999 milk and milk products, eggs and meat and meat products supplements. 
The Foodfinder 3 software was used in this study as it uses a South African food 
composition data and is used by nutrition researchers in South Africa (Zingoni, 2007, 
Wrottesley, 2011). The software in Foodfinder3 was used to calculate mean daily energy, 
macro- and micronutrient intakes for each individual. 
I 
Due to the anticipated high level of illiteracy, in parts of the South African population, 
the FFQ had been specifically developed to make use of food flash cards; a set of over 
120 flashcards representing all the foods on the questionnaire. The FFQ was 
administered in paper and pen format by interview with trained, multilingual members of 
research staff to aid communication with study participants and memory recall. 
Participants were asked to separate the food flash cards into piles which differentiated 
between items that were eaten/drank nearly every day, less frequently, and hardly 
ever/never. Data were collected retrospectively about the previous seven days in order 
to estimate habitual intake for each participant. The FFQ captures information regarding 
the amount of food eaten, number of times eaten per day and portion size. Each food 
has an assigned code which is a unique four digit number obtained from food tables. 
Some additional questions on factors affecting food choice, salt use, and fast food 
consumption were added to the questionnaires for DPHRU studies (see questions 1-10 
on the modified FFQ in Appendix 4). Figure 0-1 shows an example of the food flash cards 
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which are colour coded to enable quick identification of the foods in the food photo 
manual (FPM) e.g. dairy products are blue. 
Figure 0-1 Food flashcards used as visual aid 
The food codes were identified in the FPM and entered on the FFQ by the research 
scientist (AF) (see section 4.2). 
The daily and frequently consumed items were then looked at individually and the 
participant was asked how many times per day or week the item had been consumed 
during the previous seven days. 
Portion size 
A major challenge in wit~ the use of FFQ is the estimation of portion size (Nelson et al, 
1998b, 1998a, Souverein et al, 2011). For this study portion size was estimated using 
household measures, two-dimensional life-size drawings of foods and utensils, and 
three-dimensional food models as described below (Wrottesley, 2011). 
The FPM has generic life-size sketches of food portions which show cups~ mugs, glasses, 
bowls and spoons filled to different levels. An example is shown for a mug filled to %, V2, 
% and full in (Figure 0-2) . The FPM also contains 'life-size' pictures of some foods on the 
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reverse side of the photos in the FPM to assist in portion size determination (Zingoni, 
2007). 
Food models were also used for certain foods such as pap (stiff maize porridge) (Figure 
0-3). Different sizes representing different size cups were used by the trained Research 
Assistant to assist recall and estimation of portion size. 
The food pictures and food models have been shown to assess portion size with 
reasonable accuracy in adolescents. A study was conducted in adolescents aged 12-13 
years living in Johannesburg (Steyn et al, 2006). The sample consisted of 50 black and 
42 white children recruited from relatively low and medium income schools respectively. 
Each participant was presented with a plate of food of a known weight and was required 
to select a 2-dimensional drawing and the 3-dimensional food model which closely 
resembled the portion size on the plate. There were significant (p<0.0001) positive 
linear associations between the calculated nutrients using the actual and estimated 
portion sizes using both the pictures and the food models (Steyn et al, 2006, Zingoni, 
2007). This provides some assurance that portion sizes would be estimated with 
reasonable accuracy using this tool. 
Processing of dietary intake data 
The weight 'of the food consumed daily was calculated from the paper FFQ as follows: 
(Weight of food consumed x frequency of consumption)/time period 
Where time period was per day = 1, per week = 7 
After the manual calculation of daily intake of individual foods per day by a postgraduate 
student (SW) and a research scientist (AF) the food code was entered on the 
questionnaire if it had not been done during the interview. The d ietary intake data were 
then entered into the Foodfinder 3 dietary analysis programme by SW. This is a 
computer software application developed by the Nutritional Intervention Research Unit 
and Biomedica l Informatics Research Division of the South Africa MRC. This too l enables 
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calculation of group and individual nutrient intakes. Foodfinder 3 includes the latest 
version of the SAFOODS with updates on vegetables and fruit and milk and milk 
products, eggs, meat and meat products. 
Figure 0-2 The FPM generic life-size sketches of food portions 
'h f.Jll mug ·; ful tmug 
.,, .rul muc; full m .. g 
Not to scale 
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Figure 0-3 Food flour models 
(Zingoni, 2007). 
Logistic and budget constraints as well as anticipated poor literacy levels in English 
meant dietary assessment was best carried out when participants came to the study site 
for their assessments. These took approximately 3.5 hours overall therefore a dietary 
' intake tool which did not have too great a respondent burden whilst assessing usual 
intake was required. It was crucial to maintain the ir motivation and not deter them from 
future visits. However, after the baseline visit, a decision was made to not repeat the 
FFQ at 6 and 12 month follow up visits because the FFQ took approximately 60 minutes 
to administer and many participants reported it to be time consuming and burdensome. 
As a result only baseline FFQ data were collected. At the six and 12 month study visits 
an amended and truncated dietary questionnaire was administered (see Appendix 5). 
The set-up for the dietary intake interview is as shown in Figure 0-4. 
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Figure 0-4 FFQ interview station 
The dietary data from the baseline visit can be found in, "Dietary intake and body 
composition in HIV-positive and -negative South African women" Submitted to Public 
Health Nutrition March 2013. Stephanie V Wrottesley, Lisa K Micklesfield, Matthew M 
Hamill, Gail R Goldberg, Ann Prentice, John M Pettifor, Shane A Norris and Alison B 
Feeley (Appendix 6). 
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Appendix 4 Food Frequency Questionnaire (SA MRC) 
FOOD FREQUENCY QUESTIONNAIRE (FFQ) 
Bone Health ID I I I 
Birth To Twenty ID I I I I 
I F I M I Gender 
Date .. . .............. . ... . ...... . ................ . ............ . 
Interviewer's name .... . . .................................. . 
Food habits 
1. Arf;3 you on a special diet that has been prescribed for you e.g. by a doctor or one that 
you have adopted from someone e.g. a TV star/magazine? 
~ 
2. If NO, go to question 4. 
If YES, describe what kind of diet you are on and where you got the diet from? 
3. How Jong have you been on that diet? ____ months/years. 
4. Do you currently take any vitamin and mineral supplements? 
~ 
IF YES, what do you take? 
Vitamins/vitamins and minerals 
Tonics 
Health foods 
Body building preparations 
Dietary fibre supplement 
Other: specify 
Name of product Amount/day 
5. Which meals do you skip almost on a daily basis? 
Breakfast 1 
Lunch 2 
Evening meal 3 
None 4 
6. Is salt added to your food while it is being cooked? 
Always 1 
Sometimes 2 
Never 3 
Don' t know 4 
7. Do you add st to y1: for before you eat it? 
8. If yes, how much salt do you add to your food each day? 
~ teaspoon 1 
Yi teaspoon 2 
% teaspoon 3 
1 teaspoon 4 
Other specify: 5 
9. Do you add Ar~ food before you eat it? 
~ 
10. If yes, how much Aromat do you add to your food each day? 
~ teaspoon 1 
Yi teaspoon 2 
% teaspoon 3 
1 teaspoon 4 
Other specify: 5 
344 
.......... 
11. There are some factors which influence the choice of foods we eat. Which of the 
following statements are true for you? 
Strongly Agree Disagree Strongly 
agree Disagree 
I choose to eat certain foods because they taste 1 2 3 4 
good 
The food I eat depends on whether it is 1 2 3 4 
expensive 
I choose to eat certain foods because it looks 1 2 3 4 
-
good 
The food I choose to eat differs according to my 1 2 3 4 
mood (i.e. happy/sad) 
My hunger level determines what type of food I 1 2 3 4 
eat. 
I choose foods which are not time consuming to 1 2 3 4 
prepare 
I consider whether a food is good for my health 1 2 3 4 
before eating the food. 
12. D0 you ever eat outside the home e.g. at fast food shops such as Nandos, 
KFC and Steers? 
~ 
13. IfYES, in an average month how often do you eat at the following places? 
Frequency of visits 
Times/week Times/month 
Nandos 
Spur 
Macdonalds 
Steers 
KFC 
Chicken Licken 
Debonaire' s Pizza 
Romans 
Anat 
Wimpy 
Something fishy 
Fontana 
Chinese takeaway 
Other restaurants/takeaways 
(Quarters from tuck shop) 
Rarely/never 
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Generic A. B. Tick c. D. ..., E. F. G. H. 
Sketch Food items (with FPM Description, of for Item Amount usually Eaten Eaten Eaten Never 
(look up) numbers) food item - yes code eaten(g) every every Occasionally eaten 
Generic/amount = g day week 
Times/ Times/ 
dav week 
3. Breakfast cereals 
2. Milk added to cereal 
1. Su2ar added to cereal 
9. Ice cream Full cream 
Low sugar 
9. Ice lollies 
ASK ABOUT TYPE OF BREAD.TIDCKNESS OF SLICES AND THE SPREAD 
1. Bread/rolls White 
Brown 
Whole wheat 
Traditional 
Roti 
Spread? Y I N Brand name 
1. Brick man?:arine 
1. Tub mar2arine 
1. Butter 
Cheese spread 
Fish paste 
Honev/svrup 
Jam 
Marmite/Bovril 
Sandwich spread 
Peanut butter 
Chocolate spread 
347' 
Generic A. B. Tick c. D. E. F. G. H. Sketch Food items (with FPM Description of for Item Amount usually Eaten Eaten Eaten Never (look up) numbers) food item yes code eaten(g) every every Occasionally eaten 
Generic/amount = g day week 
Times/ Times/ 
day week 
Cold meats Ham 
Polony 
Salami 
6. Cottage cheese Low fat 
Full fat 
7. Cheddar 
7. Gouda 
7. Other cheese 
8. Cheese wedges 
2. Fat cakes 
(Red) QUARTER 
4. Maize porridge stiff 
4. Maize porrid2e soft 
2. Milk on soft porridge 
1. Sugar on soft porridge 
1. Fat on soft porridge 
4. Mabele/maltabella stiff 
4. Mabele soft 
2. Milk on Mabele 
1. Sugar on Mabele 
1. Fat on Mabele 
4. Oats 
2. Milk on Oats 
1. Sugar on Oats 
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Generic A. B. Tick c. D. E. F. G. H. 
Sketch Food items (with FPM Description of for Item Amount ', usually Eaten Eaten Eaten Never 
(look up) numbers) food item ' yes code eaten(g) every every Occasionally eaten 
- Generic/amount = g day week 
Times/ Times/ 
day week 
4. Maize & pumpkin porridge 
5. Pasta/Pasta dishes 
6. Spaghetti Bolognaise 
6. Macaroni and cheese 
6. Lasa2ne 
7.Rice White 
Brown 
With fat? 
7. Samp/mealie rice With fat? 
7. Samp and beans With fat? 
X 7. Wheat rice With fat? 
8. Pizza Vegetable 
topping 
Meat topping 
Meat & 
vegetables 
8. Savoury tart 
X EGGS-YELLOW 
Boiled 
Fried 
Omelette (filling and 
quantity) 
Scrambled 
Generic A. B. Tick c. D. E. F. G. H. 
Sketch Food items (with FPM Description of for Item Amount usually Eaten Eaten Eaten Never 
349 
(look up) numbers) food item yes code eaten(g) every every Occasionally eaten 
Generic/amount = g day week 
Times/ Times/ 
day week 
FRUITS-ORANGE 
X 1. Apples 
X 2. Bananas Fresh 
Fried 
3. Berries Fresh 
Canned 
Candied 
X 4. Figs/prickly pears & Fresh 
Coconuts, dates Candied 
5. Fruit salad Fresh 
Canned juice 
Canned syrup 
X 6. Grapes 
X 7. Guavas Fresh 
Canned juice 
Canned syrup 
X 8.Man20 Fresh 
Canned juice 
Canned syrup 
8. Pawpaw Fresh 
Canned juice 
Canned syrup 
8. Kiwi fruit 
8. Leechies 
X 9. Watermelons 
9. Sweet melon 
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Generic A. B. Tick c. D. E. F. G. H. 
Sketch Food items (with FPM Description of for Item Amount usually Eaten Eaten Eaten Never 
(look up) numbers) food item yes code eaten(g) every every Occasionally eaten 
Generic/amo_unt = g day week 
Times/ Times/ 
' 
-
day week 
X 10. N aart_jies Mineola fresh 4227 
Naartiie fresh 3558 
Naartjie 3635 
canned in 
syrup 
X 11. Oranges Fresh 3560 
11. Grapefruit Fresh 3546 
X 12. Peaches Fresh 
Canned juice 
Canned syrup 
X 12. Nectarines Fresh 
X 13. Pears Fresh 
Canned juice 
Canned syrup 
14. Pineapple Fresh 
Canned juice 
Canned syrup 
X 15. Plums Fresh 
15. Apricots 
16. Dried fruit 
16. Dry stewed fruit 
16. Raisins 
17. Fruit .iuice Fresh 
Sweetened 
Unsweetened 
Generic A. B. Tick c. D. E. F. G. H. 
Sketch Food items (with FPM Description of for Item Amount usually Eaten Eaten Eaten Never 
(look up) numbers) food item yes code eaten(g) every every Occasionally eaten 
.3.51 
Generic/amount = g day week 
Times/ Times/ 
day week 
SOUPS, LEGUMES, NUTS 
1. Soups Homemade 
Commercial 
Vegetable 
Meat 
Meat & 
vegetable 
With bones 
2. Beans and lentils Anything 
added 
3. Nuts 
3. Peanuts 
FISH & SEAFOOD- BEIGE 
1. Fried fish 
1. Fish cakes 
1. Fish fingers 
1. Calamari 
2. Grilled/smoked/dried fish 
2. Haddock 
3. Pilchards & sardines Canned water 
Canned tomato 
sauce 
Mayonnaise 
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Generic A. B. Tick c. D. E. F. G. H. 
Sketch Food items (with FPM Description of for Item Amount usually Eaten Eaten Eaten Never 
(look up) numbers) food item yes code eaten(g) 
--.... 
every every Occasionally eaten 
Generic/amount = g day week 
~ Times/ Times/ 
day week 
3. Tuna In brine water 
In oil 
Mayonnaise 
3. Pickled fish 
MEAT-RED 
How do you eat meat 1= with fat 2= fat trimmed 
1. Roast beef 
1. Beef chops 
1. Beef steak (bone) 
1. Beef steak (no bone) 
1. Beef stir-fry 
1. Beef stew / carrots 
1. Beef stew / cabbage 
2. Beef patties 
2. Mince Regular 
Lean 
With fat 
With 
vegetables 
X 2. Meatballs 
2. Cottage pie 
3. Burgers Homemade 
Fried 
Takeaway 
Crumbed 
3. Hot dog 
3. Pita with ... 
Generic A. B. Tick c. D. E. F. G. H. 
Sketch Food items (with FPM Description of for Item Amount usually Eaten Eaten Eaten Never (look up) numbers) food item yes code eaten(g) every every Occasionally eaten 
Generic/amount = g day week 
Times/ Times/ 
day week 
3. Chicken burger Crumbed 
Not crumbed 
Takeaway 
Home made 
Shop bought 
3. Chicken nuggets 
4. Chicken stew 
4. Fried chicken pieces With skin 
Without skin 
4. Roast chicken With skin 
Without skin 
4. Chicken stir-fry 
4. Chicken schnitzel 
1 
6. Fat cake & mince 
7. Meat pies Home made 
King pie / pie city Commercial 
7. Samoosas Meat 
Vegetable 
7. Sausage rolls 
7. Spring rolls 
Generic A. B. Tick c. D. E. F. G. H. 
Sketch Food items (with FPM Description of for Item Amount usually Eaten Eaten Eaten Never (look up) numbers) food item yes code eaten(g) every every Occasionally eaten 
1 See BLUE for 5 cold meats 
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--
Generic/amount = g day week 
Times/ Times/ 
:'":· day week 
8. Mutton stew no veg 
' 
8. Mutton stew with veg 
8. Mutton le2 chop 
8. Mutton loin chop 
8. Roast mutton 
9. Spare ribs 
9. Pork chops 
9. Bacon 
9. Roast pork 
10. Pork sausages 
10. Viennas 
10. Frankfurters 
10. Boerewors 
11. Traditional I organ 
meats 
Chicken livers 
Chicken organ meats 
Chicken head & feet 
Liver & fat 
Sheep intestine / lun2s 
Pork shank 
Mopani worms 
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Generic A. B. Tick C. D. E. F. G. H. Sketch Food items (with PPM Description of for Item Amount usually Eaten Eaten Eaten Never (look up) numbers) food item yes code eaten(g) every every Occasionally eaten 
Generic/amount = g day week 
Times/ Times/ 
12. Ve2etarian products 
day week 
13. Dry sausages 
13. Bilton2 
VEGETABLES -GREEN 
1. Asparaims Fresh 
Canned 
Fat added 
Sugar added 
2. Avocado Fresh 
3. Baby marrows Fat added 
Sugar added 
Sauce 
4. Beetroot Boiled 
5. Butternut/pumpkin Fat added 
Sugar added 
6. Broccoli Fat added 
6. Cauliflower , Fat added 
7. Cabba2e Boiled 
Fried 
8. Carrots Boiled 
Fat added 
Sugar added 
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Generic A. B. Tick c. D. E. F. G. H. 
Sketch Food items (with FPM Description of for Item Amount usually Eaten Eaten Eaten Never 
(look up) numbers) food item yes code eaten(g) every every Occasionally eaten 
for Generic/ambunt = g day week 
' yes 
~ Times/ Times/ 
day week 
9. Gem squash Boiled 
Sugar added 
Sauce 
10. Green beans Fat added 
Sugar added 
With onion 
With potato 
Sauce 
11. Mealies Fat added 
Creamed 
12. Mixed ve2etables Frozen 
Fat added 
Sugar added 
Sauce 
13. Mushrooms Fat added 
Sauce 
14. Peas Fat added 
Sauce 
15. Potatoes Boiled 
Roasted 
Baked 
Mash with fat 
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Generic A. B. Tick C. D. E. F. G. H. 
Sketch Food items (with FPM Description of for Item Amount usually Eaten Eaten Eaten Never (look up) numbers) food item yes code eaten(g) every every Occasionally eaten 
Generic/amount = g day week 
Times/ Times/ 
day week 
15. Potato Salad 
16. Potato chips Homemade 
Fried oil 
Oven baked 
Takeaway 
Mayonnaise 
Tomato sauce 
17. Salad ve2etables Mayonnaise 
Dressing 
17. Cucumber 
17. Penners 
18. Spinach/moro20 Fat added 
Sauce added 
With onions 
With potatoes 
19. Sweet potatoes Fat added 
Sugar added 
20. Tomatoes Raw 
Cooked 
With onion 
Fat added 
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Generic A. B. Tick c. D. E. F. G. H. 
Sketch Food items (with FPM Description of for Item Amount usually Eaten Eaten Eaten Never 
(look up) numbers) food item yes code eaten(g) ·•·: every every Occasionally eaten 
' 
Generic/amount = g day week 
- Times/ Times/ 
day week 
FATS-TAN 'oromot' 
1. Tub mar!!arine Where used 
Number of 
spoons 
Number m 
fami ly 
1, Butter 
1. Brick Mar!!arine 
2. White margarine (type of 
fat) 
3. Cream and substitutes 
(brand, real dairy/plant fats) 
4. Oils Where used 
Number of 
spoons 
Number m 
family 
5. Salad dressin!!s Homemade 
Shop bought 
5. Mayonnaise Where used 
Number of 
spoons 
Number m 
family 
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Generic A. B. Tick c. D. E. F. G. H. 
Sketch Food items (with FPM Description of for Item Amount usually Eaten Eaten Eaten Never (look up) numbers) food item yes code eaten(g) every every Occasionally eaten 
for Generic/amount = g day week 
yes 
Times/ Times/ 
day week 
BISCUITS, CAKE & PUDDING - PURPLE 
1. Biscuits/cookies Homemade 
Shop bought 
2. Biscuits/savoury 
Spread 
3. Special buns Spread 
3.Muffins Spread 
3. Scones Spread 
4. Tart 
4. Cake Iced/Cream 
Plain 
5. D0u2hnuts Plain 
5. D0u2hnuts Filled 
5. eclairs 
5. Koeksisters 
6. Pancakes/crumpets Spread 
Syrup 
Ice-cream 
6. Waffles Spread 
Syrup 
Ice-cream 
7. Trifle 
7. Baked Puddin2 
7. Instant pudding 
7. Custard 
8. Rusks 
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Generic A. B. Tick c. D. E. F. G. H. 
Sketch Food items (with FPM Description of for Item Amount ·, usually Eaten Eaten Eaten Never 
(look up) numbers) food item 
' 
yes code eaten(g) every every Occasionally eaten 
- for Generic/amount = g day week 
yes 
Times/ Times/ 
day week 
9. Special breads 
Spread 
SNACKS, SWEETS & COLD DRINKS-PINK 
1. Carbonated cold drinks 
e.g. coke 
1. Diet cold drinks e.g. diet 
coke 
2.Ma2eu 
2. Cold drinks (powder) 
2. Ener2y drinks 
2. Squashes 
3. Crisps 
3.Popcorn 
4. Sweets 
Lollipops 
4. Chocolates 
SAUCES & CONDIMENTS-GREY 
1. Cheese sauce Full cream 
milk 
Butter 
Margarine 
1. White sauce Full cream 
milk 
Butter 
Margarine 
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Generic A. B. Tick C. D. E. F. G. H. 
Sketch Food items (with FPM Description of for Item Amount usually Eaten Eaten Eaten Never (look up) numbers) food item yes code eaten(g) every every Occasionally eaten 
for Generic/amount = g day week 
yes 
Times/ Times/ 
day week 
2. Chakalaka 
2. Atjar 
2. Tomato sauce & other 
2. Chutney 
ALCOHOLIC DRINKS-GREY 
1. Beer 
(regular/low alcohol) 
1. Cider 
Coolers 
2. Wine 
2. Champa2ne 
3. Spirits (any carbonated 
drink e.g. coke added) 
4. Liqueurs & Fortified 
wine 
OTHER 
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Appendix 5 Six and 12 month dietary questionnaire 
Women's Bone Study (WBS) dietary assessment 
Study ID [II=a=J 
Visit (circle) 16 month 112 month I 24 month 
Date .......................................................... . 
Interviewer's name ... . .... . .... .................. . ........ . 
THESE QUESTIONS RELATE TO YOUR FOOD HABITS SINCE WE LAST SAW YOU 
Food habits 
1. Are you on a special diet that has been prescribed for you e.g. by a doctor or one that you have 
adopted from someone e.g. a TV star/magazine? 
~ 
If YES ,Where did you get this advice to change your diet (tick all that apply)? 
Tick 
Magazine/TV /radio/internet 
Friend/Family 
Clinic/Hospital: 
1. Doctor 
2. Nurse 
3. Dietician 
My own decision 
Other - please write in: 
Describe what kind of diet you are on: 
Does it involve excluding certain foods, if so what? _________ _ 
Does it involve including certain foods, if so what? _________ _ 
2. If NO, go to question 4. 
3. How long have you been on that diet? _____ weeks/months/years. 
4. Do you currently take any vitamin and mineral or other dietary supplements? 
~ 
IF YES, what do you take? 
Name of product Amount/day 
(or how 
many tablets) 
Vitamins/vitamins and minerals 
Tonics 
Vitamin D only 
Calcium only 
Body building preparations 
Dietary fibre supplement 
Other: specify 
5. Which meals do you skip almost on a daily basis? 
Breakfast 1 
Lunch 2 
Evening meal 3 
None 4 
6. Is salt added to your food while it is being cooked? 
Always 1 
Sometimes 2 
Never 3 
Don't know 4 
7. Do you add sal~l-°T~~r efore you eat it? 
~ 
8. If yes, how much salt do you add to your food each day? 
\4 teaspoon 1 
Yi teaspoon 2 
% teaspoon 3 
1 teaspoon 4 
Other specify: 5 
9. Do you add Aro~od before you eat it? 
~ 
10. If yes, how much Aromat do you add to your food each day? 
\4 teaspoon 1 
Yi teaspoon 2 
% teaspoon 3 
1 teaspoon 4 
Other specify: -- 5 
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11. There are some factors which influence the choice of foods we eat. Which of the following 
statements are true for you? 
Strongly Agree Disagree Strongly 
agree Disagree 
I choose to eat certain foods because they taste good 1 2 3 4 
The food I eat depends on whether it is expensive 1 2 3 4 
I choose to eat certain foods because it looks good 1 2 3 4 
The food I choose to eat differs according to my mood 1 2 3 4 
(i.e. happy/sad) 
My hunger level determines what type of food I eat. 1 2 3 4 
I choose foods which are not time consuming to 1 2 3 4 
prepare 
I consider whether a food is good for my health before 1 2 3 4 
eating the food. 
12. Do you ever eat outside t~ fast food shops such as Nandos, KFC and Steers? 
~ 
13. IfYES, in an average month how often do you eat at the following places? 
Nandos 
Spur 
Macdonalds 
Steers 
KFC 
Chicken Licken 
Debonaire's Pizza 
Romans . . 
Anat 
Wimpy 
Something fishy 
Fontana 
Chinese takeaway 
Other restaurants/takeaways 
(Quarters from tuck shop) 
Frequency of visits 
Times/week Times/month Rarely/never 
~ 
14. Have you made any changes to your diet since your last visit? 
(Double check that there are no changes in appetite, seasonal foods etc.) 
If No then go to question 15. (Double check that there are no changes in appetite, seasonal foods 
etc.) 
If Yes, are you eating: 
More than y 1 If Y, is it more often? 
before? N 0 
or 
Less than y 1 If Y, is it less often? 
before? N 0 
Are you eating y 1 If Y, which foods: 
foods you have N 0 1. 
never eaten 2. 
before? 3. 
Have you y 1 IfY, which foods: 
stopped eating N 0 1. 
foods you used 2. 
to eat? 3. 
Food that lS y 1 IfY, which foods: 
more available N 0 1. 
m certain 2. 
seasons? (e.g 3. 
mango) 
Have you y 1 If Y, which foods: 
changed the N 0 1. 
amount that 2. If Y, is it you snack? 3. More 1 
Less 0 
For subjects y 1 If Y, has this changed 
taking ARTs: N 0 the way you eat? 
If you have ~ started ART are you getting 0 
nausea or 
sickness? 
15. Has your appetite changed since your last visit? 
If Yes has it increased or decreased? 
y 1 Is it y 1 
N 0 bigger N 0 
portions? 
y 1 Is it y 1 
N 0 smaller N 0 
portions? 
Notes (why): 
Notes (why): 
Notes: 
Notes (why): 
y 1 
N 0 
If Y, do Which foods, if any, 
you eat: do you avoid? 
More 1. 
~ 2. 3. 0 Which foods, if any, 
or 
Less 
y 
N 
do you eat more of? 
1. 1 2. 
0 3. 
~ 
Increased 1 
Decreased 0 
Any other information about changes in diet since last visit: 
------- -- ----
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16. Alcohol 
Do you drink alcohol? 
ITJIJ [EI!] 
If Yes, how much in an average week 
Type of alcohol Brand name 
Beer 
Cider 
Coolers (e.g. Storm) 
Wine 
Champagne 
Spirits 
Liqueurs & fortified wine 
Other 
Amount e.g. 1 small glass 
or bottle 
Has the amount you drink changed since your last visit? ITJIJ ~ 
If Yes, has it increased or decreased? Increased 1 
Decreased 0 
Number of times per 
week e.g. 3 days 
Any other comments 
---------------------------
Checked by: ........ .......... ....... .. ..... .... ..... Date .......................................................... . 
Data entry by: .. , ...................................... Date ............. ........ ................................. .... . 
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16.Alcohol 
Do you drink alcohol? 
ITID ~ 
If Yes, how much in an average week 
Type of alcohol Brand name 
Beer 
Cider 
Coolers ( e.g. Storm) 
Wine 
Champagne 
Spirits 
Liqueurs & fortified wine 
Other 
Amount e.g. 1 small glass 
or bottle 
Has the amount you drink changed since your last visit? ITID ~ 
If Yes, has it increased or decreased? Increased 1 
Decreased 0 
Number of times per 
week e.g. 3 days 
Any other comments _________________________ _ 
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39 Abstract 
40 Objective: This paper examines dietary intake and body composition in ARV-nai."ve HIV-positive 
41 compared to HIV-negative SA women, as well as the impact of disease severity on these variables. 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
Design: Baseline data from a longitudinal study assessing bone health in HIV-negative and HIV-
positive pre-menopausal SA women over 18 years of age were used. Anthropometry and body 
;t· 
composition, measured by dual energy X-ray absorptiometry (DXA), were analysed together with 
dietary intake data assessed using an interviewer based qualitative food frequency questionnaire 
(FFQ). 
Setting: Soweto, Johannesburg, South Africa 
Subjects: Black, urban SA women were divided into three groups: HIV-negative (n=98), HIV-
positive with preserved CD4 counts (HIV+ non-ARV; n=74) and HIV-positive with low CD4 counts 
' due to start ARV treatment (HIV+ pre-ARV; n=75). 
Results: The prevalence of overweight and obesity was high in this population (59%). The HIV+ 
pre-ARV group was lighter and had a lower BMI than the other two groups (all p<0.001). Pre-
ARV subjects also had lower fat and lean masses and% body fat than their HIV-negative and HIV+ 
54 non-ARV counterparts. After adjustment, there were no differences in macronutrient intakes across 
55 
56 
57 
58 
59 
60 
study groups; however, fat and sugar intakes were high and consumption of predominantly refined 
food items was common overall. 
Conclusion: HIV-associated immunosuppression may be a key determinant of body composition in 
HIV-positive women. However, in populations with high obesity prevalence, these differences 
become evident only at advanced stages of infection. 
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l 62 Introduction 
63 The introduction of antiretroviral (ARV) therapy has dramatically altered the morbidity profile of 
64 HIV-positive populations, with an increase in prevalence of non-communicable disease (NCD) risk 
65 factors such as overweight and obesity being observedC1;2). This is of particular concern in South 
66 Africa where, amongst adults over 15 years of age, 17.8% were estimated to be living with HIV in 
67 2008(3) and approximately 45% were found to be overweight or obese in the 2003 Demographic and 
68 Health Survey (SADHSi4). 
69 Although the public health impact of HIV and associated NCD risk is greatest in low-middle-
' 70 income countries (LMICs), to date most studies have been conducted in high-income countries, on 
I 
71 predominantly ARY-treated male subjects with low BMiscs-s)_ Lipodystrophy, a commonly 
72 
73 
74 
i5 
76 
77 
78 
79 
80 
81 
82 
83 
84 
85 
86 
87 
88 
89 
IQ 
91 
12 
recognized side-effect of certain ARV drugs, has been linked to visceral fat accumulation and 
metabolic disorders such as dyslipidaemia and glucose intoleranceC9)_ In black SA women ARV-
associated increases in body mass index (BMI), fat mass, body fat percentage and waist 
circumference, but not in lean body mass or waist: hip ratio, have been shown( JO)_ This increase in 
fat, as well as, the proposed tendency towards visceral rather than subcutaneous fat 
accumulation() I)' must therefore be further explored in this population due to the potential long-term 
negative-effects on disease risk and healthC 12). 
While the evidence for body composition changes associated with ARV drugs continues to grow, 
there is less research focusing on the effect of the HIV infection itself. Radigan et a1C 13) found that, 
independent of ARV, HIV-positive women in the USA demonstrated a higher percentage body fat 
and truncal fat and a lower percentage lean body mass than HIV-negative controls. In addition, 
other data suggest that HIV-positive patients with higher BMis, skinfold thicknesses and insulin 
concentrations prior to ARV initiation may be more likely to develop lipodystrophy over 2 years of 
ARV drug useC 14)_ 
Although HIV-positive status has traditionally been associated with low energy intake, most likely 
as a result of reduced appetiteC 15\ SA data show energy intake in HIV-positive subjects to be 
equivalent to, or in excess of, their HIV-negative counterpartsc 16). However, high total and 
saturated fat, as well as low n-3 polyunsaturated fat and fibre intakes, have also been reported in 
HIV-positive populations, which may indicate overall poor diet qualityC 16- 19). This suggests that 
HIV patients may be as affected by the global obesity epidemic as the wider population, and that 
poor diet quality may be a key factor in the increasing prevalence of overweight and obesity in 
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HIV-positive populations. The majority of these studies, however, did not include HIV-negative 
control groups; thereby making the impact of HIV infection itself difficult to ascertain. 
In this paper we examined dietary intake and body composition (fat and lean tissue) in ARY-naive 
HIV-positive and HIV-negative black urban SA women. In addition, we explored whether the 
relationships between HIV infection, body composition and dietary variables are influenced by 
differences in disease severity by comparing affected women with low and relatively preserved CD4 
counts. 
Methods 
SUBJECTS 
102 This study was a baseline dietary intake and body composition analysis of HIV-negative and HIV-
103 positive black women participating in a longitudinal assessment of bone health in urban SA. The 
104 aim was to recruit 95 (+/-5) HIV-negative and 73 (+/-10) in each of the two HIV-positive groups. 
105 This sample size was based on calculations for the longitudinal study to detect a 2% change in 
106 lumbar spine BMD, allowing for a between-individual coefficient of variation in BMD of 5%, with 
107 95% confidence and 80% power. Inclusion criteria required women to be over 18 years of age, pre-
108 menopausal, not pregnant or not planning to become pregnant for at least 12 months of the follow-
109 up, and, if HIV positive, not yet using ARVs, and free from any current AIDS-related illness, as 
110 defined by WHO or Centers for Disease Control (CDC). 247 HIV-positive (HIV+; n=149) and 
111 HIV-negative (HIV-; n=98) women were recruited at Chris Hani Baragwanath Academic Hospital 
112 in Soweto, through contact with either the 'ZAZI' voluntary counselling and testing (VCT) centre 
' 113 or the hospital's 'HIV clinic. Subjects were divided as follows: HIV-negative (group 1; HIV-, 
114 n=98), HIV-positive with preserved CD4 counts, not eligible for ARV therapy (2: 350 xl06 cells/I) 
115 (group 2; HIV+ non-ARV, n=74) and HIV-positive with low CD4 counts, eligible for ARV therapy 
116 (:S200 x106 cells/1) due to start ARV (group 3; HIV+ pre-ARV, n=75). 
117 
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ANTHROPOMETRY 
Weight was measured to the nearest 0.1 kg using a digital scale (Dismed, USA) and height was 
measured to the nearest 1 mm using a wall-mounted Stadiometer (Holtain, UK) in the Frankfort 
horizontal plane. These measurements were used to calculate the body mass index (BMI [ weight 
(kg)/height (m2)]) of each individual. Underweight, normal, overweight and obese were defined as 
BMI <18.5, 18.5-24.9, 25-29.9, ~30.0 kg/m2, respectively. Waist circumference, taken 
approximately half-way between the iliac crest and the lowest rib, and hip circumference, taken at 
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the maximum circumference around the hips, were measured using a non-stretchable measuring 
tape to the nearest 1 cm. All measurements were carried out by trained investigators using 
standardised procedures and participants wore minimal clothing and no shoes while measurements 
were taken. 
BODY COMPOSITION 
Dual energy X-ray absorptiometry (DXA) scans were performed according to standard procedures 
using a Hologic QDR 4500A dual-energy X-ray absorptiometer (software version 12.5:7, Hologic 
Inc., Bedford, MA, USA). Whole body fat and lean mass were analysed as whole body less head 
(WBLH) because many of the women wore wigs and hair weaves, which could have affected the 
DXA measurements in the head region. These data have been published by Hamill et a1<20)_ Trunk 
!JS and limb (arms and legs) fat masses were derived from DXA scans. Percent fat mass for WBLH, as 
136 well as for the trunk and limbs as percentages of WBLH fat mass, were calculated. To compare 
!l7 body fat distribution between the groups, the ratio of trunk: limb fat mass was determined. The ratio 
lil8 of fat mass: lean mass2 was also calculated as this was shown to best describe the relationship 
il9 between fat and lean mass in this population<20)_ 
140 DIETARY INTAKE 
141 The dietary assessment tool used in this study was an interviewer-conducted quantitative food 
42 frequency questionnaire (FFQ) developed for use in SA. The questionnaire took on average 40 
43 minutes to complete and included a total of 214 commonly eaten foods. These food items were 
44 derived from analyses of 11 dietary surveys conducted in rural and urban SA since 1983, and the 
45 list includes all foods eaten by at least 3% of the population<21 >. The FFQ was extensively piloted on 
46 SA adolescents from the Birth to Twenty cohort at both 15 years (interviewing both adolescents and 
47 their primary caregivers, n=l 50<22)) and 17 years of age (n=l 700 (Feeley et al, unpublished results)), 
48 as well as on adult research assistants during training, and modified accordingly. 
49 
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To cater for illiteracy in the SA population, the FFQ utilises food flash cards (high quality 
photographs) of the food items<23)_ Data were collected on the previous ~eek's (7 d) dietary intake, 
including convenience food products, in order to estimate habitual intake for each participant. 
Participants were asked to separate the food flash cards into a series of piles: firstly, they went 
through each food card and created a pile of food items they 'rarely/never' ate or drank. Thereafter, 
they went through the remaining food cards and created a pile of food items they eat/drink less 
frequently ('occasional' ), and a pile they eat regularly and in the past seven days. The participant 
was then prompted for information on the frequency and amounts of the regular food items in their 
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diet consumed, the details of which were recorded on the FFQ. Portion sizes were estimated using 
household measures and a combination of two-dimensional life-size drawings of foods and utensils, 
and three-dimensional food models as described and validated by Steyn et a1C24)_ Items eaten 
occasionally or rarely/never were also recorded. 
Coding involved the conversion of the household measures (for example one cup/one servmg 
spoon/one slice) to grams so that an average intake over the previous seven days could be 
calculated. Nutrient composition (energy and macronutrients) was estimated, using FoodFinder3, a 
nutrient analysis software program based on the South African Medical Research Council (MRC) 
food composition tablesC25)_ 
Quality control for dietary data acquisition was undertaken by extensive and repeated training of 
interviewers, reviewing the questionnaires for missing or spurious data, questioning participants on 
ambiguous answers and spot-checking questionnaires by a second interviewer (usually the senior 
nutritionist). The plausibility of the reported energy intake data was assessed according to study 
specific cut-offs as described by Goldberg et a1C26) and B1ackC27)_ 
United States DRisc2s) for energy and macronutrients were selected for assessing the intakes of the 
groups compared to recommendations as these are most commonly used in SA and the most useful 
for comparison with other published data. Nutrient intakes were therefore compared with the 
Estimated Energy Requirement (EER), the Recommended Dietary Allowance (RDA) for protein 
and carbohydrate and the Adequate Intake (AI) for fibre in adult women aged 19 to 50 years. The 
median intakes for carbohydrate, protein and fat as proportions of total energy intake were 
calculated and compared with the Acceptable Macronutrient Distribution Ranges (AMDR). 
Variation in the food items consumed between groups was assessed by comparing the 20 most 
180 commonly consumed items, as well as their respective food groups. The top 20 reported food items 
181 
182 
183 
were ranked from the most to the least consumed according to the mean intake reported in grams 
per day. 
SOCIO-ECONOMIC STATUS AND EDUCATION 
184 Socio-economic status (SES) was assessed using an asset index similar to that used by McVeigh et 
185 
186 
187 
188 
189 
a1C29)_ This scored each participant according to the number of household assets they possessed out 
of a possible 12 ( electricity, television, radio, motor vehicle, fridge, washing machine, telephone, 
video machine, microwave, MNET television channel, DSTV satellite television, cellular 
telephone). An asset score percentage was then calculated for each participant ((number of 
recorded household assets/12) x 100). 
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Level of education was assessed according to the number of years completed at primary, secondary 
or tertiary level. 
ETHICS 
The study was approved by the University of the Witwatersrand Human Research Ethics 
Committee (HREC Number: Ml01525) and the Gauteng Department of Health. 
STATISTICAL ANALYSIS 
Data were analysed using STATA 11.0 (StataCorp, USA). Where 'inaccurate reporters' were 
identified, dietary data were truncated using Goldberg cut-offs so that energy and macronutrient 
intakes represented the lowest or highest plausible intake for under- or over-reporters respectively, 
according to body size. Continuous variables for subject characteristics, as well as anthropometric 
and body composition measurements and dietary intake, were not normally distributed and were 
therefore summarised using the median and interquartile range. Education level and BMI 
categories were summarised as % in each group. Continuous and categorical variables for subject 
characteristics were compared between the three study groups using the Kruskal-Wallis test for 
non-parametric data, and the Chi2 test, respectively. Age was found to be significantly different 
between groups; therefore all subsequent analyses were adjusted for age. Regression analyses were 
performed to compare differences in anthropometric and body composition variables between the 
HIV- group and the HIV+, non-ARV and HIV+, pre-ARV groups combined. Between group 
comparisons were then made using multiple linear regression models with dummy variables created 
to distinguish between the HIV+ groups. These methods were repeated for analysis of dietary 
intake data; however, in addition to age-adjusted analyses, subsequent regression analyses were 
controlled for both age and total energy intake in order to adjust for the dietary variation attributed 
12 to differences in body size between groups. Finally, multiple regression models were used to 
13 
14 
15 
explore whether any of the variables found to differ between groups were independent predictors of 
anthropometric and body composition differences. Where appropriate hypotheses were conducted 
using Bonferonni adjusted alpha levels of 0.016 per test (0.05/3). 
16 Results 
17 
18 
19 
10 
11 
Table 1 summarises the subject characteristics and · anthropometric variables for the three study 
groups (previously described, in part, by Hamill et al (20)). The HIV+ pre-ART group had a 
significantly lower median CD4 count (175) than the HIV+ non-ARV group (420) as a result of 
study design. Both SES score and level of education were similar across all groups. The HIV+ pre-
AR V group had significantly lower body weight, BMI and waist and hip circumference than the 
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other groups. The prevalence of overweight and obesity was high in the whole sample; with 59% of 
subjects being overweight or obese. There was a significant difference in the distribution of 
subjects across BMI categories between the groups, with the HIV+ pre-ARV group having 
significantly fewer obese subjects (16%) than both the HIV- (30%; p=0.01) and HIV+ non-ARV 
(37%; p=0.01) groups. The HIV+ pre-ARV group also had a higher underweight prevalence 
(11 %); approximately 3- and 11-fold higher than the HIV- and HIV+ non-ARV groups, 
respectively. 
There was a significant difference in fat mass between the groups, with the HIV+ pre-ARV group 
having lower total, trunk and limb fat masses, and body fat percent than the other two groups (Table 
2). However, when expressed as a % of whole body fat mass, trunk and limb fat percentages were 
no longer different between the groups. The HIV+ pre-ARV group had a lower fat/lean2 ratio than 
the other two groups, however trunk: limb fat mass ratio was not different between the groups. 
Table 3 presents the results of multiple regression analyses for BMI , WBLH fat mass and lean 
mass, trunk fat mass and limb fat mass. Only the variables which contributed significantly to the 
models are pfesented. The overall models explain 14% of the variance in both BMI and WBLH fat 
mass 34% of the variance in WBLH lean mass and 13% of the variance in both trunk and limb fat 
' 
masses. Age and being in the HIV+ pre-ARV group significantly contributed to the models for 
BMI, WBLH fat mass and trunk fat mass, with HIV+ pre-ARV group status being associated with 
an approximately 4.5 kg/m2 decrease in BMI, an 8 kg decrease in fat mass and a 3.5 kg decrease in 
trunk fat mass. Age, height and being in the HIV+ pre-ARV group were significant contributors to 
the variation in both WBLH lean mass and limb fat mass, with an approximately 3 kg lower lean 
mass and 4 kg low~r limb fat mass being associated with HIV+ pre-ARV group status. 
The daily energy and macronutrient intakes are presented in Table 4. None of the components of 
245 dietary intake were different between HIV- and HIV+ subjects, with the exception of total protein 
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and animal protein intake which were significantly lower in the HIV- than the HIV+ subjects. 
However, when adjusted for total energy intake, the differences in total and animal protein intake 
were no longer significant. Between group analyses similarly found no differences between HIV-, 
HIV+ non-ARV and HIV+ pre-ARV groups in any of the dietary intake variables. Dietary intake 
exceeded the EER, the RDA for carbohydrate and protein, as well as the AI for fibre across all three 
study groups. 
Carbohydrate, protein, fat and fibre contributed to approximately 54%, 11 %, 30% and 4%, 
respectively of total energy intake across all three groups (data not shown). Intakes, as percentages 
of total energy intake, were therefore within the AMDR for carbohydrate (45-65%), protein (10-
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35%) and fat (20-35%) for all groups. Approximately 8%, 5% and 21% of subjects in the sample 
had carbohydrate, fat and protein intakes, respectively, below the acceptable range, while 5% and 
19% had carbohydrate and fat intakes, respectively, above the acceptable range. Alcohol 
contributed to less than 1 % of total energy intake in all groups. 
The 20 most commonly consumed food items and their respective food groups are shown in table 5. 
Data are presented for the whole sample due to the lack of differences seen in the food items 
consumed between study groups. The HIV+ pre-ARV group consumed the highest amount of food 
mass from the top 20 items (1176 g/d) when compared to the HIV- and HIV+ non-ARV groups 
(929 and 1142 g/d respectively). The most commonly consumed food item was maize meal (made 
into a stiff porridge/'pap') at a mean intake of 258 g/d. The most commonly recorded food group 
was cereal and cereal products (featured four times in the top 20); with most cereal products being 
highly refined 'white carbohydrate'. Fruit and vegetables both featured twice; however the 
vegetable component included french fries which are high in fat (usually sunflower oil). Sugar 
consumption was high overall, with granulated white sugar being the most frequently recorded food 
item in the sample (reported 533 times at an average of 15 g/d) and sweetened carbonated drinks 
being ranked second with a mean consumption of 197 g/d and equating to approximately 340 kJ of 
energy per day. Meat and meat products featured three times in the top 20 food items; however the 
cuts of meat tended to be highly processed and fried in sunflower oil ( e.g. polony and battered fried 
chicken). In addition, fish did not feature in the top 20 food items. Use of fats and oils were very 
common, with brick/hard margarine and sunflower oil being the regularly reported products (13 g/d 
and 6 g/d respectively). Condiments, high in fat and/or sugar, were regularly added to meals and 
snacks, with both atchar, a spicy condiment of mangoes and honey, (19g/d) and tomato sauce (1 O 
g/d) featuring in the top 20 food items consumed. 
Discussion 
In this sample of black, urban, SA women, HIV-positive subjects had lower weight and BMis, as 
well as lower fat and lean mass and percent body fat than their HIV-negative counterparts. This was 
primarily as a result of the HIV-positive subjects with low CD4 counts having low measures. 
Multiple regression analyses showed that HIV+ pre-ARV, but not HIV+ non-ARV, status was a key 
contributor to differences in WBLH fat mass and WBLH lean mass, as well as both trunk and limb 
fat masses; associated with 8kg and 3kg less fat and lean mass respectively, as well as 3.5 kg less 
trunk fat and 4kg less limb fat. This challenges the stereotypical view of HIV as a disease 
associated with involuntary weight loss and wasting prior to ARV initiation and suggests that 
weight loss may only become a symptom in this population at more severe disease states. 
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Although WBLH fat mass, as well as trunk and limb fat masses, were lower in the HIV+ pre-ARV 
group than the other study groups, there were no differences in relative terms (trunk and limb fat 
percentages) across all groups. This, together with the similarity found in trunk: limb fat ratio 
between study groups, suggests lower body fat across all sites rather than an altered fat distribution 
with advanced HIV infection. This contradicts previous U.S. data which showed an increase in 
both percent trunk fat and trunk: limb fat ratio and a decrease in peripheral fat independent of ARV 
treatment in HIV-positive women compared to HIV-negative controls (l 3)_ In addition, it suggests a 
different pattern of fat loss than that associated with ARV-treatment, where lipodystrophy is 
characterised by abdominal fat accumulation and subcutaneous fat loss, predominantly at the face, 
limbs and buttocks (30). This is speculative, however, and a longitudinal study is currently being 
undertaken in this population, which will hopefully provide more definitive answers. 
As previously documented by Hamill et al (20), the HIV+ pre-ARV group had a lower fat/lean2 ratio 
300 than the other two study groups, demonstrating approximately 21% and 16% less fat for each kg of 
301 lean mass than the HIV- and HIV+ non-ARV groups, respectively. This provides evidence oflower 
302 fat mass, rather, than lean tissue, at more advanced stages of HIV infection. Although previous 
303 literature has found HIV to be associated with preferential loss of lean compared to fat tissue, 
304 particularly in male subjects, a disproportionately higher loss of fat mass has been shown in U,S. 
305 women (31 ). In addition, a preferential loss of fat rather than lean tissue mass has been demonstrated 
306 in males with high body fat percentages at baseline, compared to those with less than 15% body fat 
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(32) 
Overweight and obesity were common in the sample overall, with a combined prevalence of 59%, a 
I 
prevalence higher than that of the national estimate of 55% reported for black women in the 2003 
SADHS (4) _ Although the distribution of women across BMI cut-offs differed significantly between 
the HIV+ pre-ARV group and the other two study groups, there was still a 44% prevalence of 
overweight and obesity in this group, while another 11 % were classified as underweight. Even at 
more advanced stages of HIV infection, women are affected by obesity and this needs to be 
addressed in the population as a whole. 
There were no reported differences in dietary intake across study groups, with the exception of total 
and animal protein intakes which were lower in the HIV- group than in the HIV+ groups combined. 
However, when adjusted for total energy intake, these differences were no longer significant. All 
variation seen for protein intake may therefore have been a result of non-significant differences in 
total energy consumption rather than real differences in diet quality between groups. These results 
also highlight that all groups, including the pre-ART group with lower median BMI, consume an obesogenic 
diet. Given the high levels of inflammation and high carbohydrate intake, these participants are likely to have 
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a high prevalence of insulin resistance and other metabolic abnormalities. These are areas for potential future 
research. 
Food item and food group analyses showed similar consistency of consumption across the groups, 
regardless of HIV status. The main contributor to the variation in food mass consumed between the 
three groups seemed to be pap (maize), which differed by approximately 135 g/d between the HIV+ 
pre-ARV and the HIV- group and approximately 92 g/d between the HIV pre-ARV group and the 
HIV+ non-ARV group. Diets in the sample as a whole were very high in refined carbohydrate, 
which is reflected by the high total digestible carbohydrate intakes (approximately three-fold higher 
than the RDA of 130 g/d). Consumption of processed and fast food products was common and that 
of fruits and vegetables rare, with the vegetable items consumed ( e.g. tomato and onion stew) 
usually containing added sugar and/or fat. In addition to added sugar intakes, high sugar-based 
products were also common; with carbonated soft drinks featuring second in the top 20 food items 
J34 consumed. This is a concern due to the link seen between sugar-sweetened beverage intake and 
l35 weight gain, as well as diabetes and cardiovascular disease risk(33;34)_ The lack of fish, and therefore 
J36 n-3 polyunsaturated fatty acids, in the top 20 reported food items should also be addressed due to 
l37 the important role that these essential fatty acids have in regulating immune function(35)_ The highly 
Ins processed nature of food products, as well as high sugar and fat and low vegetable consumption in 
ll39 the sample is an important health issue and highlights the urgent need to address obesity and its risk 
l40 factors throughout the population. 
l41 Although providing an overall picture of habitual energy and macronutrient intake, as well as of 
142 commonly consumed food items, the dietary data had certain limitations. The proportion of women 
l43 classified as 'under-reporters' was very high (31 %, data not shown), suggesting that a substantial 
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number were under-estimating their consumption. This may have been due to the high prevalence 
of overweight and obesity in the sample, as high BMI has been previously shown to predict 
underreportinl36). Due to the negative impact that excluding these participants would have had on 
sample size, truncation was therefore chosen as the best possible method of minimising the effects 
of under-reporting on study results. Classification of food items based on the South African FCT 
was also flawed as it misclassified items such as french fries into the vegetable group, thereby over-
estimating vegetable consumption in the sample. This classification should be revised in the future 
to ensure that vegetables high in starch with added fat are more accurately categorised. 
A key limitation of the study was that the participants were not a random sample of the adult female 
population of Soweto and the surrounding area, as inclusion in the study required the women to 
present at the Chris Hani Baragwanath Hospitals PHRU, HIV clinic, or VCT centre. Women must, 
therefore, both know that the services exist and have access to them, must be healthy enough to 
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356 present at the hospital, and must have sufficient information on HIV and its risks to be motivated to 
357 seek counselling or care. This could mean that the HIV-positive and HIV-negative participants 
358 included in the study are not a truly representative sample and may also have better knowledge of 
359 poor dietary practices and other health risks than the wider population. 
360 Regardless of these weaknesses, this paper provides unique data on diet and body composition 
361 differences between HIV-negative and HIV-positive women at varying levels of 
362 immunosuppression prior to treatment. In addition, the longitudinal design of the broader study 
363 will allow for future analysis of the changes in anthropometric, body composition and dietary 
364 variables in this population at 6 months, 12 months, and 24 months follow up. 
365 In conclusion, our data shows that immunosuppression may be a predictor of anthropometric and 
366 body composition changes in HIV-positive women and that, in populations with high obesity 
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N 
00 
,;j" 
1 
BMI (kg/m2) 27.3 (23.1-31.7) 27 .8 (23.3-32.3) 23.5 (20.4-27) <0.002 1-2 0.479 
1-3 <0.001 
2-3 <0.001 
Overweight BMI (%) 35 28 28 
Obese BMI (%) 30 37 16 '--: <O.Olb 
Underweight BMI (%) 4 1 11 
Waist circumference (cm) 86 (76-94) 86 (79-99) 81 (73-88) 0.251 1-2 0.517 
1-3 0.009 
2-3 <0.002 
Hip circumference ( cm) 106 (97-113) 106.5 (98-116) 96.5 (90-106) <0.001 1-2 0.497 
1-3 <0.001 
2-3 <0.001 
483 Data are summarised as median (interquartile range) unless otherwise indicated 
484 aKruskal-Wallis test, P<0.05 
485 hChi2 test, P<0.05 
486 cMultiple regression adjusted for age, P<0.05 
487 
488 
385 
489 Table 2. Body composition variables of study groups 
DXA [n=245] HIV- (n=97) (1) HIV+, non-ARV HIV+, pre-ARV HIV- vs HIV+, Between group pa 
(n=74) (2) (n=74) (3) pa comparison 
WBLH fat mass (kg) 24.45 (17.35-30.57) 25.31 (18.06-32.88) 18.43 (12.45-25.32) 0.002 1-2 0.458 
1-3 <0.001 
2-3 <0.001 
WBLH lean mass (kg) 37.68 (34.21-41.28) 39.67 (34.86-42.26) 36.18 (33.56-39.84) 0.201 1-2 0.512 
1-3 0.005 
2-3 0.001 
Body fat% 39.55 (34.07-43.22) 39.5 (33.06-44.67) 32.24 (26. 79-41.21) <0.001 1-2 0.372 
1-3 <0.001 
2-3 <0.001 
Fat/lean2 (kg/kg2) 17.19 (13.76-20.38) 15.92 (13.36-19.85) 13.84 (10.15-18.88) <0.003 1-2 0.181 
1-3 <0.001 
2-3 0.021b 
Trunk fat (kg) 9.72 (6.68-13.56) 11.38 (7.39-15.28) 7.48 (4.64-11.81) 0.007 1-2 0.592 
1-3 <0.001 
2-3 <0.001 
Trunk fat% 41.56 (37.67- 45.65) 42.85 (38.54-46.38) 40.92 (35.75-47.07) 0.717 1-2 0.602 
1-3 0.259 
2-3 0.117 
Limb fat (kg) 14 (10.32 - 16.7) 13.97 ( 10.74-17.93) 10.75 (7.32-14.15) <0.001 1-2 0.375 
1-3 <0.001 
2-3 <0.001 
386 
" oO N) Table 3. Multiple regression analyses for BMI, WBLH fat mass and WBLH lean mass 
~ 95% Confidence Interval p 
""" 
BMI N 0\ t- t- ir) 
0 lr) ...... 
'° """ 
0 
\0 C"! ...... ir) "": C"! Age 0.257 0.146, 0.367 <0.001 0 0 0 0 0 0 
HIV- (ref.) 0 R2 0.14 
HIV+, non-ARV -0.691 -2.61 , 1.227 0.479 Adjusted R2 0.13 
HIV+, pre-ARV -4.487 -6.394, -2.575 <0.001 p <0.001 N (") (") N (") (") I I I I I I 
...... ...... N ...... ...... N 
WBLH fat mass 
Age 0.347 0.166, 0.527 <0.001 
t- t- HIV- (ref.) 0 R2 0.137 ...... 0 
t- 0\ 
HIV+, non-ARV -1.614 -4.767, 1.539 0.314 Adjusted R2 0.123 0 0 
HIV+, pre-ARV -7.884 -11.014, -4.753 <0.001 p <0.001 
-
ir) 
WBLH lean mass C"! 
""" 
~ \0 00 
0.214 0.128, 0.3 <0.001 
I 
0 Age (") 
~ I \0 
Height 50.826 40.207, 61.445 <0.001 N "1 ir) 
'-' 0 
00 '-' 
C: 0\ \0 0\ 
0 R2 0.342 
ir) 0 HIV- (ref.) 
HIV+, non-ARV -0.439 -1.949, 1.07 0.567 Adjusted R2 0.331 
-
'° HIV+, pre-ARV -3.411 -4.91, -1.912 <0.001 p <0.001 ~...... 
-
'° 
\0 
I 00 
Trunk fat N 0 
'° 
I 
(") (") 
Age 0.208 0 .116, 0.3 <0.001 \0 ir) 0 '-' 
ir) '-' 
...... ir) 
t- t-
ir) 0 
HIV-(ret) 0 R2 0.134 
-
Q; 
Oil 
HIV+, non-ARV -0.621 -2.232, 0.99 0.448 Adjusted R2 0.12 = = 
-
i. (") 
- HIV+, pre-ARV -3.521 -5.121, -1.921 <0.001 p <0.001 
(") ~ Ill = c--i 
- = 
Q; 
'° -
i. 0 5 I 
""" 
= 
- Limb fat ir) 00 = V "' (") 0 C" i:i.. = ~ i.. .... I Q; cJ' 'Cl Age 0.139 0.043, 0.234 0.004 ir) ~ - Oil = '-' 0 = = ·a 
""" 
'-' 
::., 
i.. 
= Height 12.128 0.41 7, 23.84 0.042 ~
...... 
= .s i.. 00 I'-: = i.. ir) 0 :a 'Cl ~ 
Q; Q; 
= -5 "'  
= ~ "' .... HIV-(ret) 0 R2 0.129 .9 = 'Cl = ... 'Cl = -~ Q; 
= 
Q; 
Adjusted R2 i. "' .s = HIV+, non-ARV 0.993 ~2.658, 0.672 0.241 0.114 ... ·c 
"' 
'Cl 
~ = "' .... 5 Q; = HIV+, pre-ARV -4.362 -6.016, -2.71 <0.001 p <0.001 .c i.. = 5 Oil u ~ 9 
= 
Q; 
= = i.. .... 
All variables included in the above models were those which showed significance in prior analyses, P<0.05 
... 
.... 
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V a r i a b l e  
H I V - ( n = 9 8 )  ( 1 )  H I V +  n o n - A R V  H I V +  p r ' e - A R V  H I V - v s  H I V - v s  
( n = 7 4 )  ( 2 )  ( n = 7 5 )  ( 3 )  
H I V + , P a  H I V + , P b  
E n e r g y  ( k J / d )  
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0 . 8 2 5  
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2 7  ( 2 0 - 3 4 )  2 7  ( 2 0 - 3 6 )  2 6  ( 2 0 - 3 7 )  
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Summary: 
This is the first report examining vitamin D status and bone mass in African women with HIV infection 
using DXA with an appropriate HIV-negative control group. Unlike previous publications it 
demonstrates no difference in BMD or vitamin D status in HIV-positive, at different disease stages, 
vs . HIV-negative subjects. 
Word count: 3210 
391 
Abstract: 
Purpose: Low bone mass and poor vitamin D status have been reported among HIV-positive patients; 
suggesting HIV or its treatment may increase the risk of osteoporosis, a particular concern for women 
in countries with high HIV prevalence such as South Africa . We describe bone mass and vitamin D 
status in urban premenopausal South African women, who were HIV positive but not on ARV therapy. 
Methods: Cross-sectional measurement of BMD and body composition by DXA and vitamin D status 
by serum 25(0H)D concentration. Subjects were recruited into three groups: HIV-negative (n=98) and 
HIV-positive with preserved CD4 cell count (non-ARV) (n=74) or low CD4 cell counts prior to ARV 
initiation (pre-ARV) (n=75). 
Results: Mean (SD) age of women was 32.1 (7.2) years. Mean CD4 (SD) counts (x106/L) were 413 
(91) and 161 (70) in non-ARV and pre-ARV groups (p<0.0001 ). Pre-ARV women were significantly 
lighter and had lower mean BMI than the other two groups (p<0.002). The pre-ARV group also had 
significantly less fat and lean mass compared with non-ARV and HIV-negative subjects (p:50.05). After 
full adjustment, there were no significant differences in BMD at any site (p>0.05) between the groups, 
nor was vitamin D status significantly different between groups (p>0.05); the mean (SD) cohort 
25(0H)D being 60 (18) nmol/L. 
Conclusions: Contrary to previous studies, these HIV-positive women did not have lower BMD or 
25(0H)D concentrations than HIV-negative controls, despite the pre-ARV group being lighter with 
lower BMI. 
Key words: Body composition, bone mineral density, Dual energy X-ray absorptiometry, HIV 
infection, Vitamin D 
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Introduction: 
HIV infection and the use of antiretroviral (ARV) medication have been associated with low bone 
mineral density (BMD) and poor vitamin D status. In a meta-analysis, the prevalence of low BMD in 
HIV-positive individuals was three times higher than in HIV-negative controls [1-3]. Similarly studies 
have described high prevalence of low 25-hydroxyvitamin D (25(0H)D) concentrations in HIV-positive 
patients [4]. Some studies of the effects of HIV and/or its treatment on bone are limited by 
retrospective design, a preponderance of white, male subjects and lack of HIV-negative controls [5] 
while others are prospective [6] and do include women [7, 8]. Other studies are limited by confounding 
by low body weight or other risk factors for low BMD, such as intravenous drug use (IOU), exposure to 
a large variety of ARV regimes, and measurement of BMD and vitamin D status after varying duration 
of ARV exposure [6]. The few prospective studies focusing on women have also been limited by some 
of these aspects [6, 9], and as a result it is difficult to ascertain with certainty if HIV infection and/or its 
treatment or factors unrelated to HIV infection are contributing factors to the low bone mass and low 
vitamin D status described in the current literature. In contrast there are data to suggest that after 
adjusting for body weight BMD is normal or near normal, and that patients on ARV do not have 
increased rates of bone loss [10, 11 ]. As a result there is not a definitive consensus on the 
contribution of HIV infection or ARV exposure on BMD in infected individuals. 
In South Africa, eslimates of HIV prevalence for 2010 are 10.5% for the total population and 29.3% for 
women attending antenatal clinics. The epidemic is described as "hyper endemic" because of the high 
prevalence and continuing drivers of transmission [12-14]. In South Africa individuals generally 
become eligible for ARV treatment when their CD4 count is less than a nationally-specified threshold. 
By 2009 56% of those requiring ARV were able to receive them, with the Government intending to 
increase ARV coverage to 80% by 2011 [12]. 
Vitamin D has well-known associations with bone health via its role in calcium and phosphate 
homeostasis, and vitamin D status is considered an important modulator of immune function by some 
authors [15-17]. In South Africa, adults are largely dependent on the cutaneous synthesis of vitamin D 
to maintain vitamin D status, as only small amounts of vitamin D are obtained from the diet due to 
limited food fortification. In Johannesburg (26°S latitude), there is sufficient UVB radiation in sunshine 
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throughout the year for dermal synthesis of vitamin D [18]. Nevertheless, vitamin D deficiency has 
been described in tropical/subtropical countries despite the potential for adequate skin exposure to 
UVB-containing sunshine [19]. 
The aim of the study presented here was to describe BMD, body composition and vitamin D status in 
South African women with and without HIV infection, prior to a planned longitudinal study of this 
cohort to chart the changes in these outcomes over time. We hypothesised that HIV-positive women 
with low CD4 counts, below the threshold that would make them eligible for ARV treatment, would 
have lower bone mass, less fat and muscle mass and inferior vitamin D status than HIV-positive 
women with preserved CD4 counts and HIV-negative women in South Africa. 
Methods: 
Subjects: 
Urban, black, premenopausal, South African women (n=247) were recruited from clinics in Soweto, 
Greater Johannesburg, and enrolled into the study between February and July 2010. Subjects were 
recruited from a Voluntary Counselling and Testing (VCT) clinic and local health clinics. The aim was 
to recruit 95 HIV-negative and 73 (+/-10) in each of two HIV-positive groups (with or without -low CD4 
counts). This sample size was based on calculations for the longitudinal study to detect a 2% change 
in lumbar spine BMD, allowing for a between-individual coefficient of variation in BMD of 5%, with 
95% confidence and 80% power. For the study presented here, this sample size was sufficient for a 
comparison of three groups to allow the detection of mean differences between each pair of groups of 
around 0.4 SD at 5% significance and 80% power. The study was approved by the University of the 
Witwatersrand Human Research Ethics Committee (HREC Number: M101525) and the Gauteng 
Department of Health. 
Eligible subjects were adult females (defined as aged greater than 18 years) and premenopausal 
(defined as regular menses). Other inclusion criteria included a documented negative HIV-test within 
the last 12 weeks for HIV-negative women and a documented positive HIV-test for all other women. 
Patient-retained clinic records were scrutinised whenever possible to confirm medical history, current 
CD4 count, prior exposure to ARVs and concurrent medication use. Exclusion criteria included 
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conditions associated with abnormal bone metabolism or current use of medication likely to affect 
bone or vitamin D status such as bisphosphonates. Pregnant and lactating women were excluded as 
were those with an acute medical condition. The group with the lowest CD4 count were largely 
recruited after the other groups: May to June and February to April respectively. 
Study posters were displayed in the clinic and training sessions undertaken with clinic staff. Women 
who expressed an interest in the study underwent initial telephone screening, in her language, to 
ensure inclusion and exclusion criteria were met. Prior to enrolment potential subjects completed a 
medical and health related questionnaire to assess past and current health status and medication use 
and to further assess compliance with inclusion and exclusion criteria. Women who remained eligible 
were enrolled in the full study after they had provided written consent. 
The enrolled women consisted of HIV-negative (n=98) and HIV-positive (n=149) subjects. The HIV-
positive women were recruited into two prespecified groups: those with relatively preserved CD4 
counts (>350 xfo6 cells/I), not requiring ARV therapy (non-ARV group) (n=74) and those with low CD4 
counts (in the region of 200 x106 cells/I) requiring ARV initiation (pre-ARV group) (n=75) according to 
the current SA treatment guidelines [20]. HIV-negative status was confirmed using the Determine™ 
rapid HIV-antibody test (Alere San Diego, Inc. San Diego, CA), while HIV-positive status was 
established using a second platform. HIV-positive women were either newly diagnosed or known to 
be HIV-positive, but not on ARVs. All HIV-positive women provided an up-to-date (within 3 months) 
CD4 count prior to ~nrolling into the study. All HIV-positive women received South African standard of 
care with respect to ARV provision and clinical follow up. Women requiring urgent ARV initiation were 
managed in such a way that there would be no delay in ARV initiation if they were to participate in the 
study. 
Women attended the Developmental Pathways for Health Research Unit (DPHRU) facility at the Chris 
Hani Baragwanath Academic Hospital, after an overnight fast and underwent phlebotomy, 
anthropometry, and DXA assessment of bone mass and body composition (BC). After phlebotomy, 
subjects were given breakfast and each received ZAR 50.00 (==US$6.25) for travel expenses. 
Anthropometry: 
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Height was measured to the nearest millimetre using a stadiometer (Holtain, Crosswell, UK). Weight 
was measured to the last 100 g using a digital scale (Tanita, TBF-410 MA Body Composition 
Analyzer, Tanita Corporation of America, Inc., Illinois, USA) with participants wearing light clothing 
and no shoes. BMI was calculated as the participant's weight in kilograms divided by the square of 
their height in metres (kglm2). Underweight, normal, overweight and obese were defined as BMI 
<18.5, 18.5-24.9, 25-29.9, ~30.0 kg/m2 respectively [21]. 
Bone absorptiometry and body composition measurements: 
DXA was performed using an Hologic QDR 4500A dual-energy X-ray absorptiometer (DXA) (Model: 
Discovery W (S/N 71201) software version 12.5:7 Hologic, Inc., Waltham, MA, USA) according to 
standard procedures. Scans were conducted using the automatic scan mode, i.e. 'array', 'fast array' 
or 'slow array', depending on the weight of the subjects . Subjects wore light clothing having removed 
metal objects, jewellery etc. DXA was used to measure bone mineral content (BMC g), bone area 
(BA, cm 2} and areal BMD (g/cm2>, of whole body (WB), total hip (TH}, femoral neck (FN) and lumbar 
spine (LS). The coefficients of variation (CV%) for repeated measurements of the manufacturer's 
phantom were 0.3%; 0.4% and 0.2% for BA, BMC, and BMD respectively. The CV for repeated 
measurement by the DXA operator of the LS and TH BMD were 0.7% and 1.0% respectively. DXA 
scans for WB were analysed using WB less head (WBLH) as many women wore wigs and hair 
weaves that could not be removed prior to scanning. This artificial hair was of similar density to soft 
tissue and therefore could cause measurement artefact. Total fat and lean body mass (g) were also 
measured by DXA. 
Laboratory analysis: 
Blood was collected for 25-hydro~yvitamin D (25(0H)D) analysis, measured by chemi-luminescent 
immunoassay (Liason) kit (DiaSorin Inc., Stillwater, Minnesota, USA). The blood samples were 
allowed to clot for a minimum of 20 minutes at room temperature, and the serum was aliquoted and 
stored at -20°C until analysed. All samples were run in duplicate. The inter-assay CV for low and 
higher 25(0H)D controls was 10% and 9%, respectively, whereas the intra-assay CV was 8% and 6% 
respectively. The DPHRU laboratory participates in the International Vitamin D External Quality 
Assessment Scheme (DEQAS) and holds the certificate of proficiency [22]. 
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Statistical analysis: 
Data were analysed using DataDesk 6.3.1 (Data Description Inc, Ithaca, NY) and summary statistics 
were documented as mean (standard deviation (SD)) or median (interquartile range), depending on 
the distribution. Comparisons were made between the three groups of women using hierarchical 
linear models; ANOVA (or ANCOVA) and Scheffe post hoe tests were used to compare group means 
(standard error (SE)). To consider the possible influence of group differences in bone and body size, 
bone mineral data were adjusted for age, weight, height and bone area, and bone area was adjusted 
for age, weight and height, using ANCOVA [17). Preliminary plots of the relationship between fat 
mass and lean mass in this sample population demonstrated non-linearity. Regression of fat mass on 
lean mass in the HIV-negative control group with data in natural logarithms gave a power exponent 
2.05 ± 0.18 (SE) , indicating that fat mass-to-lean mass2 best described the relationship in this 
population. The exponent was similar when the data from all three groups were included in the model; 
2.07± 0.14. Consequently, a fat mass-to-lean mass2 term was used to describe differences in body 
.,. 
composition between the groups, and logarithmic regression was used to adjust fat mass for lean 
mass in statistical models. BMD SO-scores (SOS) were generated using HIV-negative subjects as 
the reference population (ref) against which the SOS for each individual HIV-positive woman (i) was 
derived as follows: [(BMDi- mean BMDret )/SD,et-1 A p value of :s0.05 was considered to be statistically 
significant. 
Results: 
Subject characteristics (Table 1): 
By design, the mean CD4 count (x 106 cells/I) in the pre-ARV group was significantly lower than that in 
the non-ARV group (412 (91) and 161 (70) respectively, p<0.0001 ). The mode of acquisition of HIV 
infection was via heterosexual transmission in all subjects, only one subject reporting IOU in the past. 
Mean age (SD) was 32.1 (7.2) years with HIV-negative women being significantly but only slightly 
younger than both groups of HIV-positive women. The age ranges were similar in the three groups 
(18-49, 22-48 and 19-47 years in HIV-negative, non-ARV and pre-ARV women respectively). Median 
{IQR) gravidity was 2 (1 ;3) with both HIV-positive groups having a higher median gravidity compared 
to the HIV-negative group. 
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Anthropometry and body composition (Table 1): 
HIV-negative women tended to be shorter than both groups with HIV infection (p=0.06), while HIV 
positive, pre-ARV women were significantly lighter than the other two groups {p<0.05). Median (IQR) 
BMI of the study cohort was 26.1 (22.4; 31) kg/m 2 with BMI in pre-ARV women being significantly 
lower than in HIV-negative and non-ARV women. Combined overweight and obesity represented 
66%, 65% and 44% of subjects in HIV-negative, non-ARV and pre-ARV women respectively , while 
underweight was present in 4%, 1 % and 11 % respectively. 
There were significant differences in fat mass between groups with pre-ARV women having 
significantly lower fat mass than non-ARV women (p:s0.001 ). Although lean mass was also lower in 
pre-ARV compared with non-ARV women (p=0.005) the pre-ARV group had lower fat mass to lean 
mass
2 
ratio than the other two groups (p=0.002). When fully adjusting for lean mass using logarithmic 
regression, the pre-ARV group had significantly lower fat mass for their lean mass than the other two 
groups; such that for each unit of lean mass the pre-ARV group (Group 3) had a mean difference (SE) 
of 21 (5)% less fat than the controls (Group 1 ), p=0.0002, and 16 (5)% less fat than the non-ARV 
group (Group 2), p=0.02. 
Bone measures (Table 2): 
No significant differences in BMD at the TH, FN, LS and WBLH were found, and age and size 
adjustment did not reveal any differences between groups .. When expressed as SO-scores there 
were no significant differences between pre-ARV and non-ARV groups in BMD for any site measured 
(p>0 .05) and all the mean values were within a -0.5 SD of the HIV-negative reference group. In 
addition no significant differences were found in BMC values except at WBLH when fully adjusted for 
age, size and BA (p=0.03). Un.adjusted BA was significantly greater in both groups of HIV-positive 
women than HIV-negative women at some sites but these differences disappeared after adjusting for 
age and size (see supplementary material for BA and BMC data). 
Vitamin D status (Table 1): 
Mean (SD) 25(0H)D for the whole cohort was 60.1 (1 8.4) nmol/1 and there were no significant 
differences between groups {p>0.05). 25(0H)D concentration was <50 nmol/L in 29.6% of 
individuals; with similar proportions in each of the groups in this category (26.5%, 29.7% and 33.3% in 
398 
HIV-negative, non-ARV and pre-ARV respectively). Very few subjects had a 25(0H)D concentration 
<25 nmol/L (1.0%, 2.7% and 5.3% in the three groups respectively), despite the slightly greater 
number of pre-ARV subjects whose blood samples for 25(0H)D measurement were obtained during 
the winter months. 
Discussion: 
The aim of this study was to determine whether South African HIV-positive women with preserved 
CD4 counts differed from those with low CD4 counts making them eligible for ARV and to compare 
each group with HIV-negative women. In this group of urban, South African women, pre-ARV women 
were significantly lighter than HIV-negative and non-ARV subjects and had lower fat mass than 
expected for their lean mass, raising the possibility that women with advancing HIV disease 
preferentially lose fat rather than lean mass. There were no significant differences between groups in 
BMC or BMD at any site before or after adjustment for age, BA, weight and height and the observed 
smaller BA in thlHIV negative women disappeared after adjustment for age, height and weight. 
There was no significant difference in vitamin D status between groups with the majority of subjects 
having a serum concentration >50 nmol/1. 
The assessment of 'optimal' vitamin D status is problematic because varying cut offs are used to 
define sufficiency, insufficiency and deficiency [23]. A concentration below 25 nmol/1 is generally 
recognised as indicating an increased risk of rickets and osteomalacia [24] . The 2010 Institute of 
Medicine (IOM) report considered that a blood 25(0H)D concentration of 20ng/ml (50nmol/l) to be 
sufficient for good bone health in "practically all individuals" [25]. However, it noted that evidence was 
lacking to make a similar statement regarding non-skeletal health. In the context of HIV infection and 
ARV use, the optimal vitamin D status remains undefined because there may be different 
requirements for maximal bone health and immune functioning compared with HIV-negative 
populations. However, in contrast to other reports [4, 26], in our study there were no indications that 
HIV infection was associated with inferior vitamin D status because there were no significant 
differences in vitamin D status between the 3 groups, the distributions of 25(0H)D concentration were 
similar, and vitamin D status appeared to be generally adequate with very few women having a 
concentration <25 nmol/1. 
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Contrary to previous reports [9], we found no significant differences in BMD between either group of 
HIV-positive and HIV-negative women. Full adjustment for bone and body size did not alter these 
results. This lack of any differences is surprising as HIV-positive women with low CD4 counts, 
requiring ARV initiation, were significantly lighter, with lower fat and lean mass, than the other women. 
However, it may reflect the selection criteria for this study because despite recruiting women with low 
CD4 counts, of clinical concern, women with severe clinical disease received immediate ARV therapy 
and were thus excluded from the study. It may also be influenced by the fact that the subjects were 
not intravenous drug users and thus not exposed to the additional effect on BMD that this poses. 
Another limitation may be that the groups were different in terms of duration of hormonal 
contraception use, parity and total duration of lactation, however at the time of the study no women 
were pregnant or lactating. The findings are also limited by the fact that the sample of HIV-positive 
women was likely to be heterogeneous with respect to immune status and duration of infection. 
However, most other studies have also recruited HIV-positive subjects in a similar manner and this is 
unlikely to account for the different findings in our study. 
The rates of combined overweight and obesity of 66% and 65% in HIV-negative and non-ARV 
subjects in this study were greater than the national average in South Africa of 51.5% [27]; even 
women with advanced HIV-disease (pre-ARV group) had a combined overweight and obesity rate of 
44%. It is possible, therefore, that the typically high weight of South African women has a sparing 
effect on bone in those with HIV infection, even with CD4 counts below the threshold for initiation of 
ARV intervention. 
Historically, overweight has been viewed as protective against osteoporotic fracture, although 
evidence is emerging that overweight and obesity may be a risk factor for leg fragility fractures in 
women [28]. In the study population of younger black women in South Africa, there were no significant 
differences in SD-score, expressed relative to the HIV negative group, according to HIV status at any 
site. The effects of HIV and its treatment on fracture risk in South Africa are unknown. 
The lack of difference between the groups which is at variance from previously reported studies may 
be the result of true lack of effect of HIV infection or reflect important differences in bone response to 
HIV between black Africans and Caucasians. The study design in which two distinct groups of HIV-
positive women, based on South African eligibility criteria for ARV-treatment plus the inclusion of a 
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HIV-negative control group strengthens the finding that HIV infection with varying degree of 
immunosuppression does not appear to be driving alterations in BMD or vitamin D status in these 
young, urban women. The high rates of overweight may be masking more dramatic differences in 
BMD and vitamin D in those subjects with advanced clinical HIV-disease not included in this study. 
Further work is required to address the effects of ARV exposure on bone and vitamin D status as well 
as the relative effect of 'traditional' osteoporosis risk factors in this population. The data from this 
study provide an insight into bone health, body composition and vitamin D status in African women 
living with HIV. They challenge our own hypotheses and previously reported differences in BMD and 
vitamin D status in HIV-positive subjects living in developed countries and highlight the importance of 
studying subjects prior to ARV exposure. 
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Table 1. Subject characteristics, anthropometric measurements and vitamin D status as measured by serum 25(0H)D. 
Group 1 Group 2 Group 3 Group effect 
HIV-negative HIV-positive, non-ARV HIV-positive, pre-ARV ANOVA 
n=98 n= 74 n= 75 p 
Age years 30.0 (8.1) 33.5 (6.1)"' 33.4 (6.5) B 0.001 
HIV status Ne.gative Positive Positive 
Current CD4 count x 10° cells/I ND 412(91) 161 (69)E <0.001 Median (IQR) 420 (127;409) 175 (120;165) 
Min NA 240 18 
Max NA 604 275 
Gravidity range 0-5 0-6 0-6 
Median (IQR) 1 (0;2) 2 (2;3) A 2(1;3) 8 
Current hormonal contraceptive use(%) 34 (35.4) 26 (36.6) 25 (33.3) 0.9 
Current smoking(%) 10.2 13.5 8 0.2 
Height(cm) 157.6 (5.9) 159.4(5.9) 159.2 (5.3) 0.06 
Weight(kg) 69.7 (17.0) 72.0 (17.4) 62.3 (15.2) C,F <0.001 
BMI (kg/mi) Median (IQR) 27.3(23.1;31.7) 27.8 (23.3;32.3) 23.5 (20.5;27.Q) D,F Overweight BMI >24.9 kg/m2 , <30 kg/m 2 (%) 
Obese BMI >30 kg/m2 (%) 35 28 28 <0.001 
Underweight BMI <18.5 kg/m2 (%) 30 37 16 4 1 11 
WBLH Fat (kg) 26.1 (11.5) 26.1 (98.3) 19. 7 (92.9) D,E <0.0001 
WBLH Lean (kg) 38.3 (60.8) 39.5 (62.4) 36.4 (48.1) F 0.005 
Fat /lean2 (kg/kg2) 17.32 (4.80) 15.92 (4.56) 14.58 (5.47) B,G 0.002 
25(0H)D (nmol/L) 59.7 (16.5) 59.2 (16.5) 61.6 (22.3) 0.7 
25(0H)D (nmol/L) >50, (%) 73.5 70.3 66.7 
25(0H)D (nmol/L) <50, (%) 26.5 29.7 33.3 
25(0H)D (nmol/L) <25, (%) 1.0 2.7 5.3 
All values are Mean (SO) unless indicated. 25(0H)D, 25 hydroxyvitamin D; ARV, Antiretroviral therapy; cm, centimetres; IQR, interquartile range; kg, 
kilograms; SO, Standard Deviation. # Value multiplied 1 OOO to illustrate the relative differences in kg. 
Letters are used to indicate significance of between-group differences as tested by ANOVA/Scheffe 
A Significantly different from group 1 P s0.01. 
8 Significantly different from group 1 P s0.01. 
c Significantly different from group 1 P SO.OS. 
0 Significantly different from group 1 P s0.001. 
E Sign ificantly different from group 2 P s0.001 
F Significantly different from group 2 P s0.01 
G Significantly different from group 2 P SO.OS. 
Table 2. BMD of the three groups of South Africa women 
BMD g/cm2 
Mean (SO) 
Group 1 Group 2 
HIV-negative HIV-positive, non-ARV 
n=98 n= 74 
Total Hip 1.013(0.131) 0.985 (0.124) 
Femoral Neck 0.930 (0.114) 0.916 (0.125) 
Lumbar Spine 1.018(0.118) 1.021 (0.109) 
WBLH 0.958 (0.079) 0.943 (0.071) 
Group 3 
HIV-positive, pre-ARV 
n= 75 
0.988 (0.125) 
0.923 (0.131) 
1.006 (0.128) 
0.947 (0.080) 
Group 
effect* 
p 
0.3 
0.8 
0.7 
0.4 
ARV, Antiretroviral therapy; BMD, bone mineral density (g/cm2); SO, Standard Deviation; WBLH, whole body less head. 
*Group effect by ANOV A. There were no significant differences between pairs of groups by Scheffe post hoe tests 
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Appendix 8 Original Ethics, sec and Health Department approval letters 
:': 
UNIVERSITY OF THE WITWATERSRAND. JOHANNESBURG 
Division of the Deputy Registrar (Research) 
HUMAN RESEARCH ETHICS COMMITTEE (MEDICAL) 
Rl4/49 Dr Matthew Hamill 
CLEARANCE CERTIFICATE 
PROJECT 
INVESTIGATORS 
DEPARTMENT 
DATE CONSIDERED 
DECISION OF THE COMM1TTEE* 
HIV Vitamin D and Bone Health in South 
African Women (An investigation into changes 
in bone mineral density and vitamin D status in 
black, urban South African HI V positive 
women and HJV negative controls) 
Dr Matthew Hamill. 
Perinatal HIV Research Unit 
29/10/2010 
Approved unconditionally 
Unless otherwise specified this ethical clearance is valid for 5 yean and may be renewed upon 
application. 
29/ 10/2010 
~ ?, ~ 
CHAIRPERSON ----- ------ ----- --~{/gµ_ ______ __ _ 
(Professor PE Cleaton-Jones) 
*Guidelines for written ' informed consent' attached where applicable 
cc: Supervisor : Dr Neil Martinson 
------ ------- -------------
-------------------
DECLARATION OF INVESTIGATOR(S) 
To be completed in duplicate and ONE COPY returned to the Secretary at Room I 0004, 10th Floor, 
Senate House, University _ 
I/We fully understand the conditions under which I am/we are authorized to carry out the abovcmcntioncd 
research and I/we guarantee to ensure compliance with these conditions_ Should any departure to be 
contemplated from the research procedure as approved I/we undertake to resubmit the protocol to the 
Committee_ I agree to a completion of a yearly progress report. 
PLEASE QUOTE THE PROTOCOL NUMBER IN ALL ENQUIRJES __ _ 
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,,,, ... 
FwCom:ilttloo11SCC 
OIClll~!71SC:C: 4b'ltl010 
=-=~==·~1 ~JA. 
--
-
health and 
social development 
~ ~ inl5ocn llewAJpllltf 
GAIJTENG PIO'VINa 
BANK OF USSON BUR.DING 
37 SAUER STREET JHB 
PRIVATE BAG X085 
MARSHALLTOWN 
Tel: (Oll) 3SS 3310 / 3831 / 2467 
Fax: (011) 355 3505 
GAUTENG DEPARTMENT OF HEAL. TH AND SOCIAL DEVELOPMENT 
RESEARCH PROPOSAL EVALUATION FORM 
Researcher Name Dr Matthew Hamill / Prof J Pettifor / Associate Prof S. Norris/ Dr N. Martinson/ 
Associate Prof A. Karstaedt / Dr A. Prentice 
Researcher's contact detl!Hs Matthew.Hamil!@mrc·hnr.~m.ac.u k 
Institution Medical Research Council: Human Nutrition Research 
Researdl Topic HIV, vitamin D and bone health in South African women: An investigation into 
changes in bone mineral density and vitamin D status in blaclc, urban south 
African HIV positive women and HIV negative controls 
Date Received by the Directorate PPR 6m June2011 
Date Received Reviewer 30'" June 2011 
Final Review Date 3~ July2011 
Date Submitted to Director of PPR 4"' July2011 
Research Site(s) Volunteers wlll be retrulted from the Perinatal HIV Research Unit, the adult 
HIV Treatment clinic at Chris Hani Baragwanath Hospital and local 
community clinics In Soweto. 
Type of research Prospective cohort study 
CRITERIA YES NO COMMENTS 
1. Is this research project within the scope of 
the Department of Health key policy X 
priorities/directives? 
2. Content of Research: X 
. Original work 
• New facts, Ideas X 
. Confirmation of uncertain data X 
. Repetition of known data and 
consequently of limited lmpOrtance JC 
. lnsuffident research Information JC 
• Confusion of topics/questions X 
3. Is the title of the research project suitablei' X 
4. Are the objectives of the resea_rch project 
JC 
adequate? 
5. Could the objectives be limited to better X focus on the project's main objective? 
6. Writing style 
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CRITERIA YES NO COMMENTS 
. The text of the proposal Is clear X 
• The nomenclature used is correct X 
• The references used are relevant, 
comprehensive and acairate X 
. The spelling and grammar are correct X 
. The language needs Improvement X 
• The research proposal needs re-
styling and re-writing 
l( 
7. Are the research methods appropriate to X the study? 
8. Is data collection method In line with the X 
study design? 
9. Does the study have ethical approval? If X Wits: Ml0102S yes, name the ethics committee. 
10. Is the definition and measurement of 
variables consistent with the scope of the X 
proposal? 
11. Is the tlme frame of the proposal X 
adeauate to meet the objectives? 
12. Is the method of dissemination of the X It is recommended that the researchers specify how the 
results of the research project stated? results will be shared/ disseminated 
13. Is any possible conflict of Interests 
n/a 
clarified? 
14. Are financial Implications and financial 
support transparent? X 
SUMMARY OF PROPOSAL 
This study will determine the prevalence of and examine factors associated with low bone mineral density (BMO) and 
vitamin O status in urban black South African women. It will measure baseline BMD, 25-hydroxy vitamin O (25 OHO) and 
biocnemlcal markers of bone turnover in 2 groups of HIV+ women; those commencing antiretrovirat therapy (ART) and 
those not requiring ART. These will be compared with data collected from an HIV negative control group. Measurements 
will be repeated.at 12 months. Lifestyle, dietary and physical activity data wilt also be collected. 
The Initial evaluation will be over 12 months lfor the purpose of Matthew Hamilrs PhO programme); volunteers will be Invited for 
further llisits at 2 and 3 years. 
The research is a collaboration between the following partners: 
1. Dr Hammill: conducting PhO research with the Nutrition and Bone Health programme based at MRC Human 
Nutrition Research (HNR), Cambridge UK; 
2. The South African MAC/University of the Witwatersrand Mineral Metabolism Research Unit IMMRU) and the 
University of the Wltwatersrand's Birth to Twenty (Bt20} cohort I Professor John Pettlfor and Or Shane Norris) 
3. Perinatal HIV Research Unit (PHRU) (Or Nell Martinson) for expertise on HIV-Infection. 
Baclcground 
HIV and osteoporosis have been viewed for decades as affecting disparate sections of the world's population, with HIV 
typically seen as a disease of the young and those of reproductive age In Africa and osteoporosis a disease of the elderly in 
the west. Howevl!r this perception is changing. In the last decade there has been a steady increase in interest In HIV 
2 
associated bone disease with an emphasis on osteoporosis and osteopenla. The advent of highly active anti HIV therapy 
(ART) has dramatlcally changed the pro1nosis of HIV disease and seen a ·switch In emphasis from infection to non-
communicable related morbidity. A:i a result there Is a merging of these 2 major global health problems. 
Early studies found no relationship between HIV and loss of bone , but since 2000 there have been numerous reports of low bone 
mineral density (BMO) and HIV disease. In recent years there has been a growing interl!st in the association between HIV Infection 
and reduced vitamin O concentrations with skeletal and non-skeletal ramifications. Most data describing reduced BMD and 
vitamin D In the context of HIV are cross sectional or retrospective and come predomfnantly from white, male populations In 
North America and Europe. The burden of HIV lies squarely In SUb Saharan Africa and it Is in areas of high HIV prevalence that long 
term skeletal sequelae are likely to be of greatest Importance. Furthermore women are tradltlonally at greatest risk of fragfllty 
fractures making a study of black African women even more pertinent. 
To date there is conflicting evidence about the prevalence of bone disease in HIV Infected individuals. The global costs of 
osteoporosis are enormous, and it is also estimated that fracture risk is likely to be particularly prominent in the 
developing world with its adoption of a more westernised lifestyle. There Is a paucity of data on Sub Saharan African 
osteoporosis and associated costs. Estimates for global costs of HIV are also enormous. Combined, these two conditions, 
partlcular1y if svnerglstic, have the potential to pose a huge disease burden to rapidly developing countries such as South 
Africa that have growing communicable and non communicable disease epidemics such as diabetes and HIV. It is possible 
that South Africa will, in the future, develop an epidemic of fragilfty fractures to mirror its HIV epidemic. It is therefore 
possible that there will be overlapping epidemics of HIV Infection and osteoporosis in aging populatlons in SSA. 
Objectives 
The study will investigate whether HIVasS<lciated bone loss and low 2SOHC> are prevalent in black, urban South African 
women and allow quantification of the magnitude of any effects ;md their clinical relevance. 
Nature of the nudy 
This Is a prospective cohort study. It will use subjects who are patients (HIV+) and controls (HIV-) however it is not a 
cllnlcal trial. There will be no intervention component to this study. The study design has 2 distinct elements; the first is a 
12 month follow up period that will allow for data analysis and hypothesis testing within the time constraints of the PhO 
project. Secondly the study design will allow for subjects to be followed up at 2 and 3 years post enrolment to assess 
changes In bone markers, BMD and vitamin D status. This aspect of the design will allow more longitudinal analysis of the 
effects of HIV Infection and ART on bone outcomes. 
METHODS 
Samples/le 
217 subjects will be recruited, consisting of SS HIV-negative control women and 66 In each HIV-positive group (i.e. 132) 
Cases wRJ be split 50:50 into those who start on ART (Group la) and those who will bi! anticipated to remain ART naive 
through the duration of follow up {Group lb). To account for potential drop outs 146 cases and 95 controls (n•24l) wilt be 
recruit~. 
Participants wlll be Black Urban South African adult, premenopausal women from Soweto, Johannesburg and the 
surrounding areas. Volunteers will be approached from various sources. These will include the Perinatal HIV research unlt, 
the adult HIV Treatment clinic at Chris Hani Baragwanath Hospital and local community clinics in Soweto. Health workers 
and potential subjects will be informed that the study will recruit both HIV-negative and HIV-positive women. 
Srudy desfgn 
All subjects will be assessed for eligibility and informed consent taken before enrolment. Enrolment wlll be considered 
complete when the subject undergoes and completes baseline evaluation (I.e. blood sampling. urine sampflng. 
anthropometry measurement, BP, grip strengtn, DXA measurement for bone and body composition). After the ba5ellne 
visit all subjects will be contacted monthly via telephone (or home visit if unavallable on the telephone) to undertake a 
morbidity questionnaire. A mid study visit will take place at 6 months post baseline (blood sampling, dietary evaluation, 
C>XA measurement etc), and the final study visit for the first stage of the study will take place at 12 months post baseline, 
when they will be tested again. All subjects will be Invited to take part Jn a 2 year and 3 yeai (post enrolment) follow up. 
3 
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Volunteers will be asked to attend a further visit at 2 years post baseline, and at this visit will be asked to attend a further 
visit at 3 years (36 months) post baseline. 
REVIEWER'S FINAL CONCLUSION 
The proposed study will contribute towards a better understanding of the possible future challenges associated with having a 
large proportion of the population on ART and Is recommended for approval. 
Recommended/ not recommended 
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Dietary intake and body composition in HIV-positive and 
-negative South African women 
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Abstract 
Objective: The present paper examines dietary intake and body compos1t1on 
in antiretroviral (ARV)-nai:Ve HIV-positive compared with HIV-negative South 
African women, as well as the impact of disease severity on these variables. 
Design: Baseline data from a longitudinal study assessing bone health in HIV-
negative and HIV-positive premenopausal South African women over 18 years of 
age were used. Anthropometry and body composition, measured by dual energy 
X-ray absorptiometry, were analysed together with dietary intake data assessed 
using an interviewer-based quantitative FFQ. 
Setting: Soweto, Johannesburg, South Africa. 
Subjects: Black, urban South African women were divided into three groups: 
(i) HIV-negative (HIV-; n 98); (ii) HIV-positive with preserved CD4 counts (HIV+ 
non-ARV; n 74); and (iii) HIV-positive with low CD4 counts and due to start ARV 
treatment (HIV+ pre-ARV; n 75) . 
Results: The prevalence of overweight and obesity was high in this population 
(59 %) . The HIV+ pre-ARV group was lighter and had a lower BMI than the other 
two groups (a ll P < 0·001). HIV+ pre-ARV women also had lower fat and lean 
masses and percentage body fat than their HIV- and HIV+ non-ARV counter-
parts. After adjustment, there were no differences in macronutrient intakes across 
study groups; however, fat and sugar intakes were high and consumption of 
predominantly refined food items was common overall. 
Conclusion: HIV-associated immunosuppression may be a key determinant of 
body composition in HIV-positive women. However, in populations with high 
obesity prevalence, these differences become evident only at advanced stages 
of infection. 
Keywords 
HIV 
Diet 
Body composition 
Obesity 
The introduction of antiretroviral (ARV) therapy has 
dramatically altered the morbidity profile of HIV-positive 
populations, w ith an increase in prevalence of non-
communicable disease risk factors such as overweight 
and obesity being observed0 ·2). This is of particular 
concern in South Africa where, among adults over 15 years 
of age, 17 ·8 % were estimated to be living with HIV in 2008(3) 
and approximately 45 % were found to be overweight 
o r obese in the 2003 Demographic and Health Survey 
(SADHSi4). 
disorders such as dyslipidaemia and glucose intoleranceC9) _ 
In black South African (SA) women, ARY-associated 
increases in BMI, fat mass, percentage body fat and waist 
circumference, but not in lean body mass or waist:hip 
ratio, have been shown°0). This increase in fa t, as well as 
the proposed tendency towards visceral rather than sub-
cutaneous fat accumulation° 1\ must therefore be further 
explored in this population due to the potential long-term 
negative effects on disease risk and healthc12). 
Although the public health impact of HIV and associated 
non-communicable disease risk is greatest in low- to 
middle-income countries, to date most studies have been 
conducted in high-income countries, on predominantly 
ARY-treated males with low BMf5--S)_ Lipodystrophy, a 
commonly recognized side-effect of certai:n ARV drugs, 
has been linked to visceral fat accumulation and metabolic 
' Corresponding author: Email alison.feeley@gmail.com 
While the evidence , for body composition changes 
associated with ARV drugs contin ues to grow, there is less 
research focusing on the effect of the HIV infection itself. 
Hadigan et at.°3) found that , independent of ARY, HIV-
positive women in the USA demonstrated a higher per-
centage body fat and truncal fat and lower percentage 
lean body mass than HIV-negative controls. In addition, 
other data suggest that HIV-positive patients with higher 
© MRC/ Wits DPHRU, The Unive rsity of the Witwatersrand 2013 I 
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BMI, skinfold thicknesses and insulin concentrations prior 
to ARV initiation may be more likely to develop lipodys-
trophy over 2 years of ARV drug use04) . 
Although HIV-positive status has traditionally been 
associated with low energy intake, most likely as a result 
of reduced appetite05>, SA data show energy intake in 
HIV-positive individuals to be equivalent to, or in excess 
of, that of their HIV-negative counterparts06). However, 
high total and saturated fat intakes, as well as low n-3 
PUFA and fibre intakes, have also been reported in 
HIV-positive populations, which may indicate overall 
poor diet qualit/16-19). This suggests that HIV patients 
may be as affected by the global obesity epidemic as the 
wider population, and that poor diet quality may be a key 
factor in the increasing prevalence of overweight and 
obesity in HIV-positive populations. The majority of these 
studies, however, did not include HIV-negative control 
groups; thereby making the impact of HIV infection itself 
difficult to ascertain. 
In the present paper we examine dietary intake 
and body composition (fat and lean tissue) in ARV-na"ive 
HIV-positive and HIV-negative black urban SA women. 
In addition, we explore whether the relationships 
between HIV inJection , body composition and dietary 
variables are influenced by differences in disease severity 
by comparing affected women with low and relatively 
preserved CD4 counts. 
Methods 
Participants 
The present study was a baseline dietary intake and body 
composition analysis of HIV-negative and HIV-positive 
black women participating in a longitudinal assessment of 
bone health in urban South Africa. The aim was to recruit 
ninety-five (±5) HIV-negative and seventy-three (±10) in 
each of the two HIV-positive groups. This sample size 
was based on calculations for the longitudinal study to 
detect a 2 % change in lumbar spine bone mineral density, 
allowing for a between-individual CV in bone mineral 
density of 5 %, with 95 % confidence and 80 % power. 
Inclusion criteria required women to be over 18 years of 
age; premenopausal; not pregnant or not planning to 
become pregnant for at least 12 months of the follow-up; 
and, if HIV positive , not yet using ARV and free from any 
current AIDS-related illness as defined by the WHO or the 
US Centers for Disease Control and Prevention. Two 
hundred and forty-seven women in total , HIV-positive 
(HIV\ n 149) and HIV-negative (HIV-; n 98), were 
recruited at Chris Hani Baragwanath Academic Hospital 
in Soweto, through contact with either the 'ZAZI' voluntary 
counselling and testing centre or the hospital's HN clinic. 
Participants were divided as follows: (i) HN-negative 
(group 1; HN- , n 98); (ii) HN-positive with preserved CD4 
counts (2:350 X 106 cells/I), not eligible for ARV therapy 
SV Wrottesley et al. 
(group 2; HIV+ non-ARV, n 74); and (iii) HIV-positive 
with low CD4 counts (:5200 X 106 cells/ I), eligible 
for ARV therapy and due to start ARV (group 3; HIV+ 
pre-ARV, n 75). 
Anthropometry 
Weight was measured to the nearest 0·1 kg using a digital 
scale (Scales 2000, Durban, South Africa) and height was 
measured to the nearest 1 mm using a wall-mounted 
stadiometer (Holtain, Crymych, UK) and with the partici-
pant's head in the Frankfort horizontal plane. These 
measurements were used to calculate the BMI (weight 
(kg) divided by the square of height (m2)) of each partici-
pant. Underweight, normal weight, overweight and obese 
were defined as BMI < 18·5 kg/m2, BMI = 18·5-24·9 kg/m2, 
BMI = 25·0-29·9 kg/m2 and BMI 2: 30·0 kg/m2, respect-
ively. Waist circumference, taken approximately half-way 
between the iliac crest and the lowest rib, and hip 
circumference, taken at the maximum circumference 
around the hips, were measured using a non-stretchable 
measuring tape to the nearest 1 cm. All measurements 
were carried out by trained investigators using standar-
dised procedures and participants wore minimal clothing 
and no shoes while measurements were taken. 
Body composition 
Dual energy X-ray absorptiometry (DXA) scans were 
performed according to standard procedures using a · 
Hologic QDR 4500A dual-energy X-ray absorptiometer 
(software version 12·5:7; Hologic Inc. , Bedford, MA, 
USA). Whole-body fat and lean mass were analysed as 
whole body less head (WBLH) because many of the 
women wore wigs and hair weaves, which could have 
affected the DXA measurements in the head region. 
These data have been published by Hamill et at.<20) _ 
Trunk and limb (arms and legs) fat masses were derived 
from DXA scans. Percentage fat mass for WBLH, as well 
as for the trunk and limbs as percentages of WBLH fat 
mass, were calculated. To compare body fat distribution 
between the groups, trunk:limb fat mass was determined. 
Fat mass:lean mass2 was also calculated as this was shown 
to best describe the relationship between fat and lean 
mass in this population<20). 
Dietary intake 
The dietary assessment tool used in the present study was 
an interviewer-conducted quantitative FFQ developed for 
use in South Africa. The questionnaire took on average 40 
min to complete and included a total of 214 commonly 
eaten foods. These food items were derived from ana-
lyses of eleven dietary surveys conducted in rural and 
urban South Africa since 1983, and the list includes all 
foods eaten by at least 3 % of the population <20 The FFQ 
was extensively piloted on SA adolescents from the Birth 
to Twenty cohort at both 15 years (interviewing both 
adolescents and their primary caregivers, n 150<22)) and 
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17 years of age (n 1700 (AB Feeley, unpublished results)) , 
as well as on adult research assistants during training, and 
modified accordingly. 
To cater for illiteracy in the SA population, the FFQ 
utilises food flash cards (high-quality photographs) of the 
food items<23)_ Data were collected on the previous 
week's (7 d) dietary intake, including convenience food 
products, in order to estimate habitual intake for each 
participant. Participants were asked to separate the food 
flash cards into a series of piles. First, they went through 
each food card and created a pile of food items they 
'rarely/ never' eat or drink. Thereafter, they went through 
the remaining food cards and created a pile of food items 
they eat/drink less frequently ('occasional'), and a pile 
they eat regularly and in the past 7 d. The participant was 
then prompted for information on the frequency and 
amounts of the food items consumed regularly in her diet, 
the details of which were recorded on the FFQ. Portion 
sizes were estimated using household measures and a 
combination of two-dimensional life-size drawings of 
foods and utensils and three-dimensional food models as 
described and validated by Steyn et at.<24)_ Items eaten 
occasionally or rarely/never were also recorded. 
Coding involved the conversion of the household 
measures (e.g. one cup/one serving spoon/one slice) to 
grams so that an average intake over the previous 7 d 
could be calculated. Nutrient composition (energy and 
macronutrients) was estimated using FoodFinder3, a 
nutrient analysis software program based on the SA 
Medical Research Council food composition tables<2s)_ 
Quality control for dietary data acquisition was under-
taken by extensive and repeated training of interviewers, 
reviewing the questionnaires for missing or spurious data, 
questioning participants on ambiguous answers and spot-
checking questionnaires by a second interviewer (usually 
the senior nutritionist). The plausibility of the reported 
energy intake data was assessed according to study-specific 
cut-offs as described by Goldberg et at.<26) and Black<27J_ 
The US Dietary Reference Intakes<2B) for energy and 
macronutrients were selected for assessing the intakes of 
the study groups compared with recommendations, as 
these are most commonly used in South Africa and the 
most useful for comparison with other published data. 
Nutrient intakes were therefore compared with the Estimated 
Energy Requirement, the RDA for protein and carbohydrate 
and the Adequate Intake for fibre in adult women 
aged 19-50 years. The median intakes for carbohydrate, 
protein and fat as proportions of total energy intake 
were calculated and compared with the Acceptable 
Macronutrient Distribution Ranges. 
Variation in the food items consumed between study 
groups was assessed by comparing the twenty most 
commonly consumed items, as well as their respective 
food groups. The top twenty reported food items were 
ranked from the most to the least consumed according to 
the mean intake reported in grams per day. 
3 
Socio-economic status and education 
Socio-economic status (SES) was assessed using an 
asset index similar to that used by McVeigh et at.<29)_ This 
scored each participant according to the number of 
household assets she possessed out of a possible twelve 
(electricity, television, radio, motor vehicle, fridge, 
washing machine , telephone, video machine, microwave, 
MNET television channel, DSTV satellite television, cellular 
telephone). An asset score percentage was then calculated 
for each participant ((number of recorded household 
assets/12) X 100). 
Level of education was assessed according to the 
number of years completed at primary, secondary or 
tertiary level. 
Ethics 
The study was approved by the University of the Wit-
watersrand Human Research Ethics Committee (HREC 
Number: M101525) and the Gauteng Department of 
Health. Individuals gave written consent prior to enrol-
ment into the study. 
Statistical analysis 
Data were analysed using the statistical software package 
STATA 11 ·0. Where 'inaccurate reporters' were identified, 
dietary data were truncated using Goldberg cut-offs 
so that energy and macronutrient intakes represented 
the lowest or highest plausible intake for under- or 
over-reporters, respectively, according to body size. 
Continuous variables for participant characteristics, as 
well as anthropometric and body composition measure-
ments and dietary intake, were not normally distributed 
and were therefore summarised using the median and 
interquartile range. Education level and BMI categories 
were summarised as percentage in each group. Con-
tinuous and categorical variables for participant char-
acteristics were compared between the three study 
groups using the Kruskal-Wallis test for non-parametric 
data and the x2 test, respectively. Age was found to be 
significantly different between groups; therefore all 
subsequent analyses were adjusted for age. Regression 
analyses were performed to compare differences in 
anthropometric and body composition variables between 
the HIV- group and the HIV+ non-ARV and HIV+ pre-
ARV groups combined. Between-group comparisons 
were then made using multiple linear regression models 
with dummy variables created to distinguish between the 
HIV+ groups. These methods were repeated for analysis 
of dietary intake data; however, in addition to age-
adjusted analyses, subsequent regression analyses were 
controlled for both age and total energy intake in order to 
;:idjust for the dietary variation attributed to differences in 
body size between groups. Finally, multiple regression 
models were used to explore whether any of the variables 
found to differ between groups were independent 
predictors of anthropometric and body composition 
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differences. Where appropriate, hypotheses were con-
ducted using Bonferonni-adjusted a levels of 0·016 per 
test (0·05/3). 
Results 
Table 1 summarises the participant characteristics and 
anthropometric variables for the three study groups 
(previously described, in part, by Hamill et a/_czo>-y _ The 
HIV+ pre-ARV group had a significantly lower median 
CD4 count (175 X 106 cells/I) than the HIV+ non-ARV 
group (420 X 106 cells/I) as a result of the study design 
(P< 0·001). Both SES score and level of education were 
similar across all groups. The HIV+ pre-ARV group had 
significantly lower body weight, BMI and waist and hip 
circumference than the other groups (most P< 0·001). 
The prevalence of overweight and obesity was high in the 
whole sample, with 59 % of women being overweight or 
obese. There was a significant difference in the distribu-
tion of participants across BMI categories between the 
groups, with the HIV+ pre-ARV group having significantly 
fewer obese individuals (16%) than both the HIV- (30%; 
P= 0·01) and m y + non-ARV (37%; P= 0·01) groups. 
The HIV+ pre-ARV group also had a higher underweight 
prevalence (11 %; P< 0·01), approximately three- and 
eleven-fold higher than the HIV- and HIV+ non-ARV 
groups, respectively. 
There was a significant difference in fat mass between 
the groups, with the HIV+ pre-ARV group having lower 
total (P< 0·001), trunk (P< 0·001) and limb fat masses 
(P< 0·001), and percentage body fat (P< 0·001), than 
the other two groups (Table 2) . However, when expres-
sed as a percentage of whole-body fat mass, trunk and 
limb fat percentages were no longer different between 
the groups. The HIV+ pre-ARV group had lower fat 
mass:lean mass2 than the other two groups; however, 
trunk:limb fat mass w; s not different between the groups. 
Correlations confirmed the relationship between CD4 count 
and fat mass (r= 0·273; P= 0·019) and CD4 count and lean 
mass (r= 0·299; P= 0·05) . 
Table 3 presents the results of multiple regression 
analyses for BMI, WBLH fat mass and lean mass, trunk fat 
mass and limb fat mass. Only the variables which con-
tributed significantly to the models are presented. The 
overall models explain 14 % of the variance in both BMI 
and WBLH fat mass, 34 % of the variance in WBLH lean 
mass and 13 % of the variance in both trunk and limb fat 
masses. Age and being in the HIV+ pre-ARV group 
significantly contributed to the models for BMI, WBLH fat 
mass and trunk fat mass (all P< 0·001), with HIV+ pre-
ARV group status being associated with an approximately 
4·5 kg/m2 decrease in BMI, an 8 kg decrease in WBLH fat 
mass and a 3·5 kg decrease in trunk fat mass. Age, height 
and being in the HIV+ pre-ARV group were significant 
contributors to the variation in both WBLH lean mass 
SY Wrottesley et al. 
(all P< 0·001) and limb fat mass (P= 0·004, P= 0·042 
and P< 0·001, respectively) , with an approximately 3 kg 
lower lean mass and 4 kg lower limb fat mass being 
associated with HIV+ pre-ARV group status. 
The daily energy and macronutrient intakes are 
presented in Table 4. None of the components of dietary 
intake were different between HIV- and HIV+ partici-
pants, with the exception of total protein and animal 
protein intakes which were significantly lower in the 
HIV- than the HIV+ individuals (P= 0·023 and P= 0·015, 
respectively) . However, when adjusted for total energy 
intake, the differences in total and animal protein intake 
were no longer significant. Between-group analyses 
similarly found no differences between HIV-, HIV+ non-
ARV and HIV+ pre-ARV groups in any of the dietary 
intake variables. Dietary intake exceeded the Estimated 
Energy Requirement, the RDA for carbohydrate and 
protein, as well as the Adequate Intake for fibre across all 
three study groups. 
Carbohydrate, protein, fat and fibre accounted for 
approximately 54%, 11 %, 30% and 4%, respectively, of 
total energy intake across all three groups (data not shown) . 
Intakes, as percentages of total energy intake, were there-
fore within the Acceptable Macronutrient Distribution 
Ranges for carbohydrate ( 45--65 %), protein (10-35 %) and 
fat (20-35 %) for all groups. Approximately 8 %, 5 % and 
21 % of participants in the sample had carbohydrate, fat 
and protein intakes, respectively, below the acceptable 
range, while 5 % and 19 % had carbohydrate and fat intakes, 
respectively, above the acceptable range. Alcohol accoun-
ted for less than 1 % of total energy intake in all groups. 
The twenty most commonly consumed food items and 
their respective food groups are shown in Table 5. Data 
are presented for the whole sample due to the lack of 
differences seen in the food items consumed between 
study groups. The HIV+ pre-ARV group consumed the 
highest amount of food mass from the top twenty items 
(1176g/d) compared with the HIV- and HIV+ non-ARV 
groups (929 and 1142 g/d, respectively). The most com-
monly consumed food item was maize meal (made into 
a stiff porridge/ pap') at a mean intake of 258 g/d. The 
most commonly recorded food group was cereal and 
cereal products (featured four times in the top twenty), 
with most cereal products being highly refined 'white 
carbohydrate'. Fruit and vegetables both featured twice; 
however, the vegetable component included French fries 
which are high in fat (usually sunflower oil). Sugar con-
sumption was high overall, with granulated white sugar 
being the most frequently recorded food item in the 
sample (reported 533 times at an average of 15 g/ d) and 
sweetened carbonated drinks being ranked second 
with a mean consumption of 197 g/ d and equating to 
approximately 340 kJ of energy daily. Meat and meat 
products featured three times in the top twenty food 
items; however, the cuts of meat tended to be highly 
processed and fried in sunflower oil (e.g. polony and 
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Table 1 Participant characteristics and anthropometric variables according to study group: premenopausal black women, Soweto, Johannesburg, South Africa 
HIV- (n 98) HIV+ non-ARV (n 74) HIV+ pre-ARV (n 75) 
(1) (2) (3) 
Variable Median IQR Median IQR Median IQR P, HIV- v. HIV+ 
Between-group 
comparison 
Age (years) 28 23-37 33 29-37 33 28-39 <0·001t (1) V. (2) 
(1) V. (3) 
Current CD4 count (X 1 o• cellsA) (2) V. (3) ND 420 345-472 175 105-226 NA (2) V. (3) 
SES (n 217) 
SES score (%) 66·67 58·33-83·33 66·67 58·33-83·33 66·67 50·0D-75·00 0·207t 
Education (%) (n 220) 
Primary 2·4 4·1 6·1 
Secondary 91·5 93·2 90·8 0·206* 
Tertiary 6·1 2·7 3·1 
Anthropometry 
Weight (kg) 67·1 56·8-78·3 69·75 59·6-82·8 61 ·4 50·9-68·6 0·033 (1) V. (2) 
(1) V. (3) 
Height (m) 1·58 1·54-1·62 1·59 1·56-1·62 
(2) V. (3) 
1·59 1 ·55-1·63 0·015 (1) V. (2) 
(1) V. (3) 
BMI (kg/m2 ) 27·3 23·1-31·7 27·8 23·3-32·3 
(2) V. (3) 
23·5 20·4-27·0 < 0·002 (1) V. (2) 
(1) V. (3) 
Overweight (%) 35 28 
(2) V. (3) 
28 
Obese(%) 30 37 16 <0·01* 
Underweight (%) 4 1 11 
Waist circumference (cm) 86 76-94 86 79-99 81 73-88 0·251 (1) V. (2) 
(1) V. (3) 
Hip circumference (cm) 106·0 97-113 106·5 98-116 
(2) V. (3) 
96·5 9D-106 < 0·001 (1) V. (2) 
(1) V. (3) 
(2) V. (3) 
ARV, antiretroviral : IQR, interquartile range; SES, socio-economic status; ND, not determined; NA, not applicable. 
Data are presented as median and interquartile range unless otherwise indicated. 
*Multiple regression analysis adjusted for age, P < 0·05 indicates significance. 
tKruskal-Wams lest, P < 0·05 indicates significance. 
;/ test, P < 0·05 indicates significance. 
,,. 
<0·001 
<0·002 
0·92 
<0·001 
0·945 
<0·001 
<0·001 
0·029 
0·05 
0·822 
0·479 
<0·001 
<0·001 
0·517 
0·009 
<0·002 
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<0·001 
< 0·001 
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Table 2 Body composition vari ables according to study group: premenopausal black women, Soweto, Johannesburg, South Africa 
HIV- (n97) HIV+ non-ARV (n 74) 
(1) (2) 
DXA (n 245) Median IQR Median IQR 
WBLH fat mass (kg) 24-45 17-35---30·57 25·31 18-06---32-88 
WBLH lean mass (kg) I 37·68 34-21--41 ·28 39·67 34-86--42·26 
Percentage body fat 39·55 34·07--43·22 39·50 33-06---44·67 
Fat mass:lean mass2 (kg/kg2) 17·19 13-76---20-38 15·92 13-36---19-85 
Trunk fat mass (kg) 9·72 6·66---13·56 11 ·38 7-39--15·28 
Percentage trunk fat 41·56 37-67--45-65 42·85 38· 54--46·38 
Limb fat mass (kg) 14-00 10·32-16·70 13-97 10·74--17·93 
Percentage limb fat 58·44 54-35---62-33 57·15 53-62--61 ·46 
Trunk:limb fat mass 0·71 0·60---0·84 0·75 0 ·63--0·86 
OXA, dual energy X-ray absorptiome11)'; AAV, antiretroviral; IQA, interquartile range, WBLH, whole body less head. 
"Multiple regression analysis adjusted for age, P < 0·05 indicates significance. 
tNon-significant due to Bonferroni adjustment. 
HIV+ pre-ARV (n 74) 
(3) 
Median IQR 
18·43 12-45---25·32 
36·18 33·56---39·84 
32·24 26-79--41 ·21 
13·84 10·15---18 ·88 
7-48 4-64-11·81 
40-92 35-75--47·07 
10-75 7·32-14·15 
59·08 52-93--64·25 
0·69 0·56---0·89 
Between-group 
P', HIV- v. HIV+ comparison 
0·002 (1) V. (2) 
(1) V. (3) 
(2) V. (3) 
0·201 (1) V. (2) 
(1) V. (3) 
(2) V. (3) 
< 0·001 (1) V. (2) 
(1) V. (3) 
(2) V. (3) 
. < 0·003 (1) V. (2) 
(1) V. (3) 
(2) V. (3) 
0-007 (1) V. (2) 
(1) V. (3) 
(2) V. (3) 
0·717 (1) V. (2) 
(1) V. (3) 
(2) V. (3) 
< 0-001 (1) V. (2) 
(1) V. (3) 
(2) V. (3) 
0-717 (1) V. (2) 
(1) V. (3) 
(2) V. (3) 
0·907 (1) V. (2) 
(1) V. (3) 
(2) V. (3) 
,,. 
0-458 
< 0·001 
< 0·001 
0·512 
0·005 
0-001 
0·372 
< 0·001 
< 0·001 
0·181 
< 0 ·001 
0·021t 
0·592 
< 0·001 
< 0·001 
0·602 
0·259 
0·117 
0·375 
< 0 ·001 
< 0·001 
0·602 
0-259 
0·117 
0-567 
0-445 
0·204 
. 
..c. 
...., 
~ (I) 
I 
u 
..0 
::::, 
a.. 
HIV, diet and body composition in South African women 7 
Table 3 Multiple regression analyses for BMI, WBLH fat mass, WBLH lean mass, trunk fat mass and limb fat mass: premenopausal black 
women, Soweto, Johannesburg, South Africa 
/3 95%CI p 
BMI (kg/m2) 
Age 0·257 0·146, 0·367 < 0·001 
HIV- (ref.) 0 Ff- 0·14 
HIV+ non-ARV 
-0·691 -2·610, 1 ·227 0·479 Adjusted Ff 0·13 
HIV+ pre-ARV - 4·487 - 6·394, -2·575 < 0·001 p < 0·001 
WBLH fat mass (kg) 
Age 0·347 0·1 66, 0·527 < 0·001 
HIV- (ref.) 0 Ff- 0·137 
HIV+ non-ARV -1 ·614 -4-767, 1 ·539 0·314 Adjusted Ff- 0·123 
HIV+ pre-ARV -7·884 -11·014, -4-753 < 0·001 p < 0·001 
WBLH lean mass (kg) 
Age 0·214 0·128, 0·300 < 0·001 
Height 50-826 40·207, 61 ·445 < 0·001 
HIV- (ref.) 0 Ff- 0·342 
HIV+ non-ARV -0·439 -1 ·949, 1 ·070 0·567 Adjusted Ff- 0·331 
HIV+ pre-ARV -3·411 -4-910, -1 ·912 < 0·001 p < 0·001 
Trunk fat mass (kg) 
Age 0·208 0·116, 0·300 < 0·001 
HIV- (ref.) 0 Ff- 0·134 
HIV+ non-ARV -0-621 -2-232, 0·990 0-448 Adjusted Ff- 0·12 
HIV+ pre-ARV -3-521 -5-121 , -1 ·921 < 0·001 p < 0·001 
limb fat mass (kg) 
Age 0·139 0·043, 0·234 0·004 
Height 12·128 0·417, 23·84 0·042 
HIV- (ref.) 0 Ff- 0·129 
HIV+ non-ARV 0·993 -2·658, 0·672 0·241 Adjusted Ff- 0·114 
HIV+ pre-ARV -4·362 -6·016, -2·710 < 0·001 p < 0·001 
WBLH, whole body less head; ref., reference category; ARV, antiretroviral. 
All variables included in the above models were those which showed significance in prior analyses, P< 0·05. 
battered fried chicken). In addition, fish did not feature in 
the top twenty food items. Use of fats and oils was very 
common, with brick/hard margarine and sunflower oil 
being the regularly reported products (13 g/d and 6 g/d, 
respectively). Condiments, high in fat and/ or sugar, were 
regularly added to meals and snacks, with both atchar (a 
spicy condiment of mangoes and honey, 19 g/ d) and 
tomato sauce (10 g/d) featuring in the top twenty food 
items consumed. 
Discussion 
In this sample of black, urban, SA women, HIV-positive 
individuals had lower weight and BMI, as well as lower fat 
and lean masses and percentage body fat, than their HIV-
negative counterparts. This was primarily as a result of the 
HIV-positive individuals with low CD4 counts having low 
measures. Multiple regression analyses showed that HIV+ 
pre-ARY status, but not HIV+ non-ARY status, was a key 
contributor to differences in WBLH fat mass and WBLH lean 
mass, as well as both trunk and limb fat masses; associated 
with 8 kg and 3 kg less fat and lean mass, respectively, as 
well as 3·5 kg less trunk fat and 4 kg less limb fat. This 
challenges the stereotypical view of HIV as a disease asso-
ciated with involuntary weight loss and wasting prior to ARY 
initiation and suggests that weight loss may- only become a 
symptom in this population at more severe disease states . 
Although WBLH fat mass, as well as trunk and limb fat 
masses, were lower in the HIV+ pre-ARY group than the 
other study groups, there were no differences in relative 
terms (trunk and limb fat percentages) across all groups. 
This, together with the similarity found in trunk:limb 
fat mass between study groups, suggests lower body fat 
across all sites rather than an altered fat distribution with 
advanced HIV infection. This contradicts previous US data 
which showed an increase in both percentage trunk fat 
and trunk:limb fat and a decrease in peripheral fat inde-
pendent of ARY treatment in HIV-positive women com-
pared with HIV-negative controls03). In addition, it 
suggests a different pattern of fat loss than that associated 
with ARY treatment, where lipodystrophy is characterised 
by abdominal fat accumulation and subcutaneous fat 
loss, predominantly at the face , limbs and buttocksc3o)_ 
This is speculative, however, and a longitudinal study is 
currently being undertaken in this population which it is 
hoped will provide more definitive answers. 
As previously documented by Hamill et al.(20) , the 
HIV+ pre-ARY group , had a lower fat mass:lean mass2 
than the other two study groups, demonstrating 
approximately 21 % and 16% less fat for each kilogram of 
lean mass than the HIV- and HIV+ non-ARY groups, 
respectively. This provides evidence of lower fat mass, 
rather than lean tissue, at more advanced stages of HIV 
infection. Although previous literature has found HIV to 
be associated with preferential loss of lean compared 
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with fat tissue, particularly in male subjects, a dis-
proportionately higher loss of fat mass has been shown in 
US womenc3n_ In addition, a preferential loss of fat rather 
than lean tissue mass has been demonstrated in males 
with high body fat percentages at baseline, compared 
with those having less than 15 % body fa{32). 
Overweight and obesity were common in the sample 
overall , with a combined prevalence of 59 %, a prevalence 
higher than the national estimate of 55 % reported for black 
women in the 2003 SADHSC4)_ Although the distribution of 
women across BMI cut-offs differed significantly between 
the HIV+ pre-ARY group and the other two study groups, 
there was still a 44 % prevalence of overweight and obesity 
in this group, while another 11 % were classified as under-
weight. Even at more advanced stages of HIV infection, 
women are affected by obesity and this needs to be 
addressed in the population as a whole. 
There were no reported differences in dietary intake 
across study groups, with the exception of total and animal 
protein intakes which were lower in the HIV- group than in 
the HIV+ groups combined. However, when adjusted for 
age and total energy intake, these differences were no 
longer significant. There was no relationship between pro-
tein intake and SES (P= 0·202). These results also highlight 
that all groups, including the pre-ARY therapy group with 
lower median BMI, consume an obesogenic diet. Given the 
high levels of inflammation and high carbohydrate intake, 
these participants are likely to have a high prevalence of 
insulin resistance and other metabolic abnormalities. These 
are areas for potential futu re research. 
Food item and food group analyses showed similar 
consistency of consumption across the groups, regardless 
of HIV status. The main contributor to the variation in 
food mass consumed between the three groups seemed 
to be 'pap' (maize meal porridge), which differed by 
approximately 135 gld between the HIV+ pre-ARV group 
and the HIV- group and approximately 92 gld between 
the HIV+ pre-ARY group and the HIV+ non-ARY group. 
Diets in the sample as a whole were very high in refined 
carbohydrate, which is reflected by the high total diges-
tible carbohydrate intake (approximately three-fold 
higher than the RDA of 130 gld). Consumption of pro-
cessed and fast-food products was common and that of 
fruits and vegetables rare, with the vegetable items con-
sumed (e.g. tomato and onion stew) usually containing 
added sugar and/ or fat. In addition to added sugar 
intakes, high sugar-based products were also common; 
with carbonated soft drinks featuring second in the top 
twenty food items consumed. This is a concern due to the 
link seen between sugar-sweetened beverage intake and 
weight gain, as well as diabetes and CVD riskc33.34)_ The 
lack of fish , and therefore n-3 PUFA, in the top twenty 
reported food items should also be addressed due to the 
important role that these essential fatty acids have in 
regulating immune function<35)_ The highly processed 
nature of food products, as well as high sugar and fat and 
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Table 5 Top twenty food items consumed in the sample of premenopausal black women, Soweto, Johannesburg, South Africa 
1. 
2. 
3. 
4. 
5. 
6 . 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
16. 
17. 
18. 
19. 
20 . 
Food item 
Maize meal porridge (cooked stiff/'pap') 
Carbonated cold drink (e.g. Coca Cola) 
Brown bread/rolls 
Full fat milk 
White bread/rolls 
White rice 
Banana 
Apple 
French fries 
Tomato and onion (stewed) 
Chicken, dark meat (fried/roasted) 
Atchar (mango and honey) 
Granulated white sugar 
Brick/hard margarine 
Tomato sauce 
Batter dipped fried chicken (e.g. KFC) 
Cheddar cheese 
Polony 
Sweets (hard boiled/soft jelly type) 
Sunflower oil 
Food group* 
Cereal and cereal products 
Sugar, syrups and sweets 
Cereal and cereal products 
Milk and milk products 
Cereal and cereal products 
Cereal and cereal products 
Fruit 
Fruit 
Vegetables 
Vegetables 
Meat and meat products 
Sauces, seasonings and flavourings 
Sugar, syrups and sweets 
Fats and oils 
Sauces, seasonings and flavourings 
Meat and meat products 
Milk and milk products 
Meat and meat products 
Sugar, syrups and sweets 
Fats and oils 
Mean intake (g/d) 
258 
197 
121 
84 
69 
72 
53 
46 
34 
22 
20 
19 
15 
13 
10 
9 
8 
7 
6 
6 
*Food items grouped according to the current South African Medical Research Council food composition tables<37l. 
low vegetable consumption in the sample is an important 
health issue and highlights the urgent need to address 
obesity and its risk factors throughout the population. 
Although providing an overall picture of habitual 
energy and macronutrient intakes, as well as of com-
monly consumed food items, the dietary data had certain 
limitations. The proportion of women classified as 'under-
reporters' was very high (31 %, data not shown), sug-
gesting that a substantial number were underestimating 
their consumption. This may have been due to the high 
prevalence of overweight and obesity in the sample, as 
high BMI has previously been shown to predict under-
reporting<36). Due to the negative impact that excluding 
these participants would have had on sample size, trun-
cation was therefore chosen as the best possible method 
of minimising the effects of under-reporting on study 
results. Classification of food items based on the SA food 
composition table was also flawed as it misclassified items 
such as French fries into the vegetable group , thereby 
overestimating vegetable consumption in the sample . 
This classification should be revised in the future to 
ensure that vegetables high in starch with added fat are 
more accurately categorised. 
A key limitation of the study was that the participants 
were not a random sample of the adult female population 
of Soweto and the surrounding area, as inclusion in the 
study required the women to present at the Chris Hani 
Baragwanath Hospital 's Perinatal HIV Research Unit, HIV 
clinic, or voluntary counselling and testing centre. 
Women must, therefore, both know that the services exist 
and have access to them, must be healthy enough to 
present at the hospital , and must have sufficient infor-
mation on HIV and its risks to be motivated to seek 
counselling or care. This could mean that the HIV-posi-
tive and HIV-negative participants included in the study 
are not a truly representative sample and may also have 
better knowledge of poor dietary practices and other 
health risks than the wider population. 
Regardless of these weaknesses, the present paper 
provides unique data on diet and body composition dif-
ferences between HIV-negative and HIV-positive women 
at varying levels of immunosuppression prior to treat-
ment. In addition, the longitudinal design of the broader 
study will allow for future analysis of the changes in 
anthropometric, body composition and dietary variables 
in this population at 6 months, 12 months and 24 months 
fo llow-up. 
Conclusion 
Our data show that immunosuppression may be a pre-
dictor of anthropometric and body composition changes 
in HIV-positive women and that, in populations with high 
obesity prevalence, these differences become evident 
only at advanced stages of infection. This highlights the 
need for a change in the way diet and body composition 
are viewed in HIV-positive patients, while emphasising 
that poor dietary habits should be addressed in the SA 
female , urban population as a whole. 
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Abstract 
Summary This is the first report examining vitamin D status 
and bone mass in Afiican women with HIV infection using 
dual-energy X-ray absorptiometry (DXA) with an appropriate 
HIV-negative control group. Unlike previous publications, it 
demonstrates no difference in bone mineral density (BMD) or 
vitamin D status in HIV-positive patients, at different disease 
stages, vs. HIV-negative subjects. 
Introduction Low bone mass and poor vitamin D status 
have been reported among HIV-positive patients; suggesting 
HIV or its treatment may increase the risk of osteoporosis, a 
particular concern for women in countries with high HIV 
prevalence such as South Africa. We describe bone mass 
and vitamin D status in urban premenopausal South Afiican 
women, who were HIV positive but not on antiretroviral 
therapy (ARV). 
Methods This study is a cross-sectional measurement of 
BMD and body composition by DXA and vitamin D status 
by serum 25-hydroxyvitamin D (25(0H)D) concentration. 
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Subjects were recruited into three groups: HIV negative 
(n=98) and HIV positive with preserved CD4 cell count 
(non-ARV; n=74) or low CD4 cell counts prior to ARV initiation 
(pre-ARV; n=75). 
Results The mean (standard deviation (SD)) age of women was 
32.l (7.2) years. Mean CD4 (SD) counts (x 106/1) were 412 (91) 
and 161 (69) in non-ARVand pre-ARV groups (p<0.0001). Pre-
ARY women were significantly lighter and had lower mean BMI 
than the other two groups (p<0.002). The pre-ARV group also 
had significantly less fat and lean mass compared with non-ARV 
and HIV-negative subjects (p:S0.05). After full adjustment, there 
were no significant differences in BMD at .any site (p>0.05) 
between the groups, nor was vitamin D status significantly 
different between groups (p>0.05); the mean (SD) cohort 
25(0H)D being 60 (18) nmol/1. 
Conclusion Contrary to previous studies, these HIV-positive 
women did not have lower BMD or 25(0H)D concentrations 
than HIV-negative controls, despite the pre-ARV group being 
lighter with lower BMI. 
Keywords Body composition · Bone mineral density · Dual 
energy X-ray absorptiometry · HIV infection · Vitamin D 
Introduction 
HIV infection and the use of antiretroviral (ARV) medication 
have been associated with low bone mineral density (BMD) 
and poor vitamin D status. In a meta-analysis, the prevalence 
of low BMD in HIV-positive individuals was three times 
higher than in HIV-negative controls [1- 3]. Similarly, studies 
have described high prevalence of low 25-hydroxyvitamin D 
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(25(0H)D) concentrations in HIV-positive patients [4]. Some 
studies of the effects of HIV and/or its treatment on bone are 
limited by retrospective design, a preponderance of white, 
male subjects, and lack of HIV-negative controls [5] while 
others are prospective [6] and do include women [7, 8]. Other 
studies are limited by confounding by low body weight or 
other risk factors for low BMD, such as intravenous drug use 
(IDU), exposure to a large variety of ARY regimes and mea-
surement ofBMD and vitamin D status after varying duration 
of ARY exposure [ 6]. The few prospective studies focusing on 
women have also been limited by some of these aspects [6, 9], 
and as a result it is difficult to ascertain with certainty if HIV 
infection and/or its treatment or factors unrelated to HIV 
infection are contributing factors to the low bone mass and 
low vitamin D status described in the current literature. In 
contrast, there are data to suggest that after adjusting for body 
weight, BMD is normal or near normal, and that patients on 
ARY do not have increased rates of bone loss [10, 11 ]. As a 
result, there is not a definitive consensus on the contribution of 
HIV infection or ARY exposure on BMD in infected individuals. 
In South Africa, estimates of HIV prevalence for 20 I O are 
10. 5 % for the total population and 29 .3 % for women attending 
antenatal clinics. ~e epidemic is described as "hyperendemic" 
because of the high prevalence and continuing drivers of trans-
mission [12- 14]. In South Africa, individuals generally become 
eligible for ARY treatment when their CD4 count is less than a 
nationally specified threshold. By 2009, 56 % of those requiring 
ARY were able to receive them, with the government intending 
to increase ARY coverage to 80 % by 2011 [12]. 
Vitamin D has well-known associations with bone health 
via its role in calcium and phosphate homeostasis, and 
vitamin D status is considered an important modulator of 
immune function by some authors [14- 16]. In South Africa, 
adults are largely dependent on the cutaneous synthesis of 
vitamin D to maintain yitamin D status, as only small 
amounts of vitamin D are obtained from the diet due to 
limited food fortification. In Johannesburg (26° S latitude), 
there is sufficient ultraviolet B (UVB) radiation in sunshine 
throughout the year for dermal synthesis of vitamin D [ 17]. 
Nevertheless, vitamin D deficiency has been described in 
tropical/subtropical countries despite the potential for ade-
quate skin exposure to DVB-containing sunshine [ 18]. 
The aim of the study presented here was to describe 
BMD, body composition and vitamin D status in South 
African women with and without HIV infection, prior to a 
planned longitudinal study of this cohort to chart the 
changes in these outcomes over time. We hypothesised that 
HIV-positive women with low CD4 counts, below the 
threshold that would make them eligible for ARY treatment, 
would have lower bone mass, less fat and muscle mass and 
inferior vitamin D status than HIV-positive women with 
preserved CD4 counts and HIV-negative women in South 
Africa. 
.gi Springer 
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Methods 
Subjects 
Urban, black, premenopausal, South African women (n=247) 
were recruited from clinics in Soweto, Greater Johannesburg 
and enrolled into the study between February and July 2010. 
Subjects were recruited from a voluntary counselling and 
testing clinic and local health clinics. The aim was to recruit 
95 HIV-negative and 73 (±10) in each of two HIV-positive 
groups (with or without low CD4 counts). This sample size 
was based on calculations for the longitudinal study to detect a 
2 % change in lumbar spine BMD, allowing for a between-
individual coefficient of variation in BMD of5 %, with 95 % 
confidence and 80 % power. For the study presented here, this 
sample size was sufficient for a comparison of three groups to 
allow the detection of mean differences between each pair of 
groups of around 0.4 standard deviation (SD) at 5 % signifi-
cance and 80 % power. The study was approved by the 
University of the Witwatersrand Human Research Ethics 
Committee (HREC number: Ml01525) and the Gauteng 
Department of Health. 
Eligible subjects were adult females ( defined as aged 
greater than 18 years) and premenopausal ( defined as regu-
lar menses). Other inclusion criteria included a documented 
negative HIV test within the .last 12 weeks for HIV-negative 
women and a documented positive HIV test for all other 
women. Patient-retained clinic records were scrutinised 
whenever possible to confirm medical history, current CD4 
count, prior exposure to ARVs and concurrent medication 
use. Exclusion criteria included conditions associated with 
abnormal bone metabolism or current use of medication likely 
to affect bone or vitamin D status such as bisphosphonates. 
Pregnant and lactating women were excluded as were those 
with an acute medical condition. The group with the lowest 
CD4 count were largely recruited after the other groups: May 
to June and February to April, respectively. 
Study posters were displayed in the clinic and training 
sessions undertaken with clinic staff. Women who expressed 
an interest in the study underwent initial telephone screen-
ing, in their language, to ensure inclusion and exclusion 
criteria were met. Prior to enrolment, potential subjects 
completed a medical- and health-related questionnaire to 
assess past and current health status and medication use 
and to further assess compliance with inclusion and exclu-
sion criteria. Women who remained eligible were enrolled in 
the full study after they had provided written consent. 
The enrolled women consisted of HIV-negative (n=98) 
and HIV-positive (n= 149) subjects. The HIV-positive wom-
en were recruited into two prespecified groups: those with 
relatively preserved CD4 counts (> 350 x 106 cells/I), not 
requiring ARY therapy (non-ARY group; n=74) and those 
with low CD4 counts (in the region of 200 x 106 cells/I) 
Osteoporos Int 
requiring ARY initiation (pre-ARY group; n=75) according 
to the current South Africa (SA) treatment guidelines [19]. 
HIV-negative status was confirmed using the Determine™ 
rapid HIV-antibody test (Alere San Diego, Inc., San Diego, 
CA, USA), while HIV-positive status was established using 
a second platform. HIV-positive women were either newly 
diagnosed or known to be HIV positive, but not on ARVs. 
All HIV-positive women provided an up-to-date (within 
3 months) CD4 count prior to enrolling into the study. All 
HIV-positive women received SA standard of care with 
respect to ARY provision and clinical follow up. Women 
requiring urgent ARY initiation were managed in such a way 
that there would be no delay in ARY initiation if they were 
to participate in the study. 
Women attended the Developmental Pathways for Health 
Research Unit (DPHRU) facility at the Chris Hani 
Baragwanath Academic Hospital, after an overnight fast 
and underwent phlebotomy, anthropometry, and dual-
energy X-ray absorptiometry (DXA) assessment of bone 
mass and body composition. After phlebotomy, subjects 
were given breakfast and each received ZAR 50.00 
(;::::US$6.25) for travel expenses. 
Anthropometry 
Height was measured to the nearest millimetre using a 
stadiometer (Holtain, Crosswell, UK). Weight was mea-
sured to the nearest 100 g using a digital scale (Tanita, 
TBF-410 MA Body Composition Analyzer, Tanita Corpo-
ration of America, Inc., Arlington Heights, IL, USA) with 
participants wearing light clothing and no shoes. BMI was 
calculated as the participant's weight in kilograms divided 
by the square of their height in metres (in kilogram per 
square metre). Underweight, normal, overweight, and obese 
were defined as BMI <18.5, 18 .5-24.9, 25-29.9, 
2:30.0 kg/m2, respectively [20]. 
Bone absorptiometry and body composition measurements 
DXA was performed using a Hologic QDR 4500A DXA 
(model: Discovery W (SIN 71201) software version 12.5:7 
Hologic, Inc., Waltham, MA, USA) according to standard 
procedures. Scans were conducted u_sing the automatic scan 
mode, i.e. 'array', 'fast array' or 'slow array', depending on 
the weight of the subjects. Subjects wore light clothing 
having removed metal objects, jewellery, etc. DXA was 
used to measure bone mineral content (BMC, in grams), 
bone area (BA, in square centimetre) and areal BMD (in 
grams per square centimetre), of whole body (WB), total hip 
(TH), femoral neck (FN) and lumbar spine (LS). The co-
efficients of variation (CV%) for repeated measurements of 
the manufacturer's phantom were 0.3 , 0.4 and 0.2 % for BA, 
BMC and BMD, respectively. The CV for repeated 
measurement by the DXA operator of the LS and TH 
BMD were 0.7 and 1.0 %, respectively. DXA scans for 
WB were analysed using WB less head (WBLH) as 
many women wore wigs and hair weaves that could 
not be removed prior to scanning. This artificial hair 
was of similar density to soft tissue and therefore could 
cause 'measurement artefact. Total fat and lean body mass 
(in grams) were also measured by DXA. 
Laboratory analysis 
Blood was collected for 25(0H)D analysis, measured by 
chemi-luminescent immunoassay (Liason) kit (DiaSorin 
Inc., Stillwater, MN, USA). The blood samples were 
allowed to clot for a minimum of 20 min at room tempera-
ture, and the serum was aliquoted and stored at -20 C until 
analysed. All samples were run in duplicate. The inter-assay 
CV for low and higher 25(0H)D controls was 10 and 9 %, 
respectively, whereas the intra-assay CV was 8 and 6 %, 
respectively. The DPHRU laboratory participates in the 
International Vitamin D External Quality Assessment 
Scheme and holds the certificate of proficiency [21 ]. 
Statistical analysis 
Data were analysed using DataDesk 6.3.1 (Data Description 
Inc, Ithaca, NY, USA) and summary statistics were document-
ed as mean (SD) or median (interquartile range), depending on 
the distribution. Comparisons were made between the three 
groups of women using hierarchical linear models; ANOVA 
(or ANCOVA) and Scheffe post hoe tests were used to 
compare group means (standard error (SE)). To consider the 
possible influence of group differences · in bone and body 
size, bone mineral data were adjusted for age, weight, 
height and bone area, and bone area was adjusted for age, 
weight and height, using ANCOVA [ 16]. Preliminary plots 
of the relationship between fat mass and lean mass in this 
sample population demonstrated non-linearity. Regression 
of fat mass on lean mass in the HIV-negative control group 
with data in natural logarithms gave a power exponent 2.05± 
0.18 (SE) , indicating that fat mass-to-lean square mass best 
described the relationship in this population. The exponent 
was similar when the data from all three groups were included 
in the model; 2.07±0.14. Consequently, a fat mass-to-lean 
square mass term was used to describe differences in body 
composition between the groups, and logarithmic regression 
was used to adjust fat mass for lean mass in statistical 
models. BMD SD scores (SDS) were generated using 
HIV-negative subjects as the reference population (ref) 
against which the SDS for each individual HIV-positive 
woman (i) was derived as follows: [(BMD;-mean 
BMDrcr)/SDrcrl- A p value of :S0.05 was considered to be 
statistically significant. 
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Table I Subject characteristics, anthropometric measurements and vitamin O status as measured by serum 25(0H)O 
Group I 
HIV-negative 
n=98 
Age (years) 30.0 (8.1) 
HIV status Negative 
Current C04 count x I 06 cells/I ND 
Median (!QR) 
Min NA 
Max NA 
Gravidity median (!QR) I (0;2) 
Range 0--5 
Current hormonal contraceptive use (%) 34 (35.4) 
Current smoking(%) 10.2 
Height (cm) 157.6 (5.9) 
Weight (kg) 69.7 (17.0) 
BMI (kg/m2) Median (IQR) 27.3 (23.1 ;31.7) 
Overweight BMI >24.9 kg/m2, <30 kg/m2 (%) 35 
Obese BMI >30 kg/m2 (%) 30 
Underweight BMI <18.5 kg/m2 (%) 4 
WBLH Fat (kg) 26.1 (11.5) 
WBLH Lean (kg) 38.3 (60.8) 
Fat/lean2 (kg/kg2)* i" 17.32 (4.80) 
25(0H)O (nmol/1) 59.7 (16.5) 
25(0H)O (nmol/1) >50 (%) 73.5 
25(0H)O (nmotn) <50 (%) 26.5 
25(0H)O (nmol/1) <25 (%) 1.0 
Group 2 
HIV-positive, non-ARY 
n=74 
33.5 (6.1)" 
Positive 
412 (91) 
420 (127;409) 
240 
604 
2 (2;3)" 
0--6 
26 (36.6) 
13.5 
159.4 (5.9) 
72.0 (17.4) 
27.8 (23.3;32.3) 
28 
37 
I 
26.1 (9.8) 
39.5 (62.4) 
15.92 (4.56) 
59.2 (16.5) 
70.3 
29.7 
2.7 
Group 3 
HIV-positive, pre-ARY 
n=75 
33.4 (6.5)" 
Positive 
161 (69? 
175 (120; 165) 
18 
275 
2 (1;3)" 
0-6 
25 (33.3) 
8 
159.2 (5.3) 
62.3 (15.2)°"d 
23.5 (20.5 ;27.0le 
28 
16 
II 
19.7 (9.3?·e 
36.4 (48.tt 
14.58 (5.47)"·f 
61.6 (22.3) 
66.7 
33.J 
5.3 
Group effect 
ANOVA 
p 
0.001 
<0.001 
0.9 
0.2 
0.06 
<0.001 
<0.001 
<0.0001 
0.005 
0.002 
0.7 
All values are mean (SO) unless indicated. Letters are used to indicate significance of between-group differences as tested by ANOVA/Scheffe 
25(0H)D 25 hydroxyvitamin O, ARVantiretroviral therapy, cm centimetres, !QR interquartile range, kg kilograms, SD standard deviation, WBLH 
whole body less head, ND not determined, NA not applicable 
*Value multiplied by I ,OOO to illustrate the relative differences in kilogram 
• Significantly different from group I, p :C: 0.01 
b Significantly different from group 2, p :,::0.00 I 
0 Significantly different from group I, p :,::0.05 
• d Significantly different frQm group 2, p :,::0.0 I 
e Significantly different from group I, p :C:0.001 
r Significantly different from group 2, p :,::0.05 
Results 
Subject characteristics 
By design, the mean CD4 count (x I 06 cells/I) in the pre-
ARV group was significantly lower than that in the non-ARV 
group (412 (91) and 161 (69), respectively, p<0.0001). The 
mode of acquisition of HIV-infection was via heterosexual 
transmission in all subjects, only one subject reporting IDU in 
the past (Table I). 
Mean age (SD) was 32.1 (7.2) years with HIV-negative 
women being significantly but only slightly younger than 
both groups of HIV-positive women. The age ranges were 
similar in the three groups (18-49, 22-48 and 19-47 years 
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in HIV-negative, non-ARV and pre-ARV women, respectively). 
Median (IQR) gravidity was 2 (l; 3) with both HIV-positive 
groups having a higher median gravidity compared to the HIV-
negative group. 
Anthropometry and body composition 
HIV-negative women tended to be shorter than both groups 
with HIV-infection (p=0.06), while HIV positive, pre-ARV 
women were significantly lighter than the other two groups 
(p<0.05). Median (IQR) BMI of the study cohort was 26.1 
(22.4; 31) kg/m2 with BMI in pre-ARV women being signif-
icantly lower than in HIV-negative and non-ARV women. 
Combined overweight and obesity represented 65, 65 and 
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44 % of subjects in HIV-negative, non-ARV and pre-ARV 
women, respectively, while underweight was present in 4, I 
and 11 %, respectively (Table I). 
There were significant differences in fat mass between 
groups with pre-ARV women having significantly lower fat 
mass than non-ARV women (p:S0.001). Although lean mass 
was also lower in pre-ARV compared with non-ARV women 
(p=0.005) the pre-ARV group had lower fat mass-to-lean 
square mass ratio than the other two groups (p=0.002). When 
fully adjusting for lean mass using logarithmic regression, the 
pre-ARV group had significantly lower fat mass for their lean 
mass than the other two groups; such that for each unit oflean 
mass the pre-ARV group had a mean difference (SE) of 21 
(5)% less fat than the controls,p=0.0002, and 16 (5)% less fat 
than the non-ARV group, p=0.02. 
Bone measures 
No significant differences in BMD at the TH, FN, LS and 
WBLH were found, and age and size adjustment did not 
reveal any differences between groups. When expressed as 
SD scores, there were no significant differences between 
pre-ARV and non-ARV groups in BMD for any site measured 
(p>0.05) and all the mean values were within a -0.5 SD of the 
HIV-negative reference group (Table 2). In addition, no signif-
icant differences were found in BMC values except at WBLH 
when fully adjusted for age, size and BA (p=0.03). Unadjusted 
BA was significantly greater in both groups of HIV-positive 
women than HIV-negative women at some sites but these dif-
ferences disappeared after adjusting for age and size (see Elec-
tronic supplementary material (ESM) for BA and BMC data). 
Vitamin D status 
Mean (SD) 25(0H)D for the whole cohort was 60.1 (18.4) 
nmol/1 and there_ were no significant differences between 
groups (p>0.05). 25(0H)D concentration was <50 nmol/1 in 
29 .6 % of individuals; with similar proportions in each of the 
Table 2 BMD of the three groups of South African women 
BMO (g/cm2) 
Mean (SO) 
Group I Group 2 
groups in this category (26.5, 29.7 and 33.3 % in HIV-
negative, non-ARV and pre-ARV, respectively). Very few 
subjects had a 25(0H)D concentration <25 nmol/1 (1.0, 2.7 
and 5.3 % in the three groups, respectively), despite the 
slightly greater number of pre-ARV subjects whose blood 
samples for 25(0H)D measurement were obtained during 
the winter months. 
Discussion 
The aim of this study was to determine whether South African 
HIV-positive women with preserved CD4 counts differed from 
those with low CD4 counts making them eligible for ARV and 
to compare each group with HIV-negative women. In this 
group of urban, South African women, pre-ARV women were 
significantly lighter than HIV-negative and non-ARV subjects 
and had lower fat mass than expected for their lean mass, 
raising the possibility that women with advancing HIV disease 
preferentially lose fat rather than lean mass. There were no 
significant differences between groups in BMC or BMD at any 
site before or after adjustment for age, BA, weight and height 
and the observed smaller BA in the HIV-negative women 
disappeared after adjustment for age, height and weight. There 
was no significant difference in vitamin D status between 
groups with the majority of subjects having a serum concen-
tration >50 nmol/1. 
The assessment of'optimal' vitamin D status is problematic 
because varying cut offs are used to define sufficiency, insuf-
ficiency and deficiency [22]. A concentration below 25 nmol/1 
is generally recognised as indicating an increased risk ofrickets 
and osteomalacia [23]. The 2010 Institute of Medicine report 
considered that a blood 2S(OH)D concentration of 20 ng/mL 
(SO nmol/1) to be sufficient for good bone health in 'practically 
all individuals' [24]. However, it noted that evidence was 
lacking to make a similar statement regarding non-skeletal 
health. In the context of HIV infection and ARV use, the 
optimal vitamin D status remains undefined because there 
Group 3 
Group effect" 
p 
HIV-negative HIV-positive, non-ARY HIV-positive, pre-ARY 
n=98 n=74 n=75 
Total Hip 1.013 (0.131) 0.985 (0.124) 0.988 (0.125) 0.3 
Femoral Neck 0.930 (0.114) 0.916 (0.125) 0.923 (0.131) 0.8 
Lumbar Spine 1.018(0.118) 1.021 (0.109) 1.006 (0.128) 0.7 
WBLH 0.958 (0.079) 0.943 (0.071) 0.947 (0.080) 0.4 
ARVantiretroviral therapy, BMD bone mineral density (in gram per square centimetre), SD standard deviation, WBLH whole body less head 
"Group effect by ANO VA. There were no significant differences between pairs of groups by Scheffe post hoe tests 
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may be different requirements for maximal bone health and 
immune functioning compared with HIV-negative 
populations. However, in contrast to other reports [4, 25], in 
our study, there were no indications that HIV infection was 
associated with inferior vitamin D status because there were no 
significant differences in vitamin D status between the three 
groups, the distributions of25(0H)D concentration were sim-
ilar, and vitamin D status appeared to be generally adequate 
with very few women having a concentration <25 nmol/1. 
Contrary to previous reports [9], we found no significant 
differences in BMD between either group of HIV-positive 
and HIV-negative women. Full adjustment for bone and 
body size did not alter these results. This lack of any 
differences is surprising as HIV-positive women with low 
CD4 counts, requiring ARV initiation, were significantly 
lighter, with lower fat and lean mass, than the other women. 
However, it may reflect the selection criteria for this study 
because despite recruiting women with low CD4 counts, of 
clinical concern, women with severe clinical disease re-
ceived immediate ARV therapy and were thus excluded 
from the study. It may also be influenced by the fact that 
the subjects were not intravenous drug users and thus not 
exposed to the addjtional effect on BMD that this poses. 
Another limitation may be that the groups were different in 
terms of duration of hormonal contraception use, parity and 
total duration of lactation; however, at the time of the study, 
no women were pregnant or lactating. The findings are also 
limited by the fact that the sample of HIV-positive women 
was likely to be heterogeneous with respect to immune 
status and duration of infection. However, most other stud-
ies have also recruited HIV-positive subjects in a similar 
manner and this is unlikely to account for the different 
findings in our study. 
The rates of combined overweight and obesity 65 % in HIV-
negative and non-ARV subj~cts in this study were greater than 
the national average in ·South Africa of 51.5 % [26]; even 
women with advanced HIV-disease (pre-ARV group) had a 
combined overweight and obesity rate of 44 %. It is possible, 
therefore, that the typically high weight of South African wom-
en has a sparing effect on bone in those with HIV infection, 
even with CD4 counts below the threshold for initiation of ARV 
intervention. 
Historically, being overweight has been viewed as protective 
against osteoporotic fracture, although evidence is emerging 
that overweight and obesity may be a risk factor for leg fragility 
fractures in women [27]. In the study population of younger 
black women in South Africa, there were no significant differ-
ences in BMD SD score, expressed relative to the HIV-negative 
group, according to HIV status at any site. The effects of HIV 
and its treatment on fracture risk in South Africa are unknown. 
The lack of difference between the groups which is at 
variance from previously reported studies may be the result 
of true lack of effect of HIV infection or reflect important 
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differences in bone response to HIV between black Africans 
and Caucasians. The study design in which two distinct 
groups of HIV-positive women, based on South African 
eligibility criteria for ARV treatment plus the inclusion of 
a HIV-negative control group strengthens the finding that 
HIV infection with varying degree of immunosuppression 
does not appear to be driving alterations in BMD or vitamin 
D status in these young, urban women. The high rates of 
overweight may be masking more dramatic differences in 
BMD and vitamin D in those subjects with advanced clin-
ical HIV disease not included in this study. Further work is 
required to address the effects of ARV exposure on bone and 
vitamin D status as well as the relative effect of 'traditional' 
osteoporosis risk factors in this population. The data from 
this study provide an insight into bone health, body com-
position and vitamin D status in African women living 
with HIV. They challenge our own hypotheses and previ-
ously reported differences in BMD and vitamin D status 
in HIV-positive subjects living in developed countries and 
highlight the importance of studying subjects prior to 
ARV exposure. 
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